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ABSTRACT 
 
TRANDON A. BENDER: METHODS FOR THE SELECTIVE MODIFICATION OF 
CARBOHYDRATES AND NATURAL PRODUCTS  
(Under the guidance of Michel R. Gagné) 
 
Selective modification of complex molecular scaffolds in the form of carbohydrates 
and natural products in a controllable way is a long-standing challenge. In carbohydrates, this 
problem results from the difficulty of activating carbon oxygen (C–O) bonds that are similar 
in reactivity making it difficult to differentiate between which bonds are activated. Natural 
products present a completely unique challenge in that they often contain disparate functional 
groups that present cross reactivity issues making activation of a natural product in a 
controllable way challenging. Each presents its own challenge, but the ability to perform 
selective modification of carbohydrates and natural products offers new routes to valuable 
chiral synthons from a renewable source and the opportunity to create new chemical space in 
molecular scaffolds that are often mined for biologically active drug candidates, respectively.  
Fluoroarylborane-based catalysts (such as B(C6F5)3) are uniquely capable in this 
regard as they heterolytically activate Si–H bonds to generate an oxophilic silylium (R3Si+) 
equivalent along with a reducing borohydride (H–BR3–). Although silylium ions are 
notoriously oxophilic and aggressive electrophiles that would seemingly be a poor choice for 
carrying out selective chemistry on a complex molecule, much less one with diverse (often 
oxygenated) functionality, together these components enable the selective activation and 
reduction C–O bonds in carbohydrates and complex natural products. 
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Imperative to the selective deoxygenation of carbohydrates was the realization that 
selective neighboring group participation results in chemoselective formation of cyclic 
intermediates which are reduced with high diastereoselectivity to generate chiral synthons. 
With the observation that cyclic intermediates guide selective activation in polyoxygenated 
substrates, we expanded this application to include selective allylic C–O bond reduction in 
linear styryl-carbohydrates which also relied on cyclic intermediates to achieve high levels of 
selectivity. Ultimately, neighboring group participation in styryl-carbohyrates was harnessed 
to realize carbon-carbon bond formation to generate carbocycles in a highly 
diastereoselective fashion where cyclic intermediates are again implicated in the highly 
selective transformations. 
Investigating fluroarylborane-based catalyst activation of natural products required 
that addition of an exogenous phosphine Lewis base to modify the catalyst speciation and 
enable aggressive silylium ions to be harnessed for the selective modification of natural 
product scaffolds. Importantly, manipulation of the catalyst, the silane reagent, and the 
reaction conditions provide good control over which (and how) the functional groups are 
modified. The application of this methodology on complex bioactive compounds (natural 
products or drugs) thus provides a powerful tool for assessing how structural diversifications 
of these bioactive compounds correlates with bioactivity.
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1. Chapter 1: Introduction 
 
1.1.  Cellulosic materials in synthesis 
 
The utilization of cellulosics, specifically sugars, as starting materials to prepare 
complex molecules is a strategy with potentially far-reaching applications.1,2 The chiral pool, 
as biologically-derived chiral starting materials are referred to, is typically divided into two 
common substrate categories: (1) cellulosics (sugars) and (2) amino acids. For this brief 
introduction, the focus will be exclusively on cellulosics and synthesis from the chiral pool. 
An advantage of using carbohydrates for preparing complex molecular targets is the 
stereochemistry inherent in the carbon-oxygen (C–O) bond architecture of a sugar. Since 
most complex molecular targets contain at least one stereocenter, starting with 
stereochemical information that is provided by nature can allow one to avoid the application 
of enantioselective catalysis, ligand screening, and time expense that goes along with these 
endeavors. This approach has been successfully applied toward the synthesis of numerous 
complex natural products and has found applications in fields as diverse as asymmetric 
catalysis and polymer chemistry.1,3,4,5  
For all of the potential benefits, there are obvious downsides to using cellulosics for 
preparing complex molecules. Since most syntheses of advance molecules continue to use 
simple small molecules, which are modified to generate complexity in a “ground up” 
 2 
approach, a paradigm shift to using complex carbohydrates has yet to be realized. The status 
quo of starting simple and generating complexity, which has driven successful developments 
in synthesis, is a result of the ubiquity of petroleum derivatives and greater than 100 years of 
research and development. If a similar undertaking in developing novel methods to transform 
cellulosics into molecules that intercept current pathways this would be an attractive 
alternative. As we move away from a fossil fuel-based economy, by choice or out of 
necessity, and move towards renewable these procedures will inevitably need to be 
developed. This will require a reimagining of how we produce small molecule building 
blocks. Instead of using the by-products of crude oil refining, the small molecules would 
come from processing cellulosics.  
1.2. Cellulosics as primary chemicals to generate secondary target chemicals 
 
The proposal that we should begin using cellulose-derived chemicals for application 
in molecular synthesis has a major caveat; many new methods to generate a wide variety of 
targets are necessary. To become an attractive alternative to current small molecule building 
blocks, a broad selection of starting materials will be necessary. One way to accomplish this 
would be to gain inspiration from the production of small molecules in crude oil refinement, 
but in place of crude oil the incoming feed material would be biologically derived cellulosics. 
This would lay out the vision of a fully integrated biorefinery that converts renewable 
feedstocks into a portfolio of primary and secondary chemicals that seamlessly merge into 
existing markets, while also creating new product and market opportunities. This is an 
intriguing proposal, but also daunting to imagine its implementation because of the need to 
defunctionalize selectively, as opposed to installing one functional group at a time. The 
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products of such an integrated biorefinery could feed energy needs (e.g. fuels), chemical 
needs, and material needs into the future.  
Current biorefineries are not integrated in this way, and focus on a single product, 
usually one aimed at the energy sector (e.g. biodiesel or ethanol). These low value products 
maintain a dependence on subsidies for biorefinery products to compete with current 
petroleum alternatives. The integrated biorefinery model seeks to mitigate these constraints 
by coupling the production of low-value high-volume commodities with multiple low-
volume high-value product streams.6  
This model explicitly parallels the operation of modern refineries that convert 
petroleum feedstocks into a plethora of products, each of which has a large or niche position 
in the marketplace. A characteristic of a well-established petroleum refinery business is that 
today’s “waste” byproduct becomes tomorrow’s raw material as opportunists use innovative 
technologies to valorize inexpensive, low demand materials.  
The likely chemicals on the commodity side of the biorefinery equation are 
reasonably well established (e.g. DOE Top 10),7,8 though technology development continues 
to shuffle the candidates. The beacon created by identifying the privileged nature of these 
products has fueled a sustained effort to invent and improve technologies for their synthesis. 
By contrast, much less clarity is available on which low-volume high-value secondary targets 
will be viable, despite their importance to integrated biorefinery models.9,10,11 Therefore, this 
class of compounds is in its infancy and at a critical point the where the discovery of more 
potential secondary chemical candidates is most valuable. Imagining which compounds 
should be prepared for the highest impact is less meaningful than generating a multitude of 
products in an efficient manner to increase the likelihood that one will be a winner.  
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1.3. Selective C–O bond activation to modify cellulosics 
 
One path to prepare low-volume high-value materials is to selectively remove some 
of the functionality of parent cellulosic (i.e. reduce C–O bonds). Although this is only one 
prong to the overall approach that would need to be pursued to achieve a fully integrated 
biorefinery, it has the potential to generate numerous products that are already considered 
gold-standard biorefinery feedstocks. Examples of materials that are highly valuable in this 
class of primary chemicals are a,w-diols derived from the reduction of linear primary sources 
like sorbitol or xylitol (xylose, biopolymer). These are of significant interest as diol 
monomers in polyurethanes and polyesters, or as diacids (after oxidation) for polyester 
applications.12 The technology to selectively remove (only) the secondary C–O positions in 
one direct step does not yet exist, though approaches to this problem have been proposed and 
are potentially viable when starting from xylose.13 To this end, the ionic hydrogenation of 
glycerol is selective for the internal site to yield 1,3-propanediol.14 The aggressive conditions 
for these reactions would need to be improved for more sensitive C6O6 or C5O5 type 
feedstocks. Nevertheless, the immediate applicability of these products invites continued 
efforts. We have investigated the utilization of catalytic C–O bond hydrosilylation (method 
introduced in section 1.4) of complex cellulosics to generate partially deoxygenated chiral 
synthons discussed in Chapter 2 and 3 with the goal of increasing the number of viable chiral 
synthons available from cellulosics. 
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Figure 1.1. Representative methods for selective deoxygenation of primary chemicals. 
Beyond reducing C–O bonds to yield less functionalized materials, there are 
numerous operations that yield new classes of substrates from targeting the masked aldehyde 
at C1 in reducing carbohydrates. For example, decarbonylation of D-ribose yields erythritol 
while maintaining the parent sugars stereocenters.15 Introduction of heteroatoms into the 
carbonyl group have also been successfully demonstrated where L-arabinose can be used to 
synthesize aza-containing tetrahydrofurans like (1.1).16 Moreover, modified sugar analogous 
like isosorbide can be catalytically modified to generate the diamine compound (1.2) that is 
positioned nicely to be introduced in novel polyamide synthesis.  
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Figure 1.2. Representative methods for selective activation/modification of primary chemicals. 
In addition to introducing heteroatoms, skeletal modifications in the form of 
stereoselective formation of C–C bonds are critical to the synthesis of complex, diverse 
chemical entities, and is routinely practiced in areas as diverse as polyolefins and drug 
discovery.17 For example, Kanai et al have shown that Cu(I)-phosphine catalysts can be 
employed to stereoselectively add propargyl groups to D-glucose to yield (1.3).18 Hexitol 
(1.3) could rapidly be elaborated to the core of sialic acids which commonly terminate 
glycoproteins and glycolipids, demonstrating the potential for these routes to yield highly 
desirable chemical feedstocks for the pharmaceutical industry.19 Our labs contribution to 
generating selectively modified scaffolds focuses on generating carbocyclic cores from 
reduced sugars such as galactitol with a modification to introduce unstaturation. This process 
again utilizes a hydrosilylative approach (discussed in section 1.4 below) to achieve highly 
diastereoselective preparation of different carbocylic structures as discussed in Chapter 4. 
1.4. Lewis acid hydrosilylation of sp2 C–O bonds 
 
The hydrosilylation of carbon-oxygen (C–O) bonds of carbonyls and alcohols is a 
mild and selective reaction that has gained much interest as a chemical synthesis technique. 
Current hydrosilylation procedures can be carried out catalytically under mild conditions 
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with numerous silanes as the stoichiometric reductant. Early examples of hydrosilylation 
required a stoichiometric quantity of a strong Lewis acid such as BF3OEt2 along with a 
stoichiometric amount of the silane reductant, making these systems atom-inefficient.10 The 
proposed mechanism for these reductions is termed a nucleophilic-electrophilic 
hydrosilylation, where the substrate C–O bond is activated by a Lewis acid (e.g. ZnCl2, 
BF3OEt2). Polarization of the C–O bond by the Lewis acid results in addition of a silyl 
hydride for net reduction of the bond.20 Further polarization of the silyl hydride to increase 
reactivity is accomplished by the addition of a nucleophile, such as fluoride, to achieve a 
hypervalent nucleophilic Si–H bond (Scheme 1.1).21 
 
 
Scheme 1.1 Lewis acid hydrosilylation of carbonyls. 
 
Further investigation of these stoichiometric systems demonstrated that the propensity 
of an alcohol to undergo hydrosilylation followed the same trend as carbocation stability; 
tertiary alcohols are reduced more rapidly than secondary, which are reduced more readily 
than primary alcohols. The observed reactivity trend demonstrates the requirement of these 
systems to build up positive charge at the site of reduction prior to the delivery of hydride. 
This profile of reactivity is limiting, however, if one wishes to utilize Lewis acids for 
catalytic hydrosilylation. The necessity of the Lewis acid activation of the C-O bond results 
in a non-reversible Lewis acid-base pair forming upon hydride delivery. The ability to 
maintain the observed hydrosilylation activity under mild conditions, while becoming 
Ph
O
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catalytic, was very appealing, and a number of systems have been developed that exhibit this 
reactivity. 
 
Scheme 1.2. Stoichiometric BF3•OEt2 hydrosilylation of tertiary alcohol. 
 
 Metal and non-metal hydrosilylation catalysts have been developed that demonstrate 
impressive reactivity at carbonyl and alcohol substrates under mild conditions. A system that 
has received much attention for these transformation, because of its exceptional reactivity is 
the Lewis acid tris(pentafluorophenyl)borane B(C6F5)3. Besides reactivity, the commercial 
availability and stability of this catalyst is also highly attractive.  
Pioneering work on the catalytic hydrosilylation of aromatic aldehydes, ketones, and 
esters by Piers and co-workers demonstrated the unique reactivity of B(C6F5)3 in combination 
with the tertiary silane Ph3SiH. In this seminal paper, many of the current reactivity trends 
associated with B(C6F5)3 towards hydrosilylation were presented. The observation was made 
that the rate of substrate reduction, to the corresponding silyl protected alcohol, followed the 
trend ethyl benzoate>> acetophenone> benzaldehyde. The equilibrium constants, from 
Scheme 1.3, were determined to be 21000, 1100, 190 for R= H, Me, OEt, respectively. 
Stoichiometric Lewis acid hydrosilylation mechanisms require the formation of a Lewis acid-
substrate adduct prior to reduction. However, the Lewis acid-base adduct of the most rapidly 
reduced substrate, ethyl benzoate, has the smallest equilibrium constant indicating that 
catalytic hydrosilylation with B(C6F5)3 follows a different mechanism than the stoichiometric 
reductions. 
OH BF3•OEt2
Et3Si–H
H
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Scheme 1.3 Equilibrium equation between substrate and B(C6F5)3 
 
Piers and co-workers proposed that instead of B(C6F5)3 activating a substrate C–O 
bond (i.e. traditional Lewis acid pathway), the Lewis acid activates silane by transiently 
forming a borane/silane adduct (R3Si–H---B(C6F5)3). Various indirect experiments suggested 
that this was a reasonable proposal such as the mixing of Ph3SiD and Et3SiH which results in 
deuterium scrambling and an observed increased rate of reduction for less Lewis basic 
substrates in the presence of B(C6F5)3.22 An additional complication in demonstrating this 
mechanism was the observation that catalytically generated [Et3Si][B(C6F5)4] (from 
[Ph3C][B(C6F5)4] and H–SiEt3) is also competent at C–O bond hydrosilylation. In this 
mechanism, silylium cation acts as the catalytic Lewis acid while silyl hydride adds across 
the C–O bond to regenerate silylium and turn over the catalyst. Comparison of acetophenone 
hydrosilylation under [Et3Si][B(C6F5)4] and B(C6F5)3/H–SiEt3 conditions gives different 
product distribution (Scheme 1.4), which could be explained by a different terminal reducing 
reagent (i.e. H–B(C6F5)3–  vs H–SiEt3). Additionally, they showed that the more sterically 
hindered silane H–SiiPr3 with B(C6F5)3 does not catalyze hydrosilylation whereas 
[iPr3Si][B(C6F5)4] results in C–O bond reduction.  
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Scheme 1.4. Acetophenone reduction with H–B(C6F5)3– or H–SiEt3 as the reductant yield disparate 
outcomes. 
 
From these studies emerge a catalytic cycle that is consistent with adduct formation 
followed by substrate mediated silyl-transfer to form a silyloxocarbenium intermediate 
(Scheme 1.5 dashed box) which is rapidly reduced by the concomitantly formed H–B(C6F5)3– 
(Scheme 1.5 dashed box). A SN2 attack of substrate onto the transiently formed adduct was 
confirmed by Oestreich and co-workers where they used a chiral silane which upon reduction 
maintains high levels of entantiopurity in the silane.23 After Piers’ original proposal for this 
unique silane activation pathway, his group along with Tuononen were able to fully 
characterize a direct adduct of this type with a B(C6F5)3 derivative.24   
 
 
Scheme 1.5 Proposed B(C6F5)3 hydrosilylation catalytic cycle. 
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1.5. Hydrosilylation of sp3 C–O bonds with B(C6F5)3 
 
After Piers established that B(C6F5)3 was an active catalyst for hydrosilylation of sp2 
C–O bonds, Yamomoto and co-workers expanded the application of this catalyst to include 
sp3 C–O bonds.25,26 Interestingly, Yamamoto et. al. found that under B(C6F5)3 hydrosilylation 
conditions, primary C–O bond reduction was facile, but reduction of octadecan-2-ol with 
stoichiometric Et3Si–H performed dehydrosilylation to yield the silyl protected alcohol with 
no C–O bond reduction.  As substitution at the reactive center increased to a tertiary alcohol 
no reduction was observed. These findings further demonstrated a shift in reaction 
mechanism from traditional Lewis acid hydrosilylation chemistry, where the stability of the 
carbocation follows ease of activation towards hydrosilylation (Scheme 1.6). 
 
 
Scheme 1.6 Reactivity comparison showing that under catalytic hydrosilylation conditions the 
reactivity is primary >> secondary > tertiary 
 It was eventually disclosed that di- or mono-alkyl silanes (R2SiH2 or RSiH3) were 
competent for secondary and tertriary C–O bond reduction as the stoichiometric reductant. 
Particularly effective in this study were diethylsilane (Et2SiH2) and n-butylsilane.27 An 
additional class of sp3 C–O bonds that were shown to be more reactive than typical C–O 
bonds under this form of catalysis were cyclic allylic ethers. For example, Njardarson et. al. 
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showed that cyclic species with stabilized carbocation intermediates could be selectively 
activated over positions that were less sterically hindered (Scheme 1.7).28 
 
 
Scheme 1.7. Selective activation of an allylic 2º C–O bond over 1º due to electronic stabilization. 
 
1.6. Deoxygenation of Carbohydrates 
 
The Gagné lab originally became interested in hydrosilylation chemistry for the 
purpose of activating and cleaving C–O bonds in the environment of a complex carbohydrate. 
The dense functionality of numerous C–O presented a difficult substrate to activate under 
sterically sensitive hydrosilyliaton catalysts. Initially, Brookhart’s cationic iridium (III) pincer 
catalyst along with superstoichiometric quantities of diethylsilane was investigated and found 
to perform complete deoxygenation of numerous carbohydrates.29,30 Reaction times varied, but 
were typically sluggish. Upon testing B(C6F5)3, we found the same degree of deoxygenation 
was accomplished, but within only a few hours (Scheme 1.8). Even more intriguing was the 
ability to take partially methyl-protected cellulose and with the same catalytic system 
completely reduce the substrate to generate a mixture of hydrocarbons.31,32,33   
 
 
Scheme 1.8 Glucose to fully reduced hydrocarbons. 
 
Another aspect of this reactivity is the observation of branched alkanes and products 
containing unsaturation. The distribution of these products has a dependence on the starting 
material. Specifically, as shown in Figure 1.3, the amount of alkyl rearrangement and 
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elimination products increases when a closed-ring sugar is used as the starting material. On the 
other hand, linear hexoses have less branching. The connections between closed- and open-
ring sugars on product distribution is not fully understood; mechanistic studies are on-going to 
determine what influences these systems. However, the observation of substantial branching 
under these conditions indicates that highly reactive carbocation intermediates are likely. 
 
 An obvious limitation of this work was the large excess of silane that was necessary 
to perform complete deoxygenation to yield products with less value than the reagents being 
used. Moreover, the removal of all existing stereocenters limits the potential applications of 
these products as potentially useful chiral synthons. 
 
1.7. Occurrence of natural products in the environment 
 
Another set of complex molecules that are renewable and derived from biological 
sources are natural products. The molecular scaffolds of natural products are far more 
complex and nuanced than monosaccharides and contain numerous functional groups beyond 
simple C–O bonds. This complexity is derived from necessity; many diverse organisms in 
Figure 1.3. Ratio of hydrocarbons fromed from different carbohydrate starting materials. 
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nature create specific compounds in the form of natural products to help them survive and 
thrive in the hostile, competitive environment that they are constantly adapting to. In an 
evolutionary sense, many of these compounds are biosynthesized out of necessity. These 
organisms “must” produce toxic biomolecules that are capable of warding off intrusive 
species to survive. As a result, the molecules that are derived as a result of these 
environmental stressors provide a rich source of evolutionarily selected compounds that are 
bioactive against a wide range of pathogens. In some cases, the natural products themselves 
are active drugs for humans (e.g. penicillin, taxol), while in others the natural product is 
active but through synthetically driven investigations the activity can be refined even further 
to create more viable drug candidates.34–39  
1.8. Increasing natural product diversity through late-stage diversification 
 
As a result of the inherent role of natural products in their ecosystems these molecules 
are well advanced (and evolved) for bioavailability and potency. For this reason, it is fair to 
suggest that natural products should be investigated for new lead structures. The difficulty of 
discovering and using active natural products as drug is the potential need to modify a drug 
hit to increase desirable attributes while decreasing the negatives. Traditionally, this is 
accomplished through standard synthetic techniques where lead compounds are manipulated 
to modify a functional group that may increase bioavailability or decrease off-target 
interactions. This modification can be simple to make if you are starting from small 
molecules where simply using an alternative starting reagent will yield the desired result. 
However, this goal becomes much more daunting when a late stage modification needs to be 
realized. This difficultly typically arises from incompatibilities between the numerous 
functional groups that are typically contained within a standard natural product. Finding 
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ways around these incompatibilities through standard protecting group manipulations for 
example would be difficult and prohibitive for drug development. 
Late-stage diversification strategy has led to a growing effort to develop synthetic 
tools for diversifying natural products as a means to explore the chemical space created by 
bioactive, inherently privileged structures.40-45 Despite the desirability of this approach, the 
complexity of many natural products makes targeted synthetic manipulations challenging as 
functional group cross-reactivity hinders the chemoselectivity that is necessary for achieving 
this goal.46  
1.9. Research objectives 
 
Selective manipulation of stereochemically and functional group rich molecular 
scaffolds remains the holy grail of chemists who wish to achieve high selectivity for a select 
transformation. Selective activation of carbon-hydrogen bonds (C–H) bonds have a robust 
portfolio of success in this pursuit. However, the removal of selective C–O bonds from 
complex molecular scaffolds remain an unmet challenge. Moreover, the ability of chemists to 
selectively activate more than a single type of functional group with a single catalyst, or class 
of catalyst with disparate reactivities remains challenging. Typically, the requirement of high 
levels of regio- and chemo-selectivity limit one’s ability to perform more than a single type 
of catalytic transformation using a single system. Overcoming this difficulty would greatly 
enhance chemist’s abilities to pursue new avenues for complex molecule activation. 
Herein, we report our efforts towards the application of Lewis acid hydrosilylation to 
perform selective C–O bond reduction of C6O6 carbohydrates to prepare C6On value-added 
chiral synthons. These studies illuminate the uniquely mild and selective reactivity created by 
the combination of B(C6F5)3 and H–SiR3 to transiently generate a reactive R3Si–H---B(C6F5)3 
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adduct which directs chemoselective activation and intramolecular cyclization of linear C6On 
to mediate selective C–O bond reduction. This same approach towards chemo- and 
diastereoselective activation of C–O bonds was then expanded to include alkenyl-containing 
carbohydrates which undergo highly selective allylic C–O bond reduction through cyclic 
intermediates and also allowed us to investigate alkenes as intramolecular nucleophiles to 
perform C–C formation with concomitant C–O bond reduction. Lastly, we present our foray 
into the field of late stage functionalization of natural products. From this we discovered that, 
the combination of a fluoroaryl borane catalysts, a phosphine additive, and a silane reducing 
agent selectively modify complex bioactive natural products to achieve late-stage 
derivatization of bioactive agents of high complexity. 
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2. Chapter 2: Selective deoxygenation of carbohydrates 
 
This chapter is adapted with permission from Adduci, L. L.; Bender, T. A.; Dabrowski, J. A.; 
Gagné, M. R. Nature: Chem. 2015, 7, 576–581. Copyright © 2015 Nature Publishing Group. 
This chapter resulted from a collaboration with Dr. Laura Adduci and Dr. Jennifer 
Dabrowski.
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2.1. Synthesis of chiral synthons from carbohydrates 
 
Carbohydrate feedstocks in the form of sugars are ubiquitous in agricultural growing 
regions of the globe, but they remain a largely untapped resource for preparing fine 
chemicals for synthons that could be valuable for use in the pharma and agro-chemical 
sectors.10,47–49  Since sugars are over oxygenated for most applications we sought to utilize 
chemistry developed in our own lab where complete deoxygenation utilizing catalytic 
B(C6F5)3 with stoichiometric R2SiH2 can yield alkane products,31 but gain control so that 
these sugars could be selectively deoxygenated to complex feedstocks that would be valuable 
to the fine chemical and pharmaceutical industries.50–57 Through modulation of reactivity we 
sought to modify various C6O6 and C5O5 sugars into stereodefined, structurally homogeneous 
C6On and C5On (n = 1-4) fragments that are otherwise difficult to synthesize but would be 
enabling feedstocks for more complex structures, biologically active compounds, and high 
value materials. Chapter 2 discusses the progress our lab has made towards selectively 
cleaving primary and secondary C–O bonds in sugar molecules through substrate control and 
diligent silane reduction choice.  
2.2. Selective hydrosilylation of linear carbohydrates 
 
We previous described complete deoxygenation of various carbohydrates utilizing 
B(C6F5)3 and the dialkylsilane Et2SiH2. In this same study, we discovered that utilizing the 
trialkyl silane Me2EtSiH provided selective reduction of both primary C–O bonds on the 
open change sugar Me2EtSi-sorbitol 2.1 (also called glucitol and derived from glucose) to 
yield an internal tetraol 2.2.58–60 Optimization and isolation of the reaction also yielded a 
single major triol 2.3 beyond the major tetraol product. This simple route to generate 
stereodefined tetra- and tri-iols offered a major improvement to previously published 
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protocols which are typically lengthy (4-8 steps) and/or non-stereoselective.61–63 Utilizing 
Kishi’s stereochemical method, we discovered that generation of 2.3 required chemoselective 
reduction at C2.64  This same triol was obtained by similarly reducing mannitol, 2.4, which 
provides an 8:1 ratio of the symmetric 1,6-reduced tetraol 2.5 and the triol 2.3 (Scheme 2.1). 
 
 
 
Scheme 2.1. Chemo- and diastereoselective reduction of C6O6 to C6On products. 
 
In contrast to sorbitol and mannitol, the reduction of galactitol 2.6 continues past the 
tetraol and yields a C2-reduced triol 2.7. Applying the Kishi method to this product indicated 
that an anti-anti triol was generated as opposed to a syn-anti triol that would be expected.64 
Specifically, the stereochemical analysis indicated that the C5 carbinol center had been 
inverted to generate anit-anti triol 2.7. To justify this unexpected result, we walked through 
the anticipated mechanism in a step-wise manner (Scheme 2.2). First, reduction of 2.6 using 
only 2.5 equivalents of Me2EtSi–H gives tetraol 2.8 where the product is still symmetric. The 
second reduction required for the conversion of 2.8 or 2.7 is stereo-invertive and generates triol 
2.7 that has been epimerized at C5. 
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Scheme 2.2. Mechanistic proposal for selective reduction and inversion of stereochemistry at C5. 
To explain this behavior, we proposed that reduction of a secondary C–O bond 
proceeds through an intermediate cyclic silyl oxonium ion (2.10), which forms by 
intramolecular attack of the C2–OSi group onto an activated C5–OSi2+ (2.9). Nucleophilic 
attack by H–B(C6F5)3– (or Me2EtSi–H) proceeds via path Ha to minimize steric clash with the 
adjacent OSiR3 group (bold blue path). This step-wise reduction followed by cyclic 
intermediate and a second reduction provides the observed triol 2.7 with C5 inversion from 
galactitol. Moreover, additional linear C6O6 sugar substrates corroborated this notion as they 
also yield single triol products and inverted stereochemistry where appropriate (Scheme 2.3). 
Specifically, iditol (2.11) yields a single major triol where stereochemistry at C5 is inverted as 
we would have proposed if cyclic intermediate 2.13 is traversed during this transformation. 
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Scheme 2.3. Series of C6O6 substrates where chemo- and diastereoseletivies follow proposed cyclic 
intermediate selectivity. 
2.3. Cyclic intermediate trapping and identification 
 
We suggested that a cyclic intermediate was an operative pathway to facilitate chemo- 
and diastereoselective reduction of C6O6 substrates to numerous stereodefined tetra- and triol 
products in a two-step protocol. To validate this claim, evidence for cyclic silyl oxonium 
intermediates was obtained by generating a silylium ion equivalent that was free of a reducing 
counterion (i.e H–B(C6F5)3–). Upon combining Me2EtSiH and [Ph3C][B(C6F5)4] 
stoichiometrically an equivalent of [Me2EtSi][B(C6F5)4] is generated equivalent.65,66 Along 
with tetraol 2.8 this silylium salt yields a new species that we attribute to the silyl oxonium ion 
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2.10’ (Figure 2.1). Structural investigation with in-situ 13C{1H} NMR spectroscopy revealed 
that symmetric 2.8 converts to an asymmetric species with two methyl groups and four 
trisubstituted CH centers. Two of these trisubstituted methines had large downfield shifts 
consistent with the electron deficient nature of a silyl oxonium ion.29  
 
  
Figure 2.1. 13C{1H} monitoring of silylium mediated tetraol cyclization. 
2.4. Selective hydosilylation of 1,2-deoxycarbohydrates 
 
Motivated by the excellent chemo- and diastereoselectivity that resulted from the from 
cyclic intermediates, we began exploring this notion with additional cyclic carbohydrate 
substrates. The reactivity of 1,2-deoxy glucose and galactose was nicely informed by our 
knowledge of the propensity of these substrates to generate cyclic intermediates in a 
diastereoselective fashion through selection guidelines that minimize steric interactions with 
neighboring silyl ether groups.  In the former case, reduction with Et3SiH selectively reduces 
at C1 to open the ring to yield 2.26. However, when Me2EtSiH is used instead 1,2,3-deoxy 
sorbitol 2.27, is formed by double reduction of 2.25. This was surprising as it requires a 
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chemoselective reduction of a secondary C–O in the presence of a normally more reactive 
primary C–O bond. This selectivity can be rationalized by suggesting that instead of an SN2 
reduction of an activated C6–OSi2+ center derived from 2.28, an intramolecular addition of the 
C3–OSi group occurs to generate 2.29, which can be reduced through two competing 
pathways: attack at the primary position (C6) to give the 1,2,6-deoxy product or secondary 
reduction at C3 to give the 1,2,3-deoxy triol.  In the simple model substrate 2-methyl THF, 
similar selectivity is observed where there is a ~2:1 preference for reduction at the primary 
site.  Contrasteric charge density considerations in 2-Me THF (and 2.29) are at the root of our 
current thoughts on why reduction along the seemingly more hindered approach trajectory is 
competitive. Furthermore, steric influence on reduction is observed when reducing 1,2-deoxy 
galactose (2.30) where only the internal triol 2.31 is observed. Proposing cyclic intermediate 
2.32 elucidates that reduction at C3 is hindered by the anti substitution relationship and leads 
to exclusive reduction at C6 (Scheme 2.4). 
 
Scheme 2.4. Cyclic intermediates define selectivity in the reduction of 1,2-deoxy sugars. 
2.5. Selective deoxygenation of anhydrosugars 
 
 Finally, we wished to further elaborate on the ability of this system to take complex 
cyclic carbohydrates and perform selective reductions to yield valuable products. To this end 
the doubly dehydrated form of sorbitol, isosorbide, was investigated.67 Simple primary ring 
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opening of silyl protected isosorbide 2.33 with Et3SiH yields the same 1,6-deoxygenated 
product that one generates from sorbitol (2.2), but with fewer overall equivalents of silane. 
Interestingly, by simply using a larger reducing agent (Me2tBuSiH) selective ring opening of 
one diastereomeric THF ring yields single isomer of an interesting 1-deoxysorbitan (2.34).  
 
 
 
Scheme 2.5. Chemo- and diastereoselective reductions of isosorbide. 
 
Investigation of isomannide, which is the mannitol analogue of isosorbide, revealed 
several unexpected opportunities for selective synthesis.  Particularly interesting was the 
reactivity of in situ Ph3Si-protected isomannide where studious selection of silane reductant 
offers divergent reactivity. A limited quantity of Me2EtSiH selectively opens one of the 
symmetry equivalent THF rings at the secondary position to yield 4-deoxy sorbitan 2.35. 
Interestingly, addition of two equivalents of Me2EtSiH yields the 3,4-deoxy mannitol product 
2.36 where two secondary C–O bonds have been reduced selectively in the presence of the 
commonly more reactivity primary ring ethers.  
 
Scheme 2.6. Chemo- and diastereoselective reductions of isosorbide. 
 
When the reductant was instead Ph3SiH, a skeletal rearrangement preceded 
deoxygenation to 2.37. We proposed the mechanism for this rearrangement to involve an 
alkyl shift (2.38) to form a stabilized silyl oxonium intermediate, 2.37’, followed by 
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reduction of the resulting oxocarbenium ion (Scheme 2.7). The combination of a bulky 
protecting group and a bulky silylium ion seems to slow intermolecular hydride attack 
enough that the intramolecular process becomes competitive. 
 
 
 
Scheme 2.7. Skeletal rearrangement of isomannide through a proposed silyl-oxocarbenium 
stabilized intermediate. 
 From these conversion, we were able to provide new reaction protocols for the 
formation of numerous C6On from commercially available starting materials. We believe that 
one of the truly unique outcomes of this work is the apparent lack of simple methods to 
prepare many of the C6On derivatives prepared. This was exemplified when trying to find 
previous methods or characterization of numerous products that didn’t exist in the chemical 
space at the time we prepared them. Through this simple method, we made completely new 
materials from readily available cellulosic derived carbohydrates.  
  
2.6. Experimental section 
 
General considerations:  
Unless otherwise stated, all reactions were conducted under a nitrogen atmosphere 
using a Vacuum Atmospheres glovebox. “Dowex® resin” refers to Dowex® 50W-X8, a 
strongly acidic cation exchange resin distributed by Baker Chemical Company. Before use, 
the orange Dowex® resin beads were washed five times with methanol and five times with 
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methylene chloride and then allowed to dry at ambient pressure. All workup procedures were 
performed under air with reagent grade materials unless otherwise specified. Alumina refers 
to Brockmann activity I neutral alumina gel (Aldrich) that was treated with 10% deionzed 
water. Thin layer chromatography (TLC) was performed on SiliCycle Silica Gel 60 F254 
plates and was visualized with UV light, cerium ammonium molybdate (CAM) stain, or 
potassium permanganate (KMnO4) stain. Methylene chloride-d2 was purchased from 
Cambridge Isotope labs. Both CD2Cl2 and CH2Cl2 were degassed via three freeze-pump-thaw 
cycles, and dried over 4Å molecular sieves prior to use. Triethylsilane and 
dimethylethylsilane, were purchased from Gelest, degassed via three freeze-pump-thaw 
cycles, and dried over 4Å molecular sieves prior to use. 1-deoxyglucopyranose, a-1-methoxy 
6-deoxy glucose, b-1-methoxy-galactose, and galactitol were purchased from Carbosynth. D-
galactal and D-glucal were purchased from Chemimpex. Glucose, α-D-methylglucoside, 
glucitol, α-D-mannose, allitol, iditol, isosorbide, isomannide, 2-methoxy tetraohydropyran, 2-
methyl tetrahydropyrane, and 2-methoxy tetrahydropyran were  
purchased from Aldrich. Chlorodimethylethylsilane, trimethylchlorosilane, and 
triethylchlorosilane were purchased from TCI America. Trispentafluorophenylborane 
(B(C6F5)3) was purchased from Strem and used as received. 1,2,3-hexanetriol was purchased 
from Acros and used as received.  
Room-temperature NMR spectra were recorded using a Bruker Avance III 
spectrometer equipped with a cryoprobe operating at 600 MHz (1H) and 150 MHz (13C). 
NMR chemical shifts are reported in ppm and referenced using the residual proton peaks (d 
CHCl3 = 7.26, d CH2Cl2 = 5.32), 13C resonances of the deuterated solvent (d CDCl3 = 77.16, 
d CD2Cl2 = 53.84) or the proteo solvent (d CH2Cl2 = 54.24). Low temperature NMR spectra 
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were recorded using a Bruker Avance III spectrometer equipped with a BBO probe operating 
at 500 MHz (1H) and 125 MHz (13C). High resolution mass spectra were obtained on either 
an Agilent Accurate LC-TOF Mass Spectrometer (Agilent Series 6220) operating in positive 
ion mode with an electrospray ionization source (fragmentor = 175 V) or with a hybrid LTQ 
FT (ICR 7T) (ThermoFisher, Bremen, Germany) mass spectrometer where samples were 
introduced via a micro-electrospray source at a flow rate of 3 µL/min. The data were 
analyzed using either Agilent MassHunter Workstation Software, Qualitative Analysis (V. 
B.02.00) or Xcalibur (ThermoFisher, Breman, Germany). Specific rotations were obtained on 
a Jasco DIP-1000 digital polarimeter equipped with a sodium lamp utilizing a 3.5 x 100 mm 
cell. A NesLab cryobath CB-80 was utilized for reduced temperature reactions where 
temperature was verified by low-temperature thermometer. The numbering used for starting 
material and products is based on the parent sugar. 
General procedure 2.1: Silyl protection of polyol substrates  
Me2EtSiCl or Et3SiCl (1.2 eq. per alcohol) was added to a solution or suspension of 
the unprotected substrate in pyridine under a nitrogen atmosphere. After stirring for at least 
12 hours, the reaction mixture was diluted with water. The water layer was extracted three 
times with Et2O. The combined ether layers were washed three times with water and brine, 
dried over Na2SO4, filtered, and solvent removed under vacuum to give a colorless to pale 
yellow solution. The crude oil was passed over a flash alumina gel column (15 x 2 cm) with 
100% then 10:1 hexane:Et2O to yield the title compound. 1H NMR integration of the silyl 
groups vs. the carbon backbone was used to ensure complete hydroxyl group protection.  
General procedure 2.2: Deoxygenation of C6On substrate 
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In a nitrogen-filled glovebox, massed B(C6F5)3 and silyl-protected C6On substrate into 
a 1-dram vial. Added dichloromethane (CH2Cl2 or CD2Cl2) to fully dissolve. Silane was then 
added dropwise and transferred by pipette to a 5 mm NMR tube. The tube was capped with a 
NMR tube septum and removed from the glove box. Once full conversion by NMR was 
observed, the reaction was quenched by the addition of Et3N (0.05 mL) through the septum 
cap. The quenched reaction mixture was shaken and then immediately transferred to a vial with 
CH2Cl2 and concentrated under vacuum. The mixture was loaded onto an alumina plug 
(neutral, 10% H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 95:5 hexanes:diethyl ether 
(1.5 mL), eluting with 95:5 hexanes:diethyl ether (10 mL) into a tared vial. The solution was 
concentrated under vacuum to afford a colorless oil. 
General procedure 2.3: Silane deprotection to C6On alcohol 
 
The vial containing the silyl substrate was equipped with a stir bar and charged with 
Dowex® resin (10 beads). Methanol (5.0 mL) was added by syringe and the resulting solution 
was allowed at ambient temperature. Filtration through sand to remove the Dowex® beads and 
concentration under vacuum affords a white solid. 
General procedure 2.4: Acetate Protection 
 
A 20-mL vial equipped with stir bar was charged with substrate followed by 
dichloromethane and allowed to cool to 0 °C (ice bath). Pyridine followed by dropwise addition 
of acetyl chloride were added by syringe. The reaction stirred for 12 h as it warmed to ambient 
temperature and was then quenched by addition of a saturated solution of sodium bicarbonate, 
extracted with CH2Cl2, and passed through a plug of magnesium sulfate into a vial with 
subsequent extractions. Products were purified by silica gel chromatography (5 x 1 cm column) 
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using gradient elution (100% hexanes to 5:1 to 4:1 to 3:1 hexanes:diethyl ether) to afford the 
title product.  
General procedure 2.5: Acetate deprotection to Determine Stereochemistry 
 
A 20-mL vial equipped with stir bar was charged with K2CO3.  Acetate-substrate was 
added as a solution in CH2Cl2 by syringe followed by methanol by syringe. The resulting 
heterogeneous mixture was allowed to stir at ambient temperature until TLC shows no starting 
material (~2 h). The mixture was passed through a plug of Celite®. The solution was 
concentrated under vacuum to afford a white solid. The alcohol was purified by column 
chromatography (neutral alumina with 10% H2O, 5 x 0.5 cm). Initially, the crude reaction vial 
was rinsed with CH2Cl2 (1 mL) and loaded onto the column followed by sequential rinses with 
20:1 (3 mL), 10:1 (3 mL), 5:1 (3 mL) CH2Cl2: MeOH then 100% methanol (20 mL) to afford 
the title product. 
General Procedure 2.6: Mosher ester preparation for stereochemical analysis 
Derivatives were prepared as previously reported. To a 20 mL scintillation vial charged 
with substrate (1.0 equiv.) and a magnetic stir bar was added (S)-Mosher acid (58.0 mg, 0.248 
mmol, 3.1 equiv.), followed by N,N'-dicyclohexylcarbodiimide (DCC) (51.1 mg, 0.248 mmol, 
3.1 equiv.), and 4-(dimethylamino)pyridine (DMAP) (30.3 mg, 0.248 mmol, 3.1 equiv.). Dry 
dichloromethane was added (1.0 mL) by syringe. The reaction was allowed to stir at room 
temperature for 24 h. After the reaction period, solids was removed by passing the contents 
through plug of sand in a pipette, rinsing with additional CH2Cl2 (3 x 1 mL). Solvent was 
removed under vacuum to afford a white powder. The title residue was then isolated by column 
chromatography (5 x 1 cm) by gradient elution (100% hexane to 95% hexane/5% ethyl acetate 
to 90% hexane/10% ethyl acetate) to afford a white solid.  
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Reduction of sorbitol to yield 2.2 and 2.3 
 
 Following general procedure 2.2, 5.0 mg B(C6F5)3, 72.0 mg EtMe2Si-sorbitol and 0.5 
mL dichloromethane were combined followed by the addition of 66 µL of 
dimethylethylsilane. After 1 h full conversion of starting material by NMR was confirmed 
and the reaction was quenched. Following general procedure 2.3, the substrate was 
deprotected and subsequently general procedure 2.4 was followed to perform acetate 
protection. Products were purified by silica gel chromatography (5 x 1 cm column) using 
gradient elution (100% hexanes to 20:1 to 6:1 to 5:1 hexanes:diethyl ether) to afford 2.2 and 
2.3 (71% yield, 23.2 mg and 14% yield, 3.7 mg over three steps). Tetraol 2.2: 1H NMR (600 
MHz, CDCl3): d 5.28 (dd, J = 6.0 Hz, J = 4.8 Hz, 1H, H3 or H4), 5.19 (dd, J = 6.6 Hz, J = 4.8 
Hz, 1H, H3 or H4), 4.99 (quintet, J = 6.6 Hz, 1H, H2 or H5), 4.91 (quint, J = 6.0 Hz, 1H, H2 or 
H5), 2.11 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.23 (d, J = 6.6 Hz, 
3H, H1 or H6), 1.20 (d, J = 6.6 Hz, 3H, H1 or H6). 13C{1H} NMR (151 MHz, CDCl3): d 170.4 
(s, Ac), 170.22 (s, Ac), 170.19 (s, Ac), 170.1 (s, Ac), 72.2 (s, C3 or C4), 72.0 (s, C3 or C4), 
68.8 (s, C2 or C5), 67.5 (s, C2 or C5), 21.2 (s, Ac), 21.1 (s, Ac), 20.9 (s, Ac), 20.7 (s, Ac), 16.4 
(s, C1 or C6), 15.6 (s, C1 or C6). HRMS (ESI+): Calcd for C14H22O8Na [M+Na] +: 341.1207; 
Found: 341.1214. Specific rotation: [α]D27.3 +26. (c = 0.69 CHCl3). Triol 2.3: 1H NMR (600 
MHz, CDCl3): d 5.14 (dd, JH4,H5 = 7.2 Hz, JH4,H3 = 3.6 Hz, 1H, H4), 5.09 (ddd, JH3,H2 = 7.2 
Hz, JH3,H2’ = 6.0 Hz, JH3,H4 = 3.6 Hz, 1H, H3), 4.98 (quintet, JH5,H6 = 6.6 Hz, 1H, H5), 2.13 (s, 
3H, Ac), 2.07 (s, 3H, Ac), 2.03 (s, 3H, Ac), 1.57–1.52 (m, 2H, H2), 1.20 (d, JH6,H5 = 6.6 Hz, 
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3H, H6), 0.91 (t, J H1,H2 = 7.2 Hz, 3H, H1). 13C{1H} NMR (151 MHz, CDCl3): d 170.7 (s, Ac), 
170.4 (s, Ac), 170.3 (s, Ac), 74.0 (s, C4), 72.2 (s, C3), 67.6 (s, C5), 24.1 (s, C2), 21.2 (s, Ac), 
21.0 (s, Ac), 20.9 (s, Ac), 16.2 (s, C6), 9.6 (s, C1). HRMS (ESI+): Calcd for C12H20O6Na 
[M+Na] +: 283.1152; Found: 283.1157. Specific rotation: [a]D25.6 +9.4 (c = 0.085 CHCl3). 
 
 
Figure 2.2. 1H and 13C{1H} of tetraol 2.2. 
Reduction of mannitol to yield 2.5 and 2.3 
 
Following general procedure 2.2, 5.0 mg B(C6F5)3, 70.1 mg EtMe2Si-mannitol and 
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dimethylethylsilane. After 2 h full conversion of starting material by NMR was confirmed 
and the reaction was quenched. Following general procedure 2.3, the substrate was 
deprotected and subsequently general procedure 2.4 was followed to perform acetate 
protection. Products were purified by silica gel chromatography (5 x 1 cm column) using 
gradient elution (100% hexanes to 20:1 to 10:1 to 8:1 to 7:1 to 5:1 to 2:1 hexanes:diethyl 
ether) to afford 2.5 and 2.3 (77% yield, 24.5 mg and 10% yield, 2.6 mg over three steps). 
Tetraol 2.5: 1H NMR (600 MHz, CDCl3): d 5.26 (d, JH3,H2 = JH4,H5 7.2 Hz, 2H, H3 & H4), 
4.92 (quint, J = 6.0 Hz, 2H, H2 & H5), 2.09 (s, 6H, Ac), 2.02 (s, 6H, Ac), 1.20 (d, J = 6.0 Hz, 
6H, H1 & H6). 13C{1H} NMR (151 MHz, CDCl3): d 170.3 (s, Ac), 170.2 (s, Ac), 71.3 (s, C3 
& C4), 67.3 (s, C2 & C5), 21.2 (s, Ac), 20.8 (s, Ac), 16.3 (s, C1 & C6). HRMS (ESI+): Calcd 
for C14H22O8Na [M+Na] +: 341.1207; Found: 341.1214. Triol 2.3: 1H NMR (600 MHz, 
CDCl3): d 5.14 (dd, JH3,H2 = 7.2 Hz, JH3,H4 = 3.6 Hz, 1H, H3), 5.09 (ddd, JH4,H5 = 7.2 Hz, 
JH4,H5’ = 6.0 Hz, JH4,H3 = 3.6 Hz, 1H, H4), 4.98 (quint, J = 6.6 Hz, 1H, H2), 2.13 (s, 3H, Ac), 
2.07 (s, 3H, Ac), 2.03 (s, 3H, Ac), 1.57–1.52 (m, 2H, H5), 1.20 (d, JH1,H2 = 6.6 Hz, 3H, H1), 
0.91 (t, JH6,H5 = 7.2 Hz, 3H, H6). 13C{1H} NMR (151 MHz, CDCl3): d 170.7 (s, Ac), 170.4 (s, 
Ac), 170.3 (s, Ac), 74.0 (s, C3), 72.2 (s, C4), 67.6 (s, C2), 24.1 (s, C5), 21.2 (s, Ac), 21.0 (s, 
Ac), 20.9 (s, Ac), 16.2 (s, C1), 9.6 (s, C6). HRMS (ESI+): Calcd for C6H14O3Na [M+Na]+: 
157.0835; Found 157.0836.  
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Figure 2.3. 1H and 13C{1H} of triol 2.3. 
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Figure 2.4. 1H and 13C{1H} of tetraol 2.5. 
Reduction of galactitol to yield 2.7 
 
 Following general procedure 2.2, 5.0 mg B(C6F5)3, 69.9 mg EtMe2Si-galactitol and 
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dimethylethylsilane. After 21 hours, full conversion of starting material by NMR was 
confirmed and the reaction was quenched. Following genearl procedure 2.3, the substrate 
was deprotected and subsequently general procedure 2.4 was followed to perform acetate 
protection. Products were purified by silica gel chromatography (5 x 1 cm column) using 
gradient elution (100% hexanes to 5:1 to 4:1 hexanes:diethyl ether) to afford X (78% yield, 
20.2 mg). Triol 2.7: 1H NMR (600 MHz, CDCl3): d 5.14 (dd, JH4,H3 = 5.4 Hz, JH4,H5 = 4.8 Hz, 
1H, H4), 5.08 (dq, JH5,H6 = 6.6 Hz, JH5,H4 = 4.8 Hz, 1H, H5), 4.98 (ddd, JH3,H2 = 9.0 Hz, JH3,H2’ 
= 3.6 Hz, JH3,H4 = 5.4 Hz, 1H, H3), 2.09 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.03 (s, 3H, Ac), 1.71–
1.64 (m, 1H, H2), 1.61–1.53 (m, 1H, H2’), 1.24 (d, JH6,H5 = 6.0 Hz, 3H, H6), 0.89 (t, J H1,H2 = 
7.2 Hz, 3H, H1). 13C{1H} NMR (151 MHz, CDCl3): d 170.6 (s, Ac), 170.3 (s, Ac), 170.2 (s, 
Ac), 73.8 (s, C4), 73.1 (s, C5), 68.7 (s, C3), 23.3 (s, C2), 21.3 (s, Ac), 21.1 (s, Ac), 21.0 (s, 
Ac), 15.4 (s, C6), 9.7 (s, C1). HRMS (ESI+): Calcd for C12H20O6Na [M+Na] +: 283.1152; 
Found: 283.1158. Specific rotation: [a]D26 +93 (c = 0.7 CHCl3). 
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Figure 2.5. 1H and 13C{1H} of triol 2.7. 
Reduction of galactitol to yield 2.8  
 
Following general procedure 2.2, 5.0 B(C6F5)3, 71.1 mg EtMe2Si-galactitol and 0.5 mL 
dichloromethane were combined followed by the addition of 33 µL of dimethylethylsilane. 
After 40 minutes, full conversion of starting material by NMR was confirmed and the reaction 
was quenched. Following genearl procedure 2.3, the substrate was deprotected and 
subsequently general procedure 2.4 was followed to perform acetate protection. Products were 
purified by silica gel chromatography (5 x 1 cm column) using gradient elution (100% hexanes 
to 5:1 to 4:1 to 3:1 hexanes:diethyl ether) to afford 2.8 (79% yield, 25.6 mg). Tetraol 2.8: 1H 
NMR (600 MHz, CDCl3): d 5.19 (app s, 2H, H3 & H4), 5.08 (app q, J = 6.6 Hz, 2H, H2 & H5), 
2.11 (s, 6H, Ac), 2.04 (s, 6H, Ac), 1.12 (d, J = 6.6 Hz, 6 H, H1 & H6). 13C{1H} NMR (151 
MHz, CDCl3): d 170.6 (s, Ac), 170.2 (s, Ac), 70.8 (s, C3 & C4), 67.2 (s, C2 & C5), 21.2 (s, Ac), 
OAc
OAc
OAc
OAc
10 mol % B(C6F5)3
2.5 equiv. HSiMe2Et
CH2Cl2, RT, 40 min;
OSi
OSi
OSi
OSi
SiO
OSi
2.8
79% yield
deprotection;
protection
Si = SiMe2Et
2.6
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20.8, (s, Ac), 16.3 (s, C1 & C6). HRMS (ESI+): Calcd for C14H22O8Na [M+Na] +: 341.1207; 
Found: 341.1213. 
 
 
Figure 2.6. 1H and 13C{1H} of tetraol 2.8. 
Reduction of iditol to yield 2.12 and 2.14 
 
OSi
SiO
OSi
OSi
OSi
OSi
Si = Me2EtSi
11 mol % B(C6F5)3
7.1 equiv. HSiMe2Et
CH2Cl2, RT, 8 h;
deprotection;
protection OAc
OAc
OAc
OAc
OAc
OAc
OAc
2.12
28% yield
2.14
65.5% yield
+
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 38 
Following general procedure 2.2, 5.7 mg B(C6F5)3, 68.9 mg EtMe2Si-iditol and 0.5 
mL dichloromethane were combined followed by the addition of 92.5 µL of 
dimethylethylsilane. After 8 hours, full conversion of starting material by NMR was 
confirmed and the reaction was quenched. Following general procedure 2.3, the substrate 
was deprotected and subsequently general procedure 2.4 was followed to perform acetate 
protection. Products were purified by silica gel chromatography (5 x 1 cm column) using 
gradient elution (100% hexanes to 20:1 to 10:1 to 7:1 to 5:1 to 4:1 to 3:1 hexanes:diethyl 
ether) to afford 2.14 (65.5% yield, 16.8 mg) and 2.12 (28% yield, 6.8 mg). Tetraol 2.12: 1H 
NMR (600 MHz, CDCl3): d 5.19–5.17 (m, 2H, H3 & H4), 5.05–5.01 (m, 2H, H2 & H5), 2.11 
(s, 6H, Ac), 2.05 (s, 6H, Ac), 1.22 (d, J = 6.6 Hz, 6 H, H1 & H6). 13C{1H} NMR (151 MHz, 
CDCl3): d 170.2 (s, both Ac groups), 72.4 (s, C3 & C4), 68.9 (s, C2 & C5), 21.2 (s, Ac), 20.8 
(s, Ac), 16.5 (s, C1 & C6). HRMS (ESI+): Calcd for C14H22O8Na [M+Na]+: 341.1207; Found: 
341.1212. Triol 2.14: 1H NMR (600 MHz, CDCl3): d 5.13 (dd, JH4,H5 = 7.2 Hz, JH4,H3 = 3.6 
Hz, 1H, H4), 5.10–5.07 (m, 1H, H3), 4.98 (quint, JH5,H6 = 6.6 Hz, 1H, H5), 2.13 (s, 3H, Ac), 
2.02 (s, 3H, Ac), 1.58–1.49 (m, 2H, H2), 1.19 (d, JH6,H5 = 6.6 Hz, 3H, H6), 0.90 (t, JH1,H2 = 7.8 
Hz, 3H, H1). 13C{1H} NMR (151 MHz, CDCl3): d 170.6 (s, Ac), 170.4 (s, Ac), 170.3 (s, Ac), 
74.0 (s, C4), 72.2 (s, C3), 67.6 (s, C5), 24.1 (s, C2), 21.2 (s, Ac), 21.0 (s, Ac), 20.9 (s, Ac), 
16.2 (s, C6), 9.6 (s, C1). HRMS (ESI+): Calcd for C12H20O6Na [M+Na]+: 283.1152; Found: 
283.1155. Specific rotation: [𝛼]$%.'(  +39.4  (c = 0.55 CHCl3). 
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Figure 2.7. 1H and 13C{1H} of tetraol 2.12. 
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Figure 2.8. 1H and 13C{1H} of triol 2.14. 
Reduction of allitol to yield 2.16 and 2.18 
 
 Following general procedure 2.2, 5.6 mg B(C6F5)3, 70.0 mg EtMe2Si-allitol and 0.5 
mL dichloromethane were combined followed by the addition of 92.5 µL of 
dimethylethylsilane. After 8 hours, full conversion of starting material by NMR was 
confirmed and the reaction was quenched. Following general procedure 2.3, the substrate 
was deprotected and subsequently general procedure 2.4 was followed to perform acetate 
protection. Products were purified by silica gel chromatography (5 x 1 cm column) using 
+
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7.0 equiv. HSiMe2Et
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OSi
OSi
OSi
OSi
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OAc
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gradient elution (100% hexanes to 20:1 to 10:1 to 7:1 to 5:1 to 4:1 to 3:1 hexanes:diethyl 
ether) to afford 2.16 (80% yield, 25.6 mg) and 2.18 (3% yield, 0.8 mg). Tetraol 2.16: 1H 
NMR (600 MHz, CDCl3): d 5.23 (app d, J = 1.2 Hz, 2H, H3 & H4), 5.06–5.05 (m, 2H, H2 & 
H5), 2.109 (s, 3H, Ac), 2.106 (s, 3H, Ac), 2.024 (s, 3H, Ac), 2.021 (s, 3H, Ac), 1.24 (d, J = 
6.6 Hz, 3H, H1 or H6), 1.23 (d, J = 6.6 Hz, 3H, H1 or H6). 13C{1H} NMR (151 MHz, CDCl3): 
d 170.3 (s, Ac), 169.9 (s, Ac), 71.5 (s, C3 & C4), 68.9 (s, C2 & C5), 21. 2 (s, Ac), 21.0 (s, Ac), 
14.9 (s, C1 & C6). HRMS (ESI+): Calcd for C14H22O8Na [M+Na]+: 341.1207; Found: 
341.1213. Triol 2.18: 1H NMR (600 MHz, CDCl3): d 5.14 (t, JH3,H4 = 4.8 Hz, 1H, H3), 5.10–
5.06 (m, 1H, H2), 5.01–4.97 (m, 1H, H4), 2.10 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.03 (s, 3H, Ac), 
1.71–1.64 (m, 1H, H5), 1.61–1.55 (m, 1H, H5), 1.25 (d, JH1,H2 = 6.6 Hz, 3H, H1), 0.90 (t, 
JH6,H5 = 7.2 Hz, 3H, H6). 13C{1H} NMR (151 MHz, CDCl3): d 170.6 (s, Ac), 170.3 (s, Ac), 
170.2 (s, Ac), 73.8 (s, C3), 73.1 (s, C4), 68.8 (s, C2), 23.3 (s, C1), 21.3 (s, Ac), 21.1 (s, Ac), 
21.0 (s, Ac), 15.4 (s, C5), 9.7 (s, C6). HRMS (ESI+): Calcd for C12H20O6Na [M+Na]+: 
283.1152; Found: 283.1157.  
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Figure 2.9. 1H and 13C{1H} of tetraol 2.16. 
Preparation of 2.10’ through cyclization  
 
 
 
In a nitrogen-filled glovebox, a 1-dram vial was charged with 20.0 mg Me2EtSi-
protected tetraol 2.8 followed by CD2Cl2 (0.5 mL) and mixed until homogeneous. The 
resulting solution was transferred via syringe into a second vial that had been charged with 
37.0 mg [Ph3C][B(C6F5)4]. The resulting dark yellow solution was transferred by syringe to a 
5 mm NMR tube, which was capped with a septum and removed from the glovebox. The 
septum was secured with Parafilm® and the NMR tube was allowed to cool in a dry 
ice/acetone bath (–78 °C). Introduced 6.2 µL of dimethylethylsilane under nitrogen, the 
NMR tube was removed from the cold bath, inverted twice to mix, and quickly replaced in 
the cold bath. No color change was observed; the solution remained bright yellow. 
Immediately prior to the acquisition of NMR spectra, the NMR tube was removed from the 
cold bath and allowed to warm to room temperature, at which time the color became pale 
brown.  NMR data were acquired at 25 ⁰C. After acquisition of NMR data was complete, 
OSi
OSi
OSi
OSi
Si = SiMe2Et
O
HO OH
1.0 equiv. [Ph3C][B(C6F5)4]
1.2 equiv. Me2EtSiH
CD2Cl2, – 78 ºC → RT;
deprotection
2.8 2.10’
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NEt3 (0.05 mL) was added by syringe through the NMR septum to quench the reaction. The 
reaction mixture was transferred to a vial using dichloromethane (3 x 1 mL) and solvent was 
removed under vacuum. The mixture was loaded onto an alumina plug (neutral, 10% H2O; 2 
x 1 cm) with 90:10 hexanes diethyl ether until TLC indicated that elution of CAM-active 
material was complete (approximately 10 mL). Solvent was evaporated under reduced 
pressure. To the resulting residue was added methanol (2 mL) and approximately 15 beads of 
Dowex® resin. The heterogeneous reaction mixture was allowed to stir for at least one hour.  
Subsequently, the resin was removed by filtration through sand, rinsing with methanol. 
Volatiles were removed from the filtrate under vacuum, and the resulting residue was 
purified by silica gel chromatography (5 x 1 cm column) with gradient elution (100% CH2Cl2 
(to remove Ph3CH) to 50:1 to 30:1 to 20:1 to 15:1 CH2Cl2/methanol) to provide 2.10’ as an 
oily residue. Stereochemistry was not established by NMR but assumed on the basis of the 
stereochemistry of the triol resulting from hydrosilylative ether cleavage of 2.10. Cyclized 
tetraol 2.10’: 1H NMR (600 MHz, CD3OD): δ 4.14 (dq, J = 6.5, 3.4 Hz, 1H, H2 or H5), 3.92–
3.90 (m, 1H, H3 or H4), 3.86 (dq, J = 8.2, 6.2 Hz, 1H, H2 or H5), 3.74 (dd, J = 8.1, 4.5 Hz, 
1H, H3 or H4), 1.24 (d, J = 6.1 Hz, 3H, H1 or H6), 1.20 (d, J = 6.5 Hz, 3H, H1 or H6). 13C{1H} 
NMR (151 MHz, CD3OD): δ 80.0 (s, C3 or C4), 77.9 (s, C2 or C5), 77.4 (s, C2 or C5), 74.4 (s, 
C3 or C4), 19.2 (s, C1 or C6), 15.3 (s, C1 or C6). 
Reduction of 1,2-deoxyglucose to yield 2.26 and 2.27 
 
Following general procedure 2.2, 2.9 mg B(C6F5)3, 41.1 mg EtMe2Si-1,2-
deoxyglucose and 0.5 mL dichloromethane were combined followed by the addition of 33.0 
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µL of dimethylethylsilane. After 4.5 hours, full conversion of starting material by NMR was 
confirmed and the reaction was quenched. Following general procedure 2.3, the substrate 
was deprotected. Products were purified by silica gel chromatography (5 x 1 cm column) 
using gradient elution (100% CH2Cl2 to 50:1 to 30:1 to 25:1 to 20:1 CH2Cl2:methanol)  to 
afford 2.26 (72% yield, 9.8 mg) and 2.27 (3% yield, 0.4 mg). Triol 2.26: 1H NMR (600 MHz, 
CD3OD): d 3.72 (dd, JH6,H6’ = 11.4 Hz, JH6,H5 = 3.6 Hz, 1H, H6), 3.56 (dd, JH6’,H6 = 11.4 Hz, 
JH6’,H5 = 6.6 Hz, 1H, H6’), 3.51–3.48 (m, 1H, H4), 3.42 (dt, JH5,H6’ = 6.6 Hz, JH5,H6 = 3.6 Hz, 
1H, H5), 1.65–1.62 (m, 1H, H3), 1.61–1.53 (m, 1H, H2), 1.42–1.34 (m, 2H, H3 & H2), 0.95 (t, 
JH1,H2 = 6.6 Hz, 3H, H1). 13C{1H} NMR (151 MHz, CD3OD): d 76.5 (s, C5), 73.5 (s, C4), 65.0 
(s, C6), 36.5 (s, C3), 20.1 (s, C2), 14.7 (s, C1). HRMS (ESI+): Calcd for C6H14O3Na [M+Na] +: 
157.0835; Found: 157.0833. Specific rotation: [a]D26.2 –3.5 (c = 0.31 CHCl3). Triol 2.27: 1H 
NMR (600 MHz, CD3OD): δ 3.78 (dq, JH5,H4 = 7.4 Hz, JH5,H6 = 6.4 Hz, 1H, H5), 3.68 (ddd, 
JH3,H2 = 8.0 Hz, JH3,H2’ = 5.9 Hz, JH3,H4 = 2.5 Hz, 1H, H3), 3.15 (dd, JH4,H5 = 7.3 Hz, JH4,H3 = 
2.5 Hz, 1H, H4), 1.58–1.53 (m, 2H, H2), 1.23 (d, JH6,H5 = 6.4 Hz, 3H, H6), 0.97 (t, JH1,H2 = 7.4 
Hz, 3H, H1).  13C{1H} NMR (151 MHz, CD3OD): δ 77.9 (s, C4), 73.1 (s, C3), 68.9 (s, C5), 
27.5 (s, C2), 20.1 (s, C6), 10.7 (s, C1). HRMS (ESI+): Calcd for C6H14O3Na [M+Na]+: 
157.0835; Found 157.0839.  
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Figure 2.10. 1H and 13C{1H} of tetraol 2.26. 
 
 
Figure 2.11. 1H and 13C{1H} of triol 2.27. 
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Reduction of 1,2-deoxygalactose to yield 2.31  
 
 Following general procedure 2.2, 2.9 mg B(C6F5)3, 42.1 mg EtMe2Si-1,2-
deoxyglucose and 0.5 mL dichloromethane were combined followed by the addition of 33.0 
µL of dimethylethylsilane. After 40 minutes, full conversion of starting material by NMR 
was confirmed and the reaction was quenched. Following general procedure 2.3, the 
substrate was deprotected. Products were purified by silica gel chromatography (5 x 1 cm 
column) using gradient elution (5:1 to 4:1 hexanes:diethyl ether) to afford 2.31 (92.5 % yield, 
24.8 mg). Triol 2.31: 1H NMR (600 MHz, CDCl3): d 5.13 (dq, JH5,H6 = 6.6 Hz, JH5,H4 = 4.2 
Hz, 1H, H5), 5.07 (dd, JH4,H5 = 7.2 Hz, JH4,H3 = 3.6 Hz, 1H, H4), 4.99 (dt, JH3,H2 = 7.8 Hz, 
JH3,H4 = 3.6 Hz, 1H, H3), 2.13 (s, 3H, Ac), 2.03 (s, 6H, Ac), 1.65–1.59 (m, 1H, H2), 1.56–1.49 
(m, 1H, H2’), 1.17 (d, JH6,H5 = 6.6 Hz, 3H, H6), 0.88 (t, JH1,H2 = 7.2 Hz, 3H, H1). 13C{1H} 
NMR (151 MHz, CDCl3): d 170.5 (s, Ac), 170.44 (s, Ac), 170.38 (s, Ac), 74.3 (s, C4), 71.7 
(s, C3), 67.7 (s, C5), 23.4 (s, C2), 21.2 (s, Ac), 21.0 (s, Ac), 20.9 (s, Ac), 16.6 (s, C6), 9.4 (s, 
C1). HRMS (ESI+): Calcd for C20H20O6Na [M+Na] +: 283.1152; Found: 283.1158. Specific 
rotation: [a]D27 +38.6 (c = 0.925 CHCl3). 
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2.4 equiv. HSiMe2Et
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Figure 2.12. 1H and 13C{1H} of triol 2.31. 
Preparation of tetraol 2.2  
 
Following general procedure 2.2, 5.0 mg B(C6F5)3, 37.4 mg Et3Si-isosorbide and 0.5 
mL dichloromethane were combined followed by the addition of 35.0 µL of triethylsilane. 
After 1 h, full conversion of starting material by NMR was confirmed and the reaction was 
quenched. Following general procedure 2.3, the substrate was deprotected and subsequently 
O
O
OSiEt3
Et3SiO H
H 10 mol % B(C6F5)32.2 equiv. Et3SiH
CH2Cl2, RT, 1 h;
deprotection;
protection OAc
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general procedure 2.4 was followed to perform acetate protection. Product was purified by 
silica gel chromatography (5 x 1 cm column) using gradient elution (100% hexanes to 20:1 to 
6:1 to 5:1 hexanes:diethyl ether) to afford 2.2 (78% yield, 24.8 mg). Tetraol 2.2:  1H NMR 
(600 MHz, CDCl3): d 5.28 (dd, J = 6.0 Hz, J = 4.8 Hz, 1H, H3 or H4), 5.19 (dd, J = 6.6 Hz, J 
= 4.8 Hz, 1H, H3 or H4), 4.99 (quint, J = 6.6 Hz, 1H, H2 or H5), 4.91 (quint, J = 6.0 Hz, 1H, 
H2 or H5), 2.11 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.23 (d, J = 
6.6 Hz, 3H, H1 or H6), 1.20 (d, J = 6.6 Hz, 3H, H1 or H6). 13C{1H} NMR (151 MHz, CDCl3): 
d 170.4 (s, Ac), 170.22 (s, Ac), 170.19 (s, Ac), 170.1 (s, Ac), 72.2 (s, C3 or C4), 72.0 (s, C3 or 
C4), 68.8 (s, C2 or C5), 67.5 (s, C2 or C5), 21.2 (s, Ac), 21.1 (s, Ac), 20.9 (s, Ac), 20.7 (s, Ac), 
16.4 (s, C1 or C6), 15.6 (s, C1 or C6). HRMS (ESI+): Calcd for C14H22O8Na [M+Na] +: 
341.1207; Found: 341.1214. Specific rotation: [α]D27.3 +26. (c = 0.69 CHCl3). 
Preparation of 1-deoxysorbitan 2.34  
 
 
 
Following general procedure 2.2, 5.0 mg B(C6F5)3, 37.4 mg Et3Si-isosorbide and 0.5 
mL dichloromethane were combined followed by the addition of 18.0 µL of Dimethyl-tert-
butylsilane. After 1 h, full conversion of starting material by NMR was confirmed and the 
reaction was quenched and then immediately transferred to a vial with CH2Cl2 (3 x 1 mL), and 
concentrated under vacuum. The mixture was loaded onto an alumina plug (neutral, 10% H2O; 
2 x 1 cm) with 100% hexanes then 95:5 hexanes:diethyl ether eluting with 95:5 hexanes:diethyl 
ether. Sample was dissolved into methanol along with a stir bar and PPTS-resin was added to 
perform silyl deprotection. Product was purified by silica gel chromatography (5 x 1 cm 
O
O
OSiEt3
Et3SiO
H
H
10 mol % B(C6F5)3
1.1 equiv. Me2tBuSiH
CH2Cl2, RT, 12 h;
20 mol % PPTS
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column) using gradient elution (90% hexanes to 85% to 75% hexanes:ethyl acetate) to afford 
2.34 (76% yield, 19.9 mg). 1-deoxysorbitan 2.34: 1H NMR (600 MHz, CD3OD): δ 4.41 (dd, 
JH4,H3 = 7.5 Hz, JH4,H5 = 5.3 Hz, 1H, H4), 4.07 (ddd, JH5,H4 = 5.5 Hz, JH5,H6’ = 3.9 Hz, JH5,H6 = 
1.9 Hz, 1H, H5), 3.97 (qd, JH2,H1 = 6.6 Hz, JH2,H3 = 2.7 Hz, 1H, H2), 3.92 (dd, JH6,H6’ = 10.1 Hz, 
JH6,H5 = 1.9 Hz, 1H, H6), 3.78 (dd, JH6’,H6 = 10.1 Hz, JH6’,H5 = 3.9 Hz, 1H, H6’), 3.71 (dd, JH3,H4 
= 7.5 Hz, JH3,H2 = 2.7 Hz, 1H, H3), 1.25 (d, JH1,H2 = 6.6 Hz, 3H, H1), 0.93 (s, 9H, -
SiC(CH3)3(CH3)2), 0.15 (s, 3H, -SiC(CH3)3(CH3)2), 0.14 (s, 3H, -SiC(CH3)3(CH3)3). 13C{1H} 
NMR (151 MHz, CDCl3): δ 82.2 (s, C3), 73.9 (s, C4), 72.8 (s, C5), 71.5 (s, C6), 65.5 (s, C2), 
25.8 (s, -SiC(CH3)3(CH3)2), 19.6 (s, C1), 18.1 (s, -SiC(CH3)3(CH3)2), -4.8 (s, -
SiC(CH3)3(CH3)2), -5.1 (s, -SiC(CH3)3(CH3)2). HRMS (ESI+): Calcd for C12H26O4Si [M+H]+: 
263.1673; Found: 263.1672. Specific rotation: [α]D26.3 + 4.48 (c = 0.550 MeOH). 
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Figure 2.13. 1H and 13C{1H} of 1-deoxysorbitan 2.34. 
Preparation of 4-deoxysorbitan 2.35  
 
 
Following general procedure 2.2, 5.0 mg B(C6F5)3, 14.6 mg isomannide, 57.0 mg 
triphenylsilane, and 0.5 mL dichloromethane were combined. After 1 h, 17.2 µL 
dimethylethylsilane was added at –10 ºC under nitrogen outside of the glovebox. After 36 the 
reaction was quenched. Following general procedure 2.3, deprotection was performed. The 
free alcohol of the product along with unconverted starting material was purified by silica gel 
chromatography (5 x 1 cm column) with gradient elution (20:1 to 15:1 to 10:1 
dichloromethane/methanol; in 10:1 dichloromethane/methanol isomannide rf = 0.4, product 
rf = 0.2). This procedure was repeated a second time on the recovered starting material to 
increase yield and conversion. The two isolated samples were combined and protected 
following general procedure 2.4. The product was purified by silica gel chromatography (5 x 
1 cm column) with gradient elution (5:1 to 2:1 to 1:1 hexane/diethyl ether gradient) to give 
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the acetate protected 2.35 (71 % yield, 19.5 mg). 4-deoxysorbitan 2.35: 1H NMR (600 MHz, 
CDCl3): δ 5.26 (m, 1H, H3), 5.16 (ddd, JH2,H3 = 7.1 Hz, JH2,H1 =  6.0 Hz, J H2,H1’ = 2.7 Hz, 1H, 
H2), 4.50 (dd, JH1’,H1 = 12.2 Hz, JH1’,H2 = 2.7 Hz, 1H, H1’), 4.15 (dd, JH1,H1’ = 12.2 Hz, JH1,H2 = 
6.0 Hz, 1H, H1), 4.09 (m, 1H, H5), 3.99 (m, 1H, H6’), 3.85 (dd, JH6,H6’ = 10.6 Hz, JH6,H5 = 4.5 
Hz, 1H, H6), 2.35 (m, 1H, H4), 2.09 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.07 (s, 3H, Ac), 1.93 (m, 
1H, H4). 13C{1H} NMR (151 MHz, CDCl3): δ 170.8 (s, Ac), 170.7 (s, Ac), 170.1 (s, Ac), 
76.5 (s, C5), 74.3 (s, C3), 73.4 (s, C6), 72.4 (s, C2), 62.8 (s, C1), 34.5 (s, C4), 21.1 (s, Ac), 21.0 
(s, Ac), 20.8 (s, Ac). HRMS (ESI+): Calcd for C12H18O7Na [M+Na]+: 297.0945; Found: 
297.0950. Specific rotation: [α]D26.3 + 3.5 (c = 0.70 CHCl3). 
 
Figure 2.14. 1H and 13C{1H} of 4-deoxysorbitan 2.35. 
Preparation of 3,4-deoxytetraol 2.36  
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Following general procedure 2.2, 5.0 mg B(C6F5)3, 14.6 mg isomannide, 57.0 mg 
triphenylsilane, and 0.5 mL dichloromethane were combined. After 1 h, 33.1 µL 
dimethylethylsilane was added at 0 ºC under nitrogen outside of the glovebox. After 12 h, the 
reaction was quenched. Following general procedure 2.3, the substrate was deprotected and 
subsequently general procedure 2.4 was followed to perform acetate protection. Product was 
purified by silica gel chromatography (5 x 1 cm column) using gradient elution (5:1 to 3:1 to 
1:1 hexanes:diethyl ether) to afford 2.36 (65% yield, 21.0 mg). Tetraol 2.36:  1H NMR (600 
MHz, CDCl3): δ 5.11–5.04 (m, 2H, H5), 4.21 (m, 2H, H1 & H6), 4.03 (m, 2H, H1’ & H6’), 2.07 
(s, 6H, Ac), 2.06 (s, 6H, Ac), 1.70–1.59 (m, 4H, H3 & H4). 13C{1H} NMR (151 MHz, 
CDCl3): δ 170.7 (s, Ac), 170.5 (s, Ac), 70.9 (s, C2 & C5), 64.7 (s, C1 & C6), 26.4 (s, C3 & C4), 
21.0 (s, Ac), 20.8 (s, Ac). HRMS (ESI+): Calcd for C14H22O8Na [M+Na]+: 341.1207; Found: 
341.1215. Specific rotation: [α]D26.3 + 4.5 (c = 0.20 CHCl3).   
 
O
O
OH
HO
H
H
10 mol % B(C6F5)3
2.2 equiv. Ph3SiH
CH2Cl2, RT, 1 h;
AcO
OAc
OAc
OAc
2.36
2.5 equiv. Me2EtSiH
 0 ºC → RT, 12 h;
deprotection;
protection
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Figure 2.15. 1H and 13C{1H} of tetraol 2.36. 
Preparation of iso-3,4-deoxytetraol 2.37  
 
Following general procedure 2.2, 5.0 mg B(C6F5)3, 14.6 mg isomannide, 161 mg 
triphenylsilane, and 0.5 mL dichloromethane were combined. Placed in a 35 °C oil bath. After 
12 h, the reaction was quenched. Following genearl procedure 2.3, the substrate was 
deprotected and subsequently acetonide protection was carried out with 1.3 mL acetone, 150 
mg copper(II)sulfate, two drops of acetic acid, and 100 µL of dichloromethane.  Quenched 
with saturated NaHCO3 solution and collected organic layers which were passed through a 
column of magnesium sulfate and the solvent was removed under vacuum. The product was 
separated from by-products by silica gel chromatography (5 x 1 cm) using gradient elution 
(100% hexanes to 90:10 hexane/ethyl acetate). Deprotection following general procedure 2.3 
was carried out and the product was purified by silica gel chromatography (5 x 1 cm column) 
with gradient elution (10:1 to 7:1 CH2Cl2/methanol) to give 2.37 (62%, 9.3 mg). Tetraol 2.37: 
O
O
OH
HO
H
H
10 mol % B(C6F5)3
6.2 equiv. Ph3SiH OH
HO
OH
OH
2.37
CH2Cl2, RT, 1 h
then 35 ºC, 12 h;
deprotection
 54 
1H NMR (600 MHz, CD3OD) δ 3.71 (m, 1H, H2), 3.65–3.53 (m, 4H, H5 & H6), 3.50–3.42 (m, 
2H, H1), 1.87 (m, 1H, H4), 1.56 (m, 1H, H3), 1.39–1.31 (m, 1H, H3’). 13C{1H} NMR (151 MHz, 
CD3OD) δ 71.4 (s, C2), 67.8 (s, C1), 64.6 (s, C5 or C6), 63.5 (s, C5 or C6), 41.5 (s, C4), 33.5 (s, 
C3). HRMS (ESI+): Calcd for C6H14O4Na [M+Na]+ : 173.0787; Found: 173.0784. Specific 
rotation: [α]D26.3 –15.5 (c = 0.30 MeOH).   
 
 
Figure 2.16. 1H and 13C{1H} of tetraol 2.37. 
Mosher ester preparation and analysis of 2.35 
 
 
Following general procedure 2.6 prepared both the S (2.35’) and R (2.35’’) Mosher 
ester derivative of 1-deoxysorbian 2.35. (S)-1-deoxysobitan Mosher ester 2.35’: 1H NMR 
O
OSitBuMe2
HO
OHH 3.1 equiv. Mosher acid
3.1 equiv. DCC
3.1 equiv. DMAP
O
OSitBuMe2
PO
OPH
P = 2.35’ (S) or 2.35’’ (R)-Mosher ester
CH2Cl2, RT, 24 h
2.35
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(600 MHz, CDCl3) δ 7.65–7.55 (m, 4H, Mosher ester Ph), 7.43–7.35 (m, 6H, Mosher ester 
Ph), 5.47–5.40 (m, 2H, H2 & H5), 4.44 (dd, JH4, H3 = 6.3 Hz, JH4, H5 = 5.2 Hz, 1H, H4), 4.23 
(dd, JH6,H6’ = 10.9 Hz, JH6,H5 = 5.7 Hz, 1H, H6), 3.98 (dd, JH6’,H6 = 10.9 Hz, JH6’,H5 = 2.8 Hz, 
1H, H6’), 3.84 (dd, JH3,H2 = 9.8 Hz, JH3, H4 = 6.3 Hz, 1H, H3), 3.60 (s, 6H, Mosher ester OMe), 
1.14 (d, JH1,H2 = 6.3 Hz, 3H, H1), 0.86 (s, 9H, -SiC(CH3)3(CH3)2), 0.03 (s, 3H, -
SiC(CH3)3(CH3)2), -0.02 (s, 3H, -SiC(CH3)3(CH3)2). 13C{1H} NMR (151 MHz, CDCl3) δ 
166.3 (s, Mosher ester carbonyl), 165.5 (s, Mosher ester carbonyl), 132.8 (s, Mosher ester 
Ph), 131.9 (s, Mosher ester Ph), 129.6 (s, Mosher ester Ph), 129.4 (s, Mosher ester Ph), 128.5 
(s, Mosher ester Ph), 128.2 (s, Mosher ester Ph), 127.4 (s, Mosher ester Ph), 127.3 (s, Mosher 
ester Ph), 80.2 (s, C3), 74.8 (s, C5), 73.1 (s, C4), 71.8 (s, C2), 69.9 (s, C6), 55.5 (s, Mosher 
ester OMe), 25.8 (s, -SiC(CH3)3(CH3)2), 18.4 (s, -SiC(CH3)3(CH3)2), 16.7 (s, C1), -5.2 (s, -
SiC(CH3)3(CH3)2), -5.4 (s, -SiC(CH3)3(CH3)2). (R)-1-deoxysobitan Mosher ester 2.35’’: 1H 
NMR (600 MHz, CDCl3) δ 7.65–7.54 (m, 5H, Mosher acid Ph), 7.44–7.35 (m, 5H, Mosher 
acid Ph), 5.50–5.40 (m, 2H, H2 & H5), 4.48 (dd, JH4,H3 = 6.5 Hz, JH4,H5 = 5.3 Hz, 1H, H4), 4.20 
(dd, JH6,H6’ = 11.1 Hz, JH6,5 = 5.7 Hz, 1H, H6), 3.89 (dd, JH6’,H6 = 11.1 Hz, JH6’,H6 = 2.4 Hz, 
1H, H6’), 3.82 (dd, JH3,H2 = 9.8 Hz, JH3,H4 = 6.5 Hz, 1H, H3), 3.60 (s, J = 1.2 Hz, 3H, Mosher 
OMe), 3.55 (s, J = 1.1 Hz, 3H, Mosher OMe), 1.33 (d, JH1,H2 = 6.3 Hz, 3H, H1), 0.91 (s, 9H, -
SiC(CH3)3(CH3)2), 0.17 (s, 3H, -SiC(CH3)3(CH3)2), 0.11 (s, 3H, -SiC(CH3)3(CH3)2). 13C{1H} 
NMR (151 MHz, CDCl3) δ 165.3 (s, Mosher ester carbonyl), 129.6 (s, Mosher ester Ph), 
129.4 (s, Mosher ester Ph), 128.5 (s, Mosher ester Ph), 128.1 (s, Mosher ester Ph), 127.7 (s, 
Mosher ester Ph), 127.5 (s, Mosher ester Ph), 80.0 (s, C3), 74.8 (s, C5), 73.4 (s, C4), 71.7 (s, 
C2), 69.8 (s, C6), 25.8 -SiC(CH3)3(CH3)2, 18.5 (s, C1), 17.0 (s, -SiC(CH3)3(CH3)2), -5.1 (s, -
SiC(CH3)3(CH3)2), -5.2 (s, -SiC(CH3)3(CH3)2). 
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Figure 2.17. 1H and 13C{1H} of S-2.35’. 
 
 
 
Figure 2.18. 1H and 13C{1H} of R-2.35’. 
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Analysis was performed following a reported general procedure for determining 
stereochemistry at C2 and C5 for 1-deoxysorbitan (2.35). 
 
      ∆δSR (= δS-δR) 
  
δ S-ester 
(ppm) 
 δ R-ester 
(ppm) ∆ppm Hz (600 MHz) 
1 1.14 1.00 -0.16 -96 
4 4.44 4.48 -0.04 -24 
6' 4.23 4.20 0.03 18 
3 3.84 3.79 0.05 30 
6 3.98 3.89 0.09 54 
 
The stereochemistry at C2 and C5 was assigned by placing the positive ΔδSR substituents 
in the location of R1 and the negative ΔδSR substituents in R2 according to previously described 
methods. Standard Cahn-Ingold assignments were then applied to determine the carbinol 
stereochemistry at C2 and C5. 
Assignment of relative stereochemistry of tetra- and triol products 
Comparison of observed coupling constants for prepared tetra- and triols to values 
previously reported. 
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Coupling constants of tetraol 2.12 (from iditol) were not determined due to the 
complexity of the ---AA'MM'XX' spin system and tetraol 2.16 (from allitol) was assigned 
based on correlation to previously published reports. 
Tetraols:
OH
OH
OHH
H
H
7.8 Hz OHH
OH
OH
OHH
H
H
7.0 Hz OHH
7.0 Hz
OH
OH
OHH
H
H
0 Hz OHH
0 Hz
Tetraol 2.8 from galactitol (2.6)
Tetraol 2.2 from sorbitol (2.1)
Tetraol 2.5 from mannitol (2.4)
OH
OH
OHH
H
H
7.5 Hz OHH
1.5 Hz
HO
anti, syn, syn tetraol from Kishi et al.
OH
OH
OHH
H
H
8.0 Hz OHH
8.0 Hz
HO
anti, syn, anti tetraol from Kishi et al.
OH
OH
OHH
H
H
0 Hz OH
H
0 Hz
HO
syn, anti, syn, tetraol from Kishi et al.
1.9 Hz
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HO
OH
OH
OHH
H
H
7.0 Hz
7.0 Hz
OH
OH
OHH
H
H
Triol 2.7 from galactitol (2.6) anti, anti triol from Kishi et al.
Triol 2.6 from 
1,2-deoxy galactose (2.30)
OH
OH
OHH
H
H
2.7 Hz
7.5 Hz
OH
OH
OHH
H
H
2.5 Hz
8.0 Hz
syn, anti triol from Kishi et al.
HO
Triols:
Triol 2.3 from sorbitol (2.1)
OH
OH
OHH
H
H
7.4 Hz
2.5 Hz
Triol 2.3 from mannitol (2.4)
OH
OH
OHH
H
H
 7.4 Hz
2.5 Hz
5.9 Hz
7.4 Hz
OH
OH
OHH
H
H
2.5 Hz
7.3 Hz
Triol 2.4 from iditol (2.11)
HO
OH
OH
OHH
H
H
8.0 Hz
2.5 Hz
anti, syn triol from Kishi et al.
HO
OH
OH
OHH
H
H
8.0 Hz
2.5 Hz
anti, syn triol from Kishi et al.
HO
OH
OH
OHH
H
H
8.0 Hz
2.5 Hz
anti, syn triol from Kishi et al.
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3. Chapter 3: Orchestrating multiple roles of B(C6F5)3 
This chapter is adapted with permission from Bender, T. A.; Dabrowski, J. A.; Gagné, 
M. R. ACS Catal. 2016, 6, 8399-8403. Copyright © 2016 American Chemical Society. 
This chapter resulted from a collaboration with Dr. Jennifer Dabrowski.
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3.1. Synthesis of chiral synthons containing a secondary functional group 
Previously, we demonstrated that chemoselective reduction of silane protected linear 
and cyclic carbohydrates was possible in a single step utilizing catalytic B(C6F5)3 and 
stoichiometric trialkyl silane (R3SiH). The reactivity trend followed that 1º C–O bond 
reduction was most facile, followed by reduction of 2º C–O bonds when combined with 
anchimeric assistance. The novel C6On products that resulted from this protocol are 
potentially valuable. To further facilitate the utilization of complex chiral synthons derived 
from carbohydrate sources, a common functional group that is easily manipulated with 
current synthetic strategies would be a great step forward in demonstrating applicability as 
functional group handle would allow for more rapid integration of these highly complex 
synthons into current synthetic routes. Chapter 3 discusses the progress our lab has made 
towards selectively cleaving secondary allylic C–O bonds in carbohydrate derived materials 
along with mechanistic insights into the multiple roles that B(C6F5)3 has in catalysis allowing 
for the tremendous degree of control one can achieve with a single catalytic species. 
3.2. Selective reduction of glucal to prepare Z-triols 
 
Reactivity of the commercially available carbohydrate derivative glucal (3.1) was 
initially investigated to answer whether we could perform selective reduction of poly-
oxygenated materials with a point of unsaturation. Initial reduction of the allylic C3-OSiR3 
was expected based on stoichiometric Lewis acid hydrosilylation background and the ability 
to form a highly-stabilized vinyl oxocarbenium intermediate (3.2).68 This would yield a 
proposed 2,3-unstaturated glycal (3.3) which would have two possible reduction pathways, 
(1) reduction at C1 following reactivity analogous to that disclosed by Njardason (blue 
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reaction arrow) to yield a linear allylic triol such as 3.4 or (2) reduction at C4 (red reaction 
pathway).28  
 
Scheme 3.1. Potential selective outcomes of glucal hydrosilylation. 
 By combining 3.5 equiv. of Et3SiH and 10 mol % B(C6F5)3 glucal 3.1 was selectively 
converted to the anti-Z-Si3-triol 3.4 following the first reaction trajectory (bold blue 
pathway). Interestingly, the product that resulted contained a single SiMe3 group and two 
SiEt3 groups. Treating 3.4 with PPTS/dichloromethane selectively removed the more labile 
SiMe3 group and revealed the differentially protected anti-Z-triol 3.5 in high yield (82%, 
Table 3.1). Me3Si-Galactal 3.6 (C4 epimer or glucal) could also be used, but with reduced Z-
selective, to yield 3.7 (Table 3.1, entry 2) and Me3Si-ribal 3.8 reacts analogously to the C6 
unsaturated sugars to selectively furnish 3.9 along with silyl group exchange at the 1º position 
(entry 3, Table 3.1). Global deprotection gives the Z-diol 3.10 in synthetically useful yields. 
To increase Z selectivity from galactal, bicycle Me2tBuSi-galactal 3.11 was investigated and 
this protecting group modification yields exclusively 3.12 as the syn-Z-Si3-triol.69 This could 
be selectively deprotected to expose a free secondary alcohol (3.13). Interestingly when no 
C5 substitution is present, Me3Si-arabinal 3.14, exclusive reduction of the 1º ethereal C–O 
bond is observed to compete with allylic bond reduction and at reduced temperatures (–30 ºC) 
yields differentially protected anti-Z-silylenolether-Si2-diol 3.15 exclusively.70–72 At room 
temperature, the reaction yields a mixture of 3.15 Z-Me3Si-monol. Deprotection followed by 
(C6F5)3B
B(C6F5)3H
O
OSi
OSi
R3SiO
OSiR3
H SiR3O
OSiR3
R3SiO
OSiR3
O
R3SiO
OSiR3
3.1 3.2
O
R3SiO
OSiR3
3.3
"H  " 3.4
3
1
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acetate protection yields the differentially protected product 3.16 in synthetically useful yields 
(Tablel 3.1, entry 5).  
Table 3.1. Scope of selective glycal reductions 
 
 
  Mechanistically, the outcomes from Table 3.1 are consistent with the previously 
described reactivity for C–O bond hydrosilylation using B(C6F5)3. Specifically, as shown in 
Figure 3.1, activation of the allylic C3 by silylium (3.1’) with subsequent reduction at C1 to 
yield 3.18 is consistent with reactivity trends. The subsequent reduction to perform ring 
opening of 3.18 to 3.19 (via 3.18’) demonstrated that the most nucleophilic site is the ring 
O
OSiMe3
Me3SiO
OSiMe33.1 glucal
1
23
4
5
6
Me3SiO
OSiEt3
3.4
Et3SiO
HO
OSiEt3
3.5
Et3SiO
25 20
>98% Z, 88% yield >98% Z, 82% yield
O
OSiMe3
Me3SiO
OSiMe33.6 galactal
4
HO
OH
3.7
HO-45 83% Z
62 % yield
O
Me3SiO
OSiMe3
3.8 ribal
-30 14
Et3SiO
Et3SiO3.9
>98% Z, 69% yield
HO
HO3.10
>98% Z, 62% yield
Entry Substrate temp 
(°C)
time
(h)
Product
1
2
3
10 mol% B(C6F5)3
3.5 equiv Et3SiH
CH2Cl2
O
SiO
OSi
n
SiO
n = 0 or 1
Si = SiMe3
polyol
45
O
O
t-Bu2Si O
OH3.11 galactal
4
–10 14 O
Si
t-Bu2
O
OSiEt3
>98% Z, 86% yield
3.12
O
Si
t-Bu2
O
OH
3.13
O
Me3SiO
OSiMe3
3.14 arabinal
5
-30 16
Me3SiO OSiEt3
OSiMe3
3.15
>98% Z, 71% yield
AcO OSiEt3
OAc
>98% Z, 50% yield
3.16
 64 
ether as compared to the secondary allylic C–OSiR3 at C4. Interestingly, reduction of glucal 
3.1 under limited silane (1.5 equiv. Et3SiH) conditions results in a mixture of ring opened 
product 3.19 and starting material, indicating that the reduction of 3.18 to 3.19, is more rapid 
than oxo-allyl-cation stabilized conversion of 3.1 to 3.18.  
 
Figure 3.1. B(C6F5)3 performs numerous catalytic modifications upon conversion of glucal to anti-Z-
Si3-triol. 
What was not expected initially was the observations made while performing 
reductions of glucal and ribal which revealed a new role for the B(C6F5)3/H–SiR3 
combination. The conversion of 3.19 à 3.20 shows that B(C6F5)3 can mediate a 
chemoselective silyl group exchange at O6 (or O5 when starting from ribal 3.8). It appears 
likely that the exchange occurs by initial formation of Et3Si-substituted 3.19 from reduction 
of (3.18), followed by a pseudo-degenerate silyl-exchange mediated by di-sila-oxonium 
3.19’, which loses the more labile SiMe3 group. We have noted silyl exchange processes in 
previous efforts, but this substrate class is the first to display selective exchange reactivity. 
B(C6F5)3
silane
activator
B(C6F5)3R3Si H
O
OSi
SiO
SiO
selective 
allylic 
reduction
SiR3
O
SiO
SiO
SiO
H-B(C6F5)3
O
SiO
SiO
B(C6F5)3
+  SiOSiR3
O
SiO
OSi
selective ring 
opening
SiR3
reducing 
agent
O
SiO
SiO
SiR3
selective 
silyl 
incorporation
B(C6F5)3
HSiR3
H-B(C6F5)3
O
SiO
O
SiR3
R3Si
H-B(C6F5)3
silyl group 
exchange 
mediator
selective silyl 
exchange
at 1º position
O
SiO
O
SiR3
R3Si
3.1
3.1’
3.18
3.18’
3.19
3.19’
3.20
R3SiH
HSiR3
HSiMe3 (g)  +
Si = SiMe3
Si
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Under the conditions developed here, the exchange can be harnessed to gain access to 
otherwise difficult to form selectively protected synthons.  
3.3. Selective reduction of styryl-carbohydrates 
 
A second intriguing class of unsaturated sugars are those derived from direct Wittig 
olefination onto a reducing sugar. As a result of the inherent basicity of Wittig reagents, only 
stabilized Wittig’s are amenable to performing olefination on sugars. This led us to first 
prepare the crystalline E-styryl functionalized derivative of galactose which was per-TMS-
protected (3.21) and used for exploratory studies.73 Reduction of the allylic C–O bond was 
the dominant outcome only when the Lewis acid was added first (1 h), followed by the 
reducing silane (Et3SiH, 15 min, Scheme 3.2). Under these conditions C3 reduction is 
accompanied by alkene migration to generate a new allylic silyl ether (~9:1, E-2,3 (3.22) vs. 
E-1,2 unsaturation), the minor product being the C3 reduced styrene isomer (entry 1, Table 
3.2). Notably, SN2 reduction of the 1º silyl ether at C7 is not observed. However, when the 
hydrogenated derivative of 3.21 (no allylic alcohol) was subjected to the same conditions, 
exclusive 1º silyl ether cleavage was observed. As described in our original hypothesis for 
examining unsaturated biomass derivatives, it was tempting to ascribe these products to 
enhanced reactivity of the allylic (C3) silyl ether facilitated by the availability of the SN2’ and 
SN2 reduction mechanisms.  
 
Scheme 3.2. Selective condensative cyclization of styryl-galactose to a cyclic intermediate that is 
selectively reduced to yield an allylic tetraol. 
SiO
OSi
SiO
OSi
SiO OH Ph
OH
OH
OH
3.21 galacto-(>98% E)
Si = SiMe3
Ph
10 mol% B(C6F5)3
O Ph
OSi
OSi
SiO 1.1 equiv. Et3SiH15 min, RT;
deprotection3.23  93% yield 
64:36 d.r.
10 mol% B(C6F5)3
CH2Cl2
RT, 1 h
3.22
7 3
2
1
1
2
37 12
3
7
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The unusual sensitivity of the reaction to the sequence of Lewis acid/silane addition, 
however, suggested the possibility of an alternative mechanism. An understanding of this 
dependence on mixing order became apparent on treating 3.21 with 10 mol% B(C6F5)3, 
which quickly catalyzes its conversion to a mixture of C3 diastereomers (64:36) of the styryl 
C-glycoside (3.23, 93%). The conversion can be monitored by 1H and 13C{1H} NMR 
analysis and it was found that an hour is optimal for 3.21; subsequent time results in 
decomposition of product. Consistent with the viability of 3.23 in the reduction of 3.21, 
resubjecting it to catalytic B(C6F5)3/Et3SiH conditions generated 3.22 in the ratio (90:10) 
observed when the reduction was carried out in a single step. 
 Similar reactivity was observed for the gluco- and manno- analogs (entries 2 & 3, 
Table 3.2). In the case of the gluco-3.24, the B(C6F5)3 catalyzed precyclization is sluggish (7 
h) which we attribute to the stereochemical array (i.e. axial orientation) of the resulting styryl 
C-glycoside. All three carbohydrate isomers converge to the E-allyl benzene migration 
products with good selectivity (entries 1-3) regardless of their starting E/Z mixtures. Steric 
(o-iodo-styryl-galactose) and electronic influences (p-Me-styryl-galactose) on the aromatic 
ring were also investigated, but demonstrated negligible influence on hydride reduction 
selectivity (90:10 in most cases). The C5-sugars were found to react similarly, though 
B(C6F5)3 pre-treatment led to furan intermediates where mixtures of diastereomers were also 
observed.74 Addition of Et3SiH to these solutions maintained a preference for SN2’ reduction 
by a margin of ~3:1 (entries 5-7, Table 3.2). The fucose-derived C6-starting material (3.28), 
which lacks a C7-OSi group, and is therefore forced to ring close to a furan, is also reduced 
with a ~3:1 preference for alkene migration (3.29, entry 4 Table 3.2). Reducing the 
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temperature and adding B(C6F5)3 and Et3SiH together to 3.32 improved the SN2’ selectivity 
to 91:9 for syn- triol 3.33, though the role of pre-cyclization is not clear in this case. 
Table 3.2. Styryl-carbohydrate allylic C–O bond activiation. 
 
 
Inspection of models for the reduction of the B(C6F5)3 generated cyclic intermediates 
was informative. The lack of primary reduction (at C7) suggests that the adjacent equatorially 
Me3Si-sugar
Ph
styryl 
carbohydrates
1) 10 mol % B(C6F5)3
CH2Cl2, RT,1 h;
1.1 equiv. Et3SiH, 15 min
2) Dowex, MeOH, 3 h
products
Entry Substrate [E/Z] SN2':SN2 Major Product
OSi
OSi
OSi
OSi
OSi
90:10
OH
Ph
OH
OH
OH
OSi
OSi
OSi
OSiH3
OSi OH
Ph
OH
OH
OH
OSi
OSi
OSi
OSi
OSi OH
Ph
OH
OH
OH
89:11 86
3.21 galacto- (>98% E)
3.24 gluco- (67:33 E/Z)
3.26 manno- (33:67 E/Z)
91
OSi
OSi
OSi
OSi
OH
OH
OH
3.30 ribo- (55:45 E/Z)
Ph
OSi
OSi
OSi
OSi
OH
OH
OH
3.32 xylo- (71:29 E/Z)
Ph
Ph1
Ph
Ph
2
3
94:6
88
Ph
4
8774:26
Ph 8675:25
(91:9 at –35 ºC)
5
7 7275:25
6
3.34 lyxo- (48:52 E/Z)
OSi
OSi
OSi
OSi
Ph
Yield [%]
OSi
OSi
OSi
OSi
Me
Ph
OH
OH
OH
3.28 fuco- (>98% E)
Ph 8769:31
7
1
23
3.22
3.25
3.27
3.29
3.31
1
2
3
6
1
2
3
1
2
36
3.33
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disposed C6 OSi group, which is the same for all investigated styryl carbohydrates, hinders 
this reduction trajectory relative to those that preferentially add by SN2 (C3) and SN2’ (C1) 
mechanisms. The greater accessibility of the C1 position presumably enhances the SN2’ 
selectivity, regardless of the C3 stereochemistry. A similar model for the furanose-derived 
sugar intermediates is suggested (Figure 3.2).  
 
Figure 3.2. Observed hydride reduction preferences. 
 
 Further highlighting the role of cyclic intermediates as determinants of reduction 
selectivity, the singly reduced galacto-derived 3.35 could be deoxygenated a second time by 
sequentially treating with B(C6F5)3 and Et3SiH to yield the syn-allylic triol 3.36 (Scheme 
3.3). Under these conditions the alkene migration pathway remains favored (71:29).  The 
THF-analogue 3.37 is obtained in the absence of silane (>98:2 d.r., 85% yield) as a single 
major diastereomer. The high diastereoselectively for this ring closure may indicate a switch 
from a SN1 type reaction when a benzyl stabilized allylic carbocation can be generated from 
activating styryl substrates to an exclusive SN2 cyclization when only allylic stabilization is 
present in 3.35.75,76 Subjecting 3.37 to hydrosilylation conditions results in selective allylic 
bond reduction with the same alkene migration selectivity. Once triol 3.36 is obtained no 
further reduction occurs under these mild reaction conditions. This lack of reactivity is 
presumably a result of no available cyclic intermediate to facilitate reduction as we have 
never seen evidence for oxetane or oxirane ring formation. 
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Scheme 3.3. Selective cyclization and reduction of galactose derived allylic tetraol. 
 
As illustrated in Figure 3.3, the B(C6F5)3 catalyst serves three distinct roles in the 
conversion of styryl-3.21 to 3.22: 1) a Lewis acid activator of the allylic C–O bond (3.21’) to 
generate 3.23, 2) an activator of the Si–H bond (via the h1-silane adduct) to generate 3.23’, 
and 3) as the terminal reductant [H–B(C6F5)3–] to produce 3.22. Orchestrating these distinct 
steps enables a selective reduction of a single C–O bond, accompanied by (predominant) 
allylic transposition.  
 
 
Figure 3.3. Multiple catalytic roles of B(C6F5)3 in the selective reduction of styryl-carbohydrates. 
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 From these investigations, we discovered how B(C6F5)3 serves many catalytic roles 
that when productively sequenced, can provide unique reaction pathways for the 
deoxygenation of complex polyol systems. These reactivities include: 1) In acyclic polyols, it 
acts as a traditional oxophilic Lewis acid to catalyze heterocyclizations via allylic silylether 
activation. 2) When non-silylated ethers are present, [B(C6F5)3–H–] [+SiR3] selectively 
activates these more basic ethers over silylethers, and enables selective allylic reduction. 3) 
Silyl group exchange can be competitive with C–O bond reduction and we have shown that 
this leads to products with easily differentiated alcohol functional groups for further 
manipulation  
3.4. Experimental Section 
 
Unless otherwise stated, all reactions were conducted under a nitrogen atmosphere 
using a Vacuum Atmospheres glovebox. “Dowex® resin” refers to Dowex® 50W-X8, a 
strongly acidic cation exchange resin distributed by Baker Chemical Company. PPTS resin 
refers to pyridinium p-toluene sulfonate polymer-bound with extent of labeling 3.5 mmol/g 
toluene for sulfonate loading and was purchased from Aldrich. Before use both resins were 
washed five times with methanol and five times with methylene chloride and then allowed to 
dry at ambient pressure. All workup procedures were performed under air with reagent grade 
reagents unless otherwise specified. Alumina refers to Brockmann activity I neutral alumina 
gel (Aldrich) that was treated with 10% deionzed water. Thin layer chromatography (TLC) 
was performed on SiliCycle Silica Gel 60 F254 plates and was visualized with UV light, 
cerium ammonium molybdate (CAM) stain, or potassium permanganate (KMnO4) stain. 
Methylene chloride-d2 was purchased from Cambridge Isotope labs. Both CD2Cl2 and 
CH2Cl2 were degassed via three freeze-pump-thaw cycles, and dried over 4Å molecular 
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sieves prior to use. D-glucal, D-galactal, and thymide were purchased from ChemImpex and 
used as received. D-galactose, D-mannose, D-glucose, D-ribose were purchased from Sigma-
Aldrich and used as received. D-xylose, D-lyxose, L-fucose, and 3,4-Di-O-acetyl-L-arabinal 
were purchase from Carbosynth and used as received. Me2EtSiH, Et3SiH, and i-Pr3SiH 
ampules were purchased from Sigma-Aldrich and stored over molecular 4Å sieves in the 
glovebox. Dioxane (anhydrous, 99%), pyridine (anhydrous, 99%), sodium methoxide, 
pyridinium-para-toluenesulfonate (PPTS), benzyltriphenylphosphonium chloride, potassium 
tert-butoxide, di-tert-butylsilyl bis(trifluoromethanesulfonate), dichloromethane, 
triethylamine, trimethylsilylchloride, and copper sulfate were purchased from Sigma-Aldrich 
and used as received. Methanol was purchased from Fisher and used as received. 
Tris(pentafluorophenyl)borane (B(C6F5)3) was purchased from Strem and used as received. 
Room-temperature NMR spectra were recorded using a Bruker Avance III 
spectrometer equipped with a cryoprobe operating at 600 MHz (1H) and 150 MHz (13C). 
NMR chemical shifts are reported in ppm and referenced using the residual proton peaks (d 
CHCl3 = 7.26, d CH2Cl2 = 5.32), 13C resonances of the deuterated solvent (d CDCl3 = 77.16, 
d CD2Cl2 = 53.84) or the proteo solvent (d CH2Cl2 = 54.24). Low temperature NMR spectra 
were recorded using a Bruker Avance III spectrometer equipped with a BBO probe operating 
at 500 MHz (1H) and 125 MHz (13C). High resolution mass spectra were obtained on either 
an Agilent Accurate LC-TOF Mass Spectrometer (Agilent Series 6220) operating in positive 
ion mode with an electrospray ionization source (fragmentor = 175 V) or with a hybrid LTQ 
FT (ICR 7T) (ThermoFisher, Bremen, Germany) mass spectrometer where samples were 
introduced via a micro-electrospray source at a flow rate of 3 µL/min. The data were 
analyzed using either Agilent MassHunter Workstation Software, Qualitative Analysis (V. 
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B.02.00) or Xcalibur (ThermoFisher, Breman, Germany). Specific rotations were obtained on 
a Jasco DIP-1000 digital polarimeter equipped with a sodium lamp utilizing a 3.5 x 100 mm 
cell. A NesLab cryobath CB-80 was utilized for reduced temperature reactions where 
temperature was verified by low-temperature thermometer. The numbering used for starting 
material and products is based on the parent sugar. 
General procedure 3.1: Wittig olefination of carbohydrates 
All alkenyl substrates were prepared following a modified protocol from a previous 
publication. A flame-dried 500 mL flask with a magnetic stir bar was placed under a flow of 
nitrogen. Benzyltriphenylphosphonium chloride (11.6 g, 30 mmol) followed by potassium 
tert-butoxide was added to the flask. A reflux condenser was attached and anhydrous dioxane 
(120 mL) was added. The reaction was allowed to stirred for 30 minutes at 25 ºC and then 
placed into an 80 ºC oil bath to stir for an additional 30 minutes. The sugar was then added 
under positive nitrogen pressure and the reaction was allowed to reflux for 2 h (the reaction 
went from dark red to yellow over the reaction time). Water (10 mL) was added and the 
reaction was concentrated under vacuum to yield a sticky yellow material. The E-olefin was 
isolated by crystallization from warm methanol. The other products were isolated by silica 
gel chromatography (30 x 5 cm column) using gradient elution (20:1 to 15:1 to 10:1 to 7:1 
CH2Cl2:MeOH) to afford the unprotected alkenyl carbohydrates.  
General procedure 3.2: Silane protection of styryl-carbohydrates 
All silane protected substrates were prepared following a modified protocol to those 
of previous publications. To a 20-mL scintillation vial charged with a magnetic stir bar, 
substrate is added (5.0 mmol, 1.0 equiv.) followed by CH2Cl2 (5.0 mL). To this, pyridine (6.5 
mmol, 1.1 equiv. per –OH group plus 1.0 equiv.) is added followed by the dropwise addition 
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of chlorotrialkylsilane (5.5 equiv., 1.1 equiv. per –OH group). The vial is capped and allowed 
to stir at 25 ºC for 12 h. After the reaction time, deoionized water is added (5.0 mL) and the 
reaction mixture is transferred to a separatory funnel, the reaction vessel is rinsed with 
diethyl ether (3 x 5 mL) and added to the separatory funnel as well. An additional 15 mL of 
diethyl ether was added and the layers separated. The aqueous layer was subsequently 
washed with diethyl ether (2 x 20 mL) and all organic layers combined. In the cases that a 
volatile substrate is being prepared, the organic layers were washed with a 10 % (w/w) of 
CuSO4 solution until the color does not visibly change to remove residual pyridine. The 
organic layers were collected and washed with water (3 x 20 mL), brine (3 x 20 mL), and 
dried over sodium sulfate. Solid was filtered off over a cotton plug and the organic 
concentrated down to yield the final product as either a white solid or colorless oil. 
Trituration with toluene was performed on non-volatile materials to remove pyridine. 
To remove residual pyridine salts the substrate was passed over an alumina column 
(neutral, 10% H2O; 3 x 1 in) using gradient elution (100% to 95:5 hexanes/diethyl ether). 
Fractions containing product were collected and concentrated down. The residue was then 
placed under high vacuum for a minimum of 12 h prior to bringing into the glovebox for use. 
When preparing 3.8 and 3.14 standard freeze-pump-thaw degassing was performed to avoid 
loss of material due to high volatility. All of the materials once degassed are then brought 
into the glovebox and stored in scintillation vials at ambient temperature and used as 
prepared.  
General procedure 3.3: Deoxygenation of cyclic carbohydrate substrates 
 
 In a nitrogen-filled glovebox, a GC vial was charged with B(C6F5)3 (5.2 mg, 0.010 
mmol, 10. mol %), triethysilane (57.0 µL, 0.357 mmol, 3.57 equiv.), and dichloromethane 
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(0.5 mL). A separate 1-dram vial was charged with cyclic carbohydrate (0.100 mmol, 1.00 
equiv.) and a magnetic stir bar. The vials were sealed with a septum cap and removed from 
the glovebox. Both vials were allowed to cool to –30 °C (dry ice/acetone bath) and the silane 
solution was transferred to the substrate vial by syringe under N2. The vial cap was wrapped 
in electrical tape and the vial was transferred to a –30 °C cryobath and allowed to stir. After 
reaction time, NEt3 (0.05 mL) was added by syringe through the septa and the solution was 
allowed to slowly warm to room temperature. The stir bar was removed, rinsing with CH2Cl2 
(0.2 mL) and the quenched reaction mixture was concentrated under vacuum and then loaded 
onto an alumina plug (neutral, 10% H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 95:5 
hexanes:diethyl ether (1.5 mL), eluting with 95:5 hexanes:diethyl ether (10 mL) into a tared 
vial. The solution was concentrated under vacuum to afford a colorless oil. 
General procedure 3.4: deprotection with PPTS 
A vial containing the silyl substrate was equipped with a stir bar and charged with 
PPTS resin (10 mg). Methanol (2.0 mL) was added by syringe and the resulting solution was 
allowed to stir at 25 °C. After 1.25 h, the solution was passed through sand (0.1 cm) to 
remove the PPTS resin into a vial, rinsing with 100% methanol. The solution was 
concentrated to afford a colorless oil. The product was purified by silica gel chromatography 
(5 x 1 cm column) using gradient elution. 
General procedure 3.5: deoxygenation of styryl-carbohydrates 
 In a nitrogen-filled glovebox, a 1-dram vial was charged with B(C6F5)3 (5.1 mg, 
0.010 mmol, 10. mol %) and a magnetic stir bar. Me3Si-styryl-carbohydrate (0.103 mmol, 
1.00 equiv.) was added by pipet and 0.5 mL dichloromethane was added by syringe. The vial 
was sealed with a cap and allowed to stir for 1-7 hours. Triethylsilane (17.7 µL, 0.111 mmol, 
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1.08 equiv.) was added by microliter syringe and the resulting solution was shaken for 30 
seconds, sealed with a septum cap, and removed from the glovebox. After 15 minutes, NEt3 
(0.05 mL) was added by syringe through the septa and the stir bar was removed, rinsing with 
CH2Cl2 (0.2 mL). The quenched reaction mixture was concentrated under vacuum and then 
loaded onto an alumina plug (neutral, 10% H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 
95:5 hexanes:diethyl ether (1.5 mL), eluting with 95:5 hexanes:diethyl ether (10 mL) into a 
tared vial. The solution was concentrated under vacuum to afford a colorless oil as a mixture 
of SN2’:SN2 products. 
General procedure 3.6: deprotection using Dowex resin 
 A vial containing the silyl substrate was equipped with a stir bar and charged with 
Dowex® resin (~10 beads). Methanol (2.0 mL) was added by syringe and the resulting 
solution was allowed to stir at 25 °C. After 2-3 h, the solution was passed through sand (0.1 
cm) to remove the Dowex® beads into a tared vial, rinsing with 100% methanol. Products 
were purified by silica gel chromatography (4 x 1 cm column) using gradient elution.  
 
Me3Si-glucal (3.1): 1H NMR (600 MHz, CDCl3): δ 6.29 (dd, J = 6.0, 
1.6 Hz, 1H), 4.58 (dd, J = 6.1, 2.0 Hz, 1H), 4.21 (app dt, J = 5.5, 1.8 
Hz, 1H), 3.84 (dt, J = 11.2, 1.8 Hz, 1H), 3.81–3.74 (m, 3H), 0.16 (s, 
18H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3) δ 143.6 (s), 
103.3 (s), 79.4 (s), 70.9 (s), 70.7 (s), 61.8 (s), 0.6 (s), 0.5 (s), -0.3 (s). 
 
 
 
Me3Si-galactal (3.6): 1H NMR (600 MHz, CDCl3): δ 6.26 (dd, J = 
6.2, 1.7 Hz, 1H), 4.55 (dd, J = 6.1, 2.0 Hz, 1H), 4.32 (app s, 1H), 3.95 
(dd, J = 3.9, 1.9 Hz, 1H), 3.92 (td, J = 6.4, 1.5 Hz, 1H), 3.83–3.68 (m, 2H), 0.14 (s, 9H), 0.13 
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(18H). 13C{1H} NMR (151 MHz, CDCl3): δ 142.9 (s), 103.4 (s), 78.0 (s), 67.0 (s), 65.3 (s), 
60.9 (s), 0.6 (s), 0.2 (s), -0.5 (s). 
 
 
Me3Si-arabinal (3.14): The title compound was prepared from the 
commercially available acetate protected glycal. Into a 20-mL 
scintillation vial equipped with a magnetic stir bar 3,4-Di-O-acetyl-L-arabinal (0.40 g, 2.0 
mmol, 1.0 equiv.) was added by pipette. Methanol (5.0 mL) was added by syringe followed 
by sodium methoxide (0.22 g, 0.40 mmol, 0.20 equiv.) in one portion. This was allowed to 
stir for 6 hours at room temperature. The solvent was removed under vacuum and the diol 
was isolated by silica gel chromatography (5 x 1 cm column) using gradient elution (100% 
CH2Cl2 to 30:1 to 25:1 to 20:1 to 15:1 to 10:1 CH2Cl2:MeOH) to afford (3S,4R)-3,4-dihydro-
2H-pyran-3,4-diol as a white solid. The solid was then subjected to standard trimethylsilyl 
protection as described above to yield a colorless oil. 1H NMR (600 MHz, CDCl3): δ 6.34 (d, 
J = 5.9 Hz, 1H), 4.78 (t, J = 5.7 Hz, 1H), 4.06–4.01 (m, 1H), 3.91–3.83 (m, 2H), 3.78–3.73 
(m, 1H), 0.16 (s, 9H, -Si(CH3)3), 0.14 (s, 9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): 
δ 145.3 (s, C1), 102.2 (s, C2), 68.0 (s, C3), 64.8 (s, C4), 63.8 (s, C5), 0.5 (s, -Si(CH3)3), 0.05 (s, 
-Si(CH3)3). 
 
Me3Si-styrylgalactose (3.21): 1H NMR (600 MHz, 
CD2Cl2): δ 7.44–7.40 (m, 2H), 7.39–7.34 (m, 2H), 7.31–
7.27 (m, 1H), 6.63 (d, JH1,H2 = 16.0 Hz, 1H, H1), 6.37 (dd, 
JH2,H1 = 16.0 Hz, JH2,H3 =  6.7 Hz, 1H, H2), 4.56 (ddd, JH3,H2 & JH3,H4 = 6.9 Hz, JH3,H1 = 1.3 
Hz, 1H, H3), 3.85 (dd, JH5,H6 = 5.3 Hz, JH5,H4 = 2.9 Hz, 1H, H5), 3.82 (ddd, JH6,H5 = 5.5, JH6,H7 
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& JH6,H7’ = 3.4 Hz, 1H, H6), 3.79–3.76 (m, 2H, H7), 3.69 (dd, JH4,H3 = 7.0 Hz, JH4,H5 = 2.9 Hz, 
1H, H4), 0.20–0.13 (m, 45H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CD2Cl2): δ 137.3 (s, Ph), 
131.1 (s, C2), 130.8 (s, C1), 128.5 (s, Ph), 127.3 (s, Ph), 126.3 (s, Ph), 80.0 (s, C4), 76.1 (s, 
C6), 74.4 (s, C3), 73.5 (s, C5), 64.4 (s, C7), 0.6, 0.34, 0.31, 0.2, -0.8 (each a s, -Si(CH3)3). 
 
 
Me3Si-styrylglucose (3.24): Prepared and used as a 67:33 
E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.41–7.36 
(m, 4H, Ph, E/Z), 7.35–7.30 (m, 4H, Ph, E/Z), 7.28–7.21 
(m, 2H, Ph, E/Z), 6.59 (d, J = 11.9 Hz, 1H, Z), 6.54 (dd, J = 16.1, 1.4 Hz, 1H, E), 6.38 (dd, J 
= 16.0, 5.7 Hz, 1H, E), 5.68 (dd, J = 11.9, 9.8 Hz, 1H, Z), 4.67 (ddd, J = 9.8, 4.9, 0.9 Hz, 1H, 
Z), 4.41 (app td, J = 5.5, 1.5 Hz, 1H, E), 3.98 (dt, J = 7.4, 2.9 Hz, 1H, E), 3.94 (ddd, J = 7.2, 
4.3, 2.9 Hz, 1H, Z), 3.83 (dd, J = 5.5, 4.3 Hz, 1H, Z), 3.77–3.71 (m, 2H, E/Z), 3.66 (dd, J = 
6.2, 5.2 Hz, 1H, E), 3.49–3.45 (m, 1H, E/Z), 0.16 (s, 9H, -Si(CH3)3), 0.15 (s, 9H, -Si(CH3)3), 
0.147 (s, 9H, -Si(CH3)3), 0.14 (s, 9H, -Si(CH3)3), 0.13 (s, 9H, -Si(CH3)3), 0.11 (s, 9H, -
Si(CH3)3), 0.10 (s, 9H, -Si(CH3)3), 0.09 (s, 9H, -Si(CH3)3), 0.07 (s, 9H, -Si(CH3)3), 0.02 (s, 
9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 137.1 (s), 136.9 (s), 132.5 (s), 131.4 (s), 
130.2 (s), 129.7 (s), 128.9 (s), 128.5 (s), 128.1 (s), 127.2 (s), 127.1 (s), 126.5 (s), 77.2 (s), 
76.7 (s), 76.4 (s), 75.8 (s), 75.1 (s), 74.8 (s), 74.3 (s), 70.0 (s), 64.0 (s), 63.8 (s), 1.05, 1.03, 
0.9, 0.84, 0.83, 0.6, 0.5, 0.4, -0.5, -0.6 (each a s, -Si(CH3)3). 
Me3Si-styrylmannose (3.26): Prepared and used as a 
33:67 E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.43–
7.40 (m, 2H, Ph, Z), 7.39–7.37 (m, 2H, Ph, E), 7.34–7.31 
(m, 4H, E/Z), 7.25–7.23 (m, 2H, E/Z) 6.63 (d, JH1,H2 = 11.7 Hz, 1H, H1, Z), 6.50 (d, JH1,H2 = 
16.0 Hz, 1H, H1, E), 6.27 (dd, JH2,H1 = 16.0 Hz, JH2,H3 = 7.4 Hz, 1H, H2, E), 5.68 (dd, JH2,H1 = 
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11.7 Hz, JH2,H3 = 9.8 Hz, 1H, H2, Z), 4.74 (dd, JH3,H2 = 9.8 Hz, JH3,H4 = 7.6 Hz, 1H, H3, Z), 
4.36 (dd, JH3,H2 = 7.4 Hz, JH3,H4 = 3.7 Hz, 1H, H3, E), 3.93–3.68 (m, 8H, H5, H6, H7, E/Z), 
3.55–3.45 (m, 2H, H4, E/Z), 0.13 (s, 9H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3), 0.116 (s, 9H, -
Si(CH3)3), 0.112 (s, 18H, -Si(CH3)3), 0.107 (s, 18H, -Si(CH3)3), 0.105 (s, 9H, -Si(CH3)3), 
0.09 (s, 18H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3).13C{1H} NMR (151 MHz, CDCl3): δ 137.0 
(s), 136.6 (s), 133.5 (s), 132.4 (s), 131.7 (s), 130.0 (s), 129.1 (s), 128.5 (s), 128.1 (s), 127.4 
(s), 127.1 (s), 126.5 (s), 77.7 (s), 75.9 (s), 75.29 (s), 75.27 (s), 73.9 (s), 69.0 (s), 64.4 (s), 63.3 
(s), 1.2, 1.1, 1.0, 0.98, 0.92, 0.9, 0.7, 0.6, -0.4, -0.6 (each a s, -Si(CH3)3). (*Note: two of the 
Z/E-olefin C–O bonds are under solvent in the carbon NMR.) 
 
Me3Si-styrylfucose (3.28): 1H NMR (600 MHz, CDCl3): δ 
7.36 (d, J = 6.0 Hz, 2H, Ph), 7.32 (t, J = 7.2 Hz, 2H, Ph), 7.23 
(t, J = 7.2 Hz, 1H, Ph), 6.52 (d, J = 16.2 Hz, 1H, H1), 6.26 (dd, J = 16.2, 7.2 Hz, 1H, H2), 
4.38 (app t, J = 7.2 Hz, 1H, H3), 3.89 (quint, J = 6.6 Hz, 1H, H6), 3.66 (dd, J = 9.0, 2.4 Hz, 
1H), 3.55 (dd, J = 6.6, 2.4 Hz, 1H), 1.16 (d, J = 6.6 Hz, 3H, H7), 0.15 (s, 9H, -Si(CH3)3), 0.12 
(s, 18H, -Si(CH3)3), 0.06 (s, 9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 137.2 (s), 
131.4 (s), 130.5 (s), 128.7 (s), 127.6 (s), 126.5 (s), 80.3 (s), 78.8 (s), 75.1 (s), 69.6 (s), 20.8 
(s), 1.0, 0.9, 0.8, 0.7 (each a s, -Si(CH3)3). 
 
Me3Si-styrylribose (3.30): Prepared and used as a 55:45 
E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 7.2 
Hz, 2H, Ph, Z), 7.37 (d, J = 7.8 Hz, 2H, Ph, E), 7.33–7.30 (m, 3H, Ph, E/Z), 7.26–7.23 (m, 
3H, Ph, E/Z), 6.57 (d, JH1,H2 = 11.4 Hz, 1H, H1, Z), 6.48 (d, JH1,H2 = 15.6 Hz, 1H, H1, E), 6.22 
(dd, JH2,H1 = 16.2 Hz, JH2,H3 = 7.8 Hz, 1H, H2, E), 5.54 (dd, JH2,H1 = 12.0 Hz, JH2,H3 = 10.2 
Me3SiO
Me3SiO
OSiMe3
123
4567
OSiMe3
3.28
OSiMe3
Me3SiO
Me3SiO
OSiMe3
124
35
6
3.30
 79 
Hz, 1H, H2, Z), 4.75 (app t, JH3,H4 & JH3,H2 = 9.6 Hz, 1H, H3, Z), 4.42 (dd, JH3,H2 = 7.2 Hz, 
JH3,H4 = 4.2 Hz, 1H, H3, E), 3.96–3.94 (m, 1H, Z), 3.76–3.74 (m, 2H, E/Z), 3.72–3.64 (m, 3H, 
E/Z), 3.54 (dd, JH6,H6’ = 10.2 Hz, JH6,H5 = 7.8 Hz, 1H, H6, E), 3.49 (dd, JH6’,H6 = 10.2 Hz, 
JH6’,H5 = 6.6 Hz, 1H, H6’, E), 0.14 (s, 9H, -Si(CH3)3), 0.13 (s, 9H, -Si(CH3)3), 0.12 (s, 9H, -
Si(CH3)3), 0.11 (s, 18H, -Si(CH3)3), 0.10 (s, 9H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3), -0.10 (s, 
9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 137.2 (s), 137.1 (s), 134.3 (s), 131.7 (s), 
131.0 (s), 129.8 (s), 129.2 (s), 128.7 (s), 128.0 (s), 127.5 (s), 127.1 (s), 126.6 (s), 78.50 (s), 
78.45 (s), 75.7 (s), 74.7 (s), 74.5 (s), 68.5 (s), 64.5 (s), 64.1 (s), 0.8, 0.7, 0.60, 0.56, 0.3, -0.36, 
-0.38 (each a s, -Si(CH3)3). (*Note: 1 triemthylsilyl group is overlapping). 
 
 
Me3Si-styrylxylose (3.32): Prepared and used as a 71:29 
E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.40–7.36 (m, 
2H, Ph), 7.35–7.30 (m, 4H, Ph, E/Z), 7.29–7.26 (m, 3H, Ph, Z), 7.25–7.21 (m, 1H, Ph, E), 
6.54 (d, JH1,H2 = 16.0 Hz, 1H, H1, E), 6.50 (d, JH1,H2 = 11.9 Hz, 1H, H1, Z), 6.27 (dd, JH2,H1 = 
16.0 Hz, JH2,H3 = 7.2 Hz, 1H, H2, E), 5.80 (dd, JH2,H1 = 11.9 Hz, JH2,H3 = 9.6 Hz, 1H, H2, Z), 
5.05 (ddd, JH3,H2 = 9.6 Hz, JH3,H4 = 2.7 Hz, JH3,H1 = 1.1 Hz, 1H, H3, Z), 4.42 (ddd, JH3,H2 = 7.3 
Hz, JH3,H4 = 6.2 Hz, JH3,H1 = 1.2 Hz, 1H, H3,, E), 3.87 (dd, J = 10.9 Hz, J = 2.4 Hz, 1H, Z), 
3.82 (m, 1H, Z), 3.75 (m, 2H, E/Z), 3.70 (dd, JH6,H6’ = 10.2 Hz, JH6,H5 = 4.5 Hz, 1H, H6, E), 
3.68–3.62 (m, 2H, E/Z), 3.57 (dd, JH6’,H6 = 10.2 Hz, JH6’,H5 = 7.2 Hz, 1H, E), 0.18 (s, 9H, -
Si(CH3)3), 0.17 (s, 9H, -Si(CH3)3), 0.16 (s, 9H, -Si(CH3)3), 0.15 (s, 9H, -Si(CH3)3), 0.128 (s, 
9H, -Si(CH3)3), 0.126 (s, 9H, -Si(CH3)3), 0.121 (s, 9H, -Si(CH3)3), 0.00 (s, 9H, -Si(CH3)3). 
13C{1H} NMR (151 MHz, CDCl3): δ 137.0 (s), 134.0 (s), 131.0 (s), 130.1 (s), 129.1 (s), 
128.8 (s), 128.5 (s), 128.2 (s), 127.4 (s), 127.0 (s), 126.4 (s), 77.4 (s), 77.1 (s), 76.8 (s), 74.9 
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(s), 74.7 (s), 67.6 (s), 64.0 (s), 63.9 (s), 0.8, 0.73, 0.68, 0.61, 0.58, 0.5, -0.4, -0.5 (each a s, -
Si(CH3)3). (*Note: One sp2 C is overlapping for E/Z isomers). 
 
Me3Si-styryllyxose (3.34): Prepared and used as a 48:52 
E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.48–7.45 (m, 
2H, Ph, E/Z), 7.40–7.37 (m, 2H, Ph, E/Z), 7.33–7.30 (m, 4H, Ph, E/Z), 7.26–7.20 (m, 2H, Ph, 
E/Z), 6.62 (d, JH1’,H2’ = 11.7 Hz, 1H, H1’, Z), 6.52 (d, JH1,H2 = 16.0 Hz, 1H, H1, E), 6.21 (dd, 
JH2,H1 = 16.0 Hz, JH2,H3 = 8.1 Hz, 1H, H2, E), 5.66 (dd, JH2’,H1’ = 11.7 Hz, JH2’,H3’ = 10.1 Hz, 
1H, H2’, Z), 4.93 (ddd, JH3’,H2’ = 10.2 Hz, JH3’,H4’ = 7.5 Hz, JH3’,H1’ = 0.9 Hz, 1H, H3, Z), 4.40 
(ddd, JH3,H2 = 8.0 Hz, JH3,H4 = 5.7 Hz, JH3,H1 = 0.9 Hz, 1H, H3 E), 3.98 (ddd, J = 7.0, 5.7, 2.4 
Hz, 1H, Z), 3.86 (ddd, J = 6.6, 5.4, 3.7 Hz, 1H, E), 3.79–3.69 (m, 2H, E/Z), 3.62–3.54 (m, 
4H, E/Z), 0.15 (s, 9H, -Si(CH3)3), 0.13 (s, 18H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3), 0.115 (s, 
9H, -Si(CH3)3), 0.105 (s, 9H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3), 0.07 (s, 9H, -Si(CH3)3). 
13C{1H} NMR (151 MHz, CDCl3): δ 137.1 (s), 136.6 (s), 133.5 (s), 132.1 (s), 131.9 (s), 
130.7 (s), 129.2 (s), 128.5 (s), 127.9 (s), 127.4 (s), 127.0 (s), 126.4 (s), 77.4 (s), 76.4 (s), 74.1 
(s), 73.8 (s), 73.2 (s), 67.5 (s), 64.1 (s), 0.8, 0.7, 0.6, -0.5 (each a s, -Si(CH3)3). (*Note: One 
C–O carbon and four -Si(CH3)3 are overlapping for E/Z isomers). 
 
TMS-galacto-tetraol (3.36): 1H NMR (600 MHz, 
CDCl3): δ 7.28 (t, J = 7.6 Hz, 2H, Ph), 7.22–7.15 (m, 3H, 
Ph), 5.79 (dt, JH2,H3 = 15.0 Hz, JH2,H3 = 6.7 Hz, 1H, H2), 
5.52 (ddt, JH3,H2 = 15.0 Hz, JH3,H4 = 7.6 Hz, JH3,H1 = 1.6 Hz, 1H, H3), 4.19–4.12 (m, 1H), 3.80 
(dt, J = 7.1, 3.7 Hz, 1H), 3.68 (dd, J = 10.4, 3.9 Hz, 1H, H1), 3.53 (dd, J = 5.8, 3.6 Hz, 1H), 
3.46 (dd, J = 10.4, 6.8 Hz, 1H), 3.39 (d, JH1,H2 = 6.6 Hz, 1H), 0.10 (s, 18H, -Si(CH3)3), 0.09 
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(s, 9H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3) δ 140.1 (s), 
132.3 (s), 131.5 (s), 128.8 (s), 128.6 (s), 126.2 (s), 80.0 (s), 74.7 (s), 73.6 (s), 63.7 (s), 38.9 
(s), 0.9 (s), 0.8 (s), 0.6 (s), -0.4 (s). 
 
Reduction of Me3Si-glucal 3.1 to prepare Z-triol 3.4 
 
Following general procedure 3.3, 5.2 mg B(C6F5)3, 56 µL triethysilane, 
dichloromethane and 36.3 mg were mixed. After 20 h the reaction was quenched and then 
loaded onto an alumina column (neutral, 10% H2O; 5 x 1 cm) with 100% hexanes collecting 
small fractions. The solution was concentrated under vacuum to afford Z-triol 3.4 as a 
colorless oil (38.1 mg, 88% overall yield, 0.088 mmol, >98:2 Z:E). Z-triol 3.4: 1H NMR (400 
MHz, CDCl3): δ 5.56 (dqd, JH2,H3 = 11.0 Hz, JH2,H1 = 6.8 Hz, JH2,H4 = 0.9 Hz, 1H, H2), 5.44 
(ddq, JH3,H2 = 11.0 Hz, JH3,H4 = 9.3 Hz, JH3,H1 = 1.7 Hz, 1H, H3), 4.54 (ddd, JH4,H3 = 9.2 Hz, 
JH4,H5 = 3.8 Hz, JH4,H2 = 0.9 Hz, 1H, H4), 3.67 (td, JH5,H6 = 6.0 Hz, JH5,H4 = 3.9 Hz, 1H, H5), 
3.57–3.40 (m, 2H, H6), 1.66 (dd, JH1,H2 = 6.8 Hz, JH1,H3 = 1.7 Hz, 3H, H1), 0.96–0.93 (m, 
18H, -Si(CH2CH3)3), 0.62–0.58 (m, 12H, -Si(CH2CH3)3), 0.09 (s, 9H, -Si(CH3)3). 13C{1H} 
NMR (101 MHz, CDCl3): δ 130.4 (s, C3), 125.9 (s, C2), 77.4 (s, C5) , 68.7 (s, C4), 64.4 (s, 
C6), 13.6 (s, C1), 6.9, 6.8, 5.0, 4.4, 0.2 (each as s, -Si(CH2CH3)3, -Si(CH2CH3)3, and -
Si(CH3)3). HRMS (ESI+): Calcd for C21H48O3Si3Na [M+Na]+: 455.2803; Found: 455.2819. 
Specific rotation: [α]D 28.7  +39.4  (c = 1.00 CH3Cl). 
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Figure 3.4. 1H and 13C{1H} NMR of triol 3.4. 
Selective deprotection of Z-triol 3.5 
 
 Followed modified general procedure 3.4, 2.4 (0.100 mmol), a magnetic stir bar, 27.6 
mg pyridinium p-toluenesulfonate (PPTS) was added in one portion, and dichloromethane. 
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Disappearance of the starting material was monitored by TLC (EtOAc/hexanes = 20/80). When 
TLC showed full consumption of the starting material the reaction was passed over a silica 
plug (2 x 1 cm) and washed with CH2Cl2 (10 mL) to collected product. Solvent was removed 
under vacuum and the residue was purified by silica gel chromatography (5 x 1) with gradient 
elution (98:2 to 95:5 hexanes/diethyl ether) to afford Z-triol 3.5 as a colorless oil (29.6 mg, 
82% overall yield, 0.0820 mmol). Z-triol 3.5: 1H NMR (600 MHz, CDCl3): δ 5.68 (dqd, JH2,H3 
= 11.1 Hz, JH2,H1 = 6.9 Hz, JH2,H4 = 1.2 Hz, 1H, H2), 5.48 (ddq, JH3,H2 = 10.7 Hz, JH3,H4 = 8.8 
Hz, JH3,H1 = 1.8 Hz, 1H, H3), 4.60–4.50 (m, 1H, H4), 3.75 (ddd, JH5,H4 = 6.4 Hz, JH5,H6’ = 5.6 
Hz, JH5,H6 = 4.5 Hz, 1H, H5), 3.67 (dd, JH6H6’ = 10.1 Hz, JH6,H5 = 5.5 Hz, 1H, H6), 3.61 (dd, 
JH6’H6 = 10.1 Hz, JH6’H5 = 6.5 Hz, 1H, H6’), 2.78 (d, J = 4.5 Hz, 1H, -OH), 1.71 (dd, JH1,H2 = 
6.9 Hz, JH1,H4 = 1.8 Hz, 3H, H1), 0.99–0.93 (m, 18H, -Si(CH2CH3)3), 0.66–0.56 (m, 12H, -
Si(CH2CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 129.2 (s, C3), 127.8 (s, C2), 75.0 (s, C5), 
70.2 (s, C4), 65.0 (s, C6), 13.6 (s, C1), 6.9, 6.8, 5.0, 4.4 (each as s, -Si(CH2CH3)3, -
Si(CH2CH3)3). Specific rotation: [α]D 28.7 +3.0  (c = 1.1 CH3Cl). 
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Figure 3.5. 1H and 13C{1H} NMR of triol 3.5. 
 
Reduction of Me3Si-glucal 3.1 to prepare Z-triol  
 
Following general procedure 3.3, 5.2 mg B(C6F5)3, 57.0 µL triethysilane 
dichloromethane, and 36.3 mg Me3Si-glucal 3.1 were combined at room temperature. The 
reaction was quenched after 20 h and then loaded onto an alumina plug (neutral, 10% H2O; 2 
x 1 cm) with 100% hexanes (1.5 mL) then 95:5 hexanes:diethyl ether (1.5 mL), eluting with 
95:5 hexanes:diethyl ether (10 mL). The solution was concentrated under vacuum to afford a 
colorless oil (80.5 mg). Following general procedure 3.4 deprotection to alcohol was 
performed subsequently. The product was purified by silica gel chromatography (5 x 1 cm 
column) using gradient elution (100% CH2Cl2 to 50:1 to 20:1 to 15:1 CH2Cl2:MeOH) to 
afford Z-triol as a white solid (10.7 mg, 81% overall yield over 2 steps, 0.0810 mmol, >98:2 
Z:E). Z-triol: 1H NMR (600 MHz, CD3OD): δ 5.70 (dq, JH2,H3 = 11.4 Hz, JH2,H1 = 6.6 Hz, 1H, 
H2), 5.52–5.48 (m, 1H, H3), 4.46 (dd, JH4,H3 = 9.0 Hz, JH4,H5 = 4.8 Hz, 1H, H4), 3.66–3.63 (m, 
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1H, H6), 3.61–3.56 (m, 2H, H5 & H6’), 1.72 (dd, JH1,H2 = 7.2 Hz, JH1,H3 = 1.8 Hz, 3H, H1). 
13C{1H} NMR (151 MHz, CD3OD): δ 131.0 (s, C3), 128.6 (s, C2), 76.3 (s, C5), 69.0 (s, C4), 
64.4 (s, C6), 13.6 (s, C1). HRMS (ESI+): Calcd for C6H13O3 [M+H]+: 133.0859; Found: 
133.0856. Specific rotation: [α]D 26.3  +7.9  (c = 0.060 CH3OH). 
Reduction of Me3Si-galactal 3.6 to prepare Z-triol 3.7 
 
Following general procedure 3.3, 5.0 mg B(C6F5)3, 50.0 µL dimethylethysilane, 36.6 
mg Me3Si-galactal 3.6, dichloromethane (0.2 mL, 0.5M) were combined at –45 ºC. 
Quenched after 45 h, concentrated under vacuum and then loaded onto an alumina plug 
(neutral, 10% H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 95:5 hexanes:diethyl ether 
(1.5 mL), eluting with 95:5 hexanes:diethyl ether (10 mL) into a tared vial. Followed general 
procedure 3.2 followed by purification by silica gel chromatography (4 x 1 cm column) using 
gradient elution (100% CH2Cl2 to 50:1 to 20:1 to 15:1 CH2Cl2:MeOH) to afford Z-triol 3.7 as 
a white solid (9.0 mg, 62% overall yield over 2 steps, 0.068 mmol, 83:17 Z:E). Z-triol 3.7: 1H 
NMR (600 MHz, CD3OD): δ 5.76 (ddq, JH2,H3 = 12.6 Hz, JH2,H1 = 7.2 Hz, JH2,H4 = 1.2 Hz, 1H, 
H2, E), 5.69–5.64 (m, 1H, H2, Z), 5.58–5.54 (m, 1H, H3, E), 5.50–5.46 (m, 1H, H3, Z), 4.43 
(dd, JH4,H3 = 9.0 Hz, JH4,H5 = 5.4 Hz, 1H, H4, Z), 4.01 (dd, JH4,H3 = 6.0 Hz, JH4,H5 = 5.4 Hz, 
1H, H4, E), 3.67–3.53 (m, 2H, H6, E/Z), 3.51–3.47 (m, 4H, H6’ & H5, E/Z), 1.72 (dd, JH1,H2 = 
7.2 Hz, JH1,H3 = 1.8 Hz, 6H, H1, E/Z). 13C{1H} NMR (151 MHz, CD3OD): δ 132.0 (s, C3, E), 
131.2 (s, C3, Z), 129.0 (s, C2, E), 128.4 (s, C2, Z), 76.6 (s, C5, Z), 76.4 (s, C5, E), 74.3 (s, C4, 
E), 68.5 (s, C4, Z), 64.2 (s, C6, E), 64.1 (s, C6, Z), 18.0 (s, C1, E), 13.5 (s, C1, Z). HRMS 
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(ESI+): Calcd for C6H12O3Na [M+Na]+: 155.0684; Found: 155.0677. Specific rotation: [α]D 
26.7  –22.  (c = 0.26 CH3OH). 
 
 
Figure 3.6. 1H and 13C{1H} NMR of triol 3.7. 
Reduction of Me3Si-ribal 3.8 to prepare Z-diol 3.9 
 
Following general procedure 3.3, 5.0 mg B(C6F5)3, 56.0 µL triethysilane, 
dichloromethane and 36.3 mg Me3Si-ribal 3.8 were combined at –30 ºC. After 14 h the 
reaction was quenched and then loaded onto an alumina column (neutral, 10% H2O; 5 x 1 
cm) with 100% hexanes collecting small fractions. The solution was concentrated under 
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vacuum to afford Z-diol 3.9 as a colorless oil (26.0 mg, 69% overall yield, 0.069 mmol, 
>98:2 Z:E). Z-diol 3.9: 1H NMR (600 MHz, CDCl3): δ 5.53 (dqd, JH2,H3 = 11.0 Hz, JH2,H1 = 
7.0 Hz, JH2,H4 = 1.2 Hz, 1H, H2), 5.32 (ddq, JH3,H2 = 12.1 Hz, JH3,H4 = 8.6 Hz, JH3,H1 = 1.8 Hz, 
1H, H3), 4.52–4.43 (m, 1H, H4), 3.57 (dd, JH5,H5’ = 10.1 Hz, JH5,H4 = 6.5 Hz, 1H, H5), 3.42 
(dd, JH5’,H5 = 10.1 Hz, JH5’,H4 = 5.8 Hz, 1H, H5), 1.66 (dd, JH1,H2 = 6.9 Hz, JH1,H3 = 1.8 Hz, 
3H, H1), 1.01–0.91 (m, 18H, -Si(CH2CH3)3), 0.59 (q, J = 8.0 Hz, 12H, -Si(CH2CH3)3). 
13C{1H} NMR (151 MHz, CDCl3): δ 132.0 (s, C3), 125.6 (s, C2), 69.4 (s, C4), 67.4 (s, C5), 
13.6 (s, C1), 6.79, 6.4, 4.9, 4.4 (each as s, -SiCH2CH3 or -Si(CH2CH3)3). Specific rotation: 
[α]D 26.3  –2.1  (c = 1.1 CH3Cl). 
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Figure 3.7. 1H and 13C{1H} NMR of triol 3.9. 
Preparation of Z-diol 3.10 
 
 
 Following general procedure 3.4 and the reduction described above, Z-diol 3.9 was 
isolated. Subsequent deprotection following general procedure 3.4 and purification by silica 
gel chromatography (5 x 1 cm column) using gradient elution (20:1 hexanes/diethyl ether to 
10:1 to 5:1 to 2:1 to 1:1 to 1:5) to afforded Z-diol 3.10 as a colorless oil (6.3 mg, 62% overall 
yield over 2 steps, 0.063 mmol, >98:2 Z:E). Z-diol 3.10: 1H NMR (600 MHz, CD3OD): δ 
5.63 (dqd, JH2,H3 = 11.1 Hz, JH2,H1 = 7.5 Hz, JH2,H4 = 1.1 Hz, 1H, H2), 5.35 (ddq, JH3,H2 = 10.9 
Hz, JH3,H4 =  8.5 Hz, JH3,H1 = 1.9 Hz, 1H, H3), 4.48 (dtd, JH4,H3 = 8.3 Hz, JH4,H5 & JH4,H5’ = 6.5 
Hz, JH4,H2 = 1.1 Hz, 1H, H4), 3.44 (dd, JH5,H5’ = 6.0 Hz, JH5,H4 = 4.2 Hz, 2H, H5), 1.70 (dd, 
JH1,H2 = 7.0 Hz, JH1,H3 = 1.8 Hz, 3H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 131.3 (s, C3), 
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128.3 (s, C2), 69.2 (s, C4), 67.1 (s, C5), 13.5 (s, C1). HRMS (ESI+): Calcd for C5H10O2Na 
[M+Na]+: 125.0578 Found: 125.0573. Specific rotation: [α]D 26.3  –3.9  (c = 0.82 CH3OH). 
 
 
Figure 3.8. 1H and 13C{1H} NMR of triol 3.10. 
 
Reduction of Me2tBuSi-galactal 3.11 to prepare Z-triol 3.12 
 
Following general procedure 3.3, 5.2 mg B(C6F5)3, 56.0 µL triethysilane, 28.6 mg 
tBu2Si-galactal 3.11, and dichloromethane were combined at –10 ºC. Quenched after 20 h 
and the product was purified by silica gel chromatography (5 x 1 cm column) using gradient 
O
OH
O
O
10 mol % B(C6F5)3
3.5 equiv Et3SiH
CH2Cl2, –10 ºC
20 h
tBu2Si
1
234
5
6 Et3SiO
OO
SitBu2
1
2
3456
3.11 3.12
 90 
elution (100% hexanes to 98:2 to 95:5 hexanes:diethyl ether) to afford Z-triol 3.12 as a white 
solid (33.3 mg, 86% overall yield, 0.086 mmol, >98:2 Z:E). Z-triol 3.12: 1H NMR (600 MHz, 
CDCl3): δ 5.69 (ddq, JH3,H2 = 10.6 Hz, JH3,H4 = 7.5 Hz, JH3,H1 = 1.3 Hz, 1H, H3), 5.63 (dqd, 
JH2,H3 = 11.0 Hz, JH2,H1 = 6.7 Hz, JH2,H4 = 1.0 Hz, 1H, H2), 4.92 (dd, JH4,H3 = 7.7 Hz, JH4,H5 = 
2.4 Hz, 1H, H4), 4.14 (dd, JH6,H6’ = 11.6 Hz, JH6,H5 = 2.1 Hz, 1H, H6), 4.02 (dd, JH6’,H6 = 11.6 
Hz, JH6’,H5 = 4.0 Hz, 1H, H6’), 3.70 (dt, JH5,H6’ = 4.2 Hz, JH5,H4 & JH5,H6 = 2.4 Hz, 1H, H5), 
1.70 (dd, JH1,H2 = 6.6 Hz, JH1,H3 = 1.3 Hz, 3H, H1), 1.06 (s, 9H, -Si(C(CH)3)), 1.05 (s, 9H, -
Si(C(CH)3)3), 0.96 (t, J = 7.9 Hz, 9H, -Si(CH2CH3)3), 0.59 (q, J = 7.9 Hz, 6H, Si(CH2CH3)3). 
13C{1H} NMR (151 MHz, CDCl3): δ 130.8 (s, C3), 125.9 (s, C2), 72.2 (s, C5), 71.2 (s, C4), 
68.9 (s, C6), 27.6 (s, -SiC(CH3)3), 27.4 (s, -SiC(CH3)3), 22.8 (s, -SiC(CH3)3), 20.8 (s, -
SiC(CH3)3), 13.5 (s, C1), 6.8 (s, -Si(CH2CH3)3), 4.8 (s, -Si(CH2CH3)3). Specific rotation: [α]D 
26.3  –2.1  (c = 0.32 CH3Cl). 
 
Selective deprotection of Z-triol 3.12 
 
Following general procedure 3.4, 3.12 was deprotected. The product was purified by 
silica gel chromatography with gradient elution (100% hexanes to 95:5 to 90:10 
hexanes/ethyl acetate) to afford Z-triol 3.13 as a colorless oil (22.3 mg, 82% overall yield, 
0.0820 mmol). Z-triol 3.13: 1H NMR (600 MHz, CDCl3): δ 5.73 (dqd, JH2,H3 = 11.1 Hz, 
JH2,H1 = 6.8 Hz, JH2,H4 = 1.1 Hz, 1H, H2), 5.65 (ddq, JH3,H2 = 10.9 Hz, JH3,H4 = 7.7 Hz, JH3,H1 = 
1.4 Hz, 1H, H3), 5.04 (ddd, JH4,H3 & JH4,H5 = 7.5 Hz, JH4,H2 = 1.6 Hz, 1H, H4), 4.27 (dd, 
JH6,H6’ = 11.9 Hz, JH6,H5 = 1.9 Hz, 1H, H6), 4.12 (dd, JH6’,H6 = 11.9 Hz, JH6’,H5 = 3.0 Hz, 1H, 
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MeOH, RT, 2 h
OH
OO
SitBu2
1
2
3456
3.12 3.13
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H6), 3.62–3.58 (m, 1H, H5), 2.26 (d, J = 8.7 Hz, 1H, -OH), 1.72 (dd, JH1,H2 = 6.7 Hz, JH1,H3 = 
1.5 Hz, 3H, H1), 1.09 (s, 9H, -SiC(CH3)3), 1.07 (s, 9H, –SiC(CH3)3). 13C{1H} NMR (151 
MHz, CDCl3): δ 129.7 (s, C3), 127.3 (s, C2), 72.3 (s, C4), 71.0 (s, C5), 67.0 (s, C6), 28.0 (s, -
SiC(CH3)3), 27.1 (s, -SiC(CH3)3), 23.0 (s, -SiC(CH3)3), 20.1 (s, -SiC(CH3)3), 13.6 (s, C1) . 
Specific rotation: [α]D 26.3  –1.3  (c = 0.45 DMSO). 
 
 
Figure 3.9. 1H and 13C{1H} NMR of triol 3.13. 
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Reduction of Me3Si-arabinal 3.14 to prepare Z-enol silane 3.15 
 
 
Following general procedure 3.3, 5.0 mg B(C6F5)3, 48.0 µL triethylsilane, 
dichloromethane and 26.1 mg Me3Si-arabinal 3.14 were combined at –30 ºC. After 16 h the 
reaction was quenched and then loaded onto an alumina column (neutral, 10% H2O; 5 x 1 
cm) with 100% hexanes collecting small fractions. The solution was concentrated under 
vacuum to afford Z-enol silane 3.15 as a colorless oil (26.7 mg, 71% overall yield, 0.073 
mmol, >98:2 Z:E). Z-enol silane 3.15: 1H NMR (600 MHz, CDCl3): δ 6.24 (dd, JH1,H2 = 5.8 
Hz, JH1,H3 = 0.9 Hz 1H, H1), 4.54 (ddd, JH3,H2 = 8.9 Hz, JH3,H4 = 3.6 Hz, JH3,H1 = 0.8 Hz, 1H, 
H3), 4.49 (dd, JH2,H3 = 8.9 Hz, JH2,H1 = 5.8 Hz, 1H, H2), 3.73 (dq, JH4,H5 = 6.3 Hz, JH4,H3 = 3.6 
Hz, 1H, H4), 1.07 (d, JH5,H4 = 6.3 Hz, 3H, H5), 0.97 (t, J = 8.0 Hz, 9H, -Si(CH2CH3)3), 0.66 
(q, J = 8.0 Hz, 6H, -Si(CH2CH3)3), 0.11 (s, 9H, -Si(CH3)3), 0.10 (s, 9H, -Si(CH3)3). 13C{1H} 
NMR (151 MHz, CDCl3): δ 139.4 (s, C1), 110.2 (s, C2), 72.1 (s, C4), 70.0 (s, C3), 19.0 (s, C5), 
6.5 (s, -Si(CH2CH3)3), 4.4 (–SiCH2CH3), 0.2 (s, -Si(CH3)3), 0.1 (s, -Si(CH3)3). Specific 
rotation: [α]D 24.6  –5.5  (c = 0.90 CH3Cl). 
O
Me3SiO
OSiMe3
10 mol % B(C6F5)3 
3.5 equiv. Et3SiH
OSiEt3
OSiMe3
Me3SiO
CH2Cl2, –30 ºC
16 h
1
234
5
12
345
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Figure 3.10. 1H and 13C{1H} NMR of triol 3.15. 
 
Preparation of Z-enol silane 3.16 
 
 
 Following general procedure 3.4, 3.15 was deprotected. Acetate protection was 
performed following general procedure 2.4 (chapter 2). The product was purified by silica 
OSiEt3OAc
OAc
OSiEt3
OSiMe3
Me3SiO
12
3
45 12
3
45
PPTS resin
80:20 CH3OH/CH2Cl2
0 ºC, 3 h;
AcCl, pyridine
CH2Cl2, 0 ºC to RT
12 h 3.163.15
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gel chromatography (5 x 1 cm column) using gradient elution (100% hexanes to 50:1 
hexanes/diethyl ether to 20:1 to 10:1 to 5:1 to 2:1) to afford Z-enol silane 3.16 as a colorless 
oil (15.8 mg, 50% overall yield over 3 steps, 0.050 mmol, >98:2 Z:E). Z-enol silane 3.16: 1H 
NMR (600 MHz, CDCl3): δ 6.41 (dd, JH1,H2 = 5.9 Hz, JH1,H3 = 1.1 Hz, 1H, H1), 5.88 (ddd, 
JH3,H2 = 8.8 Hz, JH3,H4 = 3.0 Hz, JH3,H1 = 1.1 Hz, 1H, H3), 5.16 (qd, JH4,H5 = 6.6 Hz, JH4,H3 = 
3.0 Hz, 1H, H4), 4.55 (dd, JH2,H3 = 8.8 Hz, JH2,H1 = 5.9 Hz, 1H, H2), 2.04 (s, 3H, Ac), 2.02 (s, 
3H, Ac), 1.18 (d, J = 6.6 Hz, 3H, H5), 0.97 (t, J = 8.0 Hz, 9H, -Si(CH2CH3)3), 0.67 (q, J = 8.0 
Hz, 6H, -Si(CH2CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 170.4 (s, Ac), 170.1 (s, Ac), 
143.1 (s, C1), 103.3 (s, C2), 70.8 (s, C4), 69.4 (s, C3), 21.2 (s, Ac), 21.2 (s, Ac), 15.4 (s, C5), 
6.4, 4.3 (each as a s, -Si(CH2CH3)3 or -Si(CH2CH3)3). HRMS (ESI+): Calcd for 
C15H28O5SiNa [M+Na]+: 339.1604; Found: 339.1599. Specific rotation: [α]D 24.6  –5.5  (c = 
0.90 CH3Cl). 
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Figure 3.11. 1H and 13C{1H} NMR of 3.16. 
 
Preparation of 3.22 and 3.22’ from 3.21 
 
Following general procedure 3.5, 5.0 mg B(C6F5)3, 63.1 mg Me3Si-styryl galactose 
3.21, 17.7 µL triethylsilane, and 0.5 mL dichloromethane were combined. Following general 
procedure 3.6, the reaction mixture was deprotected. Products were purified by silica gel 
chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 20:1 to 15:1 to 
10:1 to 9:1 CH2Cl2:MeOH) to afford 3.22/3.22’ as a white solid (21.6 mg, 88% overall yield 
over 2 steps, 0.0906 mmol, 90:10 SN2’:SN2). 3.22: 1H NMR (600 MHz, CD3OD): δ 7.31–
7.27 (m, 2H, Ph), 7.26–7.22 (m, 2H, Ph), 7.20–7.18 (m, 1H, Ph), 5.92 (dt, JH2,H3 = 14.9 Hz, 
JH2,H1 = 6.8 Hz, 1H, H2), 5.72 (ddd, JH3,H2 = 15.2 Hz, JH3,H4 = 6.7 Hz, JH3,H1 = 1.3 Hz, 1H, 
H3), 4.17 (app t, JH4,H3 & JH4,H5 = 6.9 Hz, 1H, H4), 3.90 (ddd, JH6,H7 = 6.5 Hz, JH6,H7’ = 5.6 Hz, 
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JH6,H5 = 2.5 Hz, 1H, H6), 3.68–3.60 (m, 2H, H7), 3.46 (dd, JH5,H4 = 7.1 Hz, JH5,H6 = 2.5 Hz, 
1H, H5), 3.43 (d, JH1,H2 = 6.8 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 141.6 (s, 
Ph), 132.9 (s, C2 or C3), 132.8 (s, C2 or C3), 129.6 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 74.5 (s, 
C5), 73.7 (s, C4), 72.1 (s, C6), 64.7 (s, C7), 39.8 (s, C1). HRMS (ESI+): Calcd for C13H18O4Na 
[M+Na]+: 261.1097; Found: 261.1100. Specific rotation: [α]D 26.3  +5.3  (c = 0.48 CH3OH). 
3.22’: 1H NMR (600 MHz, CD3OD): δ 7.43–7.38 (m, 2H, Ph), 7.31 (app s, 2H, Ph), 7.21 (d, 
J = 1.1 Hz, 1H, Ph), 6.52 (d, J = 15.9 Hz, 1H), 6.42 (dt, J = 15.6 Hz, 7.1 Hz, 1H), 3.97 (td, J 
= 6.3 Hz, 1.7 Hz, 1H), 3.80 (td, J = 8.3 Hz, 3.3 Hz, 1H), 3.62 (dd, J = 6.7 Hz, 0.9 Hz, 1H), 
3.38 (d, J = 0.9 Hz, 2H), 2.73 (ddd, J = 14.6 Hz, 7.2 Hz, 3.3 Hz, 1H), 2.39 (app dt, J = 14.8 
Hz, 7.7 Hz, 1H). 13C{1H} NMR (151 MHz, CD3OD): δ 139.2 (s, Ph), 133.4 (s, C1’), 129.4 (s, 
Ph), 128.2 (s, C2’), 127.9 (s, Ph), 74.3 (s, C4’), 72.4 (s, C6’), 71.8 (s, C5’), 64.9 (s, C7’), 38.5 (s, 
C3’). (*Note: One Ph carbon is overlapping with the SN2’ product.). 
 
 97 
 
Figure 3.12. 1H and 13C{1H} NMR of 3.22 and 3.22’. 
Preparation of cyclic intermediate 3.23 
 
 
 
Following general procedure 3.5, 5.3 mg B(C6F5)3, 61.5 mg Me3Si-styryl galactose 
3.21, and 0.5 mL dichloromethane were combined. Product was purified by alumina column 
(neutral, 10% H2O; 5 x 1 cm) and isolated with gradient elution (100% hexanes to 50:1 to 
25:1 hexanes:diethyl ether) to afford 3.23 as a colorless oil (42.1 mg, 93% overall yield, 
0.0931 mmol, 64:36 d.r.). 3.23: Reaction results in a 64:36 mixture of cyclic diastereomers. 
1H NMR (600 MHz, CDCl3): δ 7.40–7.34 (m, 4H, Ph), 7.34–7.27 (m, 4H, Ph), 7.25–7.19 (m, 
2H, Ph), 6.65 (d, J = 16.2 Hz, 1H, H1), 6.63 (d, J = 16.3 Hz, 1H, H1), 6.25 (dd, J = 16.1 Hz, 
6.3 Hz, 1H, H2), 6.23 (dd, J = 16.0 Hz, 6.7 Hz, 1H, H2), 4.23 (ddd, J = 8.6 Hz, 6.8 Hz, 1.4 
Hz, 1H, H3), 4.00 (dt, J = 6.4 Hz, 1.3 Hz, 1H, H3), 3.98–3.92 (m, 2H), 3.85 (d, J = 2.5 Hz, 
1H), 3.83 (dd, J = 2.8 Hz, 1.2 Hz, 1H), 3.76–3.73 (m, 2H), 3.64–3.58 (m, 2H), 3.48 (dd, J = 
OOSi
SiOSiO PhMe3SiO
Me3SiO
Me3SiO
OSiMe3
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8.4 Hz, 2.8 Hz, 1H), 3.27–3.18 (m, 1H), 0.17 (s, 9H, -Si(CH3)3), 0.17 (s, 9H, -Si(CH3)3), 0.14 
(s, 9H, -Si(CH3)3), 0.13 (s, 9H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3). (*Note: one of the –
Si(CH3)3 integrations accounts for two from the minor product). 13C{1H} NMR (151 MHz, 
CDCl3): δ 137.0 (s, Ar), 136.7 (s, Ar), 132.1 (s, C1), 131.8 (s, C1), 128.5 (s, Ar), 128.4 (s, 
Ar), 128.0 (s, C2), 127.6 (s, C2), 127.3 (s, Ar), 126.9 (s, Ar), 126.5 (s, Ar), 126.4 (s, Ar), 80.3 
(s), 76.5 (s), 75.9 (s), 75.6 (s), 73.3 (s), 72.0 (s), 70.5 (s), 70.3 (s), 67.5 (s), 67.3 (s), 0.7, 0.5, 
0.49, 0.3, 0.2, 0.1 (each as s, -Si(CH3)3). Specific rotation: [α]D 26.3  –12.8  (c = 1.87 CH3Cl). 
 
 
 
Figure 3.13. 1H and 13C{1H} NMR of cyclic intermediate of 3.23. 
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Preparation of 3.25 and 3.25’ from 3.24 
 
 
 
 
Following general procedure 3.5, 5.1 mg B(C6F5)3, 63.1 mg Me3Si-styryl glucose 
3.24, 17.7 µL triethylsilane, and 0.5 mL dichloromethane were combined. Following general 
procedure 3.6 the reaction mixture was deprotected. Products were purified by silica gel 
chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 20:1 to 15:1 to 
10:1 to 9:1 CH2Cl2:MeOH) to afford 3.25/3.25’ as a white solid (21.2 mg, 86% overall yield 
over 2 steps, 0.089 mmol, 89:11 SN2’:SN2). 3.25: 1H NMR (600 MHz, CD3OD): δ 7.30–7.26 
(m, 2H, Ph), 7.22 (d, J = 7.2 Hz, 2H, Ph), 7.20–7.16 (m, 1H, Ph), 5.91 (dt, JH2,H3 = 14.4 Hz, 
JH2,H1 = 7.2 Hz, 1H, H2), 5.73 (dd, JH3,H2 = 15.6 Hz, JH3,H4 = 6.6 Hz, 1H, H3), 4.33 (app d, 
JH4,H3 & JH4,H5 = 6.0 Hz, 1H, H4), 3.78 (dd, JH7,H7’ = 11.4 Hz, JH7,H6 = 3.6 Hz, 1H, H7), 3.74–
3.70 (m, 1H, H6), 3.63 (dd, JH7’,H7 = 10.8 Hz, JH7’,H6 = 6.0 Hz, 1H, H7’), 3.47–3.46 (m, 1H, 
H5), 3.42 (d, JH1,H2 = 6.6 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 141.6 (s, Ph), 
132.8 (s, C3), 132.3 (s, C2), 129.5 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 75.8 (s, C6), 73.1 (s, 
C5), 72.9 (s, C4), 64.8 (s, C7), 39.7 (s, C1). HRMS (ESI+): Calcd for C13H18O4Na [M+Na]+: 
261.1097; Found: 261.1095. Specific rotation: [α]D 27.2  –17.2  (c = 0.890 CH3OH). 3.25’: 1H 
NMR (600 MHz, CD3OD): δ 7.38 (d, J = 7.8 Hz, 2H, Ph), 7.30–7.26 (m, 2H, Ph), 7.20–7.16 
(m, 1H, Ph), 6.51 (d, J = 16.2, H1’), 6.34 (dt, J = 15.0, 7.2 Hz, 1H, H2’), 3.99 (t, J = 7.2 Hz, 
1H), 3.82 (dd, J = 11.4, 3.6 Hz, 1H), 3.74–3.70 (m, 1H), 3.66–3.62 (m, 1H), 3.47–3.46 (m, 
1H), 2.56–2.48 (m, 2H, H3’). 13C{1H} NMR (151 MHz, CD3OD): δ 139.1 (s), 133.3 (s), 
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129.5 (s), 128.1 (s), 128.0 (s), 127.0 (s) 73.9 (s), 71.4 (s), 65.1 (s), 38.6 (s) (*Note: One C–O 
C is overlapping with SN2’ product). 
 
 
Figure 3.14. 1H and 13C{1H} NMR of 3.25 and 3.25’. 
Preparation of 3.27 and 3.27’ from 3.26 
 
Following general procedure 3.5, 5.1 mg B(C6F5)3, 63.1 mg Me3Si-styryl mannose 
3.26, 17.7 µL triethylsilane, and 0.5 mL dichloromethane were combined. Following general 
procedure 3.4, the reaction mixture was deprotected. Products were purified by silica gel 
chromatography (4 x 1 cm column) using gradient elution (50:1 to 20:1 to 15:1 to 10:1 to 9:1 
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CH2Cl2:MeOH) to afford 3.27/3.27’ as a white solid (22.3 mg, 91% overall yield over 2 
steps, 0.094 mmol, 94:6 SN2’:SN2). 3.27: 1H NMR (600 MHz, CD3OD): δ 7.30–7.26 (m, 2H, 
Ph), 7.22 (d, J = 7.2 Hz, 2H, Ph), 7.20–7.16 (m, 1H, Ph), 5.91 (dt, JH2,H3 = 14.4 Hz, JH2,H1 = 
7.2 Hz, 1H, H2), 5.73 (dd, JH3,H2 = 15.6 Hz, JH3,H4 = 6.6 Hz, 1H, H3), 4.33 (d, JH4,H3 & JH4,H5 
= 6.0 Hz, 1H, H4), 3.78 (dd, JH7,H7’ = 11.4 Hz, JH7,H6 = 3.6 Hz, 1H, H7), 3.74–3.70 (m, 1H, 
H6), 3.63 (dd, JH7’,H7 = 10.8 Hz, JH7’,H6 = 6.0 Hz, 1H, H7’), 3.47–3.46 (m, 1H, H5), 3.42 (d, 
JH1,H2 = 6.6 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 141.6 (s, Ph), 132.8 (s, C3), 
132.3 (s, C2), 129.5 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 75.8 (s, C6), 73.1 (s, C5), 72.9 (s, C4), 
64.8 (s, C7), 39.7 (s, C1). HRMS (ESI+): Calcd for C13H18O4Na [M+Na]+: 261.1097; Found: 
261.1095. Specific rotation: [α]D 27.2  –17.9  (c = 0.910 CH3OH). 3.27’: 1H NMR (600 MHz, 
CD3OD): δ 7.38 (d, J = 7.8 Hz, 2H, Ph), 7.30–7.26 (m, 2H, Ph), 7.20–7.16 (m, 1H, Ph), 6.51 
(d, J = 16.2 Hz, H1’), 6.34 (dt, J = 15.0 Hz, J = 7.2 Hz, 1H, H2’), 3.99 (t, J = 7.2 Hz, 1H), 3.82 
(dd, J = 11.4, 3.6 Hz, 1H), 3.74–3.70 (m, 1H), 3.66–3.62 (m, 1H), 3.47–3.46 (m, 1H), 2.56–
2.48 (m, 2H, H3’). 13C{1H} NMR (151 MHz, CD3OD): δ 139.1 (s), 133.3 (s), 129.5 (s), 128.1 
(s), 128.0 (s), 127.0 (s) 73.9 (s), 71.4 (s), 65.1 (s), 38.6 (s) (*Note: One C–O carbon is 
overlapping with SN2’ product). 
Preparation of 3.29 and 3.29’ from 3.28 
 
Following general procedure 3.5, 4.7 mg B(C6F5)3, 53.3 mg Me3Si-styryl fucose 3.28, 
17.7 µL triethylsilane, and 0.5 mL dichloromethane were combined. Following general 
procedure 3.6, the reaction mixture was deprotected. Products were purified by silica gel 
chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 20:1 to 
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15:1 CH2Cl2:MeOH) to afford 3.29/3.29’ as a white solid (19.5 mg, 87% overall yield over 2 
steps, 0.088 mmol, 69:31 SN2’:SN2). 3.29: 1H NMR (600 MHz, CD3OD): δ 7.24–7.20 (m, 
3H, Ph), 7.16 (d, J = 7.8 Hz, 2H, Ph), 5.83 (dt, JH2,H3 = 15.0 Hz, JH2,H1 = 6.6 Hz, 1H, H2), 
5.64 (dd, JH3,H2 = 15.0 Hz, JH3,H4 = 7.2 Hz, 1H, H3), 4.06 (dd, JH4,H3 & JH4,H5 = 6.6 Hz, 1H, 
H4), 3.88–3.84 (m, 1H, H6), 3.36 (d, JH1,H2 = 6.6 Hz, 2H, H1), 3.19–3.15 (m, 1H, H5), 1.14 (d, 
JH7,H6 = 6.6 Hz, 3H, H7). 13C{1H} NMR (151 MHz, CD3OD): δ 141.6 (s, Ph), 132.9 (s, C2 or 
C3), 132.5 (s, C2 or C3), 129.6 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 78.4 (s, C5), 74.1 (s, C4), 
68.1 (s, C6), 39.8 (s, C1), 19.7 (s, C7). HRMS (ESI+): Calcd for C13H18O3Na [M+Na]+: 
245.1148; Found: 245.1148. Specific rotation: [α]D 27.1  –16.9  (c = 0.955 CH3OH). 3.29’: 1H 
NMR (600 MHz, CD3OD): δ 7.33 (d, J = 7.8 Hz, 2H, Ph), 7.14–7.11 (m, 3H, Ph), 6.45 (d, 
JH1’,H2’ = 15.6 Hz, 1H, H1’), 6.34 (dt, JH2’,H1’ = 15.6 Hz, JH2’H3’ = 7.2 Hz, 1H, H2’), 4.02–3.99 
(m, 1H, H6’), 3.72–3.69 (m, 1H, H4’), 3.19–3.15 (m, 1H, H5’), 2.61 (ddd, JH3’H3’’ = 10.2 Hz, 
JH3’,H4’ = 7.2 Hz, JH3’,H2’ = 3.6 Hz, 1H, H3’), 2.33 (quint, JH3’’,H4’ & JH3’’,H2’ = 7.2 Hz, 1H, H3’’), 
1.19 (d, JH7’,H6’ = 6.6 Hz, 3H, H7’). 13C{1H} NMR (151 MHz, CD3OD): δ 139.2 (s, Ph), 133.3 
(s, C1), 129.4 (s, 2Ph), 128.2 (s, C2), 127.9 (s, Ph), 77.8 (s, C5), 72.7 (s, C4), 67.6 (s, C6), 38.4 
(s, C3), 20.0 (s, C7). 
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Figure 3.15. 1H and 13C{1H} NMR of 3.29 and 3.29’. 
Preparation of Hydrogenated 3.29 for stereochemical analysis 
 
 
 
A 20-mL scintillation vial was charged with substrate 3.29 (20.9 mg, .0940 mmol, 1.0 
equiv.) then Pd/C (4.3 mg, 0.21 equiv., 20 wt% Pd/C). Ethanol (2.0 mL) was added by 
syringe. A septum was attached and sealed with electrical tape. The vial was purged with N2 
for 10 minutes then with H2 (balloon volume, 2x). The turbid mixture was allowed to stir for 
15.5 hours at 25 °C under H2 atmosphere (balloon). The vial was then purged with N2 for 10 
minutes and water (100 µL) was added by microliter syringe. The solution was swirled and 
then passed through a plug of Celite® (3 x 1 cm), rinsing with 9:1 CH2Cl2:MeOH (~5 mL). 
The solution was concentrated to afford a colorless oil. The product was purified by silica gel 
chromatography 5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 40:1 to 
30:1 to 20:1 CH2Cl2:MeOH) to yield 3.29’’  (6.6  mg,  31% yield, 0.029 mmol). 3.29’’: 1H 
NMR (600 MHz, CD3OD): δ 7.24 (t, J = 7.8 Hz, 2H, Ph), 7.19 (d, J = 4.8 Hz, 2H, Ph), 7.13 
(app t, J = 7.2 Hz, 1H, Ph), 3.97 (dq, JH6,H7 = 6.6 Hz, JH6,H5 = 3.0 Hz, 1H, H6), 3.61 (dt, JH4,H5 
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HO
HO
OH
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25 3 1
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= 9.6 Hz, JH4,H3 = 3.0 Hz, 1H, H4), 3.11 (dd, JH5,H4 = 7.2 Hz, JH5,H6 = 2.4 Hz, 1H, H5), 2.69–
2.59 (m, 2H, H1), 1.92–1.85 (m, 1H, H2), 1.77–1.72 (m, 1H, H3), 1.71–1.64 (m, 1H, H2’), 
1.48–1.41 (m, 1H, H3’), 1.19 (d, JH7,H6 = 6.6 Hz, 3H, H7). 13C{1H} NMR (151 MHz, 
CD3OD): δ 143.9 (s, Ph), 129.5 (s, Ph), 129.3 (s, Ph), 126.6 (s, Ph), 78.3 (s, C5), 72.8 (s, C4), 
67.8 (s, C6), 37.0 (s, C1), 34.2 (s, C3), 28.8 (s, C2), 19.9 (s, C7). 
 
 
Preparation of 3.31 and 3.31’ from 3.30 
 
 
Following general procedure 3.5, 4.8 mg B(C6F5)3, 53.3 mg Me3Si-styryl ribose 3.30, 
15.8 µL dimethylethylsilane, and 0.5 mL dichloromethane were combined. Following 
general procedure 3.6, the reaction mixture was deprotected. Products were purified by silica 
gel chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 30:1 
to 20:1 to 15:1 CH2Cl2:MeOH) to afford 3.31/3.31’ as a white solid (17.7 mg, 87% overall 
yield over 2 steps, 0.085 mmol, 74:26 SN2’:SN2). 3.31: 1H NMR (600 MHz, CD3OD): δ 7.28 
(t, J = 7.2 Hz, 2H, Ph), 7.25 (d, J = 3.6 Hz, 2H, Ph), 7.22 (t, J = 7.2 Hz, 1H, Ph), 5.91–5.86 
(m, 1H, H2), 5.67 (ddt, JH3,H2 = 15.6 Hz, JH3,H4 = 7.2 Hz, JH3,H1 = 1.2 Hz, 1H, H3), 4.06 (dd, 
JH4,H5 & JH4,H3 = 5.4 Hz, 1H, H4), 3.68–3.61 (m, 1H, H6), 3.60–3.55 (m, 2H, H5 & H6’), 3.42 
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(d, JH1,H2 = 6.6 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 141.6 (s, Ph), 133.2 (s, 
C3), 131.9 (s, C2), 129.6 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 76.2 (s, C5), 74.5 (s C4), 64.5 (s, 
C6), 39.8 (s, C1). HRMS (ESI+): Calcd for C12H16O3Na [M+Na]+: 231.0992; Found: 
231.0993. Specific rotation: [α]D 24.5  –18.4  (c = 0.525 CH3OH). 3.31’: 1H NMR (600 MHz, 
CD3OD): δ 7.38 (d, J = 7.2 Hz, 2H, Ph), 7.29–7.28 (m, 2H, Ph), 7.26–7.16 (m, 1H, Ph), 6.51 
(d, JH1’,H2’ = 15.6 Hz, 1H, H1’), 6.38 (dt, JH2’,H1’ = 16.2 Hz, JH2’,H3’ = 6.6 Hz, 1H, H2’), 3.79 
(dd, J = 11.4, 4.2 Hz, 1H), 3.68–3.61 (m, 2H), 3.60–3.52 (m, 1H), 2.63 (dddd, JH3’,H3’’ = 14.4 
Hz, JH3’.H2’ = 7.2 Hz, JH3’,H4’ = 3.6 Hz, JH3’,H1’ = 1.2 Hz, 1H, H3’) 2.38 (ddd, JH3’’,H3’ = 15.6 
Hz, JH3’’,H2’ = 8.4 Hz, JH3’’,H4’ = 7.2 Hz, 1H, H3’’). 13C{1H} NMR (151 MHz, CD3OD): δ 
139.2 (s), 133.4 (s), 129.5 (s), 129.4 (s), 128.1 (s), 128.0, 75.9 (s), 73.4 (s), 64.7 (s), 38.0 (s). 
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Figure 3.16. 1H and 13C{1H} NMR of 3.31 and 3.31’. 
Preparation of 3.33 and 3.33’ from 3.32 
 
 
Following general procedure 3.5, 4.8 mg B(C6F5)3, 51.2 mg Me3Si-styryl xylose 3.32, 
16.0 µL dimethylethylsilane, and 0.5 mL dichloromethane were combined. Following 
general procedure 3.6, the reaction mixture was deprotected. Products were purified by silica 
gel chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 30:1 
to 20:1 to 15:1 CH2Cl2:MeOH) to afford 3.33/3.33’ as a white solid (17.9 mg, 86% overall 
yield over 2 steps, 0.086 mmol, 75:25 SN2’:SN2). 3.33: 1H NMR (600 MHz, CD3OD): δ 7.26 
(t, J = 7.6 Hz, 2H, Ph), 7.21–7.14 (m, 3H, Ph), 5.88 (dtd, JH2,H3 = 15.0 Hz, JH2,H1 = 6.8 Hz, 
JH2,H4 = 1.1 Hz, 1H, H2), 5.60 (ddt, JH3,H2 = 15.3 Hz, JH3,H4 = 7.0 Hz, JH3,H1 = 1.5 Hz, 1H, H3), 
4.05 (app t, JH4,H3 & JH4,H5 = 6.7 Hz, 1H, H4), 3.65–3.61 (m, 1H, H5), 3.52–3.46 (m, 2H, H6), 
3.38 (dd, JH1,H2 = 6.9 Hz, JH1,H3 = 1.4 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 
141.5 (s, Ph), 133.0 (s, C2), 132.0 (s, C3), 129.6 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 76.3 (s, 
3.32 xylo- (71:29 E:Z)
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C5), 74.0 (s, C4), 64.2 (s, C6), 39.7 (s, C1). HRMS (ESI+): Calcd for C12H16O3Na [M+Na]+: 
231.0992; Found: 231.0991. Specific rotation: [α]D 26.3  +2.9  (c = 1.0 CH3OH). 3.33’: 1H 
NMR (600 MHz, CD3OD): δ 7.38–7.36 (m, 2H), 7.31–7.24 (m, 2H), 7.19–7.14 (m, 1H), 6.50 
(d, JH1’,H2’ = 15.7 Hz, 1H, H1’), 6.33 (dt, JH2’,H1’ = 15.8 Hz, JH2’,H3’ = 7.2 Hz, 1H, H2’), 3.74 
(ddd, J = 8.3, 5.4, 3.3 Hz, 1H), 3.69–3.66 (m, 1H), 3.64–3.58 (m, 1H), 3.60–3.54 (m, 1H), 
2.51 (dddd, J = 14.2, 7.1, 5.4, 1.4 Hz, 1H), 2.47–2.41 (m, 1H). 13C{1H} NMR (151 MHz, 
CD3OD): δ 138.7 (s, Ph), 133.0 (s), 129.1 (s, Ph), 127.6 (s, Ph), 127.6 (s, Ph), 74.5 (s), 72.2 
(s), 64.2 (s), 37.8 (s). (*Note: One of the SN2 alkene peaks overlaps with the SN2’ product 
peaks.).  
 Following modified conditions where the reaction is combined at –30 ºC and 
triethylsilane is used instead of dimethylethylsilane, selectivity is improved to give 3.31/3.31’ 
in a 91:9 SN2:SN2’. 
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Figure 3.17. 1H and 13C{1H} NMR of 3.33 and 3.33’. 
 
 
 
Figure 3.18. 1H and 13C{1H} NMR 3.33 and 3.33’ with optimized selectivity for 3.33. 
 
 
 109 
Preparation of 3.33 and 3.33’ from 3.34 
 
 
Following general procedure 3.5, 5.0 mg B(C6F5)3, 51.2 mg Me3Si-styryl xylose 3.34, 
16.0 µL dimethylethylsilane, and 0.5 mL dichloromethane were combined. Following 
general procedure 3.6, the reaction mixture was deprotected. Products were purified by silica 
gel chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 30:1 
to 20:1 to 15:1 CH2Cl2:MeOH) to afford 3.33/3.33’ as a white solid (15.0 mg, 72% overall 
yield over 2 steps, 0.072 mmol, 75:25 SN2’:SN2). 3.33: 1H NMR (600 MHz, CD3OD): δ 7.26 
(t, J = 7.6 Hz, 2H, Ph), 7.21–7.14 (m, 3H, Ph), 5.88 (dtd, JH2,H3 = 15.0 Hz, JH2,H1 = 6.8 Hz, 
JH2,H4 = 1.1 Hz, 1H, H2), 5.60 (ddt, JH3,H2 = 15.3 Hz, JH3,H4 = 7.0 Hz, JH3,H1 = 1.5 Hz, 1H, H3), 
4.05 (app t, JH4,H3 & JH4,H5 = 6.7 Hz, 1H, H4), 3.65–3.61 (m, 1H, H5), 3.52–3.46 (m, 2H, H6), 
3.38 (dd, JH1,H2 = 6.9 Hz, JH1,H3 = 1.4 Hz, 2H, H1). 13C{1H} NMR (151 MHz, CD3OD): δ 
141.5 (s, Ph), 133.0 (s, C2), 132.0 (s, C3), 129.6 (s, Ph), 129.4 (s, Ph), 127.0 (s, Ph), 76.3 (s, 
C5), 74.0 (s, C4), 64.2 (s, C6), 39.7 (s, C1). HRMS (ESI+): Calcd for C12H16O3Na [M+Na]+: 
231.0992; Found: 231.0992. Specific rotation: [α]D 26.3  +8.6  (c = 1.2 CH3OH). 3.33’: 1H 
NMR (600 MHz, CD3OD): δ 7.38–7.36 (m, 2H), 7.31–7.24 (m, 2H), 7.19–7.14 (m, 1H), 6.50 
(d, J = 15.7 Hz, 1H), 6.33 (dt, J = 15.8, J = 7.2 Hz, 1H, H2’), 3.74 (ddd, J = 8.3, 5.4, 3.3 Hz, 
1H), 3.69–3.66 (m, 1H), 3.64–3.58 (m, 1H), 3.60–3.54 (m, 1H), 2.51 (dddd, J = 14.2, 7.1, 
5.4, 1.4 Hz, 1H), 2.47–2.41 (m, 1H). 13C{1H} NMR (151 MHz, CD3OD): δ 138.7 (s, Ph), 
133.0 (s), 129.1 (s, Ph), 127.6 (s, Ph), 127.6 (s, Ph), 74.5 (s), 72.2 (s), 64.2 (s), 37.8 (s). 
(*Note: One of the SN2 alkene peaks overlaps with the SN2’ product peaks.). 
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Following modified conditions where the reaction is combined at –30 ºC and 
triethylsilane is used instead of dimethylethylsilane, selectivity is improved to give 3.33/3.33’ 
in a 91:9 SN2:SN2’. 
Preparation of 3.36 and 3.36’ from 3.35 
 
 
Following general procedure 3.5, 5.3 mg B(C6F5)3, 53.0 mg Me3Si-tetraol 3.35, 17.7 
µL triethylsilane, and 0.5 mL dichloromethane were combined. Following general procedure 
3.6, the reaction mixture was deprotected. Products were purified by silica gel 
chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 20:1 to 
15:1 CH2Cl2:MeOH) to afford 3.36/3.36’ as a white solid (18.0 mg, 81% overall yield over 2 
steps, 0.088 mmol, 71:29 SN2’:SN2). 3.36: 1H NMR (600 MHz, CD3OD): δ 7.33–7.29 (m, 
2H, Ph), 7.26–7.24 (m, 2H, Ph), 7.24–7.20 (m, 1H, Ph), 5.84 (dtd, JH3,H4 = 14.9 Hz, JH3,H2 = 
6.8 Hz, JH3,H5 = 1.1 Hz, 1H, H3), 5.61 (ddt, JH4,H3 = 15.4 Hz, JH4,H5 = 7.1 Hz, JH4,H2 = 1.5 Hz, 
1H, H4), 4.06 (dd, JH5,H4 = 6.9 Hz, JH5,H6 = 5.6 Hz, 1H, H5), 3.63 (dd, JH7,H7’ = 10.7 Hz, JH7,H6 
= 3.9 Hz, 1H, H7), 3.53–3.46 (m, 2H, H7’ & H6), 2.83–2.70 (m, 2H, H1), 2.50–2.41 (m, 2H, 
H2). 13C{1H} NMR (151 MHz, CD3OD): δ 143.0 (s, Ph), 133.4 (s, C3), 131.4 (s, C4), 129.5 
(s, Ph), 129.3 (s, Ph), 126.8 (s, Ph), 76.4 (s, C6), 74.2 (s, C5), 64.2 (s, C7), 36.6 (s, C2), 35.5 
(s, C1). HRMS (ESI+): Calcd for C13H18O3Na [M+Na]+: 245.1153; Found: 245.1148. Specific 
rotation: [α]D 28.7  + 10.6  (c = 0.780 CH3OH). 3.36’: 1H NMR (600 MHz, CD3OD): δ 7.35–
7.29 (m, 2H, Ph), 7.27–7.24 (m, 2H, Ph), 7.24–7.20 (m, 1H, Ph), 5.80–5.71 (m, 1H, H2’), 
5.66 (ddt, J = 15.3, 8.3, 1.4 Hz, 1H, H3’), 3.72–3.67 (m, 1H), 3.59 (ddd, J = 6.4, 5.0, 3.4 Hz, 
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1H), 3.42 (d, J = 6.7 Hz, 1H), 2.43–2.37 (m, 2H), 2.36–2.28 (m, 1H). (*Note: two protons are 
overlapping with the SN2 product.) 13C{1H} NMR (151 MHz, CD3OD): δ 142.0 (s, Ph), 
132.9 (s, C2’ or C3’), 129.5 (s, Ph), 129.3 (s, Ph), 129.0 (s, Ph), 126.9 (s, C2’ or C3’), 74.7 (s, 
C6’), 72.6 (s, C5’) , 64.5 (s, C7’), 40.1 (s, C1’), 37.6 (s, C4’). 
 
 
Figure 3.19. 1H and 13C{1H} NMR of 3.36 and 3.36’. 
 
 
 
Preparation of 3.37 from 3.35 
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Following general procedure 3.5, 5.3 mg B(C6F5)3, 53.0 mg Me3Si-tetraol 3.35, and 
0.5 mL dichloromethane were combined. The product was purified by alumina gel 
chromatography (5 x 1 cm column) with gradient elution (100% hexanes to 98:2 
hexanes:diethyl ether) to afford 3.37 as a colorless oil (30.9 mg, 85% overall yield, 0.0850 
mmol, >98:2 d.r.) in a 98:2 mixture with 3.35’. 3.37: 1H NMR (600 MHz, CDCl3): δ 7.29–
7.26 (m, 2H, Ph), 7.21–7.17 (m, 3H, Ph), 5.93 (dt, JH2,H3 = 15.5 Hz, JH2,H1 = 6.6 Hz, 1H, H2), 
5.60 (ddt, JH3,H2 = 15.5 Hz, JH3,H4 = 8.2 Hz, JH3,H1 = 1.6 Hz, 1H, H3), 4.39 (dd, JH4,H3 = 8.2 
Hz, JH4,H5 = 3.1 Hz, 1H, H4), 4.12 (dd, JH7,H7’ = 9.1 Hz, JH7,H6 = 4.1 Hz, 1H, H7), 4.08–4.04 
(m, 1H, H6), 3.86 (dd, JH5,H4 = 3.2 Hz, JH5,H6 =  1.5 Hz, 1H, H5), 3.59 (dd, JH7’,H7 = 9.1 Hz, 
JH7’,H6 = 1.4 Hz, 1H, H7’), 3.46–3.36 (m, 2H, H1), 0.13 (s, 9H, -Si(CH3)3), 0.10 (s, 9H, -
Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 139.9 (s, Ph), 133.89 (s, C2), 128.7 (s, Ph), 
128.3 (s, Ph), 127.3 (s, C3), 126.0 (s, Ph), 81.7 (s, C4), 79.7 (s, C5), 78.6 (s, C6), 73.9 (s, C7), 
38.9 (s, C1), 0.02, 0.005 (each as s, -Si(CH3)3). Specific rotation: [α]D 28.7  + 22.8  (c = 1.21 
CHCl3). 
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Figure 3.20. 1H and 13C{1H} NMR of 3.3
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4. Chapter 4: Synthesis of cyclopentane- and cyclopropane polyols from styryl-
carbohydrates 
This chapter is adapted with permission from Bender, T. A.; Dabrowski, J. A.; H. 
Zhong, Gagné, M. R. Org. Lett. 2016, 18, 4120-4123. Copyright © 2016 American Chemical 
Society. 
This chapter resulted from a collaboration with Dr. Jennifer Dabrowski and Hongyu 
(Aaron) Zhong. 
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4.1. Coupling deoxygenation with carbon-carbon bond formation 
 
We found previously that competent neighboring groups (e.g. ROSi) can intercept 
silyloxonium intermediates generated under B(C6F5)3 catalyzed hydrosilylation conditions. 
The resulting cyclic intermediates are typically formed in a stereospecific fashion. We sought 
to take advantage of these stereospecific transformations for the formation of interesting 
disconnection, specifically utilizing tethered alkenes to provide carbocycles through carbon-
carbon (C–C) bond formation. Chapter 4 discusses our lab’s progress towards generating 
cylcopropyl and cylcopentane cores in a highly diastereoselective fashion through 
chemoselective activation of carbohydrate derived styryl-carbohydrates. 
4.2. Chemo- and stereoselective formation of carbocycles from 2-deoxy-styryl-sugars 
 
Our initial studies began with a series of polyoxygenated alkenes of 
carbohydrate origin that establish a 1,3 (homoallylic) and 1,5 relationship between an 
olefin and the alcohol targeted for activation. The alkenyl substrate derived from 2-
deoxyribose 4.1 was used for exploratory studies. A general approach to this class of 
compounds utilized a reliable Wittig protocol with partially stabilized PPh3-ylides on 
the unprotected sugars to yield the products as E/Z mixtures.73 
Under optimized reaction conditions (Table 4.1, Entry 1), 4.1 cleanly provides 
the cyclopentane-diol 4.2 as a 9:1 mixture of diastereomers (60%). This product 
reasonably results from preferential activation (by silylium) of the single 1° C–O bond 
(to form the C6–OSi2+), followed by alkenyl attack and carbocation reduction by H–
B(C6F5)3– (Scheme 4.1). Additional mechanistic data suggests that a variant of this 
simple mechanism may also be operative (vide infra). 
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Scheme 4.1. B(C6F5)3 mediated carbocyclization of styryl-fuctionalized ribose. 
 
We reasoned that a substrate lacking the 1,5-relationship between the 
nucleophilic end of the olefin and the 1° C–O bond might favor an alternative ring 
size. Two ring sizes were considered feasible starting from 2-deoxy hexose derived 
4.3, a cyclohexane (C2 onto C7) or cyclopropane (C2 onto C4). Cyclopentane formation 
would require the addition of the alkene onto a hindered 2° position (C6). Under 
optimized reaction conditions (Table 4.1, Entry 2) only a single diastereomer of 
cyclopropane 4.4 was formed (95%), a result of preferential homoallylic C–O 
activation. The gluco-derived epimer of 4.3, 4.5, generated the diastereomeric triol 
cyclopropane (4.6) with high efficiency and selectivity (Table 4.1, Entry 3), indicating 
that the existing stereochemistry does not drastically influence the efficiency or 
selectivity of the reaction. It is worth noting, however, that the yields and/or 
diastereoselectivities are moderately silane dependent and this can be used for 
condition optimization. The silanes indicated in Table 4.1 are the optimum reductants 
for each substrate. Generally, as the steric bulk of the silane decreases, selectivity for 
the intended product also decreases. 
Diene derivatives of the 2-deoxycarbohydrates were also productive and led to 
the analogous carbocycles with a readily functionalized alkene substituent (Entries 4-
7, Table 4.1). Due to the additional stabilization of the allylic group this is consistent 
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B(C6F5)3
OSi
OSi
OSi
Ph
12
3456
PhHO
HO
126
5
4
3
SiO
OSi
O
Ph
R3SiH
Si Si
H–B(C6F5)3
 C–C bond
formation
12
6
4.1 4.2
 117 
with the previous results. It is interesting that the break in olefin conjugation by SN2’ 
is maintained in these substrates. High diastereoselectivity is observed in all cases, 
with hydride delivery to the putative allyl cation occurring to slightly prefer the more 
stable alkene 4.11, 4.13, and 4.16 (75:25 C3 vs. C1 reduction). 
Table 4.1. Formation of cyclopentane and cyclopropane rings 
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Control experiments with B(C6F5)3 alone (11 mol%) led to the slow conversion 
of 4.3 to a new species on a timescale that is slower (18 h) than catalysis. This new 
G
10 mol% B(C6F5)3
R3SiH, CH2Cl2
–30 → RT, 3–18 h;
deprotectionOSi
OSi
n
ProductSubstrate (E/Z)R
OSi
OSi
OSi
4.1 ribo- (85:15 E/Z)
Ph
12
3456
OSi
OSi
OSi
OSi
Ph
1
23
4567
OSi
OSi
OSi
OSi
4.6 gluco- (86:14 E/Z)
Ph
PhHO
HO
60 
90:10 drMe2Et
OH
HO
OH Ph
12
3
4567
H
OH
HO
OH Ph
H
95 
>98:2 dr
82
>98:2 dr
Ph3
Et3
Entry
1
2
3
Yield (%)
12
3
4 5
6
4.3 galacto- (77:23 E/Z)
OSi
OSi
OSi
OSi
3
45
6789
4.10 galacto- (76:24 E,E/E,Z)
Ph
1
2
OH
HO
OH
34
5
67
8
9
H
Ph
71
>98:2 dr
12
4.12 gluco- (65:35 E,E/E,Z)
OH
HO
OH
H
Ph
82
>98:2 dr
OSi
OSi
OSi
4.8 ribo- (76:24 E,E/E,Z)
Ph
2
3
45
678 1
HO
HO 7192:8 dr
Ph
34
8
76
5
1
2
Me2Et4
5
6
OSi
OSi
OSi
OSi
Ph
Me2Et
Me2Et
OSi
OSi
OSi
OSi
3
45
6789
4.15 galacto- (68:32 E,E/E,Z)
1
2
7 Ph3Si
OH
HO
OH
34
5
6789
H
78
>98:2 dr
1
2
GHO
or
G
HO
HO
4.7
4.4
4.2
4.9
4.11
4.13
4.16
 119 
compound was identified as the furan that results from the dehydrative cyclization of 
the C3-OSi onto the primary C7 position (4.17); the E/Z ratio of the styrene is 
unchanged at this stage.77 Subjecting 4.17 to catalytic reduction conditions utilizing 
the less sterically demanding Et3SiH yielded a mixture of primary reduction (hydride 
addition to C7) and cyclopropane 4.4. Stereochemical analysis of the primary 
reduction product confirmed that the dehydrative cyclization is stereoretentive at C3 
(i.e., O3 onto C7). Ring opening reduction of 4.17 with Ph3SiH yields only 4.4 
suggesting that 4.17 may indeed reside on the reaction coordinate (Scheme 4.2). If this 
scenario is responsible for product formation, it suggests that: 1) the enhanced basicity 
of the ethereal oxygen (relative to silyl ether) acts to sequester the silylium ion and 
direct C–C bond formation to between the C2 and C4 positions; and 2) catalytically 
generated silylium ion is even more active than BCF for cyclodehydration. The 
cyclopropanative ring opening of sila-THF+ 4.17’ also provides a model accounting 
for preferred addition of the alkene onto C4 over C7 (Scheme 4.2).78,79 If 
precyclization is a pre-requisite to cyclopropanation, this scenario also explains why 
ribo-based 4.1 only generates a cyclopentane (required 3 or 4 membered oxetane 
intermediate).  
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Scheme 4.2. Model for cyclopropane formation and selectivity. 
4.3. Skeletal rearrangement and carbocyclization from styryl-sugars 
  
The strong dependence on order of addition that we had previously observed when 
performing selective allylic C–O bond hydrosilylation which resulted from cyclic 
intermediate formation presented an interesting question in light of the new reactivity 
observed in these 2-deoxy-styryl carbohydrates. Njardarson and our group have demonstrated 
that allylic C–O bond reductions with the combination of B(C6F5)3 and a silane are facile.28,80 
However, our strategy of intramolecularly trapping the reactive intermediates prior to 
reduction, suggested the possibility of productive C–C bond formation in this class of 
compounds as well. Initial studies were conducted with the galacto-derived alkenyl sugar 
4.18, which is available by recrystallization as a single alkene isomer (E, after the Wittig 
reaction on galactose).73 A priori we thought that cyclohexane products (C2 onto C7) might be 
obtainable this way through preferential primary C–O bond activation.  
Instead of a cyclohexane, however, a single diastereomer of methyl pentene, 
4.19, was obtained as the exclusive product. Deuterium incorporation studies using 
Et3SiD indicated that the skeletal rearrangement proceeds through silyloxycarbenium 
ion 4.20 (Scheme 4.3), which is doubly reduced to 4.21 as a single diastereomer. 
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Analysis by single crystal X-ray diffraction of the p-Br-derivative 4.22 verified that 
the vinyl shift is invertive at C4 to give the indicated stereochemistry. An alternative 
mechanism, which also relies on a precyclization, traverses through sila-oxonium 
4.24, which is analogous to 4.17’ except that it additionally contains an allylic silyl 
ether at C3 and provides the means to stabilize the intermediate resulting from vinyl 
migration (sila-oxo-carbenium ion, 4.20). Methyl cation formation would preclude 
this pathway from being operative in 4.17’. 
 
Scheme 4.3. Proposed mechanism for the vinyl shift converting 4.18 to 4.19. 
Precyclization of 4.18 was performed utilizing stoichiometric quantities of 
TES+ at –78°C (obtained from a combination of TES-H and [trityl][B(C6F5)4]) to form 
4.24.65 Subjecting this THF to the reduction conditions yields 4.19 as a single 
diastereomer. It is thus possible that 4.19 first forms 4.24 on its way to generating the 
vinyl shifted product (Scheme 4.4). The benefit of a precyclization mechanism is that 
it also rationalizes how activation of a relatively hindered internal 2° position (C4) 
occurs to form product, i.e. initial activation of the more accessible 1° position 
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followed by THF formation. The enhanced Lewis basicity of the THF intermediate 
would effectively sequester the silylium ion (generating 4.24) to enable the observed 
reactivity. 
	
Scheme 4.4. Proposed cyclic intermediate yields identical product observed from linear substrate.  
As illustrated in Scheme 4.5, subjecting 4.26 to the combination of B(C6F5)3 
and Me2EtSiH led to a single diastereomer of 4.27, a product with 4 contiguous 
stereocenters (83%). Under optimized conditions, the cyclopentane core could be 
obtained in a single step from 4.18, and is thus available from galactose in three steps 
(Wittig, TMS-protection, cyclization/reduction, Table 4.2).  
	
Scheme 4.5. Cyclopentane synthesis from methyl-pentane product. 
 
Altering the stereochemical array of the poly-ol portion had little effect on the 
efficiency and selectivity of the vinyl migration/cyclization reaction cascade. The 
stereoablation of C3 converges the manno- or gluco-derived substrates on to 
cyclopentane (4.32) in identical yields and selectivities (86:14 dr, Entries 3-4, Table 
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2). Similar reactivity was observed with the diene terminated substrates (not shown), 
but the SN2/SN2’ selectivity in the reduction of the allyl cation is poor (~1:1) and 
difficult to isolate in good yields. 
Table 4.2. Cyclopentane formation from styryl-sugars. 
 
Under the reductive conditions of B(C6F5)3 and tertiary silanes, the exo-
cyclizations described herein follow the trend of 5 (1°) > 3 (2°) > 6 (1°), where the 
substitution of the activated C–O leaving group is indicated. This trend’s caveat, 
however, is the potential for transiently formed heterocyclic intermediate that alter the 
inherent kinetic profiles. The carbocyclizations themselves are operationally 
straightforward, highly selective, and efficient at converting alkene containing 
biomass-derived feedstock materials into stereochemically complex materials. Our 
experiments establish the role of neighbouring group participation in guiding the 
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reductions, while also revealing a set of reactivity principles that enable the predictive 
synthesis of new synthons from renewable feedstocks. Our results make clear that 
B(C6F5)3 and “R3Si+” provide unique Lewis acidity profiles, with consequent control 
over the extent and stereochemistry of the resulting carbocyclization reactions. 
4.4. Experimental Section 
 
Unless otherwise stated, all reactions were conducted under a nitrogen atmosphere 
using a Vacuum Atmospheres glovebox. “Dowex® resin” refers to Dowex® 50W-X8, a 
strongly acidic cation exchange resin distributed by Baker Chemical Company. PPTS resin 
refers to pyridinium p-toluene sulfonate polymer-bound with extent of labeling 3.5 mmol/g 
toluene for sulfonate loading and was purchased from Aldrich. Before use both resins were 
washed five times with methanol and five times with methylene chloride and then allowed to 
dry at ambient pressure. All workup procedures were performed under air with reagent grade 
reagents unless otherwise specified. Alumina refers to Brockmann activity I neutral alumina 
gel (Aldrich) that was treated with 10% deionzed water. Thin layer chromatography (TLC) 
was performed on SiliCycle Silica Gel 60 F254 plates and was visualized with UV light, 
cerium ammonium molybdate (CAM) stain, or potassium permanganate (KMnO4) stain. 
Methylene chloride-d2 was purchased from Cambridge Isotope labs. Both CD2Cl2 and 
CH2Cl2 were degassed via three freeze-pump-thaw cycles, and dried over 4Å molecular 
sieves prior to use. D-galactose, D-mannose, D-glucose, D-ribose were purchased from 
Sigma-Aldrich and used as received. D-xylose, D-lyxose, and L-fucose were purchase from 
Carbosynth and used as received. Me2EtSiH, Et3SiH, i-Pr3SiH, and Et3SiD ampules were 
purchased from Sigma-Aldrich and stored over molecular 4Å sieves in the glovebox. Ph3SiH 
was purchased from Sigma-Aldrich and used as received. Dioxane (anhydrous, 99%), 
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pyridine (anhydrous, 99%), benzyltriphenylphosphonium chloride, potassium tert-butoxide, 
dichloromethane, pyridinium-para-toluenesulfonate (PPTS), triethylamine, 3-bromo-1-
phenyl-1-propene (cinnamyl bromide), 3,3-dimethylallylbromide, and copper sulfate were 
purchased from Sigma-Aldrich and used as received. Methanol was purchased from Fisher 
and used as received. Aldrich and used as received. Tris(pentafluorophenyl)borane 
(B(C6F5)3) was purchased from Strem and used as received. 
Room-temperature NMR spectra were recorded using a Bruker Avance III 
spectrometer equipped with a cryoprobe operating at 600 MHz (1H) and 150 MHz (13C). 
NMR chemical shifts are reported in ppm and referenced using the residual proton peaks (d 
CHCl3 = 7.26, d CH2Cl2 = 5.32), 13C resonances of the deuterated solvent (d CDCl3 = 77.16, 
d CD2Cl2 = 53.84) or the proteo solvent (d CH2Cl2 = 54.24). Low temperature NMR spectra 
were recorded using a Bruker Avance III spectrometer equipped with a BBO probe operating 
at 500 MHz (1H) and 125 MHz (13C). High resolution mass spectra were obtained on either 
an Agilent Accurate LC-TOF Mass Spectrometer (Agilent Series 6220) operating in positive 
ion mode with an electrospray ionization source (fragmentor = 175 V) or with a hybrid LTQ 
FT (ICR 7T) (ThermoFisher, Bremen, Germany) mass spectrometer where samples were 
introduced via a micro-electrospray source at a flow rate of 3 µL/min. The data were 
analyzed using either Agilent MassHunter Workstation Software, Qualitative Analysis (V. 
B.02.00) or Xcalibur (ThermoFisher, Breman, Germany). Specific rotations were obtained on 
a Jasco DIP-1000 digital polarimeter equipped with a sodium lamp utilizing a 3.5 x 100 mm 
cell. A NesLab cryobath CB-80 was utilized for reduced temperature reactions where 
temperature was verified by low-temperature thermometer. The numbering used for starting 
material and products is based on the parent sugar. 
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General procedure 4.1 
All alkenyl substrates were prepared following a modified protocol from a previous 
publication. A flame-dried 500 mL flask with a magnetic stir bar was placed under a flow of 
nitrogen. Benzyltriphenylphosphonium chloride (11.6 g, 30 mmol) followed by potassium 
tert-butoxide was added to the flask. A reflux condenser was attached and anhydrous dioxane 
(120 mL) was added. The reaction was allowed to stirred for 30 minutes at 25 ºC and then 
placed into an 80 ºC oil bath to stir for an additional 30 minutes. The sugar was then added 
under positive nitrogen pressure and the reaction was allowed to reflux for 2 h (the reaction 
went from dark red to yellow over the reaction time). Water (10 mL) was added and the 
reaction was concentrated under vacuum to yield a sticky yellow material. The E-olefin was 
isolated by crystallization from warm methanol. The other products were isolated by silica 
gel chromatography (30 x 5 cm column) using gradient elution (20:1 to 15:1 to 10:1 to 7:1 
CH2Cl2:MeOH) to afford the unprotected alkenyl carbohydrates.  
General procedure 4.2 
All silane protected C6On substrates were prepared following a modified protocol to 
those of previous publications. To a 20-mL scintillation vial charged with a magnetic stir bar, 
substrate is added (5.0 mmol, 1.0 equiv.) followed by CH2Cl2 (5.0 mL). To this, pyridine (6.5 
mmol, 1.1 equiv. per –OH group plus 1.0 equiv.) is added followed by the dropwise addition 
of chlorotrialkylsilane (5.5 equiv., 1.1 equiv. per –OH group). The vial is capped and allowed 
to stir at 25 ºC for 12 h. After the reaction time, deoionized water is added (5.0 mL) and the 
reaction mixture is transferred to a separatory funnel, the reaction vessel is rinsed with 
diethyl ether (3 x 5 mL) and added to the separatory funnel as well. An additional 15 mL of 
diethyl ether is added and the layers are separated. The aqueous layer is subsequently washed 
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with diethyl ether (2 x 20 mL) and all organic layers are then combined. In the cases that a 
volatile substrate is being prepared, the organic layers are washed with a 10 % (w/w) of 
CuSO4 solution until the color does not visibly change to remove residual pyridine. The 
organic layers are collected and washed with water (3 x 20 mL), brine (3 x 20 mL), and then 
dried over sodium sulfate. Solid is filtered off over a cotton plug and the organic is 
concentrated down to yield the final product as either a white solid or colorless oil. 
Trituration with toluene is performed on non-volatile materials to remove pyridine. 
To remove residual pyridine salts the substrate is passed over an alumina column 
(neutral, 10% H2O; 3 x 1 in) using gradient elution (100% to 95:5 hexanes/diethyl ether). 
Fractions containing product are collected and concentrated down. The residue is then placed 
under high vacuum for a minimum of 12 h prior to bringing into the glovebox for use. All of 
the materials once degassed are then brought into the glovebox and stored in scintillation 
vials at 25 ºC and used as prepared.  
Me3Si-styryl-2-deoxyribose (4.1): Prepared and used as a 
85:15 E/Z mixture. 1H NMR (400 MHz, CDCl3): δ 7.36–7.33 
(m, 4H, Ph, E/Z), 7.33–7.28 (m, 4H, Ph, E/Z), 7.23–7.17 (m, 
2H, Ph, E/Z), 6.52 (d, J = 11.7 Hz, 1H, Z), 6.43 (d, J = 15.9 Hz, 1H, E), 6.24 (ddd, J = 15.8, 
7.8, 6.8 Hz, 1H, E), 5.76 (dt, J = 11.7, 7.4 Hz, 1H, Z), 3.83–3.78 (m, 2H, E/Z), 3.69 (dd, J = 
10.3, 3.7 Hz, 1H, E), 3.66–3.59 (m, 3H, E/Z), 3.54 (dd, J = 10.3, 6.0 Hz, 1H, E), 3.50 (dd, J = 
10.2, 6.0 Hz, 1H, Z), 2.58–2.54 (m, 2H, Z), 2.52–2.46 (m, 1H, E), 2.41–2.32 (m, 1H, E), 0.15 
(s, 9H, -Si(CH3)3), 0.13 (s, 9H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3), 0.10 (s, 9H, -Si(CH3)3), 
0.10 (s, 2H, -Si(CH3)3), 0.08 (s, 9H, -Si(CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 137.7 
(s), 137.5 (s), 132.1 (s), 130.4 (s), 129.3 (s), 128.8 (s), 128.5 (s), 128.0 (s), 127.5 (s), 126.9 
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(s), 126.5 (s), 125.9 (s), 76.6 (s), 76.57 (s), 73.6 (s), 73.5 (s), 64.0 (s), 63.9 (s), 37.1 (s), 32.3 
(s), 0.54, 0.5, 0.46, 0.4, -0.5, -0.55 (each a s, -Si(CH3)3). 
Me3Si-styryl-2-deoxygalactose (4.3): Prepared following 
general procedure 4.1 followed by general procedure 4.2 and 
used as a 77:23 E/Z mixture. 1H NMR (400 MHz, CDCl3): δ 
7.41–7.28 (m, 8H, Ph, E/Z), 7.24–7.17 (m, 2H, Ph, E/Z), 6.51 (dd, J = 11.7, 1.8 Hz, 1H, Z), 
6.41 (d, J = 15.9 Hz, 1H, E), 6.26 (dt, J = 15.8, 7.2 Hz, 1H, E), 5.74 (ddd, J = 11.7, 8.0 Hz, 
6.8 Hz, 1H, Z), 3.94 (t, J = 2.9 Hz, 1H, Z), 3.91 (ddd, J = 7.4, 4.3, 2.6 Hz, 1H, E), 3.76–3.67 
(m, 4H, E/Z), 3.66–3.63 (m, 1H, E), 3.62 (d, J = 4.5 Hz, 1H, Z), 3.58 (dd, J = 9.9 Hz, 5.2 Hz, 
1H, E), 3.55–3.48 (m, 1H, Z), 2.82–2.67 (m, 1H, Z), 2.50–2.40 (m, 3H, E/Z), 0.18 (s, 9H, -
Si(CH3)3), 0.17 (s, 9H, -Si(CH3)3), 0.14 (s, 9H, -Si(CH3)3), 0.14 (s, 9H, -Si(CH3)3), 0.13 (s, 
9H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3), 0.12 (s, 9H, -Si(CH3)3). (*Note: one Z/E-TMS group 
is overlapping.) 13C{1H} NMR (101 MHz, CDCl3): δ 137.9 (s), 137.7 (s), 131.5 (s), 130.4 
(s), 130.1 (s), 128.8 (s), 128.7 (s), 128.4 (s), 128.0 (s), 126.7 (s), 126.4 (s), 125.9 (s), 78.1 (s), 
77.9 (s), 75.5 (s), 75.4 (s), 73.7 (s), 64.1 (s), 64.1 (s), 36.4 (s), 31.8 (s), 0.7, 0.68, 0.6, 0.57, 
0.5, -0.46, -0.5 (each a s, -Si(CH3)3). (*Note: one Z/E-TMS group is overlapping and one Z/E 
C–O carbon is overlapping.) 
 
Me3Si-styryl-2-deoxyglucose (4.6): Prepared following 
general procedure 4.1 followed by 4.2 and used as a 86:14 
E/Z mixture. 1H NMR (600 MHz, CDCl3): δ 7.35–7.19 (m, 
8H, Ph, E/Z), 7.24-7.17 (m, 2H, Ph, E/Z), 6.49 (d, J = 11.8 Hz, 1H, Z), 6.42 (d, J = 15.9 Hz, 
1H, E), 6.22 (ddd, J = 14.4, 8.4 Hz, 1H, E), 5.73 (ddd, J = 14.4, 7.2 Hz, 1H, Z), 3.87–3.81 
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(m, 3H, Z/E), 3.75 (dd, J = 10.5, 3.7 Hz, 1H, E), 3.73–3.67 (m, 2H, Z), 3.64–3.56 (m, 2H, 
Z/E), 3.48 (dd, J = 7.2, 3.6 Hz, 1H, E), 3.43 (dd, J = 6.6, 3.6 Hz, 1H, Z), 2.60–2.56 (m, 2H, 
Z), 2.54–2.50 (m, 1H, E), 2.39–2.34 (m, 1H, E), 0.14 (s, 9H, -Si(CH3)3), 0.12 (s, 18H, -
Si(CH3)3), 0.10 (s, 9H, -Si(CH3)3), 0.083 (s, 9H, -Si(CH3)3), 0.071 (s, 9H, -Si(CH3)3). 
13C{1H} NMR (151 MHz, CDCl3): δ 137.9 (s), 137.7 (s), 132.1 (s), 130.4 (s), 129.4 (s), 
129.0 (s), 128.6 (s), 128.3 (s), 127.6 (s), 127.1 (s), 126.7 (s), 126.1 (s), 78.7 (s), 78.2 (s), 74.3 
(s), 74.27 (s), 74.0 (s), 73.9 (s), 64.0 (s), 63.9 (s), 37.6 (s), 33.0 (s), 0.84, 0.81, 0.66, 0.54, 
0.50, -0.51, -0.55 (each a s, -Si(CH3)3). (*Note: one Z/E-TMS group is overlapping.) 
Me2EtSi-styryl-2-deoxyribose diene (4.8): Prepared 
following general procedure 4.1 followed by 4.2 and 
used as a 76:24 E/Z mixture. 1H NMR (500 MHz, 
CDCl3): δ 7.44–7.37 (m, 4H, Ph, E,E/E,Z), 7.35–7.27 (m, 4H, Ph, E,E/E,Z), 7.25–7.17 (m, 
Ph, 2H, E,E/E,Z), 7.07 (ddd, J = 15.6, 11.0, 1.2 Hz, 1H, E,Z), 6.77 (dd, J = 15.6, 10.5 Hz, 1H, 
E/E), 6.53 (d, J = 15.6 Hz, 1H, E,Z), 6.45 (d, J = 15.6 Hz, 1H, E/E), 6.24 (dd, J = 15.6, 10.3 
Hz, 2H, E,E/E,Z), 5.83 (dt, J = 15.0, 7.4 Hz, 1H, E/E), 5.60 (dt, J = 10.7, 7.7 Hz, 1H, E,Z), 
3.80–3.76 (m, 1H, E,Z), 3.76–3.72 (m, 1H, E/E), 3.71–3.63 (m, 3H, E,E/E,Z), 3.64–3.57 (m, 
1H, E,E), 3.54–3.46 (m, 2H, E,E/E,Z), 2.58–2.44 (m, 2H, E,Z), 2.44–2.35 (m, 1H, E,E), 
2.36–2.25 (m, 1H, E,E), 1.00–0.88 (m, 18H, -Si(CH3)2(CH2CH3)), 0.68–0.52 (m, 12H, -
Si(CH3)2(CH2CH3)), 0.12 (s, 3H, -Si(CH3)2(CH2CH3)), 0.11 (s, 6H, -Si(CH3)2(CH2CH3)), 
0.109 (s, 6H, -Si(CH3)2(CH2CH3)), 0.09 (s, 9H, -Si(CH3)2 (CH2CH3)), 0.08 (s, 12H, -
Si(CH3)2(CH2CH3)). 13C{1H} NMR (151 MHz, CDCl3): δ 137.64 (s), 137.60 (s), 132.9 (s), 
132.2 (s), 130.4 (s), 130.3 (s), 129.5 (s), 129.3 (s), 128.6 (s), 127.3 (s), 127.1 (s), 126.3 (s), 
126.2 (s), 124.8 (s), 76.7 (s), 73.7 (s), 73.6 (s), 64.3 (s), 64.25 (s), 36.8 (s), 31.8 (s), 8.8, 8.7, 
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7.9, 7.0, 6.9, 6.8, -1.68, -1.7, -1.76, - 1.77, -1.8, -2.7 (each a s, -Si(CH3)2(CH2CH3), -
Si(CH3)2(CH2CH3) or -Si(CH3)2(CH2CH3)). (*Note: Two sp2 carbon peaks, 1 C–O bond and 
in the silane region there are signals overlapping). 
Me2EtSi-styryl-2-deoxygalactose diene (4.10): 
Prepared following general procedure 4.1 followed 
by 4.2  and used as a 76:34 E,E/E,Z mixture. 1H 
NMR (600 MHz, CDCl3): δ 7.45–7.36 (m, 4H, Ph, E,E/E,Z), 7.36–7.29 (m, 4H, Ph, E,E/E,Z), 
7.24–7.17 (m, 2H, Ph, E,E/E,Z), 7.10 (ddt, J = 15.5, 11.1, 1.2 Hz, 1H, E,Z), 6.76 (dd, J = 
15.7, 10.4 Hz, 1H, E,E), 6.53 (d, J = 15.6 Hz, 1H, E,Z), 6.45 (d, J = 15.7 Hz, 1H, E,E), 6.31–
6.13 (m, 2H, E,E/E,Z), 5.83 (dt, J = 14.9, 7.3 Hz, 1H, E,E), 5.59 (dt, J = 10.7, 7.7 Hz, 1H, 
E,Z), 3.91–3.81 (m, 2H, E,E/E,Z), 3.76–3.73 (m, 1H, E,Z), 3.72–3.63 (m, 5H, E,E/E,Z), 3.61–
3.53 (m, 2H, E,E/E,Z), 2.66–2.56 (m, 1H, E,Z), 2.46–2.30 (m, 3H, E,E/E,Z), 1.03–0.87 (m, 
24H, -Si(CH3)2(CH2CH3)), 0.70–0.51 (m, 16H, -Si(CH3)2(CH2CH3)), 0.18–0.06 (m, 48H, -
Si(CH3)2(CH2CH3)). (*Note: E,E/E,Z Si(CH3)2(CH2CH3) are overlapping). 13C{1H} NMR 
(151 MHz, CDCl3): δ 137.6 (s), 137.6 (s), 132.6 (s), 132.4 (s), 132.3 (s), 130.3 (s), 130.1 (s), 
129.6 (s), 129.3 (s), 128.5 (s), 128.5 (s), 127.3 (s), 127.1 (s), 126.3 (s), 126.2 (s), 124.6 (s), 
78.1 (s), 78.0 (s), 76.0 (s), 75.9 (s), 73.8 (s), 73.7 (s), 64.1 (s), 36.4 (s), 31.5 (s), 8.8, 8.78, 
8.76, 8.74, 8.7, 8.0, 7.9, 7.0, 6.96, 6.94, 6.9, 6.8, -1.66, -1.69, -1.7, -1.74, -1.77, -1.81, 1.83, -
1.85, -1.90 -2.7, -2.7, (each a s, -Si(CH3)2(CH2CH3), -Si(CH3)2(CH2CH3) or -
Si(CH3)2(CH2CH3)). (*Note: Overlap of 1 C–O bond and overlapping in silane region). 
Me2EtSi-styryl-2-deoxyglucose diene (4.12): 
Prepared following general procedure 4.1 followed 
by general procedure 4.2 and used as a 65:35 E,E/E,Z 
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mixture. 1H NMR (600 MHz, CDCl3): δ 7.45–7.36 (m, 4H, Ph, E,E/E,Z), 7.35–7.28 (m, 4H, 
Ph, E,E/E,Z), 7.23–7.19 (m, 2H, Ph, E,E/E,Z), 7.05 (ddd, J = 15.5 Hz, 11.1 Hz, 1.2 Hz, 1H, 
E,Z), 6.76 (ddd, J = 15.7, 10.4, 0.8 Hz, 1H, E,E), 6.53 (d, J = 15.6 Hz, 1H, E,Z), 6.45 (d, J = 
15.7 Hz, 1H, E,E), 6.27–6.13 (m, 2H, E,E/E,Z), 5.83 (m, 1H, E,E), 5.59 (dt, J = 10.7 Hz, 7.7 
Hz, 1H, E,Z), 3.85–3.80 (m, 2H, E,E/E,Z), 3.80–3.68 (m, 4H, E,E/E,Z), 3.62 (dd, J = 5.5 Hz, 
2.6 Hz, 1H, E,Z), 3.60 (dd, J = 5.7 Hz, 2.5 Hz, 1H, E,E), 3.51–3.42 (m, 2H, E,E/E,Z), 2.57–
2.49 (m, 2H, E,Z), 2.48–2.43 (m, 1H, E,E), 2.33–2.26 (m, 1H, E,E), 0.99–0.88 (m, 24H, -
Si(CH3)2(CH2CH3)), 0.64–0.53 (m, 16H, -Si(CH3)2(CH2CH3)), 0.11–0.06 (m, 48H, -
Si(CH3)2(CH2CH3)). (*Note: E,E/E,Z Si(CH3)2(CH2CH3) are overlapping). 13C{1H} NMR 
(151 MHz, CDCl3): δ 137.6 (s), 137.6 (s), 132.6 (s), 132.4 (s), 132.3 (s), 130.3 (s), 130.1 (s), 
129.6 (s), 129.3 (s), 128.5 (s), 128.5 (s), 127.3 (s), 127.1 (s), 126.3 (s), 126.2 (s), 124.6 (s), 
78.7 (s), 78.4 (s), 74.6 (s), 74.3 (s), 74.1 (s), 74.0 (s), 64.2 (s), 64.0 (s), 37.3 (s), 32.2 (s), 8.9, 
8.84, 8.83, 8.7, 8.0, 7.9, 7.0, 6.96, 6.95, 6.93, 6.9, 6.8, -1.5, -1.6, -1.62, -1.64, -1.69, -1.7, -
1.8, -1.9, -2.7, -2.74, -2.76, -2.8 (each a s, -Si(CH3)2 (CH2CH3), -Si(CH3)2(CH2CH3) or -
Si(CH3)2(CH2CH3)). (*Note: Overlapping in silane region). 
Me3Si-2-deoxygalactose prenyldiene (4.15): Prepared 
following general procedure 4.1 followed by 4.2 and used as 
a 68:32 E,E/E,Z mixture. 1H NMR (600 MHz, CDCl3): δ 
6.28–6.17 (m, 2H, E,E/E,Z), 6.08 (ddt, J = 11.3, 2.8, 1.4 Hz, 1H, E,Z), 5.78 (ddt, J = 10.8, 
2.4, 1.3 Hz, 1H, E,E), 5.53 (dt, J = 14.9, 7.4 Hz, 1H, E,E), 5.37 (dt, J = 11.0, 7.5 Hz, 1H, 
E,Z), 3.82–3.74 (m, 2H, E,E/E,Z), 3.69–3.59 (m, 6H, E,E/E,Z), 3.55–3.50 (m, 2H, E,E/E,Z), 
2.45–2.33 (m, 2H, E,Z), 2.31–2.27 (m, 2H, E,E), 1.79 (s, 3H, E,Z), 1.75 (s, 3H, E,E), 1.74 (s, 
3H, E,Z), 1.73 (s, 3H, E,E), 0.14 (s, 18H, E,E/E,Z), 0.13 (s, 18H, E,E/E,Z), 0.125 (s, 9H, 
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E,Z), 0. 11 (s, 18H, E,E/E,Z), 0.08 (s, 9H, E,E). 13C{1H} NMR (151 MHz, CDCl3): δ 134.6 
(s), 132.7 (s), 129.2 (s), 128.6 (s), 126.6 (s), 126.0 (s), 125.1 (s), 121.0 (s), 77.81 (s), 77.8 (s), 
75.4 (s), 75.3 (s), 73.8 (s), 73.6 (s), 64.1 (s), 64.0 (s), 36.2 (s), 30.8 (s), 26.3 (s), 25.9 (s), 18.2 
(s), 18.0 (s), 0.73, 0.71, 0.69, 0.6, 0.5, -0.48 each a s, -Si(CH3)3 . (*Note: two sets of silane 
peaks overlap in the carbon NMR). 
General procedure 4.3: Cyclopropane formation from styryl carbohydrate substrate 
In a nitrogen-filled glovebox, a 1-dram vial was charged with B(C6F5)3 (5.9 mg, 
0.012 mmol, 0.11 equiv.) then triphenylsilane (28.6 mg, 0.110 mmol, 1.02 equiv.), then  
Me3Si-styryl carbohydrate (1.00 equiv.) and a magnetic stir bar. By syringe CH2Cl2 (0.5 mL) 
was added. The vial was sealed with a septa cap and removed from the glovebox and allowed 
to stir at 22 °C. After reaction time, NEt3 (0.05 mL) was added by syringe through the septa 
and the stir bar was removed, rinsing with CH2Cl2 (2 mL). The quenched reaction mixture 
was concentrated under vacuum and then loaded onto an alumina plug (neutral, 10% H2O; 2 
x 1 cm) with 100% hexanes (1.5 mL) then 95:5 hexanes:diethyl ether (1.5 mL), eluting with 
95:5 hexanes:diethyl ether (10 mL) into a tared vial. The solution was concentrated under 
vacuum to afford a colorless oil that was subsequently deprotected vide infra. 
General procedure 4.4: Cyclopentane formation from styryl carbohydrate substrate 
  In a nitrogen-filled glovebox, a 1-dram vial was charged with Me3Si-styryl 
carbohydrate (1.00 equiv.) and a magnetic stir bar. A separate 1-dram vial was charged with 
B(C6F5)3 (5.0 mg, 0.0098 mmol, 0.098 equiv.) and CH2Cl2 (0.5 mL). The vials were sealed 
with a septa cap and removed from the glovebox. The vials were allowed to cool to –30 °C 
(dry ice/acetone bath). The B(C6F5)3 solution was transferred to the substrate by syringe and 
allowed to stir as the dimethylethylsilane (50.0 µL, 0.379 mmol, 3.79 equiv.) was added by 
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microliter syringe under positive N2 pressure. The vial cap was wrapped with electrical tape 
and transferred to a –30 °C cryobath and allowed to stir. After 12 hours, NEt3 (0.05 mL) was 
added by syringe through the septum and the stir bar was removed, rinsing with CH2Cl2 (0.2 
mL). The quenched reaction mixture was concentrated under vacuum and then loaded onto 
an alumina plug (neutral, 10% H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 95:5 
hexanes:diethyl ether (1.5 mL), eluting with 95:5 hexanes:diethyl ether (10 mL) into a tared 
vial. The solution was concentrated under vacuum to afford a colorless oil that was 
subsequently deprotected vide infra. 
General procedure 4.5: Deprotection to alcohol 
The vial containing the silyl substrate was equipped with a stir bar and charged with 
Dowex® resin (~10 beads). Methanol (2.0 mL) was added by syringe and the resulting 
solution was allowed to stir at 25 °C. After 2-3 h, the solution was passed through sand (0.1 
cm) to remove the Dowex® beads into a tared vial, rinsing with 100% methanol. Products 
were purified by silica gel chromatography (4 x 1 cm column) using gradient elution (100% 
CH2Cl2 to 20:1 to 15:1 to 10:1 to 9:1 CH2Cl2:MeOH) to afford the desired product. 
Preparation of carbocycle 4.2 
 
 
Following general procedure 4.4 combined 42.2 mg Me3Si-styryl 2-deoxyribose 4.1, 
4.9 mg B(C6F5)3, 20 µL dimethylethylsilane and 0.5 mL dichloromethane.  Quenched after 12 
hours and deprotected following general procedure 4.5. The product was purified by silica 
gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 
1) 10 mol % B(C6F5)3
1.5 equiv. Me2EtSiH, 
CH2Cl2, –30 ºC, 12 h;
2) Dowex, MeOH
RT, 2 h
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OSiMe3
OSiMe3
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to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me3Si-styryl 2-deoxyribose 4.2 as a 
colorless oil (11.5 mg, 60% overall yield over 2 steps, 0.0598 mmol, 90:10 dr). Cyclopentane 
4.2: 1H NMR (600 MHz, CD3OD): δ 7.26 (t, J = 7.2 Hz, 2H, Ph), 7.19–7.15 (m, 3H, Ph), 
3.94–3.91 (m, 2H, H4 & H5), 2.80 (d, JH1,H2 = 7.8 Hz, 2H, H1), 2.14 (app quintet, JH2,H3 = JH2, 
H6 = JH2,H1 = 8.4 Hz, 1H, H2), 1.96 (ddd, JH3/6,H3’/6’ = 14.4 Hz, JH3/6,H2= 8.4 Hz, JH3/6,H4/5 = 6.6 
Hz, 2H, H3 & H6), 1.44 (ddd, JH3’/6’,H3/6= 14.4 Hz, J H3’/6’,H2 = 8.4 Hz, J H3’/6’,H4/5 = JH = 6.0 Hz, 
2H, H3’ & H6’). 13C{1H} NMR (151 MHz, CD3OD): δ 142.9 (s, Ar), 129.8 (s, Ar), 129.2 (s, 
Ar), 126.8 (s, Ar), 74.5 (s, C5 & C4), 44.4 (s, C1), 38.5 (s, C3 & C6), 36.8 (s, C2). HRMS 
(ESI+): Calcd for C12H16O2Na [M+Na]+: 215.1043; Found: 215.1050. Specific rotation: [α]D 
24.9  +14.  (c = 0.24 CH3OH). 
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Figure 4.1. 1H and 13C{1H} spectrum for carbocycle 4.2. 
Preparation of carbocycle 4.4 
 
 
 
 
Following general procedure 4.3, combined 56.7 mg Me3Si-styryl 2-galactose 4.3, 4.9 
mg B(C6F5)3, 28.6 mg triphenylsilane and 0.5 mL dichloromethane.  Quenched after 16 hours 
and deprotected following general procedure 4.5. The product was purified by silica gel 
chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 49:1 to 
48:1 to 47:1 to 46:1 to 45:1 CH2Cl2:MeOH) to afford cyclopropane from Me3Si-styryl 2-
deoxygalactose 4.4 as a white solid (22.9 mg, 95% overall yield over 2 steps, 0.103 mmol, 
>98:2 dr). Note: Stereochemistry assigned by NOE between H4 and H1. Cyclopropane 4.4: 
1H NMR (600 MHz, CD3OD): δ 7.31–7.25 (m, 4H, Ar), 7.18–7.15 (m, 1H, Ar), 3.70–3.67 
(m, 1H, H7), 3.59–3.55 (m, 2H, H7’ & H6), 2.97 (dd, JH5,H4 = 8.4 Hz, JH5,H6 = 4.2 Hz, 1H, H5), 
2.85 (dd, JH1,H1’ = 14.4 Hz, JH1,H2 = 5.4 Hz, 1H, H1), 2.43 (dd, JH1’,H1 = 14.4 Hz, JH1’,H2 = 7.2 
1) 11 mol % B(C6F5)3
1.0 equiv. Ph3SiH, 
CH2Cl2, RT, 16 h;
2) Dowex, MeOH
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Hz, 1H, H1’), 1.12–1.06 (m, 1H, H2), 0.95 (dddd, JH4,H2 = 17.4 Hz, JH4,H3 = 8.4 Hz, JH4,H3’ = 
4.8 Hz, JH4,H5 = 4.8 Hz, 1H, H4), 0.52 (ddd, JH3,H4 = 8.4 Hz, JH3,H2 = 4.8 Hz, JH3,H3’ = 4.8 Hz, 
1H, H3), 0.46 (ddd, JH3’,H4 = 8.4 Hz, JH3’,H2 = 4.8 Hz, JH3’,H3 = 4.8 Hz, 1H, H3’). 13C{1H} 
NMR (151 MHz, CD3OD): δ 142.9 (s, Ar), 129.5 (s, Ar), 129.2 (s, Ar), 126.8 (s, Ar), 76.7 (s, 
C5), 76.3 (s, C6), 64.4 (s, C7), 40.4 (s, C1), 22.6 (s, C4), 19.0 (s, C2), 10.3 (s, C3). HRMS 
(ESI+): Calcd for C13H18O3Na [M+Na]+: 245.1148; Found: 245.1153. Specific rotation: [α]D 
24.9  –24.  (c = 0.44 CH3OH). 
 
 
 
Figure 4.2. 1H and 13C{1H} spectrum for carbocycle 4.4. 
Preparation of carbocycle 4.7: 
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Following general procedure 4.4, combined 52.7 mg Me3Si-styryl 2-glucose 4.6, 4.9 
mg B(C6F5)3, 32 µL triethylsilane and 0.5 mL dichloromethane.  Quenched after 18 hours and 
deprotected following general procedure 4.5. The product was purified by silica gel 
chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 to 
40:1 CH2Cl2:MeOH) to afford carbocycle from Me3Si-styryl 2-deoxyglucose 4.7 as a white 
solid (18.2 mg, 82% overall yield over 2 steps, 0.0819 mmol, >98:2 dr). Note: 
Stereochemistry assigned by NOE between H4 and H1. Cyclopropane 4.7: 1H NMR (600 
MHz, CD3OD): δ 7.27–7.22 (m, 4H, Ph), 7.17–7.14 (m, 1H, Ph), 3.66 (dd, JH7,H7’ = 10.2 Hz,  
JH7,H6 = 3.0 Hz, 1H, H7), 3.58-3.54 (m, 2H, H6 & H7’), 3.07 (dd, JH5,H4 = 7.8 Hz, JH5,H6 = 4.2 
Hz, 1H, H5), 2.73 (dd, JH1, H1’ = 14.4 Hz, JH1,H2 = 6.0 Hz, 1H, H1), 2.50 (dd, JH1’ H1 = 14.4 Hz, 
JH1’, H2 = 7.2 Hz, 1H, H1’), 1.03–0.91 (m, 1H, H2), 0.95–0.91 (m, 1H, H4), 0.57 (ddd, JH3,H3’ = 
9.0 Hz, JH3,H2 = JH3,H4 = 4.8 Hz, 1H, H3), 0.43 (ddd, JH3’,H3 = 9.0 Hz, JH3’,H2 = JH3’,H4 = 5.4 Hz, 
1H, H3’). 13C {1H} NMR (151 MHz, CD3OD): δ 142.8 (s, Ph), 129.5 (s, Ph), 129.3 (s, Ph), 
126.9 (s, Ph), 76.8 (s, C5), 76.5 (s, C6), 64.4 (s, C7), 40.3 (s, C1), 21.6 (s, C4), 18.9 (s, C2), 9.8 
(s, C3). HRMS (ESI+): Calcd for C13H18O3Na [M+Na]+: 245.1148; Found: 245.1153. Specific 
rotation: [α]D 24.9  –35  (c = 0.11 CH3OH). 
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Figure 4.3. 1H and 13C{1H} spectrum for carbocycle 4.7. 
Preparation of carbocycle 4.9 and 4.9’ 
 
 
 
Following general procedure 4.4, combined 49.2 mg Me3Si-styryl 2-deoxyribose 
diene 4.8, 5.1 mg B(C6F5)3, 40 µL dimethylethylsilane and 0.5 mL dichloromethane.  
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Quenched after 24 hours and deprotected following general procedure 4.5. The product was 
purified by silica gel chromatography (5 x 1 cm column) using gradient elution (100% 
CH2Cl2 to 50:1 to 45:1 to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me2EtSi-styryl-2-
deoxyribose 4.9/4.9’ as a white solid (15.4 mg, 71% overall yield over 2 steps, 0.0709 mmol, 
>98:2 dr, and 55:45 SN2’/SN2’’). Cyclopentane 4.9: 1H NMR (600 MHz, CD3OD): δ 7.33 
(app d, J = 7.3 Hz, 1H, Ph), 7.28–7.22 (m, 2H, Ph), 7.16 (app t, J = 8.2 Hz, 2H, Ph), 6.40 (d, 
JH1,H2 = 15.8 Hz, 1H, H1), 6.22 (dt, JH2,H1 = 15.7 Hz, JH2,H3 = 7.1 Hz, 1H, H2), 3.96–3.88 (m, 
2H, H6 & H7), 2.31 (app t, JH3,H4 = JH3,H2 = 7.1 Hz, 2H, H3), 2.09–2.02 (m, 2H, H8 & H5), 
2.02–1.92 (m, 1H, H4), 1.48–1.43 (m, 2H, H8’ & H5’). 13C {1H} NMR (151 MHz, CD3OD): δ 
137.8 (s, Ph), 130.6 (s, C1), 129.1 (s, C2), 128.1 (s, Ph), 126.5 (s, Ph), 125.6 (s, Ph), 73.2 (s, 
C6 & C7), 41.8 (s, C3), 39.4 (s, C5 & C8), 34.2 (s, C4). HRMS (ESI+): Calcd for C14H18O3Na 
[M+Na]+: 271.1305; Found: 271.1310. Specific rotation: [α]D 25.8  +0.5  (c = 0.86 CH3OH). 
Cyclopentane 4.9’: 1H NMR (600 MHz, CD3OD): δ 7.33 (app d, J = 7.3 Hz, 1H, Ph), 7.28–
7.22 (m, 2H, Ph), 7.16 (app t, J = 8.2 Hz, 2H, Ph), 5.53–5.51 (m, 2H, H2’ & H3’), 3.96–3.88 
(m, 2H, H6’ & H7’), 3.29 (d, JH1’,H2’ = 4.8 Hz, 2H, H1’), 2.48–2.38 (m, 1H, H4’), 2.09–2.02 (m, 
2H, H8’ & H5’), 1.56–1.49 (m, 2H, H5’’ & H8’’). 13C {1H} NMR (151 MHz, CD3OD): 142.2 (s, 
Ph), 137.7 (s, C2’ or C3’), 129.4 (s, Ph), 128.7 (s, Ph), 127.8 (s, C2’ or C3’), 126.9 (s, Ph), 74.4 
(s, C6’ and C7’), 39.8 (s, C5’ & C8’), 38.3 (s, C1’), 38.1 (s, C4’). 
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Figure 4.4. 1H and 13C{1H} spectrum for carbocycle 4.9 and 4.9’. 
Preparation of carbocycle 4.11 
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Following general procedure 4.3, combined 61.0 mg Me3Si-styryl 2-deoxygalactose 
diene 4.10, 5.1 mg B(C6F5)3, 15.8 µL dimethylethylsilane, and 0.5 mL dichloromethane.  
Quenched after 12 hours and deprotected following general procedure 4.5. The product was 
purified by silica gel chromatography (5 x 1 cm column) using gradient elution (100% 
CH2Cl2 to 50:1 to 45:1 to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me2EtSi-2-
deoxygalactose-diene 4.11/4.11’ as a white solid (17.6 mg, 71% overall yield over 2 steps, 
0.0819 mmol, >98:2 dr, and 75:25 C3/C1). Note: Stereochemistry assigned by NOE between 
H3 and H6. Carbocycle 4.11: 1H NMR (600 MHz, CD3OD): δ 7.37–7.33 (m, 2H, Ph), 7.28–
7.21 (m, 2H, Ph), 7.18–7.11 (m, 1H, Ph), 6.48 (d, JH1,H2 = 16.1 Hz, 1H, H1), 6.32 (dt, JH2,H1 = 
15.9 Hz, JH2,H3 =  6.6 Hz, 1H, H2), 3.74–3.67 (m, 1H, H9), 3.62–3.55 (m, 2H, H8 & H9’), 2.93 
(dd, JH7,H8 = 8.6 Hz, JH7,H6 = 4.3 Hz, 1H, H7), 2.29 (dtd, JH3,H3’ = 14.7 Hz, JH3,H2 = 6.6 Hz, 1.5 
Hz, 1H, H3), 2.11 (dtd, JH3’,H3 = 15.2 Hz, JH3’,H2 = 6.6 Hz, JH3’,H4 = 1.5 Hz, 1H, H3’), 0.97–
0.85 (m, 2H, H4 & H6), 0.54 (dt, JH5,H5’ = 8.3 Hz, JH5,H4 & JH5,H6 = 4.8 Hz, 1H, H5), 0.44 (dt, 
JH5’H5 = 8.5 Hz, JH5’,H4 & JH5’,H6 = 4.9 Hz, 1H, H5’). 13C {1H} NMR (151 MHz, CD3OD): δ 
139.3 (s, Ph), 130.5 (s, C1), 129.4 (s, C2), 128.3 (s, Ph), 127.0 (s, Ph), 126.9 (s, Ph), 76.9 (s, 
C8), 76.4 (s, C7), 64.5 (s, C9), 37.9 (s, C3), 22.5 (s, C6), 17.6 (s, C4), 10.1 (s, C5). HRMS 
(ESI+): Calcd for C15H20O3Na [M+Na]+: 241.1199; Found: 241.1204. Specific rotation: [α]D 
25.8  –10  (c = 1.05 CH3OH). Carbocycle 4.11’: 1H NMR (600 MHz, CD3OD): δ 7.28–7.21 
(m, 2H, Ph), 7.18–7.11 (m, 3H, Ph), 5.64 (dt, JH2’,H3’ = 15.1 Hz, JH2’,H1’ = 6.9 Hz, 1H, H2’), 
5.16 (ddt, JH3’,H2’ = 15.1 Hz, JH3’,H4’ = 8.3 Hz, JH3’,H1’ =1.5 Hz, 1H, H3’), 3.74–3.67 (m, 1H, 
H9), 3.62–3.55 (m, 2H, H9’ & H8), 3.29 (d, JH1’,H2’ = 6.9 Hz, 1H, H1’), 2.98 (dd, JH7’,H6’ = 8.6 
Hz, JH7’,H8’ = 4.1 Hz, 1H, H7’), 1.45 (tt, JH6’,H7' = JH6’,H5' = 8.7 Hz, JH6’,H5'' = JH6’H4’ 4.5 Hz, 1H, 
H6’), 1.03 (tt, JH4’,H3’ = JH4’,H5’ = 8.5 Hz, JH4’,H6’ = JH4’,H5’ = 4.9 Hz, 1H, H4’), 0.67 (dt, JH5’,H5’’ 
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= 8.5 Hz, JH5’,H4’ & JH5’,H6’ = 5.0 Hz, 1H, H5’), 0.57 (dt, JH5’,H5’’ = 8.6 Hz, JH5’,H4’ & JH5’,H6’ = 
5.0 Hz, 1H, H5’’). 13C {1H} NMR (151 MHz, CD3OD): δ 142.3 (s, Ph), 135.1 (s, Ph), 131.3 
(s, C3’), 129.5 (s, Ph), 129.3 (s, C2’), 127.8 (s, Ph), 76.3 (s, C8’), 76.2, 64.4 (s, C7’), 39.8 (s, 
C1’), 24.3 (s, C6’), 20.4 (s, C4’), 11.6 (s, C5’). 
 
 
 
Figure 4.5. 1H and 13C{1H} spectrum for carbocycle 4.11 and 4.11’. 
Preparation of carbocycle 4.13 
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Following general procedure 4.3, combined 61.0 mg Me3Si-styryl 2-deoxyglucose 
diene 4.12, 5.1 mg B(C6F5)3, 29.0 µL dimethylethylsilane, and 0.5 mL dichloromethane.  
Quenched after 12 hours and deprotected following general procedure 4.5. The product was 
purified by silica gel chromatography (5 x 1 cm column) using gradient elution (100% 
CH2Cl2 to 50:1 to 45:1 to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me2EtSi-styryl-2-
deoxyglucose 4.13/4.13’ as a white solid (18.2 mg, 82% overall yield over 2 steps, 0.0819 
mmol, >98:2 dr, and 75:25 C3/C1). Note: Stereochemistry assigned by NOE between H3 and 
H6. Carbocycle 4.13: 1H NMR (600 MHz, CD3OD): δ 7.37–7.33 (m, 2H, Ph), 7.28–7.22 (m, 
2H, Ph), 7.19–7.11 (m, 1H, Ph), 6.43 (d, JH1,H2 = 15.7 Hz, 1H, H1), 6.32 (dt, JH2,H1 = 15.8 Hz, 
JH2,H3 = 6.7 Hz, 1H, H2), 3.78–3.73 (m, 1H, H9), 3.72–3.57 (m, 2H, H8 & H9’), 3.06 (dd, 
JH7,H8 = 8.0 Hz, JH7,H6 = 4.5 Hz, 1H, H7), 2.26 (dt, JH3,H3’ = 13.9 Hz, JH3,H2 = JH3,H4 = 6.4 Hz, 
1H, H3), 2.11 (dt, JH3’,H3 = 14.2 Hz, JH3’,H2 = JH3’,H4 = 6.6, JH3’,H4 = 1.4 Hz, 1H, H3’), 0.95–
0.82 (m, 2H, H4 & H6), 0.57 (dt, JH5,H5’ = 8.3 Hz, JH5,H4 & JH5,H6 = 4.7 Hz, 1H, H5), 0.39 (dt, 
JH5’H5 = 8.3 Hz, JH5’,H4 & JH5’,H6 = 4.8 Hz, 1H, H5’). 13C {1H} NMR (151 MHz, CD3OD): δ 
137.8 (s, Ph), 130.1 (s, C1), 129.0 (s, C2), 128.1 (s, Ph), 126.5 (s, Ph), 125.6 (s, Ph), 75.5 (s, 
C8), 75.3 (s, C7), 63.2 (s, C9), 36.4 (s, C3), 20.2 (s, C6), 16.0 (s, C4), 8.1 (s, C5). HRMS 
(ESI+): Calcd for C15H20O3Na [M+Na]+: 249.1485; Found: 249.1488. Specific rotation: [α]D 
25.8  –22  (c = 1.47 CH3OH). Carbocycle 4.13’: 1H NMR (600 MHz, CD3OD): δ 7.37–7.33 
(m, 2H, Ph), 7.28–7.22 (m, 2H, Ph), 7.19–7.11 (m, 1H, Ph), 5.63 (dt, JH2’H3’ = 15.1 Hz, 
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JH2’H1’ = 6.9 Hz, 1H, H2’), 5.12 (ddt, JH3’,H2’ = 15.1Hz, JH3’H4’ = 8.5 Hz, JH3’H1’ = 1.5 Hz, 1H, 
H3’), 3.70 (m, 1H, H8’), 3.65–3.59 (m, 2H, H9’), 3.29 (d, JH1’,H2’ = 7.0 Hz, 2H, H1’), 3.08 (dd, 
J = 8.2, 4.5 Hz, 2H, H7’), 1.38 (tt, JH4’,H3’ = JH4’H5’ = 8.5 Hz, JH4’H6’ = JH4’H5’’ = 4.7 Hz, 1H, 
H4’), 1.06 (tdd, JH6’,H7’ & JH6’,H5’ = 8.3 Hz, JH6’,H5’’ = 5.4 Hz, JH6’,H4’ = 4.5 Hz, 1H, H6’), 0.73 
(dt, JH5’,H5’’ = 8.5 Hz, JH5’,H4’ & JH5’,H6’ = 5.5 Hz, 1H, H5’), 0.57–0.53 (m, 1H, H5’’). 13C {1H} 
NMR (151 MHz, CD3OD): δ 142.2 (s, Ph), 131.4 (s, C3’), 129.3 (s, Ph), 128.5 (s, C2’), 126.9 
(s, Ph), 76.5 (s, C8’), 76.3 (s, C7’), 64.5 (s, C9’), 39.8 (s, C1’), 22.9 (s, C6’), 20.2 (s, C4’), 11.1 
(s, C5’). (*Note: One aromatic carbon is overlapping with SN2’ product). 
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Figure 4.6. 1H and 13C{1H} spectrum for carbocycle 4.13 and 4.13’. 
Preparation of cyclopropane 4.16 
 
 
 
Following general procedure 4.3, combined 61.0 mg Me3Si-2-deoxygalactose diene 
4.15, 5.1 mg B(C6F5)3, 28.8 mg triphenylsilane, and 0.5 mL dichloromethane.  Quenched 
after 12 hours and deprotected following general procedure 4.5. The product was purified by 
silica gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 
45:1 to 40:1 to 35:1 to 30:1 to 25:1 CH2Cl2:MeOH) to afford cyclopropane from Me3Si-2-
deoxygalactose-diene 4.16/4.16’ as a colorless oil (22.9 mg, 95% overall yield over 2 steps, 
0.103 mmol, >98:2 dr, 83:17 C3/ C1 hydride addition). Note: Stereochemistry assigned by 
NOE between H3 and H7. Carbocyle 4.16: 1H NMR (600 MHz, CD3OD): δ 5.25 (tp, JH2,H3 = 
7.1 Hz, JH2,HMe = 1.5 Hz, 1H, H2), 3.74–3.69 (m, 1H, H9), 3.62–3.57 (m, 2H. H9’ & H8), 2.90 
(dd, J = 8.1, 4.1 Hz, 1H, H7), 2.15 (dt, JH3,H3’ = 14.0 Hz, JH3,H2 = 7.0 Hz, 1H, H3), 1.92 (dt, 
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JH3’,H3 = 14.0 Hz, JH3’,H2 = 7.0 Hz, 1H, H3’), 1.72 (d, JHMe,H2 = 1.4 Hz, 3H, HMe), 1.63 (d, 
JHMe,H2 = 1.3 Hz, 3H, HMe), 0.85–0.77 (m, 2H, H6 & H4), 0.43 (dt, JH5,H5’ = 8.0 Hz, JH5,H4 & 
JH5,H7 = 4.8 Hz, 1H, H5), 0.34 (dt, JH5’,H5 = 8.0 Hz, JH5’,H4 & JH5’,H7 = 4.8 Hz, 1H, H5’). 13C 
{1H} NMR (151 MHz, CD3OD): δ 132.4 (s, C1), 124.5 (s, C2), 76.8 (s, C8), 76.4 (s, C7), 64.4 
(s, C9), 32.7 (s, C3), 25.9 (s, CMe), 22.1 (s, C4 or C6), 18.1 (s, C6 or C4), 17.9 (s, CMe), 9.7 (s, 
C5). HRMS (ESI+): Calcd for C11H20O3Na [M+H]+: 223.1310; Found: 223.1303. Specific 
rotation: [α]D24.6  +24.  (c = 0.24 CH3OH). Carbocycle 4.16’: 1H NMR (600 MHz, CD3OD): 
δ 5.46 (dd, JH2’,H3’ = 15.3 Hz, JH2’,H1’ = 6.8 Hz, 1H, H2’), 5.03 (ddd, JH3’,H2’ = 15.3 Hz, JH3’,H4’ 
= 8.3 Hz, JH3’,H1’ = 1.3 Hz, 1H, H3’), 2.98–2.95 (m, 1H, H7’), 2.24–2.18 (m, 1H, H1’), 1.40 
(dq, JH4’,H3’ = 8.4 Hz, JH4’,H5’ = 4.3 Hz, 1H, H4’), 0.96 (s, 3H, HMe), 0.95 (s, 3H, Hme), 0.64 
(dt, JH5’,H5’’ = 8.5 Hz, JH5’,H4’ & JH5’,H6’ = 5.0 Hz, 1H, H5’), 0.53 (dt, JH5’’,H5’ = 8.6 Hz, JH5’’,H4’ 
& JH5’’,H6’ = 4.9 Hz, 1H, H5’’). (*Note: H9’ and H8’ overlap with H9 and H8. Also, H6’ overlaps 
with H3). 13C {1H} NMR (151 MHz, CD3OD): δ 136.6 (s, C2’), 130.9 (s, C3’), 76.4 (s, C8’), 
76.2 (s, C7’), 64.4 (s, C9’), 32.2 (s, C1’), 24.2 (s,), 23.1 (s, CMe), 23.1 (s, C6’) (s, CMe), 20.4 (s, 
C4’), 11.5 (s, C5’). 
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Figure 4.7. 1H and 13C{1H} spectrum for carbocycle 4.16 and 4.16’. 
Preparation of cyclic intermediate 4.17 
 
 
 
In a nitrogen filled glovebox, a 1 dram vial was charged with B(C6F5)3 (5.1 mg, 0.010 
mmol, 0.10 equiv.) then TMS-styryl 2-deoxygalactose 4.3 (52.2 mg, 0.0990 mmol, 1.00 
equiv.) and a stir bar. At 25 °C, CH2Cl2 (0.5 mL) was added by syringe. The vial was sealed 
with a septa cap and removed from the glovebox. The vial was wrapped with electrical tape 
and allowed to stir at 22 °C. After 18 hours, NEt3 (0.05 mL) was added by syringe through 
the septa and the stir bar was removed, rinsing with CH2Cl2 (0.2 mL). The quenched reaction 
mixture was concentrated under vacuum and then loaded onto an alumina plug (neutral, 10% 
H2O; 2 x 1 cm) with 100% hexanes (1.5 mL) then 95:5 hexanes:diethyl ether (1.5 mL), 
eluting with 95:5 hexanes:diethyl ether (10 mL) into a tared vial. The solution was 
concentrated under vacuum to afford a colorless oil (42.2 mg). The product was purified by 
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alumina chromatography (10% H2O, 5 x 1 cm column) using gradient elution (100% hexanes 
to 20:1 to 2:1 hexanes:Et2O) to afford cyclized TMS-styryl 2-deoxygalactose 4.17 as a 
colorless oil (27.9 mg, 77% overall yield over 2 steps, 0.0765 mmol, 74:26 E/Z). Cyclic 
intermediate 4.17: 1H NMR (600 MHz, CDCl3): δ 7.36 (d, J = 7.8 Hz, 2H, Ar), 7.32–7.27 
(m, 6H, Ar), 7.23–7.18 (m, 2H, Ar), 6.55 (d, JH1,H2 = 11.4 Hz, 1H, H1, Z), 6.47 (d, JH1,H2 = 
15.6 Hz, 1H, H1, E), 6.26 (dt, JH2,H1 = 16.2 Hz, JH2,H3 = 7.2 Hz, 1H, H2, E), 5.75 (dt, JH2,H1 = 
11.4 Hz, JH2,H3 = 7.2 Hz, 1H, H2, Z), 4.08 (dt, JH6,H7’ = 4.2 Hz, JH6,H5 = 3.0 Hz, 1H, H6, E), 
4.05 (dt, JH6,H7 = 4.8 Hz, JH6,H5 = 3.0 Hz, 1H, H6, Z), 3.96 (dd, JH7,H7’ = 9.6 Hz, JH7,H6 = 4.8 
Hz, 1H, H7, E), 3.95 (dd, JH7,H7’ = 9.6 Hz, JH7,H6 = 4.8 Hz, 1H, H7, Z), 3.87 (app t, J = 3.0 Hz, 
1H, H5, E), 3.79 (app t, J = 4.2 Hz, 1H, H5, Z), 3.79–3.75 (m, 3H, H4 (E), H4 (Z), & H7 (Z)), 
3.72 (dd, JH7’,H7 = 10.2 Hz, JH7’,H6 = 3.0 Hz, 1H, H7’, E), 2.74–2.69 (m, 1H, H3, Z), 2.64–2.62 
(m, 1H, H3’, Z), 2.59–2.50 (m, 2H, H3 &H3’, E), 0.133 (s, 9H, -SiCH3, E), 0.127 (s, 9H, -
SiCH3, E), 0.10 (s, 9H, -SiCH3, Z), 0.07 (s, 9H, -SiCH3, Z). 13C{1H} NMR (151 MHz, 
CDCl3): δ 137.7 (s, Ar, E), 137.5 (s, Ar, Z), 132.3 (s, C1, E), 130.9 (s, C1, Z), 129.0 (s, Ar, Z), 
128.6 (s, Ar, E), 128.4 (s, Ar, Z), 128.3, (s, C2, Z), 127.2 (s, Ar, E), 126.8 (s, Ar, Z), 126.7 (s, 
C2, E), 126.2 (s, Ar, E), 85.1 (s, C4, Z), 84.9 (s, C4, E), 82.2 (s, C5, Z), 82.1 (s, C5, E), 79.0 (s, 
C6, E), 78.8 (s, C6, Z), 73.54 (s, C7, Z), 73.50 (s, C7, E), 0.5, 0.4, 0.2, 0.1 (each a s, -
Si(CH3)3). 
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Figure 4.8. 1H and 13C{1H} spectrum for cyclic intermediate 4.17. 
Observation of 1º bond reduction from cyclic intermediate 4.17 
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Following general procedure 4.4, combined 27.9 mg Me3Si-cyclic intermediate 4.17, 
7.1 mg B(C6F5)3, 18.0 µL triethylsilane, and 0.5 mL dichloromethane.  Quenched after 1 hour 
and deprotected following general procedure 4.5. The product was purified by silica gel 
chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 40:1 to 
30:1 to 20:1 CH2Cl2:MeOH) to afford primary reduced 2-deoxy galactose 4.4’ as a colorless 
oil (7.1 mg, 42% overall yield over 2 steps, 0.032 mmol, 51:49 E/Z). [*Note: Remaining 
material is cyclopropyl product 4.4 (9.4 mg, 55% overall yield over 2 steps, 0.042 mmol)]. 1º 
bond reduction product 4.4’: Characterized as a 51:49 E/Z mixture. 1H NMR (600 MHz, 
CD3OD): δ 7.38 (d, J = 7.2 Hz, 2H, Ph), 7.35–7.31 (m, 4H, Ph), 7.28 (t, J = 7.2 Hz, 2H, Ph), 
7.22–7.17 (m, 2H, Ph), 6.55 (d, JH1,H2 = 11.4 Hz, 1H, H1, Z), 6.51 (d, JH1,H2 = 15.6 Hz, 1H, 
H1, E), 6.40 (ddd, JH2,H1 = 15.6 Hz, JH2,H3’ = 7.2 Hz, JH2,H3 = 6.6 Hz, 1H, H2, E), 5.88 (dt, 
JH2,H1 = 12.0 Hz, JH2,H3 = 7.2 Hz, 1H, H2, Z), 4.06 (dq, JH6,H7 = 6.6 Hz, JH6,H5 = 2.4 Hz, 1H, 
H6, E), 4.00 (dq, JH6,H7 = 6.6 Hz, JH6,H5 = 3.0 Hz, 1H, H6, Z), 3.76 (dt, JH4,H5 = 7.8 Hz, JH4,H3 
= 3.0 Hz, 1H, H4, E), 3.75–3.73 (m, 1H, H4, Z), 3.21 (dd, JH5,H4 = 7.8 Hz, JH5,H4 = 2.4 Hz, 1H, 
H4, E), 3.19 (dd, JH5,H6 = 7.2 Hz, JH5,H4 = 2.4 Hz, 1H, H4, Z), 2.84–2.79 (m, 1H, H3, Z), 2.67 
(ddd, JH3,H3’ = 14.4 Hz, JH3,H2 = 6.6 Hz, JH3,H4 = 3.0 Hz, 1H, H3, E), 2.51–2.46 (m, 1H, H3’, 
Z), 2.39 (ddd, JH3’,H3 = 14.4 Hz, JH3’,H4 = 8.4 Hz, JH3’,H2 = 7.2 Hz, 1H, H3’, E), 1.25 (d, JH7,H6 
= 6.6 Hz, 3H, H7, E), 1.21 (d, JH7,H6 = 6.6 Hz, 3H, H7, Z). 13C {1H} NMR (151 MHz, 
CD3OD): δ 139.2 (s, Ph), 139.0 (s, Ph), 133.3 (s, C1, E), 131.5 (s, C1, Z), 130.4 (s, C2, Z), 
129.9 (s, Ph), 129.5 (s, Ph), 129.1 (s, C2, E), 128.2 (s, Ph), 127.9 (s, Ph), 127.6 (s, Ph), 127.0 
(s, Ph), 78.1 (s, C5, E or Z), 77.9 (s, C5, E or Z), 73.2 (s, C4, E or Z), 72.8 (s, C4, E or Z), 
67.7 (s, C6, E & Z), 38.4 (s, C3, E), 34.0 (s, C3, Z), 20.0 (s, C7, E or Z), 19.9 (s, C7, E or Z). 
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Figure 4.9. 1H and 13C{1H} spectrum for carbocycle 4.4’. 
Relative stereochemistry determined by Kishi analysis of primary reduction product.  
[i.e. No inversion (O4 to C7)]  
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Preparation of vinyl shift product 4.19 
 
 
Following general procedure 4.4, combined 69.6 mg Me3Si-styrylgalactose 4.18, 6.5 
mg B(C6F5)3, 40.0 µL triethylsilane, and 0.5 mL dichloromethane.  Quenched after 12 hours 
and deprotected following general procedure 4.5. Products were purified by silica gel 
chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 to 
40:1 to 35:1 CH2Cl2:MeOH) to afford vinyl shifted galactose 4.19 as a white solid (18.3 mg, 
73% overall yield over 2 steps, 0.0825 mmol). Vinyl shift product 4.19: 1H NMR (600 MHz, 
CD3OD): δ 7.39 (d, J = 7.8 Hz, 2H, Ph), 7.29 (t, J = 7.8 Hz, 2H, Ph), 7.18 (t, J = 7.2 Hz, 1H, 
Ph), 6.46 (d, JH1,H2 = 16.2 Hz, 1H, H1), 6.34 (dd, JH2,H1 = 16.2 Hz, JH2,H4 = 8.4 Hz, 1H, H2), 
3.70–3.66 (m, 2H, H6 & H7), 3.63–3.60 (m, 1H, H7’), 3.49–3.47 (m, 1H, H5), 2.64–2.58 (m, 
1H, H4), 1.17 (d, JH3,H4 = 7.2 Hz, 3H, H3). 13C{1H} NMR (151 MHz, CD3OD): δ 139.2 (s, 
Ph), 133.8 (s, C2), 131.4 (s, C1), 129.5 (s, Ph), 127.9 (s, Ph), 127.1 (s, Ph), 76.1 (s, C5), 73.5 
(s, C6), 64.7 (s, C7), 41.3 (s, C4), 18.1 (s, C3). HRMS (ESI+): Calcd for C13H19O3Na [M+H]+: 
223.1329; Found: 223.1329. Specific rotation: [α]D24.6  +50.  (c = 0.44 CH3OH). 
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Figure 4.10. 1H and 13C{1H} spectrum for vinyl shifted product 4.19. 
Preparation of 4.21 
 
Following general procedure 4.4, combined 67.1 mg Me3Si-styrylgalactose 4.18, 5.2 
mg B(C6F5)3, 35.0 µL triethylsilane-d, and 0.5 mL dichloromethane.  Quenched after 24 
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hours and deprotected following general procedure 4.5. Products were purified by silica gel 
chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 to 
40:1 CH2Cl2:MeOH) to afford 4.21 as a white solid (17.5 mg, 72% overall yield over 2 steps, 
0.0778 mmol). Vinyl shift product 4.21: 1H NMR (600 MHz, CD3OD): δ 7.39 (d, J = 7.2 Hz, 
2H, Ph), 7.28 (t, J = 7.2 Hz, 2H, Ph), 7.18 (t, J = 7.8 Hz, 1H, Ph), 6.45 (d, JH1,H2 = 16.2 Hz, 
1H, H1), 6.36 (dd, JH2,H1 = 15.6 Hz, JH2,H3 = 8.4 Hz, 1H, H2), 3.70–3.66 (m, 2H, H6 & H7), 
3.63–3.60 (m, 1H, H7’), 3.49 (dd, JH5,H4 = 6.0 Hz, JH5,H6 = 3.6 Hz, 1H, H5), 2.60 (app q, JH4,H5 
= 7.2 Hz, 1H, H4), 1.14 (d, JH3,H4 = 6.6 Hz, 1H, H3). 13C{1H} NMR (151 MHz, CD3OD): δ 
139.2 (s, Ph), 133.8 (s, C2), 131.4 (s, C1), 129.4 (s, Ph), 127.9 (s, Ph), 127.1 (s, Ph), 76.1 (s, 
C5), 73.5 (s, C6), 64.7 (s, C7), 41.1 (s, C4), 17.5 (quintet, JC,D = 19.6 Hz, C3). 
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Figure 4.11. 1H and 13C{1H} spectrum for 4.21. 
Preparation of vinyl shift product 4.23 from 4.22 
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Following general procedure 4.4, combined 68.2 mg Me3Si-4-Br-styrylgalactose 
4.22, 6.2 mg B(C6F5)3, 30.0 µL dimethylethylsilane, and 0.5 mL dichloromethane.  Quenched 
after 6 hours and deprotected following general procedure 4.5. Products were purified by 
silica gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 60:1 to 
50:1 to 49:1 to 48:1 to 47:1 to 46:1 CH2Cl2:MeOH) to afford 4-Br-vinyl shift product 4.23 as 
a white solid. A single crystal was obtained by recrystallization from CH2Cl2/MeOH by slow 
evaporation at room temperature under neutral atmosphere. Note only the E isomer was 
crystalline. 4-Br-vinyl shift product 4.23: Data from the fraction that was recrystallized; a 
67:33 E/Z mixture. 1H NMR (600 MHz, CD3OD): δ 7.48 (d, J = 7.8 Hz, 2H, Ar, Z), 7.44 (d, J 
= 8.4 Hz, 2H, Ar, E), 7.32 (d, J = 8.4 Hz, 2H, Ar, E), 7.29 (d, J = 8.4 Hz, 2H, Ar, Z), 6.45 (d, 
JH1,H2 = 12.0 Hz, 1H, H1, Z), 6.44–6.35 (m, 2H, H1 & H2, E), 5.75 (dd, JH2,H1 = 11.4 Hz, 
JH2,H4 = 10.8 Hz, 1H, H2, Z), 3.69–3.64 (m, 2H, H6 & H7, E), 3.63–3.58 (m, 2H, H7’, E, & H6, 
Z), 3.51 (dd, JH7,H7’ = 10.8 Hz, JH7,H6 = 4.8 Hz, 1H, H7), 3.48 (dd, JH5,H4 = 6.0 Hz, JH5,H6 = 3.6 
Hz, 1H, H5, E), 3.44 (dd, JH5,H4 = 6.0 Hz, JH5,H6 = 4.2 Hz, 1H, H5, Z), 4.32 (dd, JH7’,H7 = 10.8 
Hz, JH7’,H6 = 6.0 Hz, 1H, H7’, Z), 3.07–3.01 (m, 1H, H4, Z), 2.64–2.58 (m, 1H, H4, E), 1.17 (d, 
JH3,H4 = 6.6 Hz, 3H, H3, E), 1.12 (d, JH4,H3 = 6.6 Hz, 3H, H3, Z). 13C{1H} NMR (151 MHz, 
CD3OD): δ 138.4 (s, Ar), 138.1 (s, Ar), 137.1 (s, C2, Z), 135.1 (s, C2, E), 132.5 (s, Ar), 132.4 
(s, Ar), 131.6 (s, Ar), 130.1 (s, C1, E), 129.0 (s, C1, Z), 128.9 (s, Ar), 121.4 (s, Ar), 76.1 (s, 
C5, E), 76.0 (s, C5, Z), 73.5 (s, C6, E), 73.4 (s, C6, Z), 64.7 (s, C7, E), 64.6 (s, C7, Z), 41.3 (s, 
C4, E), 36.0 (s, C4, Z), 18.1 (s, C3, Z), 17.9 (s, C3, E). (*Note: One Ar carbon is overlapping 
for E/Z). 
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Figure 4.12. 1H and 13C{1H} spectrum for 4.23. 
 
Crystallographic Data for stereochemical determination of 4.23 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. ORTEP representation of the solid state molecular structure of 4.23. 
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ORTEP representation of the solid state molecular structure of 4.23 derivative; 
ellipsoids drawn at 50% probability, the majority of hydrogen atoms are omitted for clarity.  
 
Table 4.3. Solid state molecular data for 4.23. 
Empirical formula C13H17BrO3 Dcalcd (Mg m-3) 1.579 
Fw 301.17 Radiation Cu Ka , λ = 
1.54178 Å 
Colour, habit Colourless, Plate Absorption coeff. (µ) 
(mm-1) 
4.39 
Crystal dimensions 
(mm) 
0.27 x 0.16 x 0.03 Absorption correction Numerical 
Crystal system  Monoclinic F(000) 308 
Space group P21 qmin to qmax (°) 2.9 to 70.0 
Z 2 Measured reflections 10189 
a (Å) 5.8040(2) Independent 
reflections 
2389 
(Rint=0.023) 
b (Å) 7.1933(2) Data/restraints/param
eters 
2389/1/155 
c (Å) 15.2241(5) Maximum shift/error <0.001 
a (°) 90.00 Goodness-of-fit on F2 1.11 
b (°) 94.904(1) Final R indices (I > 
2s(I)) 
R1 = 0.021 
wR2 = 0.052 
g (°) 90.00 
 
R indices (all data) R1 = 0.021 
wR2 = 0.052 
Collection ranges h = -7→7 
k = -8→8 
l = -18→18 
absolute structure 
parameter 
0.032(7) 
Temperature (K) 100 Extinction coefficient N/A 
Volume (Å3) 633.28(3) Largest diff. peak and 
hole (e Å-3) 
0.36 and -0.57 
 
Preparation of cyclic 4.25 by [Ph3C][B(C6F5)4] cyclization: 
 
In a nitrogen-filled glovebox, a 1-dram vial was charged with TMS-styrylgalactose 
4.25 (329.2 mg, 0.101 mmol, 1.00 equiv.), a magnetic stir bar, and [Ph3C][B(C6F5)4] (34.3 
4.18 galacto- (>98 E)
Me3SiO
Me3SiO
OSiMe3
OSiMe3
Me3SiO 123
4
5
67
0.4 equiv. [Ph3C][B(C6F5)4]
CH2Cl2, –78 ºC, 4h
0.4 equiv. HSiEt3
O
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H
Me3SiO
OSiMe3
12
3
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7
4.25
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mg, 0.0372 mmol, 0.368 equiv.). A second 1-dram vial was charged with triethylsilane (6.5 
µL, 0.376 mmol, 0.372 equiv.) and CH2Cl2 (0.5 mL). The 1-dram vials were sealed with a 
septa cap and then and wrapped in electrical tape and both were removed from the glovebox. 
The vials were allowed to cool to –78 °C (dry ice/acetone bath). The silane solution was 
transferred to the substrate by syringe and transferred to held at –78 °C and allowed to stir. 
After 4 hours, NEt3 (0.10 mL) was added by syringe through the septa and the stir bar was 
removed, rinsing with CH2Cl2 (0.2 mL). The quenched reaction mixture was concentrated 
under vacuum to yield lightly yellow oil. Products were purified by alumina gel 
chromatography (neutral, 10% H2O; 5 x 1 cm) using gradient elution (100 % hexanes to 50:1 
to 30:1 to 20:1 hexanes:diethyl ether) to afford 4.25 as a colorless oil (11.7 mg, 26.0% 
overall yield, 0.0258 mmol). Deprotection following general procedure 4.5 gave free alcohol 
(NMR spectra provided). Cyclic 4.25: 1H NMR (600 MHz, CDCl3): δ 7.38 (d, J = 7.2 Hz, 
2H, Ar), 7.31 (t, J =  7.2 Hz, 2H, Ar), 7.23 (t, J = 7.2 Hz, 1H, Ar), 6.55 (d, J = 16.2 Hz, 1H, 
H1), 6.27 (dd, JH2,H1 = 162 Hz, JH2,H3 = 6.6 Hz, 1H, H2), 4.44 (ddd, JH3,H4 = 7.8 Hz, JH3,H2 = 
6.6 Hz, JH3,H1 = 1.2 Hz, 1H, H3), 4.05–4.03 (m, 2H, H5 & H6), 3.96 (dd, JH7,H7’ = 9.6 Hz, 
JH7,H6 = 3.6 Hz, 1H, H7), 3.74–3.71 (m, 2H, H7’ & H4), 0.15 (s, 9H, -SiCH3), 0.10 (s, 9H, -
SiCH3), 0.09 (s, 9H, -SiCH3). 13C{1H} NMR (151 MHz, CDCl3): δ 137.1 (s, Ar), 131.5 (s, 
C1), 129.8 (s, C2), 128.7 (s, Ar), 127.6 (s, Ar), 126.7 (s, Ar), 89.0 (s, C4), 79.4 (s, C5 or 6), 78.9 
(s, C5 or 6), 74.0 (s, C3), 73.6 (s, C7), 0.6, 0.4, 0.2 (each a s, -Si(CH3)3). 
 160 
 
 
 
Figure 4.14. 1H and 13C{1H} spectra for cyclic intermediate 4.25. 
Preparation of vinyl shift product 4.19 from cyclic 4.25 
 
Following general procedure 4.4, combined 11.7 mg cyclized Me3Si-styrylgalactose 
4.25, 2.6 mg B(C6F5)3, 5.3 µL dimethylethylsilane, and 0.5 mL dichloromethane.  Quenched 
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after 12 hours and deprotected following general procedure 4.5. Products were purified by 
silica gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 
45:1 to 40:1 to 35:1 CH2Cl2:MeOH) to afford vinyl-shifted product 4.19. Data matched that 
from the same product derived from 4.18. 
Preparation of carbocycle product 4.27 from vinyl shifted product 4.26 
 
Following general procedure 4.4, combined 45.0 mg vinyl-shifted Me3Si-
styrylgalactose 4.26, 5.0 mg B(C6F5)3, 19.8 µL dimethylethylsilane, and 0.5 mL 
dichloromethane.  Quenched after 12 hours and deprotected following general procedure 4.5. 
Products were purified by silica gel chromatography (5 x 1 cm column) using gradient 
elution (100% CH2Cl2 to 50:1 to 49:1 to 48:1 CH2Cl2:MeOH) to afford carbocycle from 
Me3Si-styrylgalactose 4.27 as a white solid (17.6 mg, 83% yield, 0.0853 mmol). Carbocycle 
4.27: 1H NMR (600 MHz, CD3OD): δ 7.26 (t, J = 7.8 Hz, 2H, Ph), 7.19 (d, J = 7.2 Hz, 2H, 
Ph), 7.16 (t, J = 7.2 Hz, 1H, Ph), 3.92 (ddd, JH6,H7 = 6.6 Hz, JH6,H7’ = 4.2 Hz, JH6, H5 = 2.4 Hz, 
1H, H6), 3.81 (dd, JH5,H4 = 4.8 Hz, JH5,H6 = 2.4 Hz, 1H, H5), 2.88 (dd, JH1,H1’ = 13.2 Hz, JH1,H2 
= 5.4 Hz, 1H, H1), 2.47 (dd, JH1’,H1 = 13.2 Hz, JH1’,H2 = 9.0 Hz, 1H, H1’), 2.09 (ddd, JH7,H7’ = 
13.8 Hz, JH7,H2 = 8.4 Hz, JH7,H6 = 6.6 Hz, 1H, H7), 1.96–1.89 (m, 1H, H2), 1.89–1.83 (m, 1H, 
H4), 1.24 (ddd, JH7’,H7 = 13.2 Hz, JH7’,H2 = 8.4 Hz, JH7’,H6 = 4.2 Hz, 1H, H7’), 0.98 (d, JH3,H4 = 
7.2 Hz, 3H, H3). 13C{1H} NMR (151 MHz, CD3OD): δ 142.9 (s, Ph), 129.9 (s, Ph), 129.2 (s, 
Ph), 126.8 (s, Ph), 82.4 (s, C5), 78.8 (s, C6), 45.6 (s, C4), 43.3 (s, C2), 42.7 (s, C1), 39.6 (s, 
4
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C7), 13.1 (s, C3). HRMS (ESI+): Calcd for C13H18O2Na [M+Na]+: 229.1199; Found: 
229.1200. Specific rotation: [α]D 24.9  +58  (c = 0.42 CH3OH). 
 
 
 
Figure 4.15. 1H and 13C{1H} spectrum for carbocycle 4.27. 
Preparation of carbocycle product 4.27 from 4.18 
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Following general procedure 4.4, combined 61.4 mg Me3Si-styrylgalactose 4.18, 5.0 
mg B(C6F5)3, 50.0 µL dimethylethylsilane, and 0.5 mL dichloromethane.  Quenched after 12 
hours and deprotected following general procedure 4.5. The product was purified by silica 
gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 
to 40:1 to 35:1 CH2Cl2:MeOH) to afford carbocycle from Me3Si-styrylgalactose 4.27 as a 
white solid (16.9 mg, 82% overall yield over 2 steps, 0.0819 mmol). Data matched that from 
the same product derived from 4.26 vide supra. 
Preparation of carbocycle product 4.29 from 4.22 
 
 
Following general procedure 4.4, combined 61.4 mg Me3Si-styrylgalactose 4.22, 5.5 
mg B(C6F5)3, 50.0 µL dimethylethylsilane, and 0.5 mL dichloromethane.  Quenched after 12 
hours and deprotected following general procedure 4.5. The product was purified by silica 
gel chromatography (4 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 
to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me3Si-pBr-styrylgalactose 4.29 as a white 
solid (20.3 mg, 71% overall yield over 2 steps, 0.0712 mmol).  Carbocycle 4.29: 1H NMR 
(600 MHz, CD3OD): δ 7.41 (d, J = 7.8 Hz, 2H, Ar), 7.12 (d, J = 7.8 Hz, 2H, Ar), 3.92 (br s, 
1H, H6), 3.81 (br d, JH5,H6 = 3.6 Hz, 1H, H5), 2.85 (dd, JH1,H1’ = 13.2 Hz, JH1,H2 = 4.8 Hz, 1H, 
H1), 2.45 (dd, JH1’,H1 = 13.2 Hz, JH1’,H2 = 9.0 Hz, 1H, H1’), 2.09 (ddd, JH7,H7’ = 14.4 Hz, JH7,H6 
= 7.8 Hz, JH7,H2 = 6.6 Hz, 1H, H7), 1.94–1.89 (m, 1H, H2), 1.88–1.82 (m, 1H, H4), 1.21 (ddd, 
JH7’,H7 = 13.2 Hz, JH7’,H2 = 7.8 Hz, JH7’,H6 = 4.2 Hz, 1H, H7’), 0.98 (d, JH3,H4 = 7.2 Hz, 3H, 
H3). 13C{1H} NMR (151 MHz, CD3OD): δ 142.2 (s, Ar), 132.3 (s, Ar), 131.9 (s, Ar), 120.4 
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(s, Ar), 82.3 (s, C5), 78.7 (s, C6), 45.4 (s, C2), 43.2 (s, C4), 41.9 (s, C1), 39.5 (s, C7), 13.1 (s, 
C3). HRMS (ESI+): Calcd for C13H17O2BrNa [M+Na]+: 307.0304; Found: 307.0310. Specific 
rotation: [α]D 24.1  +43.8  (c = 0.535 CH3OH). 
 
 
 
Figure 4.16. 1H and 13C{1H} spectrum for carbocycle 4.29. 
 
Preparation of 4.29’ 
 165 
 
Under positive nitrogen flow, a septum capped 20-mL scintillation vial was charged 
with 22 (0.220 g, 1.00 mmol), 4-nitrobenzyl chloride (0.560 g, 3.00 mmol), 4-
dimethylaminopyridine (DMAP) (0.024 g, 0.20 mmol), and a magnetic stir bar. 
Dichloromethane was added by syringe (10.0 mL) followed by pyridine (0.400 mL, 5.00 
mmol) by syringe. The septum was replaced with the vial cap and allowed to stir at 25 ºC for 
12 h. After stirring for 12 h, 10 mL of saturated sodium bicarbonate solution was added by 
syringe. The contents of the vial were then transferred to a separatory funnel rinsing with 
Et2O (3 x 5 mL). The aqueous layer was extracted with Et2O (3 x 10 mL) and combined. The 
combined organic extractions were washed with water (3 x 10 mL), brine (3 x 10 mL), and 
dried over sodium sulfate. The organic layer was filtered into a round bottom flask and 
solvent removed under vacuum to afford a white solid. Products were purified by silica gel 
chromatography (20 x 3 cm column) using gradient elution (100% hexanes to 30:1 to 20:1 to 
15:1 to 10:1 to 7:1 to 5:1 hexanes:ethyl acetate) to afford (1R,2R,3R,4S)-4-(4-bromobenzyl)-
3-methylcyclopentane-1,2-diyl bis(4-nitrobenzoate) 4.29’ as a white solid (0.50 g, 86% 
overall yield over 0.86 mmol). This material was used to obtain a single crystal for X-ray 
analysis by vapor diffusion of hexanes into chloroform solution of 4.29’. 4.29’: 1H NMR 
(600 MHz, CDCl3): δ 8.32–8.27 (m, 4H), 8.24–8.18 (m, 2H), 8.16–8.10 (m, 4H), 7.44–7.38 
(m, 2H), 7.10–7.03 (m, 2H), 5.59 (dd, J = 6.2, 2.8 Hz, 1H), 5.38 (ddd, J = 7.2, 6.0, 2.9 Hz, 
1H), 2.95 (dd, J = 13.6, 4.8 Hz, 1H), 2.55 (dd, J = 13.6, 8.7 Hz, 1H), 2.49 (dd, J = 14.2, 7.2 
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Hz, 1H), 2.29–2.12 (m, 2H), 1.59–1.52 (m, 1H), 1.08 (d, J = 6.6 Hz, 3H). 13C{1H} NMR 
(151 MHz, CDCl3): δ 163.9, 163.8, 150.6, 150.6, 138.6, 135.0, 131.5, 130.8, 130.7, 130.7, 
123.6, 123.6, 120.1, 81.7, 79.0, 44.7, 41.1, 39.4, 36.2, 12.7. 
 
Crystallographic Data for derivative of 4.29’ for stereochemical determination 
 
 
 
Figure 4.17. ORTEP representation of solid state molecular structure of 4.29’. 
 
 
ORTEP representation of the solid state molecular structure of 4.29’ derivative for 
stereochemical determination; ellipsoids drawn at 50% probability, the majority of hydrogen 
atoms are omitted for clarity.  Disordered solvent that could not be modeled has been 
addressed using a solvent mask with Olex2. The asymmetric unit contains a solvent molecule 
(chloroform) and two molecules of 4.29’; only one molecule of 4.29’ is shown for clarity. 
 
Table 4.4. Solid state molecular structure data for 4.29’. 
Empirical formula C27H23BrN2O8·0.5
(CHCl3) 
Dcalcd (Mg m-3) 1.391 
Fw 643.07 Radiation Cu Ka , λ = 
1.54178 Å 
Colour, habit Colourless, block Absorption coeff. (µ) 
(mm-1) 
3.44 
Crystal dimensions 
(mm) 
0.41 x 0.14 x 0.10 Absorption correction Numerical 
Crystal system  Triclinic F(000) 654 
Space group P1 qmin to qmax (°) 4.4 to 66.7 
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Z 2 Measured reflections 24104 
a (Å) 9.4486(3) Independent 
reflections 
9926 
(Rint=0.046) 
b (Å) 11.0765(3) Data/restraints/param
eters 
9926/3/723 
c (Å) 16.0570(5) Maximum shift/error <0.001 
a (°) 73.497(2)  Goodness-of-fit on F2 1.03 
b (°) 87.912(2) Final R indices (I > 
2s(I)) 
R1 = 0.046 
wR2 = 0.116 
g (°) 72.630(2) R indices (all data) R1 = 0.055 
wR2 = 0.122 
Collection ranges h = -11→11 
k = -13→13 
l = -19→19 
absolute structure 
parameter 
0.034(10) 
Temperature (K) 100 Extinction coefficient N/A 
Volume (Å3) 1535.63(8) Largest diff. peak and 
hole (e Å-3) 
0.99 and -0.52 
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Figure 4.18. 1H and 13C{1H} spectrum for carbocycle 4.29’. 
 
Preparation of carbocycle product 4.32 from 4.30 
 
Following general procedure 4.4, combined 57.8 mg Me3Si-styrylmannose 4.30, 5.0 
mg B(C6F5)3, 50.0 µL dimethylethylsilane, and 0.5 mL dichloromethane.  Quenched after 12 
hours and deprotected following general procedure 4.5. The product was purified by silica 
gel chromatography (5 x 1 cm column) using gradient elution (100% CH2Cl2 to 50:1 to 45:1 
to 40:1 CH2Cl2:MeOH) to afford carbocycle from Me3Si-styrylmannose 4.32 as a white solid 
(14.3 mg, 74% overall yield over 2 steps, 0.0693 mmol, 86:14 dr). Carbocycle 4.32: 1H NMR 
(600 MHz, CD3OD): δ 7.26 (t, J = 7.2 Hz, 2H, Ph), 7.19 (d, J = 7.8 Hz, 2H, Ph), 7.16 (t, J = 
7.2 Hz, 1H, Ph), 3.94 (ddd, JH6,H7 = 10.2 Hz, JH6,H7’ = 4.8 Hz, JH6,H5 = 4.8 Hz, 1H, H6), 3.40 
(dd, JH5,H4 = 7.8 Hz, JH5,H6 = 4.8 Hz, 1H, H5), 2.88 (dd, JH1,H1’ = 13.2 Hz, JH1,H2 = 5.4 Hz, 1H, 
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H1), 2.52 (dd, JH1’,H1 = 13.2 Hz, JH1’,H2 = 9.0 Hz, 1H, H1’), 1.94 (ddd, JH7,H7’ = 13.8 Hz, JH7,H6 
= 7.8 Hz, JH7, H2 = 6.6 Hz, 1H, H7), 1.70–1.59 (m, 2H, H4 & H2), 1.39 (ddd, JH7’,H7 = 12.0 Hz, 
JH7’,H2 = 7.8 Hz, JH7’,H6 = 4.2 Hz, 1H, H7’), 0.99 (d, JH3,H4 = 6.6 Hz, 3H, H3). 13C{1H} NMR 
(151 MHz, CD3OD): δ 142.6 (s, Ph), 129.9 (s, Ph), 129.2 (s, Ph), 126.8 (s, Ph), 81.5 (s, C5), 
72.9 (s, C6), 45.0 (s, C4), 44.6 (s, C2), 38.1 (s, C7), 17.3 (s, C3). HRMS (ESI+): Calcd for 
C13H18O2Na [M+Na]+: 229.1199; Found: 229.1194. Specific rotation: [α]D 24.9  +35.  (c = 0.22 
CH3OH). 
 
 
 
Figure 4.19. 1H and 13C{1H} spectrum for carbocycle 4.32. 
 170 
  
 171 
5. Chapter 5: Chemoselective functional-group modification under B(C6F5)3 catalyzed 
hydrosilylation 
 
This chapter resulted from a collaboration with Dr. Phillipa Payne. 
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5.1. Late stage functionalization of natural products 
 
The application of B(C6F5)3 in combination with a stoichiometric hydrosilane (HSiR3) 
as a reductant has been utilized to perform reduction/activation on a plethora of diverse 
functional groups. This diversity of reactivity is phenomenal for a broad scope of 
applications towards molecules that contain a targeted functional group for activation or 
reduction. Such a broad scope also has negative aspects. Specifically, this system would 
seem poorly suited to perform selective functional group activation, except in highly 
designed or contrived substrates. However, if the reactivity of this system could be 
selectively modified, the applicability of B(C6F5)3 towards the selective activation of 
complex molecules would offer a unique avenue for performing transformations that would 
be difficult to achieve with alternative approaches.  
From our previous studies, we found that the inherent reactivity of this system could 
be modulated by numerous factors such as 1) silane choice as a reductant or protecting group 
of a substrate, 2) neighboring group participation, 3) or inherent stereochemical configuration 
of substrate. Through these differences or modifications, we have been able to achieve highly 
chemoselective C–O bond reduction in complex polyoxygenated starting materials, where 
inherent reactivity order (1º C–O > 2º > 3º) was overcome in multiple examples. Moreover, 
completely new transformations were achieved when we demonstrated C–O bond reduction 
could be coupled with C–C bond formation in highly chemo- and diastereoselective 
modifications that often selected against inherent reactivity through the participation of 
neighboring groups.  
The ultimate challenge and demonstration that this chemoselectivity is translatable to 
more complex substrates, is to investigate the late-stage modification of complex natural 
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products. The development of novel methods which provide access to unusual modifications 
of natural products or advanced drug candidates is a burgeoning field and creates new 
intellectual space allowing for structure-activity relationship. Chapter 5 discuss our lab’s 
thrust forward in the field of selective modifications of complex natural products.  
5.2. Chemoselective modifications of natural products  
 
To test the notion that the highly reactive B(C6F5)3/H–SiR3 combination would be 
amenable to performing modifications of complex molecule scaffolds with high precision, 
we initially investigated reactivity of gibberellic acid (5.1). Utilization of gibberellic acid in 
late state modifications is common because of the extremely robust nature of the parent core. 
We originally thought it would nicely demonstrate whether or not functional group 
differentiation under hydrosilylation would be possible. With a lactone, carboxylic acid, and 
allylic alcohols we assumed that multiple or all of these functional groups could be activated 
in a standard hydrosilylation experiment. To our surprise treating 5.1 with catalytic quantities 
of B(C6F5)3 and excess silane leads exclusively to lactone C–O reduction accompanied by 
allylic transposition in 93% yield (Scheme 5.1). Although this reaction can be accomplished 
under dissolving metal reduction conditions, the mild conditions, high yields, and 
amenability to the small scales often associated with complex natural products chemistry 
outline an appealing approach to gibberellin derivatives.81 Moreover, no over-reduction or 
complex mixtures were observed. A second complex molecule and common late stage 
functionalization candidate is the modified antimalarial drug dihydroartemisinin (5.3). Single 
site reactivity was also observed with dihydroartemisinin (Scheme 5.1). Although hemiacetal 
reduction was not unexpected, the high chemoselectivity is remarkable as the acetal and 
endo-peroxide were considered candidates for silane attack. 
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Scheme 5.1. Selective modification of gibberellic acid (5.1) and dihydroartemisinin (5.3). 
 Both 5.1 and 5.3 contain functional groups that have previously been shown to be 
compatible with B(C6F5)3 mediated hydrosilylation and they also contain only C–O bonds in 
various oxidation states. To truly demonstrate late stage functionalization of complex natural 
products, we sought to test the feasibility of these chemoselective reductions on even more 
complex molecules. The anti-fungal agent natamycin presented a number of challenges to the 
B(C6F5)3/silane reduction protocol, including an array of reducible functional groups 
(epoxide, enoate, allylic ether, acetal, hemiacetal, polyene, alcohols, acid, etc.), and groups 
that could deactivate the catalyst by Lewis acid/base pair formation, Figure 5.2. Since the 
mycosamine sugar is key to its biological activity82,83 and we suspected that it might 
deactivate the B(C6F5)3 catalyst we converted it to 5.5, which is also soluble in organic 
solvents.84 
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Figure 5.1. Natamycin functional groups that can be reduced by R3Si–H–B(C6F5)3. 
The need for a strong fluoroaryl boron Lewis acid to ionize the silane in the Piers 
mechanism and initiate the catalytic cycle was one point of concern for a sensitive molecule 
like natamycin, which contains a number of basic functional groups that could either 
sequester the catalyst or provide sites for Lewis acid-accelerated decomposition. These 
concerns were not unfounded as B(C6F5)3 rapidly decomposes 5.5 to a complex mixture. The 
rate of decomposition could be reduced but never eliminated in less polar solvents such as 
toluene, or by carrying out reactions at cryogenic temperatures. Attempts to outcompete 
catalyst-induced substrate decomposition under hydrosilylation conditions were largely 
unsuccessful.  
To mitigate this decomposition, we reasoned that a Lewis base additive might 
sufficiently lower the free B(C6F5)3 concentration to inhibit substrate decomposition but still 
allow for silane activation. This requirement is achieved when bulky Lewis bases create 
frustrated Lewis pairs (FLP) with B(C6F5)3.85 The FLP concept thus allows Lewis acids and 
bases to act cooperatively to heterolyze non-polar bonds like H–H and Si-H (Scheme 5.2). A 
classic frustrated Lewis pair exists between B(C6F5)3 and triphenylphosphine (Ph3P), which 
stoichiometrically forms the B-P Lewis pair but reacts through low concentrations of the 
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non-paired components. Consistent with this behavior, the addition of 1.1 equiv of PPh3 
(relative to B(C6F5)3) completely inhibits the decomposition of 5.5.  
 
 
 
Scheme 5.2. Silyl-phosphonium arrests B(C6F5)3 as the anionic borohydride H–B(C6F5)3– 
 
More importantly, when combined with Me2EtSiH, the B(C6F5)3/PPh3 mixture 
catalyzes a highly selective transformation on 5.5. As shown in Scheme 5.3, this combination 
catalyzes enoate conjugate reduction to 5.6 (55% isolated yield) without affecting any of the 
other functional groups in the molecule, including its flanking epoxide. To the extent that 
small molecule studies are relevant, this reduction likely proceeds by silylium 
coordination/activation of the ester (I) followed by HB(C6F5)3– addition to yield a silyl 
ketene acetal (II), which is hydrolyzed on work up.  
 
 
 
Scheme 5.3. Chemeoselective activation of enoate. 
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With the goal of altering chemoselectivity in the reduction, several variants of 
B(C6F5)3 were synthesized that modify the steric and electronic environment around the 
electrophilic boron center. The fluoroaryl boranes tris[2,4,5-trifluoromethyl)phenyl]borane 
(BAr3F3) and tris[3,5-bis(trifluoromethyl)phenyl]borane (BArF3) (Scheme 5.4) have similar 
Lewis acid strengths and both are weaker than B(C6F5)3. Their steric profiles, however, differ 
as the former contains ortho-fluorine atoms that sterically shield the boron atom. Importantly, 
these Lewis acid catalysts (and PPh3) were also chemoselective, but for different products 
(Scheme 5.4). Instead of exclusive conjugate reduction with B(C6F5)3, BArF3 hydrosilylates 
the enoate to α-silylester 5.7 in 53% isolated yield (>10:1 dr, 19% recovered sm). BAr3F3 
behaves differently, and with Et2MeSiH combines enoate hydrosilylation with lactol 
elimination to α-silyl/enol ether 5.8 in 46% yield (>10:1 dr, 20% recovered sm). In simple 
molecules, Chung has shown that conjugate reduction to the silyl-ketene acetal precedes an 
intermolecular B(C6F5)3-catalyzed silyl transfer to the alpha position.86 Cooling the BAr3F3-
catalyzed reaction of 5.5 with Me2EtSiH changed the dominant product from 
hydrosilylation/lactol elimination (5.8) to hydrosilylation/lactol reduction (5.9, 53% isolated, 
>10:1 dr). 
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Scheme 5.4. Chemoselective conversion of natamycin under catalyst control. 
The relative reactivity of the competing functional groups under BArF-type catalysis 
was refined by step-wise addition of a single equivalent of the silane. With all three catalysts 
and Me2EtSiH, the first step is dehydrosilylation of the carboxylic acid proton to generate a 
gas (H2) and the corresponding silylester (from in-situ NMR spectroscopy). Quenching of the 
reaction at this stage returns this new species to the free carboxylic acid. 1H NMR analysis 
reveals that a second equivalent of MeEt2SiH converts the enoate to the α-silyl ester product. 
When BAr3F3 is used, lactol elimination occurs once enoate hydrosilylation is complete.  
Since the carboxylic acid is first to react, we reasoned that a secondary silane would 
install a reactive silyl ester in the northeast quadrant of the structure (III, Scheme 5.4) and set 
up a directed reduction in this region. The combination of BAr3F3 /Ph3P with Et2SiH2 quickly 
evolves gas to generate the putative silyl ester III, however, no further reaction occurs 
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(quenching and work-up yields the free carboxylic acid). However, if the more electrophilic 
B(C6F5)3/Ph3P catalyst is added after the initial dehydrosilylation, a rapid conversion of III to 
enol ether 5.10 occurs without competitive enoate reduction. This new compound could also 
be obtained more conveniently in a single step from 5.5 when BArF3/PPh3 was used as the 
catalyst.  
5.3. Mechanistic investigations to understand the role of phosphine in chemoselective 
reductions 
 
The role of the phosphine Lewis base in the chemistry of FLPs suggested that PPh3 
might be doing more than simply lowering the free [B(C6F5)3] by Lewis pair formation. 
Control experiments combining B(C6F5)3, PPh3, and a tertiary silane confirmed this 
suspicion. B(C6F5)3 and PPh3 together generate a poorly soluble Lewis adduct (B) that 
quickly solubilizes upon silane addition to yield the H–B(C6F5)3–/Me2EtSi–PPh3+ ion pair as 
verified by 19F and 31P NMR spectroscopy (Figure 5.2). The para-F of the B(C6F5)3 
characteristically shifts upfield (-145 ppm to -165 ppm) upon formation of H–B(C6F5)3– (C, 
Figure 5.2). The stabilizing effect of added PPh3 on the reactions with 5.5 is thus not to 
simply lower the B(C6F5)3 concentration by Lewis pair formation, but to convert it to the H–
B(C6F5)3– reducing agent. This speciation also changes the silylium ion source (Me2EtSi–
PPh3+) to one that is stabilized (less reactive) but present in stoichiometric quantities. 
Consistent with this assertion, in situ monitoring of the reduction of 5.5 B(C6F5)3 indicates 
that H–B(C6F5)3–  is the major species. Broad peaks in the 31P NMR spectrum make it 
difficult to assess if the silylium ion remains localized on PPh3. 
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Figure 5.2. 19F{1H} NMR study of B(C6F5)3 speciation with Ph3P and Me2EtSiH. 
 
In this altered vision, the phosphine acts as a silylium carrier, delivering the ion to the 
most reactive Lewis base sites on the substrate for subsequent reduction by the stoichiometric 
(and ion paired) H–B(C6F5)3–. One can readily envision manipulating the steric and 
electronic character of the carrier to influence which site becomes activated and perhaps even 
how that site reacts once it has become activated. 
Interestingly, the same control experiments on the combination of BAr3F3, PPh3 and 
Me2EtSiH revealed that while a soluble Lewis pair forms, the subsequent reaction with silane 
is not favorable. The heterolysis could be driven partially forward, however, with the more 
basic P(p-tol)3 to generate BAr3F3–H–. Under the more complex conditions of a catalytic 
reduction of 5.5 with BAr3F3/PPh3, two new fluoroaryl boranes environments were observed, 
one of which is consistent with BAr3F3–H–, while the second matches the 19F chemical shifts 
of the Lewis pair formed between N-butylbenzamide, a model for the amide in 5.5. The 
fluoroaryl borane thus sits as either BAr3F3–H– or bound to the substrate’s amide. Notably 
this does not trigger rapid substrate decomposition suggesting that it is (an)other Lewis basic 
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site(s) on 5.5 that promotes this detrimental reactivity, and that PPh3 inhibits the coordination 
of Lewis acid to this site.  
5.4. Chemoselective amide activation over other active functional groups 
 
The viability of catalyst control over chemoselectivity was also demonstrated upon 
switching to the mixed fluoroaryl/alkyl borane catalyst (3-hexyl)2(C6F5)B (3-hex-BArF2) 
which is obtained in a single step by hydroboration of 3-hexene with the Piers borane (H–
B(C6F5)2). 87 Initial investigations of 3-hex-BArF2 catalyzed hydrosilylation of 5.5 lacked 
selectivity and added PPh3 completely inhibits catalysis in these cases. A more controlled 
reaction was observed when the acetamide derivative 5.11 was investigated. Amazingly, the 
acetamide group was selectively reduced to the N-ethyl mycosamine derivative of natamycin 
(5.12, Scheme 5.5), in a reaction that has not previously been observed for this catalyst type. 
The selective reduction of an amide (the most Lewis basic site) in the presence of all the 
normally more reactive functional groups represents a significant opportunity for 
chemoselectivity. Efforts to enhance the conversion led to competing enoate reduction as 
seen above. Key to a successful optimization of the conversion and yield was the lack of a 
rapid gas (H2) evolution with 3-hex-BArF2 (c.f. BArF3-type catalysts), suggesting that 3-hex-
BArF2 preferentially activates amides over carboxylic acids. To avoid off-target reductions, 
we utilized the same strategy as above where a secondary silane directs reactivity to the most 
activated site. Optimization of these reaction conditions led to good yields of 5.12, with no 
competing reactivity at other positions (Figure 5.5).88 Moreover, selectivity for the 
mycosamine amide remained intact in the presence of a second amide that was installed at 
the natamycin carboxylic acid position (5.13) to yield amine product 5.14 (Scheme 5.5). 
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Scheme 5.5. Selective amide reduction without activation of positions observed with BArF3 systems. 
To test the feasibility of the fluoroaryl borane methodology for creating new structure 
space around a complex but structurally distinct class of natural products (terpenoid versus 
polyproprionate/acetate), we investigated the late-stage functionalization of 10-deacetoxy-
baccatin III (5.15), a precursor to the gold-standard chemotherapeutic Paciltaxel. Depending 
on the catalyst or presence of silane, multiple novel transformations were observed. B(C6F5)3 
alone catalyzes a high-yield conversion of 5.15 to a new species, ene-al 5.16, which is ideally 
set up for combinatorial diversification. Lewis acid-catalyzed rearrangenment is also 
chemoselective with BAr3F3 and high yielding, but for a different set of products (5.18 and 
5.19), both of which offer opportunities for additional diversification. When silane is 
included, BAr3F3 was the better behaved Lewis acid and oxetane ring opening occurs 
concomitant to acetate reduction to form a single diastereomer of 5.21, a hallmark of 
neighboring group assistance and the intermediacy of a dioxocarbenium ion (IV). 89,90 The 
lack of chemistry at the ketone, benzoate, and allyl alcohol is noteworthy (Scheme 5.6).  
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Scheme 5.6. Selective modification of 10-deacetoxybaccatin III utilizing BArF derivatives as 
hydrosilylation and oxophilic Lewis acid catalysts. 
The application of the BArF3/silane method on a new structure is operationally 
straightforward and provides novel variants poised for biological testing and/or additional 
diversification. Although our academic interests draw us to develop a predictive reactivity 
algorithm, the utility and usability of the methodology does not rely on, nor is it constrained 
by, any such predictions. We believe that this have wider benefits as a way to enhance the 
structural diversity of many complex structures of interest. 
5.5. Experimental Section 
 
Unless otherwise stated, all reactions were conducted under a nitrogen atmosphere 
using a Vacuum Atmospheres glovebox. “Dowex® resin” refers to Dowex® 50W-X8, a 
strongly acidic cation exchange resin distributed by Baker Chemical Company. PPTS resin 
refers to pyridinium p-toluene sulfonate polymer-bound with extent of labeling 3.5 mmol/g 
toluene for sulfonate loading and was purchased from Aldrich. Before use both resins were 
washed five times with methanol and five times with methylene chloride and then allowed to 
dry at ambient pressure. All workup procedures were performed under air with reagent grade 
reagents unless otherwise specified. Thin layer chromatography (TLC) was performed on 
10 mol% BAr3F3
CH2Cl2, RT, 1h
11 mol% Ph3P
2.2 equiv. Me2EtSiH
10 mol% B(C6F5)3
CH2Cl2, RT, 3h
5.15 (-OH)
5.17 (-SiEt3)
5.20 (-SiMe2Et)
5.16, (68%)
5.21, (72%)
+
5.18, (45 %)
5.19, (39 %)
10 mol% 
BAr3F3
CH2Cl2
RT, 2h
OSi
O
O
H O
L.A.
IV
PO
HO O OP
HO OBz
OH
O
O
HO
HO O
OH
HO OBz O
H
EtMe2SiO
EtMe2SiO O
OSiMe2Et
HO OBz
OSiMe2EtH
O
O
Et3SiO
HO O
OSiEt3
HO OBz
O
H
Et3SiO
HO O
OSiEt3
HO OBz
O
H
O
OO
H
O
 184 
SiliCycle Silica Gel 60 F254 plates and was visualized with UV light, cerium ammonium 
molybdate (CAM) stain, or potassium permanganate (KMnO4) stain. Methylene chloride-d2 
was purchased from Cambridge Isotope labs. Both CD2Cl2 and CH2Cl2 were degassed via 
three freeze-pump-thaw cycles, and dried over 4Å molecular sieves prior to use. Me2EtSiH, 
Et3SiH, and i-Pr3SiH ampules were purchased from Sigma-Aldrich and stored over molecular 
4Å sieves in the glovebox. Natamycin and gibberellic acid were purchased from Carbosynth. 
Natamycin was azeotroped with anhydrous benzene (3 X 10 mL) prior to use and gibberellic 
acid was used as received. 10-deacetoxybaccatin III was purchase from AEchem Scientific 
Corporation, USA (Naperville, IL. USA) and used a received. Dihydroartemisinin was 
purchased from Sigma Aldrich and used as received. Dichloromethane, benzene, imidazole, 
anhydrous DMF, anhydrous N,N-dimethylacetamide (DMAC), acetic anhydride, 4-
dimethylaminopyridine (DMAP), benzoic anhydride, sodium phosphate monobasic, sodium 
phosphate dibasic, and THF were purchased from Sigma-Aldrich and used as received. 
Pyridinium p-toluenesulfonate polymer bound (~3.5 mmol/g toluene 4-sulfonate loading) 
was purchased from Sigma-Aldrich and rinsed with dichloromethane (3 x 10 mL), methanol 
(3 x 10 mL), and dried under nitrogen purge prior to use. Methanol was purchased from 
Fisher and used as received. Tris(pentafluorophenyl)borane (B(C6F5)3) was purchased from 
Strem and used as received. It is worth noting that the source of B(C6F5)3 is important to this 
chemistry and best results were found when using the source above. Triphenylphosphine was 
purchased from Sigma-Aldrich and re-crystalized from toluene prior to use. The following 
boron compounds were synthesized following literature procedures with rigorous exclusion 
of oxygen and moisture in oven-dried Schlenk glassware on a dual-manifold Schlenk line or 
in a nitrogen-filled glovebox:  tris[(3,5-bis(trifluoromethyl)phenyl]borane (B(ArF3)91, and 
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tris[(2,4,6-trifluorophenyl]borane (B(Ar3F3). Piers’ bis(pentafluorophenyl)borane was 
prepared from B(C6F5)3 as previously described.87 Natamycin protections were carried in an 
analogous manner to a previously described method.84  
Room-temperature NMR spectra were recorded using a Bruker Avance III 
spectrometer equipped with a cryoprobe operating at 600 MHz (1H) and 150 MHz (13C). 
NMR chemical shifts are reported in ppm and referenced using the residual proton peaks (d 
CHCl3 = 7.26, d CH2Cl2 = 5.32), 13C resonances of the deuterated solvent (d CDCl3 = 77.16, 
d CD2Cl2 = 53.84) or the proteo solvent (d CH2Cl2 = 54.24). Low temperature NMR spectra 
were recorded using a Bruker Avance III spectrometer equipped with a BBO probe operating 
at 500 MHz (1H) and 125 MHz (13C). High resolution mass spectra were obtained on either 
an Agilent Accurate LC-TOF Mass Spectrometer (Agilent Series 6220) operating in positive 
ion mode with an electrospray ionization source (fragmentor = 175 V) or with a hybrid LTQ 
FT (ICR 7T) (ThermoFisher, Bremen, Germany) mass spectrometer where samples were 
introduced via a micro-electrospray source at a flow rate of 3 µL/min. The data were 
analyzed using either Agilent MassHunter Workstation Software, Qualitative Analysis (V. 
B.02.00) or Xcalibur (ThermoFisher, Breman, Germany). Specific rotations were obtained on 
a Jasco DIP-1000 digital polarimeter equipped with a sodium lamp utilizing a 3.5 x 100 mm 
cell. A NesLab cryobath CB-80 was utilized for reduced temperature reactions where 
temperature was verified by low-temperature thermometer.  
Amide protection of natamycin 
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Acetate protection of natamycin was carried out following an established protocol. 
Natamycin (3.32 g, 5.00 mmol, 1.00 equiv.) was dissolved into a 1:1 chloroform/methanol 
mixture and brought to 0 ºC. Acetic anhydride (0.93 mL, 10. mmol, 2.0 equiv.) was added 
dropwise and the reaction was quenched after 2 h by crashing out the product in a rapidly 
stirring flask of diethylether. Solid was collected by filtration and dried under high-vacuum 
before silane protection. 
 
 
 
Benzoate protection of natamycin was carried out following a slightly modified 
established protocol. Natamycin (3.32 g, 5.00 mmol, 1.00 equiv.) was dissolved into a 1:1 
chloroform/methanol mixture and brought to 0 ºC. Benzoic anhydride (2.26 g, 10.0 mmol, 
2.00 equiv.) was added in one portion and the reaction was warmed to room temperature and 
quenched after 12 h by crashing out the product in a rapidly stirring flask of diethylether. 
Solid was collected by filtration and dried under high-vacuum before silane protection. 
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General procedure 5.1: Silane protection of natamycin derivatives 
 
Amide protected natamycin (2.00 g, 2.80 mmol, 1.00 equiv.) was transferred to a 
250-mL round bottom flask equipped with a magnetic stir bar. Imidazole (2.30 g, 33.6 mmol, 
12.0 equiv.) was added. The reaction vessel was capped with a rubber septum and a positive 
flow of nitrogen was introduced to the reaction vessel. THF (38.4 mL) and DMF (21.0 mL) 
were introduced to the reaction flask by syringe. The reaction was then placed into a 0 °C ice 
bath and allowed to stir for 20 minutes. Triethylchlorosilane (4.20 mL, 25.1 mmol, 9.00 
equiv.) was added by syringe and the reaction was allowed to stir at 0 °C for 4 h. After the 
reaction time was complete, saturated sodium bicarbonate solution (50 mL) was added to the 
reaction and allowed to stir for 10 minutes while maintained at 0 °C. The reaction contents 
were then transferred to a separatory funnel and the reaction vessel was rinsed with diethyl 
ether (3 x 30 mL). The aqueous phase was extracted and the resulting organic layer was 
collected. The aqueous phase was extracted with diethyl ether twice more (40 mL ether) and 
the organic layers were combined, rinsed with water (3 x 40 mL), brine (3 x 40 mL), 
collected and dried over sodium sulfate. The solid was removed by filtration into a round 
bottom flask and the solvent removed under vacuum. The resulting orange oil was triturated 
with acetonitrile (3 x 15 mL). The product was purified by silica gel chromatography (20 x 4 
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cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 
hexanes:ethyl acetate) to afford the title product. 
Preparation of 5.13 
 
 
 
 
 
Substrate 5.13 was prepared by analogy to a previously published protocol.92 NAc-
Natamycin (2.3 g, 3.00 mmol, 1.00 equiv.) was transferred to a flame dried 250-mL round 
bottom flask equipped with a magnetic stir bar. The reaction vessel was capped with a rubber 
septum and a positive flow of nitrogen was introduced to the reaction vessel. By syringe 
N,N-dimethylacetamide (40 mL) was added. By syringe Et3N (4.5 mL, 48.0 mml, 16 equiv.), 
n-butylamine (3.0 mL, 30.0 mmol, 10 equiv.), and diphenyl phosphoryl azide (6.45 mL, 30.0 
mmol, 10 equiv.) were added in this order. The reaction was allowed to stir at 25 ºC for 4 h. 
After the reaction time, the reaction contents were transferred quantitatively to a 500-mL 
round bottom flask with stirring diethyl ether (250 mL). Solid material crashed out of 
solution and this was allowed to stir for 30 minutes. After 30 minutes of stirring, the mixture 
was filtered over fine Whatman paper, and the filter cake was rinsed with additional diethyl 
ether (3 x 10 mL). The isolated solid was transferred to a 100-mL round bottom flask and 
placed under high vacuum for 12 h. Silane protection was carried out following general 
procedure 5.1. The product was purified by silica gel chromatography (20 x 4 cm column) 
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using gradient elution (100% hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 hexanes:ethyl 
acetate) to afford the 5.13. 
Preparation of 5.20 
 
 
 
 
 
10-deacetylbaccatin (0.586 g, 1.00 mmol, 1.00 equiv.) was transferred to a 100-mL 
round bottom flask equipped with a magnetic stir bar. The reaction vessel was capped with a 
rubber septum and a positive flow of nitrogen was introduced to the reaction vessel. 
Dichloromethane (10.0 mL) was added by syringe. To the heterogeneous stirring solution 
pyridine (0.40 mL, 5.0 mmol, 5.0 equiv.) was added by syringe followed by Me2EtSiCl (0.56 
mL, 4.0 mmol, 4.0 equiv.). The reaction was allowed to stir for 12 h at 25 ºC. After the 
reaction time was complete water (20 mL) was added and the reaction contents were 
transferred to a separatory funnel and with diethyl ether rinses (3 x 30 mL). The aqueous 
phase was extracted and the resulting organic layer was collected. The aqueous phase was 
extracted with diethyl ether twice more (40 mL ether) and the organic layers were combined, 
rinsed with water (3 x 40 mL), brine (3 x 40 mL), collected and dried over sodium sulfate. 
The solid was removed by filtration into a round bottom flask and the solvent removed under 
vacuum. The resulting white solid was triturated with toluene (3 x 15 mL). The product was 
purified by silica gel chromatography (20 x 4 cm column) using gradient elution (100% 
hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 to 1:1 hexanes:ethyl acetate) to afford the title 
product.  
HO
HO O OH
HO OBz
OH
O
O
Me2EtSiCl (4.0 equiv.)
pyridine (5.0 equiv.)
CH2Cl2, 25 ºC, 12 h
EtMe2SiO
HO O OSiMe2Et
HO OBz
OH
O
O
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Preparation of 5.20 
 
 
10-deacetylbaccatin (1.8 g, 3.00 mmol, 1.00 equiv.) was transferred to a 100-mL 
round bottom flask equipped with a magnetic stir bar. The reaction vessel was capped with a 
rubber septum and a positive flow of nitrogen was introduced to the reaction vessel. 
Dichloromethane (20.0 mL) was added by syringe. To the heterogeneous stirring solution 
DMAP (0.073 g, 0.60 mmol, 0.20 equiv.) was added in one portion. Pyridine (2.2 mL, 27 
mmol, 9.0 equiv.) was added by syringe followed by Et3SiCl (2.3 mL, 18 mmol, 6.0 equiv.). 
The reaction was allowed to stir for 12 h at 25 ºC. After the reaction time was complete water 
(20 mL) was added and the reaction contents were transferred to a separatory funnel and with 
diethyl ether rinses (3 x 30 mL). The aqueous phase was extracted and the resulting organic 
layer was collected. The aqueous phase was extracted with diethyl ether twice more (40 mL 
ether) and the organic layers were combined, rinsed with water (3 x 40 mL), brine (3 x 40 
mL), collected and dried over sodium sulfate. The solid was removed by filtration into a 
round bottom flask and the solvent removed under vacuum. The resulting white solid was 
triturated with toluene (3 x 15 mL). The product was purified by silica gel chromatography 
(20 x 4 cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 
3:1 to 1:1 hexanes:ethyl acetate) to afford the title product.  
Et3SiCl (6.0 equiv.)
pyridine (9.0 equiv.)
DMAP (0.2 equiv)
CH2Cl2, 25 ºC, 12 hHO
HO O OH
HO OBz
OH
O
O
Et3SiO
HO O OSiEt3
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O
O
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1H NMR (600 MHz, CDCl3): δ 7.81–7.75 (m, 2H), 7.54–7.48 (m, 1H), 7.48–7.42 (m, 2H), 
6.67 (s, 1H), 6.28 (dd, J = 15.6, 8.3 Hz, 1H), 6.26–6.14 (m, 3H), 6.08–6.01 (m, 6H), 6.01–
5.91 (m, 1H), 5.65–5.56 (m, 1H), 5.51 (ddd, J = 15.2, 10.3, 5.2 Hz, 1H), 5.12–5.03 (m, 1H), 
4.59 (s, 1H), 4.46–4.38 (m, 2H), 4.34 (td, J = 10.6, 4.7 Hz, 1H), 4.26 (qd, J = 7.2, 2.9 Hz, 
1H), 4.21 (td, J = 8.8, 3.1 Hz, 1H), 4.12 (ddd, J = 10.8, 7.3, 3.1 Hz, 1H), 4.00 (d, J = 1.3 Hz, 
1H), 3.65 (t, J = 8.1 Hz, 1H), 3.40 (p, J = 6.5 Hz, 1H), 3.11 (dd, J = 8.2, 2.1 Hz, 1H), 2.95 (d, 
J = 8.5 Hz, 1H), 2.48–2.36 (m, 2H), 2.11 (dt, J = 13.4, 10.6 Hz, 1H), 2.05–1.99 (m, 1H), 1.96 
(ddd, J = 14.3, 7.1, 2.5 Hz, 1H), 1.90–1.82 (m, 3H), 1.77 (dd, J = 14.1, 7.5 Hz, 1H), 1.69 
(ddd, J = 14.4, 8.7, 3.1 Hz, 1H), 1.33 (d, J = 6.3 Hz, 3H), 1.27 (d, J = 6.6 Hz, 3H), 1.25–1.23 
(m, 1H), 0.97 (t, J = 7.9 Hz, 9H), 0.92 (t, J = 8.0 Hz, 9H), 0.88 (td, J = 7.9, 1.9 Hz, 18H), 
0.67–0.49 (m, 24H). 13C{1H} NMR (151 MHz, CDCl3): δ 175.6, 166.7, 166.0, 143.7, 134.8, 
134.2, 133.3, 132.3, 132.1, 132.0, 131.5, 129.3, 128.5, 126.7, 125.7, 98.5, 96.3, 78.1, 73.9, 
72.5, 69.8, 67.4, 67.0, 66.4, 56.4, 56.3, 56.1, 55.5, 46.4, 43.4, 41.3, 37.0, 20.2, 19.0, 6.9, 6.9, 
6.8, 6.8, 5.2, 5.1, 4.9, 4.8. (*Note: 2 aryl and olefin peaks overlap.) 
O Et3SiO O
O O OH OSiEt3
OO
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Figure 5.3. 1H and 13C{1H} NMR spectrum of 5.5. 
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1H NMR (600 MHz, CDCl3) δ 6.28 (dd, J = 15.7, 7.9 Hz, 1H), 6.23–6.12 (m, 3H), 6.07–6.03 
(m, 3H), 5.99–5.93 (m, 1H), 5.72 (d, J = 9.6 Hz, 1H), 5.63–5.56 (m, 1H), 5.51 (ddd, J = 15.3, 
10.2, 5.4 Hz, 1H), 5.02 (dqd, J = 12.6, 6.1, 2.8 Hz, 1H), 4.54 (s, 1H), 4.48 (br s, 1H), 4.42 
(td, J = 9.7, 3.8 Hz, 1H), 4.34 (td, J = 10.8, 4.7 Hz, 1H), 4.28 (qd, J = 7.6, 3.3 Hz, 1H), 4.13 
(ddd, J = 10.2, 6.5, 3.3 Hz, 1H), 3.95 (td, J = 9.5, 2.9 Hz, 1H), 3.83 (d, J = 2.9 Hz, 1H), 3.43 
(t, J = 9.0 Hz, 1H), 3.27 (dq, J = 8.5, 6.2 Hz, 1H), 3.11 (dd, J = 7.9, 2.0 Hz, 1H), 2.85 (d, J = 
8.1 Hz, 1H), 2.46–2.34 (m, 2H), 2.11 (dt, J = 13.5, 10.5 Hz, 1H), 2.03 (s, 3H), 2.00–1.90 (m, 
2H), 1.92–1.86 (m, 2H), 1.79 (dd, J = 14.1, 6.5 Hz, 1H), 1.75–1.65 (m, 2H), 1.33 (d, J = 6.2 
Hz, 3H), 1.27–1.23 (m, 1H), 1.22 (d, J = 6.3 Hz, 3H), 0.97 (t, J = 7.9 Hz, 9H), 0.95–0.91 (m, 
27H), 0.69–0.52 (m, 24H). 13C{1H} NMR (151 MHz, CDCl3): δ 174.9, 170.1, 165.9, 143.4, 
135.0, 134.1, 132.7, 132.4, 132.3, 132.1, 131.9, 128.9, 125.5, 98.6, 96.5, 77.7, 73.6, 72.5, 
72.2, 69.9, 67.4, 67.2, 66.8, 56.4, 55.8, 55.3, 46.1, 43.8, 40.9, 40.2, 37.0, 23.4, 20.2, 18.4, 7.0, 
6.9, 6.8, 6.8, 5.3, 5.0, 4.9, 4.8. (*Note: two aryl peaks are overlapping.) 
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Figure 5.4. 1H and 13C{1H} NMR spectrum of 5.11. 
 
1H NMR (600 MHz, CDCl3): δ 6.23 (dd, J = 15.6, 8.8 Hz, 1H), 6.16 (dd, J = 6.0, 3.2 Hz, 
3H), 6.06–5.99 (m, 3H), 5.95–5.89 (m, 1H), 5.66 (d, J = 9.5 Hz, 1H), 5.62–5.54 (m, 1H), 
5.51 (t, J = 5.6 Hz, 1H), 5.46 (ddd, J = 15.2, 10.8, 4.7 Hz, 1H), 5.15 (dqd, J = 12.6, 6.2, 2.9 
Hz, 1H), 4.40 (d, J = 1.1 Hz, 1H), 4.25 (ddd, J = 11.0, 9.7, 4.8 Hz, 1H), 4.18 (td, J = 9.8, 3.2 
Hz, 2H), 4.09 (td, J = 9.8, 3.2 Hz, 1H), 3.99 (s, 1H), 3.92 (td, J = 9.5, 3.0 Hz, 1H), 3.79 (d, J 
= 3.0 Hz, 1H), 3.41 (t, J = 8.9 Hz, 1H), 3.28 (ddt, J = 12.5, 8.7, 6.1 Hz, 1H), 3.22 (dq, J = 
O Et3SiO O
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OO
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NH
OSiEt3
O
Me
O
H
N
5.13
 196 
8.6, 6.2 Hz, 1H), 3.17–3.07 (m, 3H), 2.44 (dt, J = 12.7, 3.8 Hz, 1H), 2.12–2.01 (m, 1H), 1.98 
(s, 3H), 1.94–1.75 (m, 5H), 1.71 (ddd, J = 13.9, 10.7, 2.9 Hz, 2H), 1.55–1.39 (m, 2H), 1.37–
1.29 (m, 5H), 1.21 (t, J = 6.7 Hz, 4H), 0.96 (t, J = 8.0 Hz, 10H), 0.95–0.87 (m, 28H), 0.66–
0.56 (m, 10H), 0.57–0.51 (m, 14H). 13C{1H} NMR (151 MHz, CDCl3): δ 171.2, 169.5, 
166.3, 144.2, 134.7, 133.7, 132.6, 132.2, 131.8, 129.8, 129.8, 126.0, 99.0, 96.0, 79.2, 77.2, 
73.9, 72.6, 72.3, 69.8, 67.3, 66.8, 66.4, 58.8, 56.5, 56.2, 55.4, 47.0, 43.5, 42.0, 39.4, 38.2, 
37.0, 31.8, 23.8, 20.3, 20.3, 18.7, 13.9, 7.1, 7.0, 7.0, 6.9, 5.5, 5.2, 5.0, 4.9. 
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Figure 5.5. 1H and 13C{1H} NMR spectrum of 5.13. 
 
1H NMR (600 MHz, CDCl3): δ 8.14–8.04 (m, 2H), 7.65–7.55 (m, 1H), 7.52–7.44 (m, 2H), 
5.60 (d, J = 7.1 Hz, 1H), 5.15 (d, J = 1.9 Hz, 1H), 4.99–4.92 (m, 2H), 4.40 (dd, J = 10.7, 6.6 
Hz, 1H), 4.30 (d, J = 8.4 Hz, 1H), 4.27 (d, J = 2.0 Hz, 1H), 4.16 (dd, J = 8.4, 1.1 Hz, 1H), 
3.88 (dd, J = 7.1, 1.1 Hz, 1H), 2.46 (ddd, J = 14.3, 9.7, 6.6 Hz, 1H), 2.29 (s, 3H), 2.22 (dd, J 
= 15.3, 8.4 Hz, 1H), 2.11 (dd, J = 15.2, 8.7 Hz, 1H), 2.03 (d, J = 1.5 Hz, 3H), 1.89 (ddd, J = 
14.4, 10.7, 2.3 Hz, 1H), 1.72 (s, 3H), 1.57 (s, 6H), 1.01 (t, J = 7.9 Hz, 9H), 0.93 (t, J = 8.0 
Hz, 9H), 0.67 (qd, J = 7.9, 4.7 Hz, 6H), 0.60–0.50 (m, 6H). 13C{1H} NMR (151 MHz, 
CDCl3): δ 210.6, 170.2, 167.2, 143.7, 134.1, 133.7, 130.2, 129.6, 128.7, 84.4, 79.7, 77.2, 
Et3SiO
HO O OSiEt3
HOOBz
OH
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76.7, 75.5, 74.7, 72.9, 68.6, 57.8, 46.8, 43.1, 40.3, 37.3, 26.8, 22.5, 20.9, 15.1, 10.2, 7.1, 6.9, 
5.3, 5.0. 
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Figure 5.6. 1H and 13C{1H} NMR spectrum of 5.16. 
 
1H NMR (600 MHz, CDCl3): δ 8.13– 8.05 (m, 2H), 7.60 (td, J = 7.4, 1.3 Hz, 1H), 7.48 (t, J = 
7.8 Hz, 2H), 5.61 (d, J = 7.0 Hz, 1H), 5.11 (s, 1H), 4.96 (dd, J = 9.7, 2.1 Hz, 1H), 4.91 (td, J 
= 8.5, 1.7 Hz, 1H), 4.36 (dd, J = 10.6, 6.6 Hz, 1H), 4.31 (d, J = 8.5 Hz, 1H), 4.28–4.24 (m, 
1H), 4.14 (dd, J = 8.4, 1.1 Hz, 1H), 3.89 (d, J = 6.9 Hz, 1H), 2.42 (ddd, J = 14.5, 9.7, 6.6 Hz, 
1H), 2.28 (s, 3H), 2.20 (dd, J = 15.3, 8.2 Hz, 1H), 2.10 (dd, J = 15.4, 8.8 Hz, 1H), 2.01 (d, J 
= 1.4 Hz, 3H), 1.88 (ddd, J = 14.4, 10.7, 2.3 Hz, 1H), 1.72 (s, 3H), 1.15 (s, 3H), 1.08 (s, 3H), 
0.99 (t, J = 7.9 Hz, 3H), 0.90 (t, J = 7.9 Hz, 3H), 0.71–0.56 (m, 2H), 0.54–0.40 (m, 2H), 0.15 
(d, J = 8.0 Hz, 6H), 0.06 (d, J = 2.1 Hz, 6H). 13C{1H} NMR (151 MHz, CDCl3): δ 210.7, 
EtMe2SiO
HO O OSiMe2Et
HOOBz
OH
O
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170.2, 167.3, 143.6, 134.0, 133.8, 130.2, 129.5, 128.7, 84.4, 80.8, 79.6, 77.2, 76.6, 75.3, 74.7, 
73.0, 68.6, 57.8, 46.9, 43.1, 40.1, 37.3, 26.7, 22.6, 20.7, 15.3, 10.2, 8.9, 8.6, 7.0, 6.8, -1.5, -
1.8, -2.1, -2.3. 
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Figure 5.7. 1H and 13C{1H} NMR spectrum of 5.20. 
General procedure 5.2 
In a nitrogen-filled glovebox, a 1-dram vial was charged with 2,4,6-F-BCF (2.0 mg, 0.0050 
mmol, 0.10 equiv.) and Ph3P (1.4 mg, 0.0055 mmol, 0.11 equiv.). To this dichloromethane 
(0.20 mL) was added by syringe and agitated to dissolve solid. Once homogeneous, 
Et2MeSiH (0.032 mL, 0.23 mmol, 4.5 equiv.) was added by microliter syringe. In a second 1-
dram vial 5.5 (0.061 g, 0.050 mmol, 1.0 equiv.) was weighed and dissolved into 
dichloromethane (0.25 mL). The solution containing BCF/Ph3P was transferred via syringe to 
the substrate vial with a subsequent dichloromethane (0.050 mL) rinse that was combined 
with the reaction mixture. The contents were agitated and transferred to a J-young capped 
NMR tube. After 6 h the reaction was quenched by transferring the contents of the tube 
quantitatively into a separatory funnel with pH 7 phosphate buffer. Rinsed the reaction tube 
with additional dichloromethane (4 x 3 mL). Collected the organic layer and washed the 
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aqueous layer with additional dichloromethane (5 x 10 mL). Combined the organic layers, 
washed with brine (1 x 10 mL), collected, and dried over sodium sulfate. Filtered off solid, 
collected in round bottom flask, and concentrated down under vacuum to yield a white solid. 
The product was purified by silica gel chromatography (10 x 2 cm column). All reaction 
yields are from a 2 run minimum average. 
General procedure 5.3 
In a nitrogen-filled glovebox, a 1-dram vial was charged with HB(C6F5)2 (1.7 mg, 
0.0050 mmol, 0.10 equiv.). To this toluene (0.20 mL) was added by syringe followed by 
trans-hex-3-ene (1.0 µL). After five minutes, full conversion to active catalyst is achieved 
and Et2SiH2 (0.023 mL, 0.175 mmol, 3.5 equiv.) was added by microliter syringe. In a 
second 1-dram vial natural product (0.050 mmol, 1.0 equiv.) was weighed and toluene was 
added (0.25 mL). The substrate solution was transferred via syringe to the catalyst vial with a 
subsequent toluene (0.050 mL) rinse that was combined with the reaction mixture. The 
contents were agitated and transferred to a J-young capped NMR tube. After reaction time, 
the reaction was quenched by transferring the contents to the tube quantitatively into a 
separatory funnel with pH 7 phosphate buffer. Rinsed the reaction tube with additional 
dichloromethane (4 x 3 mL). Collected the organic layer and washed the aqueous layer with 
additional dichloromethane (5 x 10 mL). Combined the organic layers, washed with brine (1 
x 10 mL), collected, and dried over sodium sulfate. Filtered off solid, collected in round 
bottom flask, and concentrated down under vacuum to yield a white solid. The product was 
purified by silica gel chromatography (10 x 2 cm column). All reaction yields are from a 3 
run minimum average. 
General procedure 5.4 
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In a nitrogen-filled glovebox, a 1-dram vial was charged with 2,4,6-BCF (2.0 mg, 
0.0050 mmol, 0.10 equiv.), 10-deacetalbaccatin derivative (0.050 mmol, 1.0 eqiuv.) and 
dichloromethane (0.50 mL) was added by syringe. The vial was capped with a Teflon lined 
lid and removed from the glovebox. After reaction time, the reaction was quenched with 
Et3N (0.050 mL) by syringe through the reaction vessel septum. Volatiles were removed 
under vacuum and the product was purified by silica gel chromatography.  
Representative procedure for speciation studies 
 
 
Tris(pentafluorophenyl)borane (5.1 mg, 0.01 mmol, 1 equiv.) was added to a J Young 
tube with a teflon cap in a nitrogen filled glovebox. CD2Cl2 (0.50 mL) was added and the 
tube removed from the glovebox. 1H and 19F{1H} NMR spectra were collected and the tube 
was returned to the glovebox. Triphenylphosphine (2.9 mg, 0.011 mmol, 1.1 equiv.) was 
added to the tube and within minutes a white precipitate was formed. 1H, 19F{1H}, and 
31P{1H} NMR spectra were collected. Dimethylethylsilane (13.2 µL, 0.1 mmol, 10 equiv.) 
was added to the tube by micropipette and 1H, 19F, and 31P NMR spectra were collected. 
The 19F{1H} and 31P{1H} NMR spectra are included below. 
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Figure 5.8. Stacked 19F{1H} NMR of B(C6F5)3, Ph3P–B(C6F5)3, and [Me2EtSi–PPh3][H–
B(C6F5)3] 
Figure 5.9. Stacked 31P{1H} NMR of Ph3P–B(C6F5)3, and [Me2EtSi–PPh3][H–B(C6F5)3] 
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In-situ 19FNMR demonstrating that H–B(C6F5)3– is major catalyst species 
 
 
Following general procedure 4.2, 2.5 mg B(C6F5)3 1.4 Ph3P, CDCl3, 23.0 µL 
Et2MeSiH, and 61.0 mg of 5.5 were combined. After 2 h obtained in-situ 19F{1H} NMR.
 
Figure 5.10. In-situ 19F{1H} NMR demonstrating major catalyst species is H–B(C6F5)3. 
 
Observation of rapid silyl ester formation 
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In a nitrogen-filled glovebox, a 1-dram vial was charged with BAr3F3  (2.0 mg, 0.0050 
mmol, 0.10 equiv.) and Ph3P (1.4 mg, 0.0055 mmol, 0.11 equiv.). To this CDCl3 (0.25 ml) 
was added by syringe and agitated to yield a colorless solution. To this Me2EtSiH (0.007 mL, 
0.055 mmol, 1.1 equiv.) was added by microliter syringe and the vial was capped. A second 
1-dram vial was charged with 5.5 (0.061 g, 0.050 mmol, 1.0 equiv.). To this CDCl3 (0.25 
mL) was added by syringe. The substrate solution was transferred via syringe to the 
B(C6F5)3/Ph3P vial with a subsequent CDCl3 (0.050 mL) rinse that was combined with the 
reaction mixture. The contents were agitated and transferred to a J-young capped NMR tube. 
After 1 h the reaction by NMR full consumption of the starting material was observed to give 
5.5’ (see 1H NMR spectrum below). The reaction was quenched by transferring the contents 
to the tube quantitatively into a separatory funnel with pH 7 phosphate buffer. The reaction 
tube was rinsed with additional dichloromethane (4 x 3 mL). Collected the organic layer and 
washed the aqueous layer with additional dichloromethane (5 x 10 mL). The combined 
organic layers were collected and rinsed with brine (1 x 15 mL), collected, and dried over 
Na2SO4. Solid was removed by filtration and the volatiles were removed under vacuum to 
yield a white foam. The isolated material was verified to be recovered 5.5 by 1H NMR 
analysis.  
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Figure 5.11. In-situ 1H NMR of exclusive silylester formation upon addition of 1 equiv. of silane to 
5.5 
 
Preparation 5.2 
 
 
In a nitrogen-filled glovebox, a 1-dram vial was charged with a magnetic stir bar, B(C6F5)3 
(5.0 mg, 0.010 mmol, 0.10 equiv.), and gibberellic acid, 5.1 (0.034 g, 0.10 mmol, 1.0 equiv.). 
To this dichloromethane (0.50 mL) was added by syringe to yield a heterogeneous solution. 
Et3SiH (0.095 mL, 0.60 mmol, 6.0 equiv.) was added by microliter syringe. Rapid gas 
evolution was observed. After off-gassing was complete (45 minutes) the reaction was 
capped with a Teflon lined cap and removed from the glovebox. This was allowed to stir for 
HO
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3 h at 25 ºC. The reaction was quenched with Et3N (0.050 mL). The magnetic stir bar was 
removed and rinsed with dichloromethane (0.50 mL). The reaction mixture was concentrated 
down under vacuum to yield a sticky white solid. The product was purified by silica gel 
chromatography (10 x 2 cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 
10:1 to 5:1 to 3:1 to 1:1 hexanes:diethyl ether) to afford 5.2 as a white solid (74.9  mg, 93 % 
overall yield, 0.093 mmol). 5.2: 1H NMR (600 MHz, CDCl3): δ 5.11–5.04 (m, 2H), 4.91 (br 
s, 1H), 4.16 (t, J = 2.8 Hz, 1H), 3.20 (d, J = 6.0 Hz, 1H), 3.03 (ddt, J = 6.5, 4.9, 1.9 Hz, 1H), 
2.63 (dt, J = 16.1, 3.0 Hz, 1H), 2.55–2.43 (m, 2H), 2.27 (dq, J = 16.1, 2.0 Hz, 1H), 2.08–2.01 
(m, 1H), 1.91 (dd, J = 11.2, 2.7 Hz, 1H), 1.89–1.83 (m, 1H), 1.69 (s, 2H), 1.56 (ddd, J = 
11.2, 3.0, 1.2 Hz, 1H), 1.52–1.46 (m, 1H), 1.25 (s, 2H), 0.99–0.91 (m, 36H), 0.80–0.69 (m, 
6H), 0.63–0.55 (m, 12H), 0.52– 0.45 (m, 12H). 13C{1H} NMR (151 MHz, CDCl3): δ 177.0, 
174.4, 155.5, 142.5, 108.8, 105.9, 80.9, 77.2, 71.8, 51.6, 50.6, 50.1, 49.6, 46.5, 46.4, 39.9, 
39.6, 32.6, 31.7, 22.8, 19.0, 14.3, 7.2, 7.1, 6.9, 6.7, 6.7, 6.7, 6.6, 6.5, 5.9, 5.2, 4.7, 4.7. 
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Figure 5.12. 1H and 13C{1H} NMR spectrum of 5.2. 
 
Preparation of 5.4  
 
 
 
In a nitrogen-filled glovebox, a 1-dram vial was charged with a magnetic stir bar, 
B(C6F5)3 (2.5 mg, 0.0050 mmol, 0.10 equiv.), dihydroartemisinin, 5.3 (0.014 g, 0.050 mmol, 
1.0 equiv.), and triphenylsilane (0.033 g, 0.125 mmol, 2.5 equiv.). To this dichloromethane 
(0.50 mL) was added by syringe and gas evolution was observed. The reaction was capped 
with a Teflon lined lid and allowed to stir for 24 h at 25 ºC. The reaction was quenched with 
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2.5 equiv. Ph3SiH
O
O
O
O
H
H
CH2Cl2, RT
24 h
5.3 5.4
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Et3N (0.050 mL) via syringe through the reaction vessel septum. The magnetic stir bar was 
removed and rinsed with dichloromethane (0.50 mL). The quenched reaction mixture was 
concentrated under vacuum and then loaded onto an alumina plug (neutral, 10% H2O; 2 x 1 
cm) with 100% hexanes (1.5 mL) and collected by gradient elution (100% hexanes to 20:1 
hexanes:diethyl ether to 100% diethyl ether) into a tared vial (39.0 mg crude mass). The 
product was purified by silica gel chromatography (10 x 2 cm column) using gradient elution 
(100% hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 to 1:1 hexanes:ethyl acetate) to afford 5.4 
as a white solid (12.3  mg, 92 % overall yield, 0.046 mmol).  
Preparation of 5.6 
 
 
 
Following general procedure 5.2, 2.5 mg B(C6F5)3 1.4 Ph3P, d-chloroform, 23.0 µL 
Et2MeSiH, and 61.0 mg of 5.5 were combined. After 2 h the reaction was quenched. Post 
work up, the product was purified by silica gel chromatography (10 x 2 cm column) using 
gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 
5:1 to 4:1 to 3:1 hexanes:ethyl acetate) to afford 5.6 as a white solid (31.8  mg, 58% overall 
yield, 0.029 mmol). Starting material was also recovered as a white solid and eluted off the 
column after the major product (6.7 mg, 11% overall yield, 0.006 mmol, Rf = 0.4, 
hexanes:ethyl acetate 3:1). 5.6: 1H NMR (600 MHz, CD2Cl2): δ 7.79–7.74 (m, 2H, Ar), 7.58–
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7.51 (m, 1H, Ar), 7.50–7.44 (m, 2H, Ar), 6.51 (d, J = 9.3 Hz, 1H, NH), 6.18–6.01 (m, 6H, H5 
& H6 & H7 & H8 & H9 & H10), 5.65–5.56 (m, 2H, H4 & H11), 5.14 (dqd, J = 12.5 Hz, JH2,H1 = 
6.7 Hz, 2.9 Hz, 1H, H2), 4.93 (d, J = 1.9 Hz, 1H, –OH), 4.64 (br s, 1H, H32), 4.49–4.45 (m, 
1H, H12), 4.38 (ddt, JH20,H19 = 11.0 Hz, 5.7 Hz, JH20,H19’ & J20,H21’ = 2.6 Hz, 1H, H20), 4.33 
(ddd, J = 11.2 Hz, JH16,H15 = 10.1 Hz, JH16,H17 = 4.6 Hz, 1H, H16), 4.20–4.11 (m, 2H, H14 & 
H30), 3.92 (d, JH31,H30 = 2.9 Hz, 1H, H31), 3.60 (dd, J = 9.4 Hz, JH29,H28 = 8.2 Hz, 1H, H29), 
3.40 (dq, JH28,H29 = 8.3 Hz, JH28,H27 = 6.2 Hz, 1H, H28), 2.66 (dt, J = 8.7, 2.4 Hz, 1H, H22), 
2.51 (t, JH15,H16 & JH15,H14= 10.1 Hz, 1H, H15), 2.46–2.38 (m, 2H, H3 & H23), 2.37 (t, JH24,H24’ 
& JH24,H25 = 6.8 Hz, 1H, H24), 2.31 (dd, JH24’,H25 = 8.1 Hz, JH24’,H24 = 6.3 Hz, 1H, H24’), 2.21 
(dt, JH21,H21’ = 14.4 Hz, 10.9 Hz, 1H, H21), 2.04 (ddd, J = 14.6, 10.4, 4.2 Hz, 1H, H13), 1.98 
(dd, J = 12.3 Hz, JH17,H16 = 4.6 Hz, 1H, H17), 1.91 (dd, J = 14.3 Hz, JH19,H20 = 11.0 Hz, 1H, 
H19), 1.88–1.81 (m, 2H, H3’ & H13’), 1.71 (ddt, JH25,H25’ = 13.9 Hz, JH25,H24’ = 8.1 Hz, JH25,H24’ 
= 6.3 Hz, 1H, H25), 1.63 (dt, JH25’,H25 = 13.9 Hz, JH25’,H24 = 6.5 Hz, 1H, H25’), 1.42 (dd, 
JH19’,H19 = 14.2 Hz, JH19’,H20 = 2.6 Hz, 1H, H19’), 1.29 (d, J = 6.2 Hz, 1H, H27), 1.25 (d, J = 6.4 
Hz, 3H, H1), 1.24–1.20 (m, 1H, H17’), 1.13 (ddd, JH21’,H21 = 14.8 Hz, JH21’,H22 = 8.8 Hz, 
JH21’,H20 = 2.6 Hz, 1H, H21’), 1.00–0.84 (m, 36H, -Si(CH2CH3)3), 0.69–0.52 (m, 24H, -
Si(CH2CH3)3). 13C{1H} NMR (151 MHz, CD2Cl2): δ 174.1 (s, C34), 172.3 (s, C26), 167.0 (s, 
C33), 136.3 (s, polyene), 134.4 (s, Ar), 133.6, 133.0, 132.9, 132.9, 132.4, 132.0 (all s, 
polyene), 131.4 (s, Ar), 131.3 (s, polyene), 129.0 (s, Ar), 127.0 (s, Ar), 99.1 (s, C32), 97.4 (s, 
C18), 77.8 (s, C12), 74.3 (s, C28), 73.0 (s, C29), 72.8 (s, C31), 69.7 (s, C2), 68.6 (s, C20), 67.9 (s, 
C16), 67.7 (s, C30), 56.6 (s, C23), 56.2 (s, C14), 55.3 (s, C22), 55.2 (s, C15), 45.3 (s, C19 or C17), 
45.1 (s, C19 or C17), 41.2 (s, C3 or C21), 41.2 (s, C3 or C21), 37.9 (s, C13), 31.7 (s, C24), 28.0 (s, 
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C25), 20.7 (s, C1), 18.8 (s, C27), 7.1, 7.0, 6.9, 6.9, 5.7, 5.4, 5.4, 5.1 (all s, as -Si(CH2CH3)3 or -
Si(CH2CH3)3). 
HRMS: C64H109NO14Si4Na+: 1250.6821, Actual: 1250.6806. 
Important interactions to elucidate structure 
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Figure 5.13. 1D and 2D NMR data for characterization of 5.6. 
 
Preparation of 5.7 
 
 
Following general procedure 5.2, 3.3 mg BArF3, 1.4 mg Ph3P, dichloromethane, 30.0 µL 
EtMe2SiH and 61.0 mg 5.5 were combined. After 4 h the reaction was quenched. Post work 
up, the product was purified by silica gel chromatography (10 x 2 cm column) using gradient 
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elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 
to 3:1 hexanes:ethyl acetate) to afford 5.7 as a white solid (36.1  mg, 55% overall yield, 
0.028 mmol). Starting material was also recovered as a white solid and eluted off the column 
after the major product (11.7 mg, 19% overall yield, 0.0095 mmol, Rf = 0.4, hexanes:ethyl 
acetate 3:1). 5.7: 1H NMR (600 MHz, CD2Cl2): δ 7.82–7.75 (m, 2H, Ar), 7.59–7.52 (m, 1H, 
Ar), 7.50–7.45 (m, 2H, Ar), 6.52 (d, JHNH,H30 = 9.0 Hz, 1H, NH), 6.24–6.10 (m, 5H, H6–H10), 
6.03 (m, H5), 5.74 (dd, JH11,H10 = 15.0 Hz, JH11,H12 = 7.7 Hz, 1H, H11), 5.57 (ddd, JH4,H5 = 15.0 
Hz, JH4,H3’ = 9.2 Hz, JH4,H3 = 5.7 Hz, 1H, H4), 5.05 (dqd, JH2,H3’ = 9.3 Hz, JH2,H1 = 6.5 Hz, 
JH2,H3 = 3.5 Hz, 1H, H2), 4.82 (s, 1H, –OH), 4.65 (s, 1H, H32), 4.54–4.48 (m, 1H, H12), 4.33 
(ddd, J = 11.1, 10.0, 4.6 Hz, 1H, H16), 4.30–4.23 (m, 1H, H20), 4.20 (dt, J = 11.1 Hz, JH14,H13 
= 3.9 Hz, 1H, H14), 4.14 (td, JH30,HNH & JH30,H29 = 9.2 Hz, JH30,H31 = 2.9 Hz, 1H, H30), 3.97 (d, 
J = 2.8 Hz, 1H, H31), 3.64 (dd, JH29,H30 = 9.3 Hz, JH29,H28 = 8.2 Hz, 1H, H29), 3.43 (dq, JH28,H29 
= 8.2 Hz, JH28,H27 = 6.3 Hz, 1H, H28), 3.35 (ddd, J = 10.4, 8.1, 2.1 Hz, 1H, H22), 2.54–2.49 
(ddd, JH3,H3’ = 14.1 Hz, JH3,H4 = 5.5 Hz, JH3,H2 = 3.6 Hz, 1H, H3), 2.49–2.42 (m, 2H, H15 & 
H21), 2.18 (dt, JH3’,H3 = 14.2 Hz, JH3’,H4 & JH3’,H2 = 9.2 Hz, 1H, H3’), 2.10 (ddd, JH13,H13’ = 
14.8 Hz, 9.1 Hz, JH13,H14 = 3.9 Hz, 1H, H13), 1.96 (dd, J = 12.3, 4.6 Hz, 1H, H17), 1.88–1.80 
(m, 1H, H13’), 1.53 (ddd, J = 14.7, 7.2, 2.1 Hz, 1H, H19), 1.47–1.37 (m, 3H, H19’ & H21’ & 
H23), 1.36–1.34 (m, 1H, H25), 1.31 (d, JH27,H28 = 6.2 Hz, 3H, H27), 1.25 (d, JH1,H2 = 6.3 Hz, 
3H, H1), 1.24–1.21 (m, 1H, H17’), 1.05 (dt, JH24,H24’ = 8.6 Hz, 4.3 Hz, 1H, H24), 0.97–0.85 (m, 
41H,-Si(CH2CH3)3 or -Si(CH2CH3)(CH3)2), 0.81 (ddd, JH24’,H24 = 8.6, 6.7, 4.2 Hz, 1H, H24’), 
0.66–0.52 (m, 32 H, -Si(CH2CH3)3 or -Si(CH2CH3)(CH3)2), 0.13–0.10 (m, 6H, -
Si(CH2CH3)(CH3)2). 13C{1H} NMR (151 MHz, CD2Cl2): δ 173.5 (s, C34 & C26), 167.3 (s, 
C33), 136.7 (s, polyene), 134.3 (s, Ar), 134.1, 133.5, 132.4, 132.2, 132.1 (all as s, polyene), 
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131.6 (s, Ar), 129.8 (s, polyene), 129.4 (s, polyene), 129.0 (s, Ar), 127.1 (s, Ar), 98.9 (s, C32), 
98.0 (s, C18), 76.4 (s, C12), 74.6 (s, C28), 72.8 (s, C29), 71.7 (br s, C22), 71.5 (s, C31), 69.3 (s, 
C2), 68.6 (s, C20), 67.9 (s, C16), 67.5 (s, C14), 56.5 (s, C30), 55.8 (s, C15), 45.6 (s, C17  or C21), 
45.4 (s, C17  or C21), 40.3 (s, C3), 38.3 (s, C13), 29.6 (s, C23), 20.0 (s, C1), 18.9 (s, C27), 18.2 (s, 
C25), 16.2 (s, C24), 9.4, 7.2, 7.15, 7.1, 7.0, 6.9, 6.88, 5.8, 5.5, 5.46, 5.44, 5.2, -1.3, -1.6 (all as 
s, -Si(CH2CH3)3, -Si(CH2CH3)3, -Si(CH2CH3)(CH3)2, -Si(CH2CH3)(CH3)2, or -
Si(CH2CH3)(CH3)2). 
HRMS: C68H119NO14Si5Na+: 1336.7373, Actual: 1336.7389. 
Important interactions to elucidate structure 
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Figure 5.14. 1D and 2D NMR data for characterization of 5.7. 
 
Preparation of 5.8 
 
 
 
Following general procedure 5.2, 2.0 mg BAr3F3, 1.4 mg Ph3P, dichloromethane, 29.0 µL 
Et2MeSiH, and 61.0 mg 5.5 were combined. After 4 h the reaction was quenched. Post work 
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up, the product was purified by silica gel chromatography (10 x 2 cm column) using gradient 
elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 
to 3:1 hexanes:ethyl acetate) to afford 5.8 as a white solid (30.2  mg, 46% overall yield, 
0.023 mmol). Starting material was also recovered as a white solid and eluted off the column 
after the major product (12.3 mg, 20% overall yield, 0.010 mmol, Rf = 0.4, hexanes:ethyl 
acetate 3:1). 5.8: 1H NMR (600 MHz, CD2Cl2): δ 7.82–7.77 (m, 2H, Ar), 7.59–7.55 (m, 1H, 
Ar), 7.50 (app t, J = 7.7 Hz, 2H, Ar), 6.49 (d, JNH,H30 = 9.0 Hz, 1H, NH), 6.28 (ddd, JH10,H11 = 
15.3 Hz, 9.8, 1.6 Hz, 1H, H10), 6.25–6.13 (m, 4H, H6 & H7 & H8 & H9), 5.99 (dd, JH5,H4 = 
15.0 Hz, 8.9 Hz, 1H, H5), 5.73 (dd, JH11,H10 = 15.3 Hz, JH11,H12 = 5.1 Hz, 1H, H11), 5.60 (ddd, 
JH4,H5 = 14.6 Hz, JH4,H3’ = 8.4 Hz, 6.0 Hz, 1H, H4), 5.03 (dqd, JH2,H3’ = 8.6 Hz, JH2,H1 = 6.3 
Hz, JH2,H3 = 3.4 Hz, 1H, H2), 4.66 (dd, JH16,H15 = 9.2 Hz, JH16,H17 = 1.6 Hz, 1H, H16), 4.65–
4.61 (m, 1H, H12), 4.52 (s, 1H, H32), 4.44 (d, JH17,H16 = 1.6 Hz, 1H, H17), 4.10 (td, JH30,NH & 
JH30,H29 = 9.0 Hz, JH30,H31 = 2.6 Hz, 1H, H30), 4.08–4.05 (m, 1H, H14), 4.04 (d, JH31,H30 = 2.6 
Hz, 1H, H31), 3.79–3.74 (m, 1H, H20), 3.66 (t, JH29,H30 & JH29,H28 = 9.0 Hz, 1H, H29), 3.43–
3.34 (m, 2H, H28 & H22), 2.56–2.52 (m, 1H, H3), 2.49 (dd, J = 11.3 Hz, JH15,H16 = 9.2 Hz, 1H, 
H15), 2.32–2.24 (m, 2H, H13 & H19), 2.20 (dt, JH3’,H3 = 16.0 Hz, JH3’,H4 = 8.5 Hz, 1H, H3’), 
1.95 (dd, J = 13.7 Hz, J = 2.1 Hz, 1H, H19’), 1.93–1.89 (m, 1H, H13’), 1.56 (m, 2H, H21), 
1.47–1.42 (m, 1H, H23), 1.34–1.32 (m, 1H, H24), 1.31 (d, JH27,H28 = 6.1 Hz, 3H, H27), 1.25 (d, 
JH1,H2 = 6.4 Hz, 3H, H1), 1.06 (m, 1H, H24’), 1.00 (t, J = 8.0 Hz, 1H, H25), 0.97–0.86 (m, 50H, 
-Si(CH2CH3)3 & -Si(CH2CH3)2CH3), 0.70–0.47 (m, 35H, -Si(CH2CH3)3 & -
Si(CH2CH3)2CH3), 0.06 (s, 3H, -Si(CH2CH3)2CH3). 13C{1H} NMR (151 MHz, CD2Cl2): δ 
174.2 (s, C34), 174.1 (s, C33), 168.0 (s, C26), 152.8 (s, C18), 134.8, 134.2, 134.0, 133.8, 132.8, 
132.7, (all as s, polyene), 131.9 (s, Ar), 129.6 (s, Ar), 129.5 (s, polyene), 129.4 (s, Ar), 127.4 
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(s, Ar), 102.6 (s, C17), 97.7 (s, C32), 75.3 (s, C12), 74.7 (s, C22 or C28), 73.1 (s, C29), 72.5 (s, 
C14), 71.7 (s, C22 or C28), 69.5 (s, C2), 68.3 (s, C16 or C20), 68.2 (s, C16 or C20), 57.5 (s, C30), 
54.2 (s, C15 overlapping with solvent), 45.8 (s, C21), 42.8 (s, C19), 39.8 (s, C3), 36.6 (s, C13), 
30.1 (s, C23), 20.6 (s, C1), 18.9 (s, C27), 18.8 (s, C25), 7.9, 7.8, 7.6, 7.59, 7.5, 7.46, 7.4, 7.3, 
7.2, 7.17, 6.2, 5.8, 5.7, 5.65, 5.6, 5.5, -3.3. (all as s, -Si(CH2CH3)3, -Si(CH2CH3)3, -Si(CH-
2CH3)2CH3, -Si(CH2CH3)2CH3 or -Si(CH2CH3)2CH3). (*Note: one olefin polyene peak is 
overlapping and C31 is overlapping).  
HRMS: C69H119NO13Si5Na+: 1332.7424, Actual: 1332.7418. 
Important interactions to elucidate structure 
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Figure 5.15. 1D and 2D NMR data for characterization of 5.8. 
 
Preparation of 5.9  
 
 
 
Following general procedure 5.2, 2.0 mg BAr3F3, 1.4 mg Ph3P, dichloromethane, 29.0 µL 
Et2MeSiH, and 61.0 mg 5.5 were combined at –10 ºC. After 18 h the reaction was quenched. 
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Post work up, the product was purified by silica gel chromatography (10 x 2 cm column) 
using gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 
6:1 to 5:1 to 4:1 to 3:1 hexanes:ethyl acetate) to afford 5.9 as a white solid (34.8  mg, 53% 
overall yield, 0.026 mmol). Starting material was also recovered as a white solid and eluted 
off the column after the major product (12.3 mg, 20% overall yield, 0.010 mmol, Rf = 0.4, 
hexanes:ethyl acetate 3:1). 5.9: 1H NMR (600 MHz, CD2Cl2): δ 7.86–7.80 (m, 2H, Ar), 7.62 
(app t, J = 7.3 Hz, 1H, Ar), 7.54 (t, J = 7.7 Hz, 2H, Ar), 6.51 (d, JNH,H30 = 8.5 Hz, 1H, NH), 
6.31–6.15 (m, 5H, polyene), 6.09–6.02 (m, 1H, H5), 5.76 (dd, J = 14.5, 4.9 Hz, 1H, H11), 
5.63 (ddd, JH4,H5 = 14.8 Hz, 8.4 Hz, JH4,H3 = 6.0 Hz, 1H, H4), 5.07 (dqd, JH2,H3’ = 9.8 Hz, 
JH2,H1 = 6.4 Hz, JH2,H3 = 3.6 Hz, 1H, H2), 4.66–4.61 (m, 1H, H12), 4.55 (s, 1H, H32), 4.11 (d, 
JH31,H30 = 1.9 Hz, 1H, H31), 4.11–4.06 (m, 1H, H30), 4.05 (td, J = 10.6, 4.7 Hz, 1H, H16), 3.84 
(dd, J = 10.6, 6.4 Hz, 1H, H18), 3.72 (t, JH29,H28 = 8.8 Hz, 1H, H29), 3.57 (dd, J = 10.3 Hz, 
JH14,H13’ = 6.9 Hz, 1H, H14), 3.43 (dq, JH28,H29 = 8.8 Hz, JH28,H27 = 6.1 Hz, 1H, H28), 3.41–3.33 
(m, 1H, H22), 3.21–3.16 (m, 1H, H20), 2.54 (ddd, JH3,H3’ = 14.7 Hz, JH3,H4 = 5.9 Hz, JH3,H2 = 
3.9 Hz, 1H, H3), 2.30 (dd, JH13,H13’ = 15.7, 5.4 Hz, 1H, H13), 2.27–2.20 (m, 2H, H3’ & H15), 
1.88–1.75 (m, 3H, H13 & H17 & H19), 1.61 (ddd, J = 14.6, 6.5, 1.8 Hz, 1H, H19’), 1.54–1.48 
(m, 2H, H21 & H21’), 1.45 (tdd, JH23,H24’ = 8.5 Hz, JH23,H22 = 6.4 Hz, JH23,H24 = 4.1 Hz, 1H, 
H23), 1.35 (d, JH27,H28 = 6.3 Hz, 3H, H27), 1.29 (d, JH1,H2 = 6.3 Hz, 3H, H1), 1.26–1.21 (m, 1H, 
H17’), 1.11 (dt, JH24,H24’ = 8.7 Hz, JH24,H23 = 4.3 Hz, 1H, H24), 1.00–0.92 (m, 39H, -
Si(CH2CH3)3 & -Si(CH2CH3)2CH3), 0.89–0.86 (m, 1H, H24’), 0.66–0.57 (m, 26H, -
Si(CH2CH3)3 & -Si(CH2CH3)2CH3), 0.13–0.10 (m, 6H, -Si(CH2CH3)2CH3). (*Note: H25 
overlaps with H27 and H24’ overlaps with silane peaks.) 13C{1H} NMR (151 MHz, CD2Cl2): δ 
173.7 (s, C26 & C34), 168.0 (s, C33), 135.1 (s, C11), 134.0 (s, C5), 133.9, 133.8 (as s, polyene), 
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132.6 (s, Ar), 132.5, 132.0, 131.2 (as s, polyene), 129.2 (s, C4), 129.1 (s, Ar), 129.0 (s, Ar), 
127.1 (s, Ar), 97.2 (s, C32), 75.1 (s, C28), 74.7 (s, C12), 74.5 (s, C20), 72.5 (s, C29 or C14), 72.5 
(s, C29 or C14), 72.2 (s, C31), 71.4 (s, C16 & C22), 69.2 (s, C2), 69.0 (s, C18), 58.0 (s, C15), 57.5 
(s, C30), 45.3 (s, C19), 45.1 (s, C21), 42.3 (s, C17), 39.8 (s, C3), 36.7 (s, C13), 30.0 (s, C23), 20.3 
(s, C1), 18.7 (s, C27), 18.5 (s, C25), 15.4 (s, C24), 9.4, 7.3, 7.2, 7.1, 7.0, 6.9, 5.9, 5.5, 5.4, 5.3, -
1.26, -1.3 (all as s, -Si(CH2CH3)3, -Si(CH2CH3)3, -Si(CH2CH3)2CH3, -Si(CH2CH3)2CH3 or -
Si(CH2CH3)2CH3). 
HRMS: C69H119NO13Si5Na+: 1320.7424, Actual: 1320.7496. 
Important interactions to elucidate structure 
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Figure 5.16. 1D and 2D NMR data for characterization of 5.9. 
 
Preparation of 5.10 utilizing BArF3 
 
 
 
Following general procedure 5.2, 3.3 mg BArF3, 1.4 mg Ph3P, dichloromethane, 7.1 µL 
Et2SiH2 and 61.0 mg 5.5 were combined. After 2 h the reaction was quenched. Post work up, 
the product was purified by silica gel chromatography (10 x 2 cm column) using gradient 
5.5 5.10
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O O OH OSiEt3
OO
Et3SiO
NH
OSiEt3
O
O
OH 10 mol% BArF3
10 mol% Ph3P
1.1 equiv. Et2SiH2
CH2Cl2, RT
2  h
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O
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elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 
to 3:1 hexanes:ethyl acetate) to afford 5.10 as a white solid (29.3  mg, 46% overall yield, 
0.023 mmol). Starting material was also recovered as a white solid and eluted off the column 
after the major product (13.0 mg, 21% overall yield, 0.011 mmol, Rf = 0.4, hexanes:ethyl 
acetate 3:1). 5.10: 1H NMR (600 MHz, CD2Cl2): δ 7.87–7.82 (m, 2H, Ar), 7.65–7.59 (m, 1H, 
Ar), 7.57–7.51 (m, 2H, Ar), 6.56 (d, JHNH,H30 = 9.1 Hz, 1H, NH), 6.46 (dd, JH24,H25 = 15.6 Hz, 
JH24,H23 = 7.1 Hz, 1H, H24), 6.36–6.30 (m, 3H, polyene), 6.32–6.05 (m, 3H, polyene), 6.02 (d, 
JH25,H24 = 15.4 Hz, 1H, H25), 5.83 (dd, JH11,H10 = 14.2 Hz, JH11,H12 = 7.5 Hz, 1H, H11), 5.64 
(ddd, JH4,H5 = 15.3 Hz, JH4,H3’ = 9.5 Hz, JH4,H3 = 6.0 Hz, 1H, H4), 5.03 (dqd, JH2,H3’ = 9.2 Hz, 
JH2,H1 = 6.4 Hz, JH2,H3 = 3.1 Hz, 1H, H2) 4.74 (dd, JH16,H15 = 9.1 Hz, JH16,H17 = 1.5 Hz, 1H, 
H16), 4.61 (td, JH12,H13 & JH12,H11 = 7.5 Hz, JH12,H13’ = 2.8 Hz, 1H, H12), 4.59 (s, 1H, H32), 4.56 
(d, JH17,H16 = 1.5 Hz, 1H, H17), 4.24 (ddd, JH14,H15 = 11.1 Hz, JH14,H13 = 6.5 Hz, JH14,H13’ = 2.0 
Hz, 1H, H14), 4.19 (td, JH30,HNH & JH30,H29 = 9.1 Hz, JH30,H31 = 2.8 Hz, 1H, H30), 4.06 (d, 
JH31,H30 = 2.6 Hz, 1H, H31), 4.05–3.97 (m, 1H, H20), 3.69 (dd, JH29,H30 = 9.2 Hz, JH29,H28 = 8.4 
Hz, 1H, H29), 3.44 (dq, JH28,H29 = 8.4 Hz, JH28,H27 = 6.2 Hz, 1H, H28), 3.11 (dd, JH23,H24 = 7.1 
Hz, JH23,H22 = 1.5 Hz, 1H, H23), 2.69 (dt, JH22,H21 = 8.9 Hz, JH22,H23 & JH22,H21’ = 1.5 Hz, 1H, 
H22), 2.57 (dd, JH15,H14 = 11.1 Hz, JH15,H16 = 9.0 Hz, 1H, H15), 2.48 (ddd, JH3,H3’ = 14.0 Hz, 
JH3,H4 = 5.3 Hz, JH3,H2 = 3.1 Hz, 1H, H3), 2.33 (ddd, JH13,H13’ = 15.4 Hz, JH13,H12 = 7.5 Hz, 
JH13,H14 = 2.0 Hz, 1H, H13), 2.28–2.16 (m, 1H, H19), 2.14–2.05 (m, 2H, H21 & H19’), 2.01 
(ddd, JH13’,H13 = 15.4 Hz, JH13’,H14 = 6.5 Hz, JH13’,H12 = 2.8 Hz, 1H, H13’), 1.36 (overlapping d, 
JH27,H28 & JH1,H2 = 6.4 Hz, 6H, H1 & H27), 1.34–1.32 (m, 1H, H21’), 1.28 (dt, JH3’,H3 = 14.0 Hz, 
JH3’,H2 & JH3’,H4 = 9.2 Hz, 1H, H3’), 1.07 (t, J = 8.0 Hz, 9H, -Si(CH2CH3)3), 1.01–0.91 (m, 
27H, -Si(CH2CH3)3), 0.74–0.56 (m, 24H, -Si(CH2CH3)3). 13C{1H} NMR (151 MHz, 
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CD2Cl2): δ 173.9 (s, C34), 167.5 (s, C33), 165.5 (s, C26), 151.5 (s, C18), 144.9 (s, C24), 135.3 (s, 
C11), 134.5 (s, polyene), 134.1 (s, Ar), 132.9, 132.7, 132.3 (s, polyene), 132.1 (s, Ar), 130.9 
(s, polyene), 129.8 (s, C4), 129.1 (s, Ar), 127.1 (s, Ar), 124.4 (s, C25), 103.4 (s, C17), 98.1 (s, 
C32), 76.0 (s, C12), 74.7 (s, C28), 72.9 (s, C29), 72.3 (s, C14 & C31), 69.7 (s, C2), 68.9 (s, C20), 
68.0 (s, C16), 59.6 (s, C22), 56.7 (s, C30), 55.0 (s, C23), 52.9 (s, C15), 44.1 (s, C19), 41.2 (s, C21), 
40.4 (s, C3), 36.9 (s, C13), 20.3 (s, C1), 18.7 (s, C27), 7.2, 7.1, 7.0, 6.9, 5.8, 5.5, 5.5, 5.1 (all as 
s, -Si(CH2CH3)3 or -Si(CH2CH3)3). (* Note: 2 polyene carbon peaks are overlapping). 
HRMS: C64H105NO13Si4H+: 1208.674, Actual: 1208.6734. 
Important interactions to elucidate structure 
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Figure 5.17. 1D and 2D NMR data for characterization of 5.10. 
 
Preparation of 5.10 utilizing BAr3F3/B(C6F5)3 
 
 
 
Following general procedure 5.2, 2.0 mg BAr3F3, 1.4 mg Ph3P, dichloromethane, 7.1 
µL Et2SiH2, and 61.0 mg 5.5 were combined. After 1 h full conversion to silyl-ester 
intermediate. Added a 0.1 mL dichloromethane solution of 2.5 B(C6F5)3 to this. After 3 h the 
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reaction was quenched. Post work up, the product was purified by silica gel chromatography 
(10 x 2 cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 
9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 to 3:1 hexanes:ethyl acetate) to afford 5.10 as a white 
solid (24.2  mg, 40% overall yield, 0.020 mmol). Starting material was also recovered as a 
white solid and eluted off the column after the major product (13.0 mg, 20% overall yield, 
0.010 mmol, Rf = 0.4, hexanes:ethyl acetate 3:1). Data match product obtained vide supra. 
 
Preparation of 5.12  
 
 
 
Following general procedure 5.3, 1.7 mg HB(C6F5)2, toluene, 1.0 µL trans-hex-3-ene, 23.0 
µL Et2SiH2, and 58.0 mg 5.11 were combined. After 8 h the reaction was quenched. Post 
work up, the product was purified by silica gel chromatography (10 x 2 cm column) using 
gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 
5:1 to 4:1 to 3:1 hexanes:ethyl acetate) to afford 5.12 as a white solid (34.5 mg, 60 % overall 
yield, 0.030 mmol). Starting material was also recovered as a white solid and eluted off the 
column after the major product (9.3 mg, 16% overall yield, 0.008 mmol, Rf = 0.4, 
hexanes:ethyl acetate 3:1). 5.12: 1H NMR (600 MHz, CDCl3): δ 6.28 (dd, J = 15.6, 8.1 Hz, 
1H, H24), 6.23–6.11 (m, 3H, polyene), 6.08–6.01 (m, 3H, H25 & polyene), 5.95 (ddd, JH5,H4 = 
14.8 Hz, 6.8, 3.8 Hz, 1H, H5), 5.60 (ddd, J = 13.9, 9.4, 4.7 Hz, 1H, H11), 5.50 (ddd, JH4,H5 = 
O Et3SiO O
O O OH OSiEt3
OO
Et3SiO
NH
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O
Me
O
OH
5.11
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15.2 Hz, JH4,H3’ = 10.5 Hz, 5.2 Hz, 1H, H4), 5.06 (dqd, J = 12.5, 6.0, 2.9 Hz, 1H, H2), 4.51 (s, 
1H, –OH), 4.40–4.31 (m, 2H, H12 & H16), 4.29 (s, 1H, H32), 4.28–4.23 (m, 1H, H14), 4.11 
(ddd, J = 10.6 Hz,  7.2 Hz, JH20,H21 = 3.1 Hz, 1H, H20) 3.92 (d, J = 2.8 Hz, 1H, H31), 3.19 (t, 
JH29,H30 & JH29,H28 = 9.0 Hz, 1H, H29), 3.15–3.08 (m, 2H, H23 & H28), 2.91 (br d, J = 8.4 Hz, 
1H, H22), 2.77 (dq, JH33,H33’ = 10.5 Hz, JH33,H35 = 6.9 Hz, 1H, H33), 2.45–2.34 (m, 3H, H3 & 
H15  & H33’), 2.21 (dd, JH30,H29 = 9.3, JH30,H31 = 2.9 Hz, 1H, H30), 2.10 (dt, J = 13.4 Hz, JH3’,H4 
= 10.7 Hz, 1H, H3’), 2.04–1.97 (m, 1H, H19), 1.94 (ddd, J = 14.3 Hz, JH21,H22 = 8.0 Hz, 
JH21,H20 = 2.9 Hz, 1H, H21), 1.90–1.81 (m, 3H, H13 & H17 & H19’), 1.78–1.67 (m, 2H, H13’ & 
H21’), 1.33 (d, J = 6.3 Hz, 3H, H1), 1.28–1.21 (m, 1H, H17’), 1.19 (d, J = 6.1 Hz, 3H, H27), 
1.07 (t, JH35,H33 = 7.1 Hz, 3H, H35), 0.99–0.89 (m, 40H, -Si(CH2CH3)3), 0.68–0.60 (m, 12H, -
Si(CH2CH3)3), 0.60–0.54 (m, 12H, -Si(CH2CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 
176.5 (s, C34) 166.1 (s, C26), 143.7 (s, C24), 135.0 (s, C5), 134.3 (s, C11), 133.0, 132.4, 132.4, 
132.2 (s, polyene), 129.3 (s, C4), 125.8 (s, polyene), 99.9 (s, C32), 96.6 (s, C18), 78.1 (s, C18), 
74.2 (s, C28), 73.8 (s, C29), 70.0 (s, C2), 69.2 (s, C31), 67.5 (s, C16), 67.2 (s, C20), 66.7 (s, C14), 
64.3 (s, C30), 56.6 (s, C23 or C22), 56.5 (s, C23 or C22), 56.3 (s, C33 or C15), 46.4 (s, C13), 43.8 
(s, C17), 41.6 (s, C33 or C15), 41.4 (s, C3), 39.8 (s, C21), 37.4 (s, C19), 20.4 (s, C1), 18.8 (s, C27), 
15.5 (s, C35), 7.2, 7.2, 7.0, 6.9, 5.7, 5.4, 5.1, 5.0 (all as s, -Si(CH2CH3)3  or -Si(CH2CH3)3). 
(*Note: 2 polyene carbon peaks are overlapping and C12 is overlapping with C16 or C20). 
HRMS: C59H107NO13Si4H+: 1150.6897, Actual: 1150.6915. 
Important interactions to elucidate structure 
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Figure 5.18. 1D and 2D NMR data for characterization of 5.12. 
Preparation of 5.14  
 
 
 
Following general procedure 5.3, 1.7 mg HB(C6F5)2, toluene, 1.0 µL trans-hex-3-ene, 23.0 
µL Et2SiH2, and 58.0 mg 5.11 were combined. After 14 h the reaction was quenched. Post 
work up, the product was purified by silica gel chromatography (10 x 2 cm column) using 
gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 9:1 to 8:1 to 7:1 to 6:1 to 
5:1 to 4:1 to 3:1 hexanes:ethyl acetate) to afford 5.14 as a white solid (25.3 mg, 42 % overall 
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yield, 0.021 mmol). Starting material was also recovered as a white solid and eluted off the 
column after the major product (15.2 mg, 25% overall yield, 0.012 mmol, Rf = 0.4, 
hexanes:ethyl acetate 3:1). 5.14: 1H NMR (600 MHz, CD2Cl2): δ 6.26 (dd, JH24,H25 = 15.6 Hz, 
JH24,H23 = 8.2 Hz, 1H, H24), 6.23–6.14 (m, 3H, polyene), 6.11–6.02 (m, 3H, H25 & polyene), 
5.97 (dd, JH5,H4 = 15.1 Hz, 9.4 Hz, 1H, H5), 5.63 (t, J = 5.7 Hz, 1H, -NH34), 5.59 (dd, JH11,H120 
= 14.9 Hz, JH11,H12 = 9.2 Hz, 1H, H11), 5.49 (ddd, JH4,H5 = 15.3 Hz, JH4,H3’ = 10.5 Hz, JH4,H3 = 
5.1 Hz, 1H, H4), 5.07 (dqd, JH2,H3’ = 12.6 Hz, JH2,H1 = 6.2 Hz, JH2,H3 = 2.9 Hz, 1H, H2), 4.28 
(s, 1H, H32), 4.27–4.21 (m, 2H, H12 & H20), 4.18 (ddd, J = 11.1, 9.7, 4.8 Hz, 1H, H16), 4.07 
(ddd, J = 10.8, 7.8, 3.3 Hz, 1H, H14), 3.91 (d, JH31,H30 = 2.8 Hz, 1H, H31), 3.32 (ddt, J = 12.9, 
8.5, 6.3 Hz, 1H, H36), 3.17–3.11 (m, 2H, H29 & H36’), 3.11–3.05 (m, 2H, H23 & H28), 2.96 (dt, 
J = 8.7, 2.4 Hz, 1H, H22), 2.77 (dq, JH33,H33’ = 10.6 Hz, JH33,H35 = 7.0 Hz, 1H, H33), 2.47–2.39 
(m, 1H, H3), 2.33 (dq, JH33’,H33 = 10.7 Hz, JH33’,H35 = 7.0 Hz, 1H, H33’), 2.16 (dd, JH30,H29 = 9.3 
Hz, JH30,H31 =2.8 Hz, 1H, H30), 2.09 (td, JH3’,H3 & JH3’,H2 = 13.3 Hz, JH3’,H4 = 10.7 Hz, 1H, 
H3’), 1.94 (dtd, J = 14.9, 7.9, 7.5, 3.2 Hz, 1H, H19), 1.90–1.81 (m, 4H, H13 & H15 & H17 & 
H21), 1.79–1.71 (m, 3H, H13’ & H19’ & H21’), 1.54–1.42 (m, 2H, H37), 1.39–1.33 (m, 2H, H38), 
1.30 (d, JH1,H2 = 6.3 Hz, 3H, H1), 1.19 (d, JH27,H26 = 6.0 Hz, 4H, H27 & H17’), 1.06 (t, JH35,H33 = 
7.1 Hz, 3H, H35), 1.00–0.88 (m, 36H, -Si(CH2CH3)3), 0.67–0.58 (m, 15H, -Si(CH2CH3)3), 
0.57–0.51 (m, 12H, -Si(CH2CH3)3). (*Note: H39 protons overlap with silane proton peaks 
between 1.00–0.88 ppm.) 13C{1H} NMR (151 MHz, CD2Cl2): δ 171.8 (s, C26), 166.3 (s, C34), 
144.2 (s, C24), 135.2, 134.5 (s, polyene), 133.6 (s, C11), 132.8, 132.8, 132.6, 132.6 (s, 
polyene), 130.1 (s, C4), 126.2 (s, C25), 100.5 (s, C32), 96.7 (s, C18), 78.7 (s, C12), 74.7 (s, C28), 
74.2 (s, C29), 70.1 (s, C2 or C31), 69.8 (s, C2 or C31), 67.8 (s, C16), 67.6 (s, C20), 67.2 (s, C14), 
64.8 (s, C30), 58.5 (s, C15), 57.1 (s, C22 or C23), 56.8 (s, C22 or C23), 47.1 (s, C13), 44.3 (s, C17), 
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41.8 (s, C3 & C36), 39.8 (s, C21 or C33), 39.7 (s, C21 or C33), 37.5 (s, C19), 32.3 (s, C37), 20.8 (s, 
C38), 20.5 (s, C1), 18.9 (s, C27), 15.7 (s, C35), 14.1 (s, C39), 7.4, 7.4, 7.2, 7.1, 6.1, 5.7, 5.4, 5.3 
(all as s, -Si(CH2CH3)3  or -Si(CH2CH3)3. (*Note: 2 olefin peaks are overlapping.) 
HRMS: C63H117N2O12Si4H+: 1205.7683, Actual: 1205.7681. 
 
Important interactions to elucidate structure 
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Figure 5.19. 1D and 2D NMR data for characterization of 5.14. 
 
Preparation of 5.16  
 
 
 
Following general procedure 5.4, 2.5 mg B(C6F5)3, 27.2 mg 5.15 and 
dichloromethane were combined. The reaction was quenched at 3 h. The product was 
purified by silica gel chromatography (10 x 2 cm column) using gradient elution (100% 
CH2Cl2 to 60:1 to 50:1 to 40:1 to 30:1 to 25:1 to 20:1 to 17:1 to 15:1 
dichloromethane:methanol) to afford 5.16 as a white solid (16.5 mg, 68 % overall yield, 
0.034 mmol). 5.16: 1H NMR (600 MHz, CDCl3): δ 9.27 (s, 1H, H18), 7.99–7.93 (m, 2H, Ar), 
5.15
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HO O OH
HO OBz
OH
O
O 5.16
HO
HO O OH
HO OBz O
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7.60 (ddt, J = 8.7, 7.2, 1.3 Hz, 1H, Ar), 7.50–7.44 (m, 2H, Ar), 6.48 (dt, J = 6.5, 2.2 Hz, 1H, 
H5), 5.66 (dd, J = 6.2, 1.4 Hz, 1H, H2), 5.08 (s, 1H, H10), 4.75–4.71 (m, 1H, H3), 4.71–4.64 
(m, 1H, H13), 4.14 (s, 1H, –OH10), 3.88 (d, J = 10.8 Hz, 1H, –OH13), 3.54 (t, J = 4.0 Hz, 1H, 
H7), 2.81 (dd, JH14,H14’ = 15.8 Hz, 3.8 Hz, 1H, H14), 2.60–2.56 (m, 1H, H6), 2.56–2.50 (m, 2H, 
H6’ & H14’), 2.05 (s, 3H, H19), 1.57 (s, 3H, H16), 1.56 (s, 5H), 1.13 (s, 3H, H20), 1.12 (s, 3H, 
H20). 13C{1H} NMR (151 MHz, CDCl3): δ 215.2 (s, C9), 193.6 (s, C18), 165.4 (s, C17), 144.3 
(s, C12), 142.2 (s, C4), 141.8 (s, C5), 135.4 (s, C11), 133.7 (s, CAr), 129.9 (s, CAr), 129.0 (s, 
CAr), 128.8 (s, CAr), 77.5 (s, C1), 76.5 (s, C10), 74.9 (s, C2), 71.1 (s, C7), 68.3 (s, C13), 55.9 (s, 
C8), 42.6 (s, C3), 42.3 (s, C15), 38.7 (s, C14), 30.6 (s, C6), 27.0 (s, C20), 19.5 (s, C20’), 16.0 (s, 
C16), 14.3 (s, C21). 
Important interactions to elucidate structure 
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Figure 5.20. 1D and 2D NMR data for characterization of 5.16. 
 
Preparation of 5.18 and 5.19 
 
 
Following general procedure 5.4, 2.0 mg BAr3F3, 38.0 mg 2-Et3Si-10-
deacetalbaccatin 5.17, and dichloromethane were combined. After 2 h of standing at 25 ºC, 
the reaction was quenched. Volatiles were removed under vacuum and the product were 
purified by silica gel chromatography (10 x 2 cm column) using gradient and gravity elution 
(100% hexanes to 20:1 to 15:1 to 10:1 5:1 to 3:1 to 1:1 hexanes:ethyl acetate) to afford 5.18 
as a white solid (17.3 mg, 45 % yield, 0.022 mmol) and 5.19 (15.1 mg, 39 % yield, 0.019 
5.17
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HO O OSiEt3
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mmol). An alternative isolation protocol that allowed for more facile isolation was 
preparative TLC utilizing 5:1 hexanes:ethyl acetate to develop the plate. This gave 
representative yields and purities. 5.18: 1H NMR (600 MHz, CDCl3): δ 9.43 (s, 1H), 7.97–
7.87 (m, 1H), 7.62–7.53 (m, 1H), 7.48–7.42 (m, 1H), 5.72–5.66 (m, 2H, H2 & H5), 5.29 (d, 
JH10,–OH = 2.0 Hz, 1H, H10), 5.02 (t, JH13,H14 & JH13,H14’= 8.1 Hz, 1H, H13), 4.20 (d, J–OH,H10 = 
1.9 Hz, 1H, –OH10), 4.10 (dd, J = 11.7 Hz, 4.4 Hz, 1H, H7), 3.79 (dd, J = 7.2 Hz, JH3,H4 = 5.3 
Hz, 1H, H3), 3.04 (ddd, JH3,H4 = 5.3 Hz, 2.7 Hz, 1.2 Hz, 1H, H4), 2.29 (dd, JH14,H14’ = 15.2 Hz, 
JH14,H13 = 8.8 Hz, 1H, H14), 2.22 (s, 3H, H20), 2.17 (d, J = 1.4 Hz, 3H, H21), 2.16–2.14 (m, 
1H, H14’), 1.95–1.88 (m, 1H, H6), 1.68–1.64 (m, 1H, H6’), 1.21 (s, 3H, H16), 1.18 (s, 3H, H22), 
1.13 (s, 3H, H22’), 1.01 (t, J = 8.0 Hz, 9H, –Si(CH2CH3)3), 0.90 (t, J = 7.9 Hz, 9H, –
Si(CH2CH3)3), 0.69 (t, J = 7.9 Hz, 6H, –Si(CH2CH3)3), 0.50 (qd, J = 7.8, 6.5 Hz, 6H, –
Si(CH2CH3)3). 13C{1H} NMR (151 MHz, CDCl3): δ 210.9 (s, C9), 200.2 (s, 18), 170.0 (s, 
C19), 167.1 (s, C17), 142.8 (s, C11 or C12), 134.3 (s, C11  or C12), 134.0 (s, Ar), 129.9 (s, Ar), 
129.0 (s, Ar), 79.8 (s, C1), 74.9 (s, C2 or C5), 74.6 (s, C10), 71.4 (s, C7), 68.9 (s, C13), 68.3 (s, 
C2 or C5), 59.5 (s, C22), 52.0 (s, C4), 43.0 (s, C15), 42.3 (s, C3), 41.3 (s, C14), 32.1 (s, C6), 27.0 
(s, C16), 21.6 (s, C20), 20.0 (s, C22), 15.4 (s, C21), 11.3 (s, C22), 7.1, 6.8, 5.2, 5.0 (s, –
Si(CH2CH3)3 or –Si(CH2CH3)3). HRMS: C41H64O10Si2Na+: 795.3936, Actual: 795.3916. 
Important interactions to elucidate structure 
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Figure 5.21. 1D and 2D NMR data for characterization of 5.18. 
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5.19: 1H NMR (600 MHz, CDCl3): δ 7.93 (dd, J = 8.3, 1.4 Hz, 2H, Ar), 7.63–7.59 (m, 1H, 
Ar), 7.50–7.45 (m, 2H, Ar), 5.53 (d, JH2,H3 = 6.7 Hz, 1H, H2), 5.22 (d, JH10,–OH10 = 2.2 Hz, 
1H, H10), 4.97–4.90 (m, 1H, H13), 4.56 (dd, JH18,H18’ = 10.6 Hz, JH18,H4 = 3.1 Hz, 1H, H18), 
4.29 (dd, JH18’,H18 = 10.6 Hz, JH18’,H4 = 3.2 Hz, 1H, H18’), 4.24 (dd, JH7,H6’ = 10.0 Hz, JH7,H6 =  
7.1 Hz, 1H, H7), 4.19 (d, J–OH,H10 = 2.1 Hz, 1H, –OH10), 3.46 (dd, J = 9.9 Hz, JH3,H2 = 6.7 Hz, 
1H, H3), 2.77 (ddd, JH6,H6’ = 18.7 Hz, JH6,H7 = 7.1 Hz, JH6,H21 = 1.1 Hz, 1H, H6), 2.43 (ddd, 
JH6’,H6 = 18.6 Hz, JH6’,H7 = 10.1 Hz, JH6’,H21 = 1.3 Hz, 1H, H6’), 2.39–2.32 (m, 2H, H14 & H4), 
2.21 (dd, JH14’,H14 = 15.1 Hz, 5.6 Hz, 1H, H14’), 2.10 (d, JH21,H6 & JH21,H6’ = 1.4 Hz, 3H, H21), 
2.02 (s, 3H, H20), 1.27 (s, 3H, H21), 1.17 (s, 3H, H22), 1.14 (s, 3H, H22’), 1.02 (t, J = 7.9 Hz, 
9H, –Si(CH2CH3)3), 0.93 (t, J = 7.9 Hz, 9H, –Si(CH2CH3)3), 0.70 (q, J = 7.9 Hz, 6H, –
Si(CH2CH3)3), 0.56 (qd, J = 7.9, 5.1 Hz, 6H, –Si(CH2CH3)3). 13C{1H} NMR (151 MHz, 
CDCl3): δ 210.6 (s, C9), 208.6 (s, C5), 170.0 (s, C20), 166.7 (s, C17), 142.6 (s, C11 or C12), 
134.2 (s, C11 or C12), 134.0 (s, Ar), 129.8 (s, Ar), 129.0 (s, Ar), 78.1 (s, C1), 76.6 (s, C2), 75.1 
(s, C10), 71.8 (s, C7), 68.6 (s, C13), 67.2 (s, C18), 58.5 (s, C22), 48.8 (s, C4), 46.1 (s, C6), 43.3 
(s, C3), 43.0 (s, C15), 41.6 (s, C14), 26.9 (s, C22), 21.2 (s, C20), 19.9 (s, C22’), 15.9 (s, C16), 11.1 
(s, C21), 7.1, 6.9, 5.2, 4.9 (s, –Si(CH2CH3)3 or –Si(CH2CH3)3). 
HRMS: C41H64O10Si2Na+: 795.3926, Actual: 795.3916. 
Important interactions to elucidate structure 
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Figure 5.22. 1D and 2D NMR data for characterization of 5.19. 
 
 
Preparation of 5.20 from 5.15 
 
 
 
 
Following general procedure 5.3, combined 2.0 mg BAr3F3, 1.4 mg Ph3P, 
dichloromethane, 14.5 µL Me2EtSiH, and 36.0 mg 5.20 were combined. After 1 h the 
reaction was quenched with Et3N. Volatiles were removed under vacuum and the product 
was purified by silica gel chromatography (10 x 2 cm column) using gradient elution (100% 
hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 to 1:1 hexanes:ethyl acetate) to afford 5.21 as a 
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white solid (33.4 mg, 75 % overall yield, 0.038 mmol). 1H NMR (600 MHz, CDCl3): δ 8.21–
8.11 (m, 2H, Ar), 7.58–7.51 (m, 1H, Ar), 7.44 (t, J = 7.8 Hz, 2H, Ar), 5.50 (d, JH2,H3 = 7.0 
Hz, 1H, H2), 5.15 (s, 1H, H10), 5.07 (q, JH19,H20 = 5.0 Hz, 1H, H19), 4.96 (td, JH13,H14 = 8.7 Hz, 
1.6 Hz, 1H, H13), 4.41 (dd, JH7,H6’ = 5.2 Hz, JH7,H6 = 4.1 Hz, 1H, H7), 4.02 (dd, JH5,H6’ = 9.6 
Hz, JH5,H6 = 4.1 Hz, 1H, H5), 3.59 (s, 2H, H18), 3.28 (d, JH3,H2 = 7.0 Hz, 1H, H3), 2.99 (dd, 
JH14,H14’ = 15.0 Hz, JH14,H13 = 8.6 Hz, 1H, H14), 2.11 (dt, JH6,H6’ = 14.3 Hz, JH6,H5 & JH6,H7 = 
4.1 Hz, 1H, H6), 2.03 (d, J = 1.4 Hz, 1H, H16), 2.01–1.90 (m, 2H, H6’ & H14’), 1.65 (d, JH20,H19 
= 5.0 Hz, 3H, H20), 1.24 (s, 3H, H21), 1.17 (s, 3H, H22), 1.16 (s, 3H, H22’), 0.97 (q, J = 7.8 Hz, 
6H, –Si(CH2CH3)(CH3)2), 0.91 (t, J = 7.9 Hz, 3H, –Si(CH2CH3)(CH3)2), 0.69 (t, J = 7.9 Hz, 
3H, –Si(CH2CH3)(CH3)2), 0.66–0.57 (m, 3H, –Si(CH2CH3)(CH3)2), 0.57–0.49 (m, 2H, –
Si(CH2CH3)(CH3)2), 0.22 (qd, J = 7.9, 5.1 Hz, 3H, –Si(CH2CH3)(CH3)2), 0.14 (d, J = 10.7 
Hz, 6H, –Si(CH2CH3)(CH3)2), 0.11 (d, J = 11.1 Hz, 6H, –Si(CH2CH3)(CH3)2), 0.08 (s, 6H, –
Si(CH2CH3)(CH3)2), -0.26– -0.30 (m, 6H, –Si(CH2CH3)(CH3)2). 13C{1H} NMR (151 MHz, 
CDCl3): δ 209.1, 167.9, 139.9, 134.9, 133.2, 130.6, 130.3, 128.5, 101.3, 84.1, 80.2, 77.2, 
76.7, 76.3, 76.0, 72.4, 68.8, 67.4, 59.0, 51.6, 43.3, 39.3, 32.5, 26.9, 20.9, 19.8, 15.4, 12.7, 9.3, 
9.1, 8.5, 7.7, 7.01, 6.99, 6.9, 6.6, -1.2, -1.3, -1.4, -1.5, -1.9, -2.3, -3.1, -3.2. 
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Figure 5.23. 1D and 2D NMR data for characterization of 5.21. 
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APPENDIX A: ADDITIONAL COMPLEX MOLECULE MODIFICATIONS 
 
 Beyond gibberellic acid, artemisinin, natamycin, and 10-deacetoxy baccatin, we have 
investigated a number of additional substrates for selective modification either under 
hydrosilylative or Lewis acid rearrangement conditions. This appendix discusses results from 
these investigations as well as some additional outcomes from investigating the natamycin 
derivative, 5.11. 
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A1.1. Fluoroaryl borane catalyzed modification of additional natural product substrates 
 
Subjecting Si2-erythomycin A1.1 to the parent Lewis acid catalyst B(C6F5)3 gave no 
hydrosilylation at room temperature. Upon warming the reaction, full conversion was 
observed, but no silane consumption accompanied this conversion as observed by 13C{1H} 
NMR monitoring of the crude reaction mixture. Upon quenching and isolating the material 
the two Lewis acid catalyzed products (A1.2) and (A1.3) were isolated in good yields. These 
species have previously been isolated under Bronstead acid catalyzed conditions.93,94  
 
Scheme A1.1. B(C6F5)3 catalyzed rearrangement of vancomycin. 
 
 The lack of hydrosilylation for this substrate most likely results from the strong 
interaction of tertiary amines with B(C6F5)3. It is interesting that at elevated temperatures 
enough free catalyst is available to achieve the observed rearrangement, but it is unable to 
activate silane. In an attempt to overcome this strong Lewis acid/base interaction and achieve 
hydrosilylation, the less Lewis acidic series of catalysts were investigated. Using BArF3 and 
B(C6F5)2(3-hexyl) no reaction was observed even at elevated temperature for the former. 
Lack of reactivity was also observed in the latter case, but upon warming conversion did 
occur, however no obvious silane consumption was observed to yield similar results to 
B(C6F5)3 rearrangement. Lack of reactivity with B(C6F5)2(3-hexyl) was surprising since we 
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have utilized this catalyst in the presence of amines in the reduction of natamycin. This is 
also the most active BArF catalyst when strong Lewis bases are present.  
 Although selective activation/reduction of A1.1 has been unsuccessful to this point, 
we have successfully performed chemoselective hydrosilylation of the alkaloid brucine 
(A1.4). Utilizing conditions that were optimized for reduction of amides in previous 
examples, A1.5 is produced in good yields with minor amounts of other impurities isolated. 
This product has been proposed by reduction (LiAlH4) of A1.4, but no definitive 
characterization has been given as a result of the relative instability of the product.95 Under 
our conditions and modified work-up protocol, we were able to isolate the title product 
cleanly and obtain full characterization data. Miraculously, the aryl methoxy groups and 
allylic cyclic ether remains untouched under these conditions. In an attempt to prepare other 
modifications of A1.4, BArF catalysts were investigated. After 1 h there is no observable 
hydrosilylation, but using B(C6F5)3 or BAr3F3 results in white solid that crashes out of 
solution. The identity of the white solid remains to be determined. By in-situ 13C{1H} NMR 
starting material remains the major species in solution.  
 
 
Scheme A1.2. Selective amide hydrosilylation of brucine. 
 Following general procedure 5.3 (refer to Chapter 5), 2.4 mg HB(C6F5)2, toluene, 1.3 
µL trans-hex-3-ene, 45.0 µL Et2SiH2, and 39.0 mg A1.4 were combined. After 18 h the 
reaction was quenched. Post work up, the product was purified by silica gel chromatography 
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(10 x 2 cm column) using gradient elution (100% CH2Cl2 (with 5% iPrNH2) to 60:1 to 50:1 to 
40:1 to 30:1 to 20:1 to 17:1 to 15:1 dichloromethane:methanol) to afford A1.5 as a white 
solid (30.3 mg, 79 % overall yield, 0.079 mmol). Starting material was also recovered along 
with additional unidentifiable products. A1.5: 1H NMR (600 MHz, CDCl3): δ 6.66 (s, 1H, 
H20), 6.12 (s, 1H, H17), 5.62–5.57 (m, 1H, H5), 4.23 (dd, J = 12.8, 8.4 Hz, 1H, H4), 4.02 (ddt, 
J = 12.8, 5.2, 1.6 Hz, 1H, H4’), 3.85 (s, 3H), 3.57 (t, J = 3.1 Hz, 1H), 3.52 (dt, J = 14.1, 3.8 
Hz, 1H), 3.24–3.13 (m, 2H), 3.12–3.07 (m, 3H), 2.78 (dt, J = 11.4, 7.6 Hz, 1H), 2.59–2.54 
(m, 1H), 2.34 (ddd, J = 12.7, 8.0, 4.5 Hz, 1H), 2.05 (dt, J = 13.6, 3.4 Hz, 1H), 1.74 (dt, J = 
13.6, 2.9 Hz, 1H), 1.68–1.49 (m, 4H), 1.30 (qd, J = 11.6, 4.2 Hz, 1H). 13C{1H} NMR (151 
MHz, CDCl3): δ 149.7, 145.2, 141.3, 137.9, 126.2, 123.5, 108.9, 93.3, 77.4, 77.3, 77.2, 76.9, 
72.5, 59.7, 58.8, 57.6, 57.1, 56.2, 53.5, 52.9, 44.4, 43.3, 42.9, 37.9, 34.0, 29.5, 29.3, 26.2, 
24.4. HRMS: C23H31N2O4+: 399.2284, Actual: 399.2284.  
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Figure A1.1. 1H and 13C{1H} spectrum of A1.5. 
Selective amide activation under B(C6F5)2(3-hexyl) hydrosilylation conditions was 
expanded when we found that the complex natural product rifampicin (A1.6) could be 
modified to yield a mixture of three species. A simple silyl-protection of the starting material 
(A1.7) was isolated along with two species that have undergone a similar silane protection 
and condensative reductive amination N–N bond cleavage to remove the piperazine ring has 
also occurred. Removal of the piperazine functional has not been demonstrated previously. 
However, starting from rifaldehyde (aldehyde at position of iminium), reduction amination of 
numerous amines is possible. The subsequent intramolecular dehydration has been studied 
under Bronstead acid catalyzed cyclization.96 
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Scheme A1.3. Selective conversion A1.6. 
 Following general procedure 5.3 (refer to Chapter 5), 2.4 mg HB(C6F5)2, toluene, 1.3 
µL trans-hex-3-ene, 45.0 µL Et2SiH2, and 39.0 mg A1.4 were combined. After 18 h the 
reaction was quenched. Post work up, The product was purified by silica gel chromatography 
(10 x 2 cm column) using gradient elution (25:1 20:1 to 17:1 to 15:1 
dichloromethane:methanol) to afford A1.7 (Rf = 0.7 17:1 dichlormethane:MeOH), A1.8 (Rf 
= 0.4 17:1 dichlormethane:MeOH), and A1.9 (Rf = 0.2 17:1 dichlormethane:MeOH) as deep 
red solids in their respective yields. 
 
A1.2. Additional selective activations of natamycin with fluoroaryl boranes 
 
Investigation of the selective activation of natural products began with the acetamide 
derivative 5.11. Under fluoroaryl borane catalysis most of the reactions with B(C6F5)3 were 
sluggish and often not selective. We assumed the reduced reactivity was based on the Lewis 
basicity of the acetamide and began investigating benzamide natamycin (5.5) to give the 
results discussed in Chapter 5. Specifically, when subjecting 5.11 to hydrosilylation 
conditions with BAr3F3 and Me2EtSiH only enoate activation was observed with no further 
lactone elimination to give A1.10. When increased amounts of silane were used the reaction 
became complex in this case. It is not immediately clear why the reaction halts at this stage 
of the reduction. Perhaps the amide becomes a resting place for the catalyst and addition 
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reduction chemistry can proceed after this. By in-situ monitoring of the reaction the 31P{1H} 
NMR shows almost exclusively free Ph3P. This seems to suggest that most of the catalyst is 
no longer in frustration with Ph3P and could explain why no addition conversion is observed. 
 
Scheme A1.4. Conversion of 5.11 to A1.10. 
Following general procedure 5.2 (refer to Chapter 5), 2.0 mg BAr3F3, 1.4 mg Ph3P, 
dichloromethane, 16.0 µL Me2EtSiH, and 57.0 mg 5.11 were combined. After 6 h the 
reaction was quenched. Post work up, the product was purified by silica gel chromatography 
(10 x 2 cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 
9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 to 3:1 1:1 hexanes:ethyl acetate) to afford 5.9 as a white 
solid (34.8  mg, 53% overall yield, 0.026 mmol). Starting material was also recovered as a 
white solid and eluted off the column after the major product. A1.1: 1H NMR (600 MHz, 
CD2Cl2): δ 6.22–6.09 (m, 6H, H6 & H7 & H8 & H9 & H10), 6.05–5.99 (m, 1H, H5), 5.75–5.69 
(m, 2H, H11 & NH), 5.57 (ddd, JH4,H5 = 14.9 Hz, JH4,H3 = 8.9 Hz, JH4,H3’ = 5.8 Hz, 1H, H4), 
5.04 (dqd, J = 9.9, 6.3, 3.6 Hz, 1H, H2), 4.86 (s, 1H, OH), 4.56 (s, 1H, H32), 4.48 (app t, J = 
8.7 Hz, 1H, H12), 4.31 (td, J = 10.8, 4.6 Hz, 1H, H14), 4.29–4.24 (m, 1H, H20), 4.16 (dt, J = 
11.0, 3.7 Hz, 1H, H14), 3.88 (td, JH30,H29 = 9.2 Hz, JH30,H31 = 2.8 Hz, 1H, H30), 3.84 (d, JH31,H30 
= 2.8 Hz, 1H, H31), 3.46 (t, JH29,H30 & JH29,H28  = 9.2 Hz, 1H, H29), 3.38–3.31 (m, 2H, H28 & 
H23), 2.56–2.49 (m, 1H, H24), 2.47 (dd, J = 14.6, 11.4 Hz, 1H), 2.41 (t, J = 10.4 Hz, 1H), 2.18 
(dt, J = 14.5, 9.4 Hz, 1H), 2.03 (s, 2H), 1.95 (dd, J = 12.3, 4.7 Hz, 1H), 1.82 (dt, J = 14.9, 2.5 
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Hz, 1H), 1.53 (ddd, J = 14.6, 7.0, 2.1 Hz, 1H), 1.47–1.39 (m, 1H), 1.36 (td, J = 10.1, 8.8, 3.6 
Hz, 1H), 1.30 (t, J = 6.3 Hz, 3H), 1.26 (dd, J = 7.6, 6.3 Hz, 6H), 1.22 (dd, J = 12.0, 2.2 Hz, 
1H), 1.05 (dt, J = 8.5, 4.1 Hz, 1H), 0.95 (ddt, J = 12.7, 11.0, 7.9 Hz, 38H), 0.72–0.53 (m, 
24H), 0.11 (d, J = 4.9 Hz, 6H). 13C{1H} NMR (151 MHz, CD2Cl2): δ 174.3, 173.7, 171.0, 
137.1, 134.3, 133.8, 132.6, 132.3, 131.6, 129.8, 129.4, 99.2, 98.1, 76.5, 74.5, 73.1, 72.8, 69.5, 
68.8, 68.0, 67.8, 56.3, 55.9, 45.8, 45.5, 40.3, 38.7, 29.8, 23.8, 20.5, 18.8, 18.3, 9.6, 7.3, 7.3, 
7.2, 7.2, 7.1, 5.9, 5.6, 5.6, 5.3, -1.2, -1.5. HRMS: C63H117N2Si5Na+: 1274.7217, Actual: 
1274.7243. 
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Figure A1.2. 1H and 13C{1H} NMR spectrum of A1.10 
 
Switching to BArF3 results in a similar outcome to generate A1.10 as observed in the 
reduction. This type of selectivity is analogous to the reduction observed when benzamide 
5.5 is the substrate, but it was interesting that instead of isolating starting material we observe 
the product from enoate activation without a-silylation A1.11. This product is analogous to 
reactivity observed with B(C6F5)3, Et2MeSiH and 5.5 (benzamide natamycin derivative). It is 
not clear if the reaction would proceed to full conversion to A1.10 with addition reaction 
times.   
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Figure A1.3. Conversions of 5.11 to A1.10 and A1.11. 
 Following general procedure 4.2 (refer to Chapter 4), 2.0 mg BArF3, 1.4 mg Ph3P, 
dichloromethane, 23.1 µL Me2EtSiH, and 58.1 mg 5.11 were combined. After 2.5 h the 
reaction was quenched. Post work up, the product was purified by silica gel chromatography 
(10 x 2 cm column) using gradient elution (100% hexanes to 20:1 to 15:1 to 13:1 to 10:1 to 
9:1 to 8:1 to 7:1 to 6:1 to 5:1 to 4:1 to 3:1 1:1 hexanes:ethyl acetate) to afford A1.10 (Rf = 
0.5, 3:1 hexanes:ethyl acetate) and A1.11 (Rf = 0.3, 3:1 hexanes:ethyl acetate). A1.10: NMR 
data matched the data given above. A1.11 (contains ~10% A1.10 impurity): 1H NMR (600 
MHz, Acetone-d6): δ 6.49 (d, J = 9.4 Hz, 1H), 6.32–6.23 (m, 4H), 6.21–6.15 (m, 2H), 6.11–
6.04 (m, 1H), 5.75–5.65 (m, 1H), 5.60 (ddd, J = 14.9, 10.5, 4.6 Hz, 1H), 5.12 (dtd, J = 12.6, 
6.3, 2.4 Hz, 1H), 4.62 (dd, J = 8.7, 2.1 Hz, 1H), 4.60–4.59 (m, 1H), 4.53–4.47 (m, 1H), 4.38 
(ddd, J = 11.1, 9.8, 4.5 Hz, 1H), 4.20 (dt, J = 10.9, 3.7 Hz, 1H), 3.90 (td, J = 9.6, 3.1 Hz, 1H), 
3.82–3.77 (m, 1H), 3.46 (dd, J = 9.7, 8.7 Hz, 1H), 3.32 (dq, J = 8.6, 6.1 Hz, 1H), 2.69 (dt, J = 
8.7, 2.3 Hz, 1H), 2.52–2.44 (m, 3H), 2.43–2.36 (m, 1H), 2.36–2.28 (m, 1H), 2.20 (dt, J = 
14.3, 10.8 Hz, 1H), 2.08 (d, J = 1.2 Hz, 1H), 2.08–2.06 (m, 1H), 2.03–1.97 (m, 1H), 1.96 (s, 
3H), 1.94–1.90 (m, 1H), 1.72–1.60 (m, 2H), 1.52 (dd, J = 14.3, 2.6 Hz, 1H), 1.27–1.21 (m, 
10H), 1.02 (t, J = 7.9 Hz, 10H), 0.97–0.90 (m, 34H), 0.72 (q, J = 7.9 Hz, 7H), 0.68–0.57 (m, 
21H). 13C{1H} NMR (151 MHz, Acetone-d6): δ 173.9, 172.3, 169.6, 137.4, 134.3, 134.1, 
133.3, 133.1, 133.0, 131.6, 131.5, 99.0, 97.9, 97.8, 77.1, 74.5, 73.6, 73.5, 69.8, 69.4, 68.5, 
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68.5, 57.0, 56.2, 56.1, 55.6, 46.0, 45.8, 41.7, 41.4, 38.0, 31.9, 30.3, 28.5, 23.4, 20.8, 19.1, 7.4, 
7.3, 7.3, 7.3, 7.2, 7.1, 7.1, 6.0, 5.8, 5.7, 5.7, 5.5, 5.5. 
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Figure A1.4. 1H and 13C{1H} NMR spectrum of A1.10 
 
A1.3. Selective activation of natamycin with alternative reducing reagent 
 
With the success of applying fluoroaryl borane hydrosilylation catalysis to active 
multiple functional groups on natamycin, we sought to further elaborate on this protocol by 
investing how alternative reducing equivalents would behave. Our lab has been investigating 
the activation of borohydride reagents such as pinacolborane (HBpin).97 The expansion of 
this protocol is on-going, but we have recently demonstrated that utilizing this reagent offers 
a completely unique activation profile of 5.11. Under standard conditions with HBpin as the 
reductant lactol elimination to give A1.12.  This product is analogous to the species prepared 
in Chapter 5 from an intramolecular silyl-acetate intermediate. Under these reaction 
conditions, conversion was incomplete after 12 h. Optimization for work-up and isolation 
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protocol will need improvements prior to being a publishable result. It worth noting that the 
work up protocol used for isolation of this product is different from the optimized method 
used in Chapter 5. 
 
Scheme A1.5. Chemoselective activation of 5.11 to A1.12 with HBpin as the reductant. 
Following general procedure 5.2 (refer to Chapter 5), 2.5 mg B(C6F5)3, 1.4 mg Ph3P, 
dichloromethane, 16.0 µL HBpin, and 58.1 mg 5.11 were combined. After 12 h the reaction 
was quenched by rapidly passing it over a plug of resin base. Post work up, the product was 
purified by silica gel chromatography (10 x 2 cm column) using gradient elution (100% 
hexanes to 40:1 to 20:1 to 15:1 to 10:1 to 5:1 to 4:1 to 3:1 to 2:1 to 1:1 hexanes:diethyl ether) 
to afford A1.12 (28.0 mg, 0.024 mmol, 48% yield with pinacol impurity). A1.12: 1H NMR 
(600 MHz, CDCl3): δ 6.45 (dd, J = 15.6, 6.9 Hz, 1H), 6.25–6.10 (m, 4H), 6.05 (td, J = 10.7, 
4.7 Hz, 2H), 6.00–5.95 (m, 2H), 5.75–5.68 (m, 1H), 5.56 (ddd, J = 14.9, 9.7, 5.6 Hz, 1H), 
5.03–4.97 (m, 1H), 4.67 (d, J = 8.9 Hz, 1H), 4.52 (td, J = 8.0, 2.8 Hz, 1H), 4.47 (d, J = 1.6 
Hz, 1H), 4.43 (s, 1H), 4.13 (ddd, J = 11.2, 6.0, 2.2 Hz, 1H), 3.97–3.84 (m, 3H), 3.53–3.38 
(m, 2H), 3.28 (dq, J = 8.4, 6.2 Hz, 1H), 3.05 (dd, J = 6.9, 1.9 Hz, 1H), 2.61 (dt, J = 9.0, 1.8 
Hz, 1H), 2.53 (dd, J = 11.1, 8.9 Hz, 1H), 2.41 (t, J = 12.1 Hz, 1H), 2.20–2.13 (m, 1H), 2.06–
2.03 (s, 3H), 1.31 (d, J = 6.3 Hz, 3H), 1.25 (s, 3H), 1.02 (t, J = 7.9 Hz, 10H), 0.99–0.90 (m, 
51H), 0.67 (td, J = 8.3, 7.0 Hz, 9H), 0.64–0.56 (m, 23H). 13C{1H} NMR (151 MHz, CDCl3): 
δ 173.8, 170.4, 165.5, 151.2, 144.5, 135.0, 134.1, 132.5, 132.3, 131.7, 131.1, 129.3, 125.5, 
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123.9, 103.2, 97.8, 83.2, 76.0, 75.1, 74.1, 72.4, 72.3, 72.0, 69.5, 68.3, 67.6, 59.2, 55.9, 54.7, 
52.0, 43.8, 40.8, 40.4, 36.7, 30.3, 24.9, 24.6, 24.6, 23.6, 20.3, 18.4, 7.0, 6.9, 6.8, 5.5, 5.1, 4.8. 
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Figure A1.5. 1H and 13C{1H} NMR spectrum of A1.10. 
 A second successful application using HBpin for selective activation came during 
attempts to increase the conversion and yield for A1.12. Additional equivalents of HBpin 
showed that increased conversion was possible. When increased equivalents were utilized 
along with heating the reaction, increased conversion was achieved but to a new product.  
 
 
Scheme A1.6. Conversion of 5.11 to A1.13 with HBpin as the reductant. 
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 The outcome of this reaction requires multiple steps. In a control experiment, a single 
equivalent of HBpin was added to 5.11 and dehydroborylation of the carboxylic acid is facile 
even in the absence of B(C6F5)3 to yield the borylester which hydrolyzes upon work up. This 
is also active when Ph3P is present. Moreover, with the outcome of generating A1.12 vide 
supra, lactol elimination appears to proceed first (Scheme A1.7, truncated structure). From 
5.12 we propose that allylic COSiEt3 activation occurs by a Lewis acid in solution (B(C6F5)3 
or possibly [Ph3PBPin], 5.12’) concomitant addition from protected ester generates an 
intermediate propiolactone (5.13’) which extrude CO2 to yield the observed product 5.14. 
Experimental evidence for such a mechanism will need to be gathered for validations. It is 
noted that upon opening the reaction tube to quench, gas is released followed by boiling off 
of dissolved gas in the solution. 
 
Scheme A1.7. Proposed rearrangement to yield A1.13. 
Following general procedure 5.2 (refer to Chapter 5), 5.1 mg B(C6F5)3, 3.0 mg Ph3P, 
dichloromethane, 32.0 µL HBpin, and 58.1 mg 5.11 were combined and placed in an oil bath 
in a J-young capped tube at 45 ºC. After 12 h the reaction was quenched by rapidly passing it 
over a plug of resin base. Post work up, the product was purified by silica gel 
chromatography (10 x 2 cm column) using gradient elution (100% hexanes to 40:1 to 20:1 to 
15:1 to 10:1 to 5:1 to 4:1 to 3:1 to 2:1 to 1:1 hexanes:diethyl ether) to afford A1.13 (28.0 mg, 
0.024 mmol, 41% yield with a minor impurity that matches 5.12 ~10-15%). Minor amounts 
of starting material are recovered in this reaction indicating that it is not as selective as 
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previously described reactions. A1.13: 1H NMR (600 MHz, CDCl3): δ 7.26–7.20 (m, 1H), 
6.55 (dd, J = 15.7, 6.7 Hz, 1H), 6.31 (t, J = 11.4 Hz, 1H), 6.16–6.05 (m, 4H), 6.01–5.82 (m, 
2H), 5.68 (d, J = 9.5 Hz, 1H), 5.62–5.47 (m, 2H), 5.03–4.95 (m, 1H), 4.48 (s, 1H), 4.35 (dq, 
J = 6.9, 5.3 Hz, 1H), 4.16 (td, J = 9.1, 3.0 Hz, 1H), 4.00–3.91 (m, 1H), 3.88 (d, J = 2.7 Hz, 
1H), 3.46 (dd, J = 9.4, 8.3 Hz, 1H), 3.27 (dq, J = 8.3, 6.2 Hz, 1H), 3.09 (dd, J = 6.8, 2.0 Hz, 
1H), 2.87 (ddd, J = 6.7, 4.3, 2.0 Hz, 1H), 2.74 (dd, J = 16.0, 7.3 Hz, 1H), 2.65 (dd, J = 16.1, 
5.7 Hz, 1H), 2.55 (d, J = 7.7 Hz, 0H), 2.48–2.35 (m, 3H), 2.29–2.13 (m, 2H), 2.01 (s, 3H), 
1.29 (d, J = 6.3 Hz, 3H), 1.27 (s, 5H), 1.24 (s, 4H), 1.23 (s, 1H), 0.98–0.92 (m, 39H), 0.69–
0.62 (m, 4H), 0.61 (s, 2H). 13C{1H} NMR (151 MHz, CDCl3): δ 199.1, 169.6, 165.4, 144.1, 
142.7, 140.4, 134.7, 133.7, 132.6, 132.4, 132.2, 132.1, 131.9, 131.4, 129.2, 124.0, 124.0, 
99.0, 83.3, 79.6, 75.2, 74.1, 72.5, 72.1, 69.9, 66.9, 58.4, 55.8, 55.4, 51.0, 40.7, 39.3, 38.8, 
30.4, 25.0, 24.7, 23.8, 20.6, 18.7, 7.2, 7.1, 7.0, 5.5, 5.3, 4.9. HRMS: C52H87NO10Si3Na+: 
992.5535, Actual: 992.5591. 
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Figure A1.6. 1D and 2D NMR spectrum for A1.13. 
A1.4. Selective modifications of natural products with transition metal catalysts 
 
Beyond the selective modifications already discussed where main group borane 
centered catalysts were used exclusively, we have also investigated selective modifications 
using other variants of hydrosilylation catalysts. In our lab’s first foray into hydrosilylation of 
carbohydrates, we investigated Brookhart’s Ir(III)POCOP catalysts.29,98,99 As an extension of 
the work above, we asked whether or not this system would also yield selective 
modifications of complex natural products as the BArF3 systems had done so successfully. 
Initial screening for selective activation of natamycin (5.11) found that selectivity for the 
lactol elimination product was dominant (A1.14). Further optimization will be necessary for 
this protocol. 
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Scheme A1.8. Selective hydrosilylation of 5.11 with Ir(POCOP). 
 Following modified general procedure 5.2 (refer to Chapter 5), 5.0 mg Ir(POCOP), 
120 mg 5.11, 66.0 µL dimethylethylsilane, and dichloromethane were combined. Reaction 
was quenched by loading directly onto a Et3N neutralized plug of silica gel. The product was 
isolated by silica gel chromatography (10 x 2 cm column) using isocratic elution (3:1 
hexanes:ethyl acetate) to afford A1.14 (40 mg, 0.035 mmol, 35%, along with unidentified 
impurity and residual triethylamine). Work up and column conditions were unoptimized. 
Earlier isolated fractions also appeared to contain free mycosamine. A1.14: 1H NMR (600 
MHz, CDCl3): δ 6.53 (dd, J = 15.6, 6.2 Hz, 1H), 6.25–6.19 (m, 2H), 6.18–6.10 (m, 2H), 
6.08–6.02 (m, 1H), 6.02–5.96 (m, 1H), 5.94 (d, J = 15.6 Hz, 1H), 5.76–5.62 (m, 2H), 5.53 
(ddd, J = 15.3, 10.3, 5.2 Hz, 1H), 5.02 (ddp, J = 12.6, 6.3, 3.2 Hz, 1H), 4.68–4.64 (m, 1H), 
4.58 (td, J = 9.3, 3.5 Hz, 1H), 4.46 (s, 1H), 4.43 (d, J = 1.8 Hz, 1H), 4.04 (ddd, J = 11.2, 5.2, 
3.0 Hz, 1H), 3.95–3.88 (m, 2H), 3.81 (d, J = 2.8 Hz, 1H), 3.48–3.40 (m, 2H), 3.29–3.21 (m, 
1H), 3.05–2.93 (m, 4H), 2.57 (dt, J = 8.8, 1.9 Hz, 1H), 2.48–2.36 (m, 2H), 2.21 (ddd, J = 
13.5, 5.1, 1.6 Hz, 1H), 2.18–2.06 (m, 2H), 2.02 (s, 3H), 2.00–1.92 (m, 1H), 1.30 (d, J = 6.2 
Hz, 3H), 1.21 (d, J = 6.3 Hz, 3H), 1.03 (t, J = 8.0 Hz, 9H), 0.98– 0.89 (m, 45H), 0.71–0.62 
(m, 6H), 0.63–0.52 (m, 24H). 13C{1H} NMR (151 MHz, CDCl3): δ 165.8, 151.3, 144.7, 
135.2, 135.0, 132.8, 132.4, 131.7, 129.7, 123.3, 103.9, 99.3, 78.1, 73.9, 72.5, 69.4, 68.6, 68.4, 
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59.8, 55.8, 54.5, 44.7, 44.3, 41.0, 40.4, 37.5, 23.6, 20.5, 18.6, 8.7, 7.1, 7.1, 7.0, 7.0, 5.6, 5.3, 
5.2, 5.1. (*Note: the silane region by 1H and 13C{1H} show an extra set of peaks, the location 
of an additional silane is not known currently). 
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Figure A1.7. 1H and 13C{1H} NMR spectrum of A1.14 
 This same system was also applied successfully to selective modification of 
Me2EtSi2-10-deacetoxybaccattin III to yield A1.15. When using BAr3F3 as the catalysts 
beyond reduction, silyl-protection of C10-oxygen occurs and that is not observed here.  
 
 
Scheme A1.9. Selective modification of Me2EtSi2-10-deacetoxybaccattin with Ir(POCOP). 
 
Following modified general procedure 5.2 (refer to Chapter 5), 4.0 mg Ir(POCOP), 36 
mg 5.20, 7.1 µL dimethylethylsilane, and dichloromethane were combined. After 1 h the 
reaction was quenched under general procedure 5.2. Post work up, the product was purified 
by silica gel chromatography (10 x 2 cm column) using gradient elution (100% hexanes to 
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20:1 to 15:1 to 10:1 to 7:1 to 5:1 to 3:1 hexanes:ethyl acetate) to afford A1.15 as a white 
solid. A1.15: 1H NMR (600 MHz, CDCl3): δ 8.18 (dd, J = 8.3, 1.3 Hz, 1H), 7.59–7.52 (m, 
1H), 7.44 (t, J = 7.8 Hz, 1H), 5.46 (d, JH2,H3 = 7.0 Hz, 1H, H2), 5.14 (d, JH10,–OH = 2.2 Hz, 1H, 
H10), 5.06 (q, JH19,H20 = 5.0 Hz, 1H, H19), 5.00 (td, JH13,H14 & JH13,H14’ = 8.7 Hz, 1.7 Hz, 1H, 
H13), 4.43 (dd, JH7,H6’ = 5.2 Hz, JH7,H6 = 4.1 Hz, 1H, H7), 4.21 (d, J–OH,H10 = 2.2 Hz, 1H, –
OH10), 4.06 (dd, J = 9.6, JH5,H6 = 4.1 Hz, 1H, H5), 3.64 (d, JH18,H18’ = 11.5 Hz, 1H, H18), 3.54 
(d, JH18’,H18 = 11.5 Hz, 1H, H18’), 3.22 (d, JH3,H2 = 7.0 Hz, 1H, H3), 2.94 (dd, JH14,H14’ = 15.0 
Hz, JH14,H13 = 8.6 Hz, 1H, H14), 2.18 (ddd, JH6,H6’ = 14.7 Hz, JH6,H7 =4.7 Hz, JH6,H5 = 2.7 Hz, 
1H, H6), 2.03 (d, J = 1.4 Hz, 3H, H16), 2.00 (dd, JH14’,H14 = 15.0 Hz, JH14’,H13 = 8.7 Hz, 1H, 
H14’), 1.87 (ddd, JH6’,H6 = 14.7 Hz, JH6’,H = 11.0 Hz, JH6’,  = 4.5 Hz, 1H, H6’), 1.65 (d, J = 5.0 
Hz, 3H, H20), 1.24 (s, 3H, ), 1.16 (d, J = 4.2 Hz, 3H), 0.97 (q, J = 7.8 Hz, 3H), 0.91 (t, J = 7.9 
Hz, 1H), 0.69 (t, J = 7.9 Hz, 1H), 0.61 (dddd, J = 16.1, 10.6, 8.1, 3.8 Hz, 2H), 0.57–0.50 (m, 
1H), 0.15 (s, 1H), 0.13 (s, 2H), 0.12 (s, 2H), 0.10 (s, 2H), 0.08 (s, 3H), -0.27 (s, 1H), -0.30 (s, 
1H). 13C{1H} NMR (151 MHz, CDCl3): δ 212.2, 167.9, 143.4, 133.3, 133.0, 130.5, 130.3, 
128.5, 101.3, 83.9, 80.1, 75.7, 74.7, 72.0, 68.8, 68.0, 58.9, 52.9, 43.2, 39.4, 32.1, 26.9, 20.7, 
20.0, 15.5, 10.6, 8.9, 8.5, 7.7, 7.0, 6.8, 6.6, -1.4, -2.0, -2.1, -2.3, -3.2. 
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Figure A1.8. 1H and 13C{1H} NMR spectrum of A1.15. 
Selective lactol activation of Me3Si2-gibberellic acid with Ir(POCOP) was observed 
as in analogy with B(C6F5)3 hydrosilylation chemistry. Beyond lactol, allylic alcohol 
reduction and elimination between the A and B ring was observed to give A1.17 along with 
an isomer in 71:29 selectivity for the major product. 
 
Scheme A1.0.10. Selective modification of gibberellic acid with Ir(POCOP). 
Following modified general procedure 5.2 (refer to Chapter 5), 2.7 mg Ir(POCOP), 24 
mg A1.16, 23 µL dimethylethylsilane, and dichloromethane were combined. After 3 h the 
reaction was quenched with Et3N. Deprotected following general procedure 5.5 (see Chapter 
4). The product was purified by silica gel chromatography (10 x 2 cm column) using gradient 
5 mol % Ir(POCOP)
3.5 equiv. Me2EtSiH
CH2Cl2, 25 ºC
8 h
deprotection
Me3SiO
O OH
H
OC
O
OSiMe3
A1.16 A1.17
O OH
H
OH
OH
O
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elution (30:1 to 25:1 to 20:1 to 15:1 to 10:1 to 7:1 CH2Cl2:MeOH) to A1.17 (11.8 mg, 72% 
yield, 0.038 mmol). A1.17: 1H NMR (600 MHz, CD3OD): 6.22 (dd, J = 9.8, 2.8 Hz, 1H), 
5.85 (dt, J = 9.8, 3.6 Hz, 1H), 5.75 (ddd, J = 9.1, 5.9, 2.2 Hz, 1H), 5.52 (dt, J = 9.8, 2.4 Hz, 
1H), 5.50 (s, 1H), 5.12 (t, J = 2.5 Hz, 1H), 5.13–5.09 (m, 1H), 4.95 (d, J = 2.2 Hz, 1H), 4.93 
(d, J = 2.2 Hz, 1H), 3.59 (d, J = 8.2 Hz, 1H), 3.21 (dd, J = 8.3, 4.4 Hz, 1H), 3.09–3.04 (m, 
1H), 2.91 (h, J = 1.3 Hz, 1H), 2.89–2.87 (m, 1H), 2.87 (s, 1H), 2.86 (s, 1H), 2.70 (t, J = 3.0 
Hz, 1H), 2.68–2.64 (m, 1H), 2.64–2.56 (m, 1H), 2.51 (t, J = 2.9 Hz, 0H), 2.50–2.42 (m, 2H), 
2.20 (q, J = 2.2 Hz, 1H), 2.18 (d, J = 2.8 Hz, 1H), 2.18–2.10 (m, 1H), 2.05 (dd, J = 10.1, 2.7 
Hz, 1H), 2.03–1.94 (m, 2H), 1.79–1.69 (m, 2H), 1.70–1.62 (m, 2H), 1.59 (dd, J = 10.1, 2.6 
Hz, 1H), 1.21 (s, 3H), 1.21 (s, 3H). 
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Figure A1.9. 1H and 13C{1H} NMR spectrum of A1.17. 
 
Beyond Ir(POCOP) we have also discovered selective activation of natamycin 5.11 
with [Ir(COE)2Cl2]2 as the pre-catalyst. Brookhart and Cheng demonstrated that 
[Ir(COE)2Cl2]2 in combination with Et2SiH2 generates a silylene-bridged iridium dimer that is 
catalyst resting state and is active in hydrosilylation of amides to amine or taking esters to 
aldehydes.100,101 Under similar conditions (Ph2SiH2 in place of Et2SiH2 for reactivity reasons) 
, we observe enoate activation that upon quenching result in aldehyde formation to yield the 
proposed product A1.16. Due to some stability issues attempts towards forming the bisulfate 
were undertake, but never produce desired results. 
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Scheme A1.0.11. [Ir(COE)2Cl2]2 modification of 5.11. 
 
Following modified general procedure 5.2 (refer to Chapter 5), 2.2 mg 
[Ir(COE)2Cl2]2, 80 µL diphenylsilane, and dichloromethane were combined. Added to 5.11. 
After 12 at 40 ºC, reaction was quenched by subjecting to a Et3N passivated silica gel column 
(5% Et3N in hexanes). The product was purified by silica gel chromatography (10 x 2 cm 
column) using gradient elution (100% hexanes to 20:1 to 15:1 to 10:1 to 5:1 to 1:1 to 1:5 to 
1:10 hexanes:diethyl ether) to afford A1.14 (50% yield).  
Lastly, we found that using the same catalyst system, but using tetramethyldisiloxane 
instead of Ph2SiH2 results in selective activation of the amide functionality of 5.11. 
 
Scheme A1.12. Selective amide activation of 5.11 with [Ir(COE)2Cl2]2. 
Following modified general procedure 5.2 (refer to Chapter 5), 2.2 mg 
[Ir(COE)2Cl2]2, 31 µL tetramethyldisiloxane, and dichloromethane were combined. Added to 
5.11. After 12 h at RT, reaction was quenched by passing over a plug of resin base. The 
product was purified by silica gel chromatography (10 x 2 cm column) using gradient elution 
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(40:1 to 30:1 to 20:1 to 15:1 to 10:1 to 5:1 to 3:1 to 1:1 to 1:5 hexanes:diethyl ether) to afford 
A1.15 (25 mg, 0.022 mmol, 44% yield). Characterization data matches 5.12 from Chapter 5. 
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